S1 M5 5351 C4591001-Fa-Interim-Protocol

PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)
Protocol C4591001
Protocol Amendment 9, 29 October 2020
A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,

DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY,
IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE
CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS
Study Sponsor: BioNTech

Study Conducted By: Pfizer
Study Intervention Number: PF-07302048
090177e195653bd7\Approved\Approved On: 30-Oct-2020 13:40 (GMT)
Study Intervention Name: RNA-Based COVID-19 Vaccines

US IND Number: 19736
EudraCT Number: 2020-002641-42
Protocol Number: C4591001
Phase: 1/2/3
Short Title: A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and
Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
This document and accompanying materials contain confidential information belonging to Pfizer. Except as
otherwise agreed to in writing, by accepting or reviewing these documents, you agree to hold this
information in confidence and not copy or disclose it to others (except where required by applicable law) or
use it for unauthorized purposes. In the event of any actual or suspected breach of this obligation, Pfizer
must be promptly notified.
CONFIDENTIAL
CT02-GSOP Clinical Protocol Template Phase 1 2 3 4 (05 December 2019)
Page 1
FDA-CBER-2021-5683-0014054
Page 1
Protocol C4591001
Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary and Rationale for Changes

Protocol amendment 9 29 October 2020  To better align with the natural history of
SARS-CoV-2 infection, added Phase 2/3
secondary efficacy objectives, estimands, and
endpoints to include COVID-19 cases that occur
from 14 days after the second dose; also
modified the existing secondary efficacy
objectives, estimands, and endpoints to include
COVID-19 cases that occur from 14 days, as
well as 7 days, after the second dose;
 Made corresponding changes to the study
design, study assessments and procedures,
and statistical analysis sections.
 For operational reasons, removed the interim
analysis planned after accrual of 32 cases.
 Clarified that interim analyses will be conducted
after accrual of at least 62, 92, and 120 cases.
 Included any participants 16 through 17 years of
age enrolled under this amendment in the

reactogenicity subset.
 Added an unblinded clinical scientist to support
DMC activities.
 Clarified that serology data after a postbaseline
positive SARS-CoV-2 test result will not be
included in the analysis based on the evaluable
immunogenicity populations.
Protocol amendment 8 15 October 2020  Removed “N-binding antibody” and
“SARS-CoV-2 detection by NAAT” as
endpoints from the third exploratory objective,
as these results are used for the determination of
the population, and are not endpoints.
 Clarified that the “Process 1” participants
included in the descriptive analysis of
“Process 1”- and “Process 2”-manufactured
study interventions will be selected randomly.
 Clarified that surveillance of potential
COVID-19 symptoms should continue even if a
participant has a positive SARS-CoV-2 test
earlier in the study.
 Further modified the circumstances in which a
local NAAT result may be used in the
COVID-19 case definition.
 Clarified that for participants who are not in the
reactogenicity subset, local reactions and
systemic events following vaccination should be
detected and reported as AEs.
 Clarified that premenarchal females are not
WOCBP.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014055
Page 2
Protocol C4591001
Document History

 Made various editorial changes.
Protocol amendment 7 06 October 2020  Reduced the lower age range to include
adolescents 12 to 15 years of age and added
corresponding objectives.
 Removed reference to COVID-19 antibody
testing in Section 2.3.2.
 Clarified with efficacy estimands and endpoints
that last dose refers to second dose.
 Added an additional exploratory objective to
describe safety and immunogenicity in
participants 16 to 55 years of age vaccinated
with study intervention produced by
manufacturing “Process 1” or “Process 2.”
 Clarified exclusion criterion 5.
 Added Section 6.1.1 to describe manufacturing
“Process 1” and “Process 2.”
 Clarified the degree of unblinding on the
unblinded submissions team in Section 6.3.3.
 Made provision for a second dose of BNT162b2
in participants who were affected by a

medication error at Visit 2 in Section 6.6.
 Provided further clarification regarding
discontinuation of study intervention in
Section 7.1.
 Modified the circumstances in which a local
NAAT result may be used in the COVID-19
case definition.
 Added that 2 periods of potential COVID-19
symptoms within 4 days will be considered as a
single illness.
 Provided guidance in Section 8.13 regarding
circumstances in which a SARS-CoV-2 test
might be required even if symptoms within 7
days following each vaccination are considered
more likely due to vaccine reactogenicity.
 Made allowance in Section 8.13 for a second
SARS-CoV-2 test to be performed within the
same potential COVID-19 illness if it is in
accordance with routine practice.
 Added Section 8.15 to describe the reporting of
SARS-CoV-2 test results and their implications
for participants receiving a second vaccine dose.
 Added statistical hypothesis and power analysis
for evaluation of noninferiority of the immune
response to BNT162b2 in participants 12 to 15
years of age to the response in participants 16 to
25 years of age.
 Amended scope of analyses of safety data in
Section 9.5.1.
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014056
Page 3
Protocol C4591001
Document History

Protocol amendment 6 23 September 2020  According to regulatory request, inclusion
(Germany-specific) criterion 1 now specifies that participants less
than 18 years of age will not be enrolled in the
EU.
Protocol amendment 6 08 September 2020  Reordered some procedures in the Phase 2/3
schedule of activities for consistency with the
main body of the protocol.
 Corrected the window for the 6-month follow-up
visit to be approximately 6 months after
Vaccination 2.
 Reduced the volume of blood draws to ~20 mL.
 Removed the need to have safety data reported
for participants to be included in the safety
objective assessment.
 Added an exploratory objective to describe
safety, immunogenicity, and efficacy in
participants with stable HIV disease.
 Increased the sample size for Phase 2/3 to
~43,998.
 Clarified that inclusion criterion 4 (ie,
participants at higher risk for acquiring COVID-
19) is applicable for Phase 2/3 only, and
provided some examples.
 Removed exclusion criterion 2 (ie, known
infection with HIV, HCV, or HBV) for Phase 3
and added criteria for HIV-positive participants.
 Decreased the lower age limit and removed the
upper age limit for inclusion in Phase 2/3 in
order to evaluate BNT162b2 30 µg in older
adolescents and those over 85 years of age;
updated the title and other references to adults to
align with this change.
 Renamed the immunological assays to align
with other program-level documents.
 Removed reference to the SARS-CoV-2 full-
length, P2 mutant, prefusion spike glycoprotein
(P2 S) being “heads up.”
 Clarified that a positive SARS-CoV-2 NAAT
result without symptoms should not result in
discontinuation of study intervention.
 Added clarification that potential COVID-19
illnesses that are consistent with the clinical
endpoint definition should not be recorded as
AEs.
 Updated the analysis population descriptions to
align with the study SAP.
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014057
Page 4
Protocol C4591001
Document History

Protocol amendment 5 24 July 2020 Following regulatory feedback:
 Renamed Stage 1 to Phase 1, removed Stage 2,
and renamed Stage 3 to Phase 2/3.
 Clarified that a single vaccine candidate,
administered as 2 doses 21 days apart, will be
studied in Phase 2/3.
 Stated that the vaccine candidate selected for
Phase 2/3 evaluation is BNT162b2 at a dose of
30 µg.
 Removed the potential to study BNT162b3.
 Immunogenicity data will be summarized for the
first 360 participants through 1 month after Dose
2, rather than through 21 days after Dose 1.
 Provided further details of sponsor staff that will
be unblinded in Phase 2/3.
 Clarified which stopping rules apply to which
phase of the study.
In addition:
 Clarified the AE reporting requirements for

potential COVID-19 illnesses.
 Updated that Visit 1 may be conducted across 2
consecutive days in Phase 2/3.
 Moved the immunogenicity objectives in
Phase 2/3 to become exploratory.
 Added an additional inclusion criterion to enroll
participants who, in the judgment of the
investigator, are at risk for acquiring COVID-19.
 Modified exclusion criterion 5, so that
participants with a previous clinical or
microbiological diagnosis of COVID-19 are
excluded from all phases of the study.
 Clarified that there will be 2 all-available
efficacy populations.
 Clarified that immunogenicity samples will be
drawn for all participants; analyses will be based
upon results from subsets of samples, according
to the purpose.
 Updated that the 3-tier approach to summarizing
AEs will only be performed in Phase 2/3.
 Updated that at each interim analysis for
efficacy, only the first primary objective will be
evaluated.
 Changed to use the same posterior probability
(99.5%) for all interim analyses, resulting in
case split changes in Tables 5, 6, and 7.
 Updated the stopping and alert rule parameters
for enhanced COVID-19.
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014058
Page 5
Protocol C4591001
Document History

Protocol amendment 4 30 June 2020 Given the rapidly evolving pandemic situation, and
the need to demonstrate VE as soon as possible, the
protocol has been amended to be powered to meet
new efficacy objectives. These new efficacy
objectives and corresponding endpoints have been
added to Section 3.
Further nonclinical data are available to support the

study of the BNT162b3 candidate in humans, and the
candidate has been added to the protocol.
The 6-month safety follow-up telephone contact has

been changed to an in-person visit for Stage 3
participants, to allow collection of an
immunogenicity blood sample.
The COVID-19 illness visit has now added

flexibility to permit a remote or in-person visit.
The COVID-19 illness symptoms have been updated

to align with the FDA-accepted definitions; this

change is also reflected in the criteria for temporary
delay of enrollment.
AEs that occur between consent and dosing will now

be reported on the AE (rather than Medical History)
CRF, to align with the latest Pfizer protocol
template.
Changes have been made to the headings to align

with the latest Pfizer protocol template.
Clarified that only an unblinded site staff member

may obtain the participant’s randomization number
and study intervention allocation.
Additional interim analyses have been added to

evaluate VE and futility during the study.
As a result of regulatory feedback, an appendix has

been added to outline the stopping and alert rules to
monitor for potential enhanced COVID-19.
Protocol amendment 3 10 June 2020 As data have become available from this study and
the BNT162-01 study in Germany, the following
decisions were made:
 Not to study the BNT162a1 and BNT162c2
vaccine candidates at this time. Therefore, these
candidates have been removed from the
protocol.
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014059
Page 6
Protocol C4591001
Document History

 To study further lower dose levels of the
modRNA candidates. Therefore, a 20-µg dose
level is formally included for BNT162b1 and
BNT162b2.
 To permit individual and group dosing
alterations for the second dose of study
intervention.
Following regulatory feedback, the BNT162b3

vaccine candidate has been removed from the
protocol until further nonclinical data are available to
support study in humans.
Given the rapidly evolving pandemic situation,

additional blood draws for exploratory COVID-19
research, intended to establish an immunological
surrogate of protection, will be taken from selected
participants who consent.
In order to increase flexibility enrolling participants,

an extended screening window (increased from 14 to
28 days) for sentinel participants in Stage 1 has been
added. This is considered acceptable since eligible
participants are expected to be either healthy or have
stable medical conditions.
To increase the number of doses that can be obtained

from available vaccine vials, not all dose levels will
result in a dosing volume of 0.5 mL. Precise dosing
instructions will be provided in the IP manual.
To facilitate the reporting of COVID-19 illness

diagnoses and potential symptoms to the
investigator, participants may utilize a COVID-19
illness e-diary.
Protocol amendment 2 27 May 2020 Given the urgent nature of the pandemic situation,
the following changes allow determination of the
appropriate human dose level for both younger and
older adults to move speedily into the next phase of
clinical evaluation:
 Added a new vaccine candidate, BNT162b3,
modRNA encoding a membrane-anchored RBD
 Added a 50-µg dose level for vaccine candidates
based on the modRNA platform (ie, BNT162b1,
BNT162b2, and BNT162b3)
 Modified the criteria required for the IRC to
determine dose escalation in the 18- to 55-year
age cohort and advancement to groups of
participants 65 to 85 years of age
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014060
Page 7
Protocol C4591001
Document History

In addition:
 Removed hemoglobin change-from-baseline
abnormalities from the laboratory abnormality
grading scale as abnormalities should be graded
based upon absolute values
Protocol amendment 1 13 May 2020  Following regulatory feedback:
 Modified exclusion criteria and prohibited
inhaled/nebulized corticosteroids for sentinel
participants in Stage 1
 Clarified that the rapid test for prior COVID-19
infection for sentinel participants in Stage 1 will
be used only for screening purposes
 Removed time frames for stopping rules
 Stated that data supporting the selection of
vaccine candidate(s)/dose level(s) and
schedule(s) for Stages 2 and 3 will be submitted
to the FDA for review
 Following preliminary experience in the

BioNTech study conducted in Germany

(BNT162-01):
 Decreased the dose levels for BNT162a1 and
BNT162c2
Additionally:
 Clarified the roles of BioNTech and Pfizer
 Amended text so that the IRC decision to
progress group(s) into Stages 2 and 3 can be
based upon safety and immunogenicity data
after Dose 1 or 2
 Clarified safety data requirements to permit dose
escalation
 Amended text so that the progression to
participants 65 to 85 years of age can be based
upon data from the same RNA platform
 Incorporated a protocol administrative change to
correct the variant designation and the encoded
antigen to BNT162c2
 Clarified that the SARS-CoV-2 neutralizing
assay does not employ wild-type virus
 Clarified that the SARS-CoV-2 spike protein–
binding antibody assay is specific for the S1
subunit
 Clarified that efficacy against COVID-19 is
based upon illness (not infection) rate ratio
state that the study placebo may be supplied in a
glass or plastic vial
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014061
Page 8
Protocol C4591001
Document History

 Corrected a typographical error in Section 6.5.1
regarding the time frame for prior receipt of
blood/plasma products or immunoglobulins
 Corrected a typographical error in Table 2
regarding the lower limit of diameter (cm) for
mild redness and swelling
 Updated the °C fever scale in Table 4 to ensure
that all potential °F values are correctly assigned
clarify that a rapid test for prior COVID-19
infection will be performed for sentinel
participants in Stage 1, and a serum sample will
be drawn for potential future assessment
 Clarified that, after screening, physical
examinations in sentinel participants in Stage 1
will be directed
 Clarified the descriptions of the populations for
analysis to align with the statistical analysis plan
 Added a complete safety and immunogenicity
analysis approximately 6 months after Dose 2

for all participants in Stage 3
 Amended text so that the stopping rules apply to
an RNA platform rather than a specific vaccine
candidate
Original protocol 15 April 2020 N/A
This amendment incorporates all revisions to date, including amendments made at the
request of country health authorities and IRBs/ECs.
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014062
Page 9
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................15
1. PROTOCOL SUMMARY...................................................................................................17
1.1. Synopsis ..................................................................................................................17
1.2. Schema ....................................................................................................................25
1.3. Schedule of Activities .............................................................................................26
1.3.1. Phase 1 ........................................................................................................26
1.3.2. Phase 2/3.....................................................................................................31
2. INTRODUCTION ...............................................................................................................34
2.1. Study Rationale .......................................................................................................34
2.2. Background .............................................................................................................34
2.2.1. Clinical Overview.......................................................................................35
2.3. Benefit/Risk Assessment.........................................................................................35
2.3.1. Risk Assessment .........................................................................................37
2.3.2. Benefit Assessment.....................................................................................39

2.3.3. Overall Benefit/Risk Conclusion................................................................39
3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS ...........................................................39
3.1. For Phase 1 ..............................................................................................................39
3.2. For Phase 2/3 ...........................................................................................................41
4. STUDY DESIGN.................................................................................................................44
4.1. Overall Design.........................................................................................................44
4.1.1. Phase 1 ........................................................................................................44
4.1.2. Phase 2/3.....................................................................................................45
4.2. Scientific Rationale for Study Design .....................................................................47
4.3. Justification for Dose ..............................................................................................47
4.4. End of Study Definition ..........................................................................................48
5. STUDY POPULATION ......................................................................................................48
5.1. Inclusion Criteria.....................................................................................................48
5.2. Exclusion Criteria....................................................................................................49
5.3. Lifestyle Considerations..........................................................................................52
5.3.1. Contraception..............................................................................................52
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014063
Page 10
Protocol C4591001
5.4. Screen Failures ........................................................................................................52

5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study
Intervention Administration ......................................................................................52
6. STUDY INTERVENTION..................................................................................................53
6.1. Study Intervention(s) Administered ........................................................................54
6.1.1. Manufacturing Process ...............................................................................54
6.1.2. Administration ............................................................................................54
6.2. Preparation/Handling/Storage/Accountability ........................................................55
6.2.1. Preparation and Dispensing ........................................................................56
6.3. Measures to Minimize Bias: Randomization and Blinding.....................................56
6.3.1. Allocation to Study Intervention ................................................................56
6.3.2. Blinding of Site Personnel ..........................................................................56
6.3.3. Blinding of the Sponsor ..............................................................................57
6.3.4. Breaking the Blind......................................................................................58
6.4. Study Intervention Compliance...............................................................................58

6.5. Concomitant Therapy..............................................................................................58
6.5.1. Prohibited During the Study .......................................................................58
6.5.2. Permitted During the Study ........................................................................59
6.6. Dose Modification...................................................................................................59
6.7. Intervention After the End of the Study ..................................................................60
7. DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT
DISCONTINUATION/WITHDRAWAL...........................................................................60
7.1. Discontinuation of Study Intervention ....................................................................60
7.2. Participant Discontinuation/Withdrawal From the Study .......................................61
7.2.1. Withdrawal of Consent ...............................................................................62
7.3. Lost to Follow-up ....................................................................................................62
8. STUDY ASSESSMENTS AND PROCEDURES...............................................................62
8.1. Efficacy and/or Immunogenicity Assessments .......................................................63
8.1.1. Biological Samples .....................................................................................66
8.2. Safety Assessments .................................................................................................66
8.2.1. Clinical Safety Laboratory Assessments (Phase 1 Participants Only) .......67
8.2.2. Electronic Diary..........................................................................................67
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014064
Page 11
Protocol C4591001
8.2.2.1. Grading Scales...........................................................................68

8.2.2.2. Local Reactions .........................................................................68
8.2.2.3. Systemic Events ........................................................................69
8.2.2.4. Fever..........................................................................................70
8.2.2.5. Antipyretic Medication .............................................................71
8.2.3. Phase 1 Stopping Rules ..............................................................................71
8.2.4. Surveillance of Events That Could Represent Enhanced COVID-19
and Phase 2/3 Stopping Rule ...........................................................................72
8.2.5. Randomization and Vaccination After a Stopping Rule Is Met .................73
8.2.6. Pregnancy Testing ......................................................................................73
8.3. Adverse Events and Serious Adverse Events..........................................................73
8.3.1. Time Period and Frequency for Collecting AE and SAE Information.......73
8.3.1.1. Reporting SAEs to Pfizer Safety...............................................74
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF...................74
8.3.2. Method of Detecting AEs and SAEs ..........................................................75

8.3.3. Follow-up of AEs and SAEs.......................................................................75
8.3.4. Regulatory Reporting Requirements for SAEs...........................................75
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational
Exposure ..........................................................................................................75
8.3.5.1. Exposure During Pregnancy......................................................76
8.3.5.2. Exposure During Breastfeeding ................................................77
8.3.5.3. Occupational Exposure .............................................................78
8.3.6. Cardiovascular and Death Events...............................................................78
8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not
Qualifying as AEs or SAEs..............................................................................78
8.3.8. Adverse Events of Special Interest .............................................................79
8.3.8.1. Lack of Efficacy ........................................................................79
8.3.9. Medical Device Deficiencies......................................................................79
8.3.10. Medication Errors .....................................................................................79
8.4. Treatment of Overdose............................................................................................80
8.5. Pharmacokinetics ....................................................................................................80
8.6. Pharmacodynamics..................................................................................................80
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014065
Page 12
Protocol C4591001
8.7. Genetics ...................................................................................................................80

8.8. Biomarkers ..............................................................................................................81
8.9. Immunogenicity Assessments .................................................................................81
8.10. Health Economics .................................................................................................81
8.11. Study Procedures...................................................................................................81
8.11.1. Phase 1 ......................................................................................................81
8.11.1.1. Screening: (0 to 28 Days Before Visit 1) ................................81
8.11.1.2. Visit 1 – Vaccination 1: (Day 1) .............................................82
8.11.1.3. Visit 2 – Next-Day Follow-up Visit (Vaccination 1): (1
to 3 Days After Visit 1) .....................................................................84
8.11.1.4. Visit 3 – 1-Week Follow-up Visit (Vaccination 1): (6 to
8 Days After Visit 1) .........................................................................86
8.11.1.5. Visit 4 – Vaccination 2: (19 to 23 Days After Visit 1) ...........87
8 Days After Visit 4) .........................................................................89

16 Days After Visit 4) .......................................................................90
8.11.1.8. Visit 7 – 1-Month Follow-up Visit: (28 to 35 Days After
Visit 4) ...............................................................................................91
8.11.1.9. Visit 8 – 6-Month Follow-up Visit: (175 to 189 Days
After Visit 4)......................................................................................92
After Visit 4)......................................................................................92
After Visit 4)......................................................................................93
8.11.2. Phase 2/3...................................................................................................93
8.11.2.3. Visit 3 – 1-Month Follow-up Visit (After Vaccination 2):
(28 to 35 Days After Visit 2).............................................................98
After Visit 2)......................................................................................99
After Visit 2)......................................................................................99
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014066
Page 13
Protocol C4591001

After Visit 2)....................................................................................100
8.12. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction ......................100
8.13. COVID-19 Surveillance (All Participants) .........................................................101
8.13.1. Potential COVID-19 Illness Visit: (Optimally Within 3 Days After
Potential COVID-19 Illness Onset) ...............................................................103
8.13.2. Potential COVID-19 Convalescent Visit: (28 to 35 Days After
Potential COVID-19 Illness Visit)................................................................104
8.14. Communication and Use of Technology.............................................................105
8.15. SARS-CoV-2 NAAT Results From Visits 1 and 2 and Potential COVID-19
Illness Visits ............................................................................................................105
9. STATISTICAL CONSIDERATIONS ..............................................................................106
9.1. Estimands and Statistical Hypotheses ...................................................................106
9.1.1. Estimands..................................................................................................106
9.1.2. Statistical Hypotheses...............................................................................107
9.1.2.1. Statistical Hypothesis Evaluation for Efficacy........................107

9.1.2.2. Statistical Hypothesis Evaluation for Immunogenicity...........107
9.2. Sample Size Determination...................................................................................107
9.3. Analysis Sets .........................................................................................................109
9.4. Statistical Analyses ...............................................................................................110
9.4.1. Immunogenicity Analyses ........................................................................110
9.4.2. Efficacy Analyses .....................................................................................115
9.4.3. Safety Analyses ........................................................................................117
9.4.4. Other Analyses..........................................................................................118
9.5. Interim Analyses ...................................................................................................119
9.5.1. Analysis Timing........................................................................................122
9.6. Data Monitoring Committee or Other Independent Oversight Committee...........122
10. SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS ........................................................................................................124
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations .............124
10.1.1. Regulatory and Ethical Considerations ..................................................124
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the
Protocol or ICH GCP.......................................................................124
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014067
Page 14
Protocol C4591001
10.1.2. Informed Consent Process ......................................................................125

10.1.3. Data Protection .......................................................................................126
10.1.4. Dissemination of Clinical Study Data ....................................................126
10.1.5. Data Quality Assurance ..........................................................................127
10.1.6. Source Documents ..................................................................................129
10.1.7. Study and Site Start and Closure ............................................................129
10.1.8. Sponsor’s Qualified Medical Personnel .................................................130
10.2. Appendix 2: Clinical Laboratory Tests ...............................................................131
10.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording,
Evaluating, Follow-up, and Reporting ....................................................................133
10.3.1. Definition of AE .....................................................................................133
10.3.2. Definition of SAE ...................................................................................134
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs.....................136
10.3.4. Reporting of SAEs..................................................................................139
10.4. Appendix 4: Contraceptive Guidance .................................................................140

10.4.1. Male Participant Reproductive Inclusion Criteria ..................................140
10.4.2. Female Participant Reproductive Inclusion Criteria...............................140
10.4.3. Woman of Childbearing Potential ..........................................................141
10.4.4. Contraception Methods...........................................................................142
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments ......144
10.6. Appendix 6: Abbreviations .................................................................................146
10.7. Appendix 7: Stopping and Alert Rules for Enhanced COVID-19 ......................150
10.8. Appendix 8: Criteria for Allowing Inclusion of Participants With Chronic
Stable HIV, HCV, or HBV Infection ......................................................................153
11. REFERENCES ................................................................................................................154
LIST OF TABLES
Table 1. Local Reaction Grading Scale ..................................................................69
Table 2. Systemic Event Grading Scale..................................................................69
Table 3. Scale for Fever..........................................................................................70
Table 4. Power Analysis for Noninferiority Assessment .....................................108
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014068
Page 15
Protocol C4591001
Table 5. Probability of Observing at Least 1 AE by Assumed True Event

Rates With Different Sample Sizes ........................................................109
Table 6. Interim Analysis Plan and Boundaries for Efficacy and Futility............120
Table 7. Statistical Design Operating Characteristics: Probability of Success
or Failure for Interim Analyses...............................................................121
for Final Analysis and Overall................................................................121
Table 9. Laboratory Abnormality Grading Scale .................................................131
Table 10. Stopping Rule: Enrollment Is Stopped if the Number of Severe
Cases in the Vaccine Group Is Greater Than or Equal to the
Prespecified Stopping Rule Value (S) ....................................................151
Table 11. Alert Rule: Further Action Is Taken if the Number of Severe Cases
in the Vaccine Group Is Greater Than or Equal to the Prespecified
Alert Rule Value (A) ..............................................................................152
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014069
Page 16
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale
A pneumonia of unknown cause detected in Wuhan, China, was first reported in

December 2019. On 08 January 2020, the pathogen causing this outbreak was identified as a
novel coronavirus 2019. The outbreak was declared a Public Health Emergency of
International Concern on 30 January 2020. On 12 February 2020, the virus was officially
named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the WHO
officially named the disease caused by SARS-CoV-2 as coronavirus disease 2019
(COVID-19). On 11 March 2020, the WHO upgraded the status of the COVID-19 outbreak
from epidemic to pandemic, which is now spreading globally at high speed.
There are currently no licensed vaccines to prevent infection with SARS-CoV-2 or

COVID-19. Given the rapid transmission of COVID-19 and incidence of disease in the
United States and elsewhere, the rapid development of an effective vaccine is of utmost
importance.
BioNTech has developed RNA-based vaccine candidates using a platform approach that
enables the rapid development of vaccines against emerging viral diseases, including
SARS-CoV-2. Each vaccine candidate is based on a platform of nucleoside-modified
messenger RNA (modRNA, BNT162b). Each vaccine candidate expresses 1 of 2 antigens:
the SARS-CoV-2 full-length, P2 mutant, prefusion spike glycoprotein (P2 S) (version 9) or a
trimerized SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD) (version 5).
The 2 SARS-CoV-2 vaccine candidates that will be tested in this study are therefore:
BNT162b1 (variant RBP020.3): a modRNA encoding the RBD;
BNT162b2 (variant RBP020.2): a modRNA encoding P2 S.
All candidates are formulated in the same lipid nanoparticle (LNP) composition. This study
is intended to investigate the safety, immunogenicity, and efficacy of these prophylactic
BNT162 vaccines against COVID-19.
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014070
Page 17
Protocol C4591001
Objectives, Estimands, and Endpoints
For Phase 1
Objectives Estimands Endpoints

Primary: Primary: Primary:
To describe the safety and tolerability In participants receiving at least 1 dose  Local reactions (pain at the
profiles of prophylactic BNT162 of study intervention, the percentage of injection site, redness, and
vaccines in healthy adults after 1 or 2 participants reporting: swelling)
doses  Local reactions for up to 7 days  Systemic events (fever, fatigue,
following each dose headache, chills, vomiting,
 Systemic events for up to 7 days diarrhea, new or worsened muscle
following each dose pain, and new or worsened joint
 Adverse events (AEs) from pain)
Dose 1 to 1 month after the last  AEs
dose  SAEs
 Serious AEs (SAEs) from Dose 1
to 6 months after the last dose
In addition, the percentage of Hematology and chemistry laboratory
participants with: parameters detailed in Section 10.2
 Abnormal hematology and
chemistry laboratory values 1 and
7 days after Dose 1; and 7 days
after Dose 2
 Grading shifts in hematology and

chemistry laboratory assessments
between baseline and 1 and 7 days
after Dose 1; and before Dose 2
and 7 days after Dose 2
Secondary: Secondary: Secondary:
To describe the immune responses In participants complying with the key
elicited by prophylactic BNT162 protocol criteria (evaluable
vaccines in healthy adults after 1 or 2 participants) at the following time
doses points after receipt of study
intervention:
7 and 21 days after Dose 1; 7 and 14

days and 1, 6, 12, and 24 months after
Dose 2
 Geometric mean titers (GMTs) at SARS-CoV-2 neutralizing titers

each time point
 Geometric mean fold rise (GMFR)
from before vaccination to each
subsequent time point after
vaccination
 Proportion of participants
achieving ≥4-fold rise from before
vaccination to each subsequent
time point after vaccination
CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014071
Page 18
Protocol C4591001

 Geometric mean concentrations S1-binding IgG levels and
(GMCs) at each time point RBD-binding IgG levels
 GMFR from before vaccination to
each subsequent time point after
vaccination
 Geometric mean ratio (GMR),  SARS-CoV-2 neutralizing titers
estimated by the ratio of the  S1-binding IgG levels
geometric mean of SARS-CoV-2  RBD-binding IgG levels
neutralizing titers to the geometric
mean of binding IgG levels at each
time point
For Phase 2/3
Objectivesa Estimands Endpoints

Primary Efficacy
To evaluate the efficacy of In participants complying with the COVID-19 incidence per 1000
prophylactic BNT162b2 against key protocol criteria (evaluable person-years of follow-up based on
confirmed COVID-19 occurring from participants) at least 7 days after central laboratory or locally
7 days after the second dose in receipt of the second dose of study confirmed NAAT in participants with
participants without evidence of intervention: no serological or virological evidence
infection before vaccination 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the
vaccine to placebo] second dose) of past SARS-CoV-2
infection
7 days after the second dose in receipt of the second dose of study confirmed NAAT
participants with and without intervention:
evidence of infection before 100 × (1 – IRR) [ratio of active
vaccination vaccine to placebo]
Primary Safety
To define the safety profile of In participants receiving at least 1  Local reactions (pain at the
prophylactic BNT162b2 in the first dose of study intervention, the injection site, redness, and
360 participants randomized (Phase 2) percentage of participants reporting: swelling)
 Local reactions for up to 7 days  Systemic events (fever, fatigue,
 Systemic events for up to 7 days diarrhea, new or worsened
following each dose muscle pain, and new or
 AEs from Dose 1 to 7 days after worsened joint pain)
the second dose  AEs
 SAEs from Dose 1 to 7 days  SAEs
after the second dose
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014072
Page 19
Protocol C4591001

To define the safety profile of In participants receiving at least  AEs
prophylactic BNT162b2 in all 1 dose of study intervention, the  SAEs
participants randomized in Phase 2/3 percentage of participants reporting:  In a subset of at least 6000
 Local reactions for up to 7 days participants:
following each dose o Local reactions (pain at the
 Systemic events for up to 7 days injection site, redness, and
following each dose swelling)
 AEs from Dose 1 to 1 month o Systemic events (fever,
after the second dose fatigue, headache, chills,
 SAEs from Dose 1 to 6 months vomiting, diarrhea, new or
after the second dose worsened muscle pain, and
new or worsened joint pain)
To define the safety profile of In participants receiving at least  Local reactions (pain at the
prophylactic BNT162b2 in 1 dose of study intervention, the injection site, redness, and
participants 12 to 15 years of age in percentage of participants reporting: swelling)
Phase 3  Local reactions for up to 7 days  Systemic events (fever, fatigue,
 AEs from Dose 1 to 1 month worsened joint pain)
after the second dose  AEs
 SAEs from Dose 1 to 6 months  SAEs
Secondary Efficacy
infection
To evaluate the efficacy of In participants complying with the Confirmed severe COVID-19
prophylactic BNT162b2 against key protocol criteria (evaluable incidence per 1000 person-years of
confirmed severe COVID-19 participants) follow-up in participants with no
occurring from 7 days and from  at least 7 days serological or virological evidence (up
14 days after the second dose in and to 7 days and up to 14 days after
participants without evidence of  at least 14 days receipt of the second dose) of past
infection before vaccination after receipt of the second dose of SARS-CoV-2 infection
study intervention:
100 × (1 – IRR) [ratio of active
vaccine to placebo]
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014073
Page 20
Protocol C4591001

confirmed severe COVID-19 participants) follow-up
occurring from 7 days and from  at least 7 days
14 days after the second dose in and
participants with and without  at least 14 days
evidence of infection before after receipt of the second dose of
vaccination study intervention:
vaccine to placebo]
To describe the efficacy of In participants complying with the COVID-19 incidence per 1000
confirmed COVID-19 (according to participants) central laboratory or locally
the CDC-defined symptoms)  at least 7 days confirmed NAAT in participants with
occurring from 7 days and from and no serological or virological evidence
14 days after the second dose in  at least 14 days (up to 7 days and up to 14 days after
participants without evidence of after receipt of the second dose of receipt of the second dose) of past
infection before vaccination study intervention: SARS-CoV-2 infection
vaccine to placebo]
the CDC-defined symptoms)  at least 7 days confirmed NAAT
occurring from 7 days and from and
14 days after the second dose in  at least 14 days

participants with and without after receipt of the second dose of
evidence of infection before study intervention:
vaccination 100 × (1 – IRR) [ratio of active
vaccine to placebo]
Secondary Immunogenicity
To demonstrate the noninferiority of GMR, estimated by the ratio of the SARS-CoV-2 neutralizing titers in
the immune response to prophylactic geometric mean of SARS-CoV-2 participants with no serological or
BNT162b2 in participants 12 to 15 neutralizing titers in the 2 age groups virological evidence (up to 1 month
years of age compared to participants (12-15 years of age to 16-25 years of after receipt of the second dose) of
16 to 25 years of age age) 1 month after completion of past SARS-CoV-2 infection
vaccination
Exploratory
To evaluate the immune response GMC/GMT, GMFR, and percentage  S1-binding IgG levels and/or
over time to prophylactic BNT162b2 of participants with titers greater than RBD-binding IgG levels
and persistence of immune response defined threshold(s), at baseline and  SARS-CoV-2 neutralizing titers
in participants with and without 1, 6, 12, and 24 months after
serological or virological evidence of completion of vaccination
SARS-CoV-2 infection before
vaccination
To evaluate the immune response  N-binding antibody
(non-S) to SARS-CoV-2 in
participants with and without
confirmed COVID-19 during the
study
To describe the serological responses  S1-binding IgG levels and/or
to the BNT vaccine candidate in cases RBD-binding IgG levels
of:  SARS-CoV-2 neutralizing titers
 Confirmed COVID-19
 Confirmed severe COVID-19
 SARS-CoV-2 infection without
confirmed COVID-19
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014074
Page 21
Protocol C4591001

To describe the safety,  All safety, immunogenicity, and
immunogenicity, and efficacy of efficacy endpoints described
prophylactic BNT162b2 in above
individuals with confirmed stable HIV
disease
To describe the safety and  All safety endpoints described
immunogenicity of prophylactic above
BNT162b2 in individuals 16 to 55  SARS-CoV-2 neutralizing titers
years of age vaccinated with study
intervention produced by
manufacturing “Process 1” or
“Process 2”b
a. HIV-positive participants in Phase 3 will not be included in analyses of the objectives, with the
exception of the specific exploratory objective.
b. See Section 6.1.1 for a description of the manufacturing process.
Overall Design
This is a Phase 1/2/3, multicenter, multinational, randomized, placebo-controlled,

observer-blind, dose-finding, vaccine candidate–selection, and efficacy study in healthy
individuals.
The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose
level(s); Phase 2/3: an expanded cohort and efficacy part. These parts, and the progression
between them, are detailed in the schema (Section 1.2).
The study will evaluate the safety, tolerability, and immunogenicity of 2 different
SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:
 As a 2-dose (separated by 21 days) schedule;
 At various different dose levels in Phase 1;
 In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12
years of age [stratified as 12-15, 16-55, or >55 years of age]).
Dependent upon safety and/or immunogenicity data generated during the course of this
study, or the BioNTech study conducted in Germany (BNT162-01), it is possible that groups
in Phase 1 may be started at the next highest dose, groups may not be started, groups may be
terminated early, and/or groups may be added with dose levels below the lowest stated dose
or intermediate between the lowest and highest stated doses.
The vaccine candidate selected for Phase 2/3 evaluation is BNT162b2 at a dose of 30 µg.
CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014075
Page 22
Protocol C4591001
Number of Participants
Each group in Phase 1 will comprise 15 participants (12 receiving active vaccine and
3 receiving placebo). In this phase, 13 groups will be studied, corresponding to a total of
195 participants.
The vaccine candidate selected for Phase 2/3, BNT162b2 at a dose of 30 µg, will comprise
21,999 vaccine recipients. The 12- to 15-year stratum will comprise up to approximately
2000 participants (1000 vaccine recipients) enrolled at selected investigational sites. It is
intended that a minimum of 40% of participants will be in the >55-year stratum. An equal
number of participants will receive placebo, ie, randomized in a 1:1 ratio.
Intervention Groups and Duration
The study will evaluate a 2-dose (separated by 21 days) schedule of various different dose
levels of 2 investigational RNA vaccine candidates for active immunization against
COVID-19 in 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3:
≥12 years of age [stratified as 12-15, 16-55, or >55 years of age]):
 BNT162b1 (BNT162 RNA-LNP vaccine utilizing modRNA and encoding the RBD):
10 µg, 20 µg, 30 µg, 100 µg
 BNT162b2 (BNT162 RNA-LNP vaccine utilizing modRNA and encoding the P2 S):
10 µg, 20 µg, 30 µg
Participants are expected to participate for up to a maximum of approximately 26 months.

The duration of study follow-up may be shorter among participants enrolled in Phase 1
dosing arms that are not evaluated in Phase 2/3.
Data Monitoring Committee or Other Independent Oversight Committee
The study will utilize an IRC, an internal Pfizer committee that will review data to allow
dose escalation or changes to continuation of specific groups.
An external data monitoring committee (DMC) will be formed and will review cumulative
unblinded data throughout the study.
Statistical Methods
The sample size for Phase 1 of the study is not based on any statistical hypothesis testing.
For Phase 2/3, the VE evaluation will be the primary objective. The VE is defined as
VE = 100 × (1 – IRR), where IRR is calculated as the ratio of the first confirmed COVID-19
illness rate in the vaccine group to the corresponding illness rate in the placebo group. With
assumptions of a true VE of 60% and 4 IAs planned, 164 COVID-19 cases will provide 90%
CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014076
Page 23
Protocol C4591001
power to conclude true VE >30%. This would be achieved with a total 43,998 participants
(21,999 vaccine recipients), based on the assumption of a 1.3% per year incidence in the
placebo group, accrual of 164 primary-endpoint cases within 6 months, and 20% of the
participants being nonevaluable. If the attack rate is much higher, case accrual would be
expected to be more rapid, enabling the study’s primary endpoint to be evaluated much
sooner. The total number of participants enrolled in Phase 2/3 may vary depending on the
incidence of COVID-19 at the time of the enrollment, the true underlying VE, and a potential
early stop for efficacy or futility.
VE will be evaluated using a beta-binomial model and the posterior probability of VE being
>30% will be assessed.
In Phase 3, up to approximately 2000 participants are anticipated to be 12 to 15 years of age.

Noninferiority of immune response to prophylactic BNT162b2 in participants 12 to 15 years
of age to response in participants 16 to 25 years of age will be assessed based on the GMR of
SARS-CoV-2 neutralizing titers using a 1.5-fold margin. A sample size of 200 evaluable
participants (or 250 vaccine recipients) per age group will provide a power of 90.8% to
declare the noninferiority in terms of GMR (lower limit of 95% CI for GMR >0.67).
The primary safety objective will be evaluated by descriptive summary statistics for local
reactions, systemic events, AEs/SAEs, and abnormal hematology and chemistry laboratory
parameters (Phase 1 only), for each vaccine group. A 3-tier approach will be used to
summarize AEs in Phase 2/3.
Except for the objective to assess the noninferiority of immune response in participants 12 to
15 years of age compared to participants 16 to 25 years of age, the other immunogenicity
objectives will be evaluated descriptively by GMT, GMC, GMFR, percentage of participants
with ≥4-fold rise, percentage of participants with ≥ specified threshold, and GMC ratio, and
the associated 95% confidence intervals (CIs), for SARS-CoV-2 neutralizing titers,
S1-binding IgG levels, and/or RBD-binding IgG levels at the various time points.
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014077
Page 24
Protocol C4591001
1.2. Schema
Phase 1 For each vaccine candidate (4:1 randomization active:placebo)
Age: 18-55 y Age: 65-85 y

Low-dose-level 2-dose group (n=15)
IRC (safety) IRC (safety Low-dose-level 2-dose group (n=15)
after Dose 1)
Mid-dose-level 2-dose group (n=15)
IRC (safety) IRC (safety Mid-dose-level 2-dose group (n=15)

after Dose 1)
High-dose-level 2-dose group (n=15)
IRC (safety High-dose-level 2-dose group (n=15)

after Dose 1)
IRC choice of group(s) for Phase 2/3

(safety & immunogenicity after Doses 1 and 2)
Phase 2/3 Single vaccine candidate (1:1 randomization active:placebo)

Safety and immunogenicity analysis of Age: ≥12
Phase 2 data (first 360 participants) (Stratified 12-15, 16-55, or >55)
by unblinded team (these participants BNT162b2 30 µg or placebo 2 doses
will also be included in Phase 3 (n~21,999 per group, total n~43.998)
analyses)
Abbreviation: IRC = internal review committee.
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014078
Page 25
Protocol C4591001
1.3. Schedule of Activities

The SoA table provides an overview of the protocol visits and procedures. Refer to the STUDY ASSESSMENTS AND
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the
protocol.
The investigator may schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or
assessments required to protect the well-being of the participant.
1.3.1. Phase 1
An unplanned potential COVID-19 illness visit and unplanned potential COVID-19 convalescent visit are required at any time
between Visit 1 (Vaccination 1) and Visit 10 (24-month follow-up visit) that COVID-19 is suspected.
Visit Number Screening 1 2 3 4 5 6 7 8 9 10 Unplanned Unplanned

Visit Description Screening Vax 1 Next- 1-Week Vax 2 1-Week 2-Week 1-Month 6-Month 12- 24- Potential Potential
Day Follow- Follow- Follow- Follow- Follow- Month Month COVID-19 COVID-19
Follow- up Visit up Visit up Visit up Visit up Visit Follow- Follow- Illness Convalescent
up Visit (Vax 1) (Vax 2) (Vax 2) up Visit up Visit Visita Visit
(Vax 1)
Visit Window (Days) 0 to 28 Day 1 1 to 3 6 to 8 19 to 23 6 to 8 12 to 16 28 to 35 175 to 350 to 714 to Optimally 28 to 35 Days
Days Days Days Days Days Days Days 189 Days 378 Days 742 Days Within 3 After
Before After After After After After After After After After Days After Potential
Visit 1 Visit 1 Visit 1 Visit 1 Visit 4 Visit 4 Visit 4 Visit 4 Visit 4 Visit 4 Potential COVID-19
COVID-19 Illness Visit
Illness
Onset
Obtain informed consent X
Assign participant number X
Obtain demography and X
medical history data
Obtain details of medications X
currently taken
Perform physical examination X X X X X X X
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014079
Page 26
Protocol C4591001

(Vax 1)
Illness
Onset
Measure vital signs X X X X X X X
(including body temperature)
Collect blood sample for ~10 mL ~10 mL ~10 mL ~10 mL ~10 mL
hematology and chemistry
laboratory testsb
Collect screening blood ~10 mL
sample for HIV, HBsAg,
HBc Ab, and HCV Ab tests
Serological test for prior ~20 mL
COVID-19 infection
Perform urine pregnancy test X X X
(if appropriate)
Obtain nasal (midturbinate) X X X
swab(s)c
Collect nonstudy vaccine X X X X X X X X X
information
Confirm eligibility X X X
Collect prohibited medication X X X X X X X X X X X
use
Review hematology and X X X X X
chemistry results
Review temporary delay X X
criteria
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014080
Page 27
Protocol C4591001

(Vax 1)
Illness
Onset
Confirm use of contraceptives X X X X X X X X
(if appropriate)
Obtain randomization number X
and study intervention
allocation
Collect blood sample for ~50 mL ~50 mL ~50 mL ~50 mL ~50 mL ~50 mL ~20 mL ~20 mL ~20 mL ~20 mL
immunogenicity assessment + + +
optionale optionale optionale
~170 mL ~170 mL ~170 mL
Administer study intervention X X
Assess acute reactions for at X X
least 30 minutes after study
intervention administrationd
Explain participant X
communication methods
(including for e-diary
completion), assist the
participant with downloading
the app, or issue provisioned
device, if required
Provide thermometer and X X
measuring device
Review reactogenicity e-diary
data (daily review is optimal
during the active diary period)
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014081
Page 28
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
reactogenicity e-diary
symptoms and obtain stop
dates
Collect AEs and SAEs as X X X X X X X X X X X X X
appropriate
Collect e-diary or assist the X
participant to delete
application
CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014082
Page 29
Protocol C4591001

(Vax 1)
Illness
Onset
Collection of X X
COVID-19–related clinical
and laboratory information
(including local diagnosis)
Abbreviations: e-diary = electronic diary; HBc Ab = hepatitis B core antibody; HBsAg = hepatitis B surface antigen; HCV Ab = hepatitis C virus antibody;
HIV = human immunodeficiency virus; NAAT = nucleic acid amplification test; vax = vaccination.
a. The COVID-19 illness visit may be conducted as an in-person or telehealth visit.
b. Hematology: hemoglobin, complete blood count with differential, and platelets. Blood chemistry: alanine aminotransferase (ALT), aspartate
aminotransferase (AST), alkaline phosphatase, total bilirubin, blood urea nitrogen (BUN), and creatinine.
c. Two swabs will be taken at Visits 1 and 4. One will be tested (if possible at the site, otherwise at the central laboratory) within 24 hours and vaccination will
only proceed if it is NAAT-negative for SARS-CoV-2 genomes. The second will be sent to the central laboratory for potential later testing.
d. The first 5 participants in in each group will be observed at the site for at least 4 hours after study intervention administration. Further vaccination will
commence no sooner than 24 hours after the fifth participant received his or her vaccination.
e. An optional blood draw of ~170 mL will be taken at 1 of the visits (from selected participants who consent) for exploratory COVID-19 research.
CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014083
Page 30
Protocol C4591001
1.3.2. Phase 2/3

between Visit 1 (Vaccination 1) and Visit 6 (24-month follow-up visit) that potential COVID-19 symptoms are reported, including
MIS-C.
Visit Number 1 2 3 4 5 6 Unplanned Unplanned

Visit Description Vaccination 1 Vaccination 2 1-Month 6-Month 12-Month 24-Month Potential Potential
Follow-up Follow-up Follow-up Follow-up COVID-19 COVID-19
Visit Visit Visit Visit Illness Visita Convalescent
Visit
Visit Window (Days) Day 1b 19 to 23 Days 28 to 35 Days 175 to 189 350 to 378 714 to 742 Optimally 28 to 35 Days
After Visit 1 After Visit 2 Days After Days After Days After Within 3 After
Visit 2 Visit 2 Visit 2 Days After Potential
Potential COVID-19
Illness Onset
Obtain demography and medical history data X
c X
Perform clinical assessment
For participants who are HIV-positive, record latest X X X X X
CD4 count and HIV viral load
Measure height and weight X
Measure temperature (body) X X
Perform urine pregnancy test (if appropriate) X X
Confirm use of contraceptives (if appropriate) X X X
Collect nonstudy vaccine information X X X X
Collect prohibited medication use X X X X X X X
Confirm eligibility X X
Review temporary delay criteria X X
Collect blood sample for immunogenicity ~20 mL/ ~20 mL/ ~20 mL/ ~20 mL/ ~20 mL/ ~20 mL/
assessmentd ~10 mL ~10 mL ~10 mL ~10 mL ~10 mL ~10 mL
Obtain nasal (midturbinate) swab X X X
CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014084
Page 31
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
Obtain randomization number and study X
intervention allocation
Assess acute reactions for at least 30 minutes after X X
study intervention administration
Explain participant communication methods X
(including for e-diary completion), assist the
participant with downloading the app, or issue
provisioned device, if required
Provide/ensure the participant has a thermometer X X
(all participants) and measuring device
(reactogenicity subset participants only)
Review reactogenicity e-diary data (daily review is
optimal during the active diary period)e
Review ongoing reactogenicity e-diary symptoms X X
and obtain stop datese
Collect AEs and SAEs as appropriate X X X Xf Xf Xf X Xf
Collect e-diary or assist the participant to delete X
application
CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014085
Page 32
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
Collection of COVID-19–related clinical and X X
laboratory information (including local diagnosis)
Abbreviations: HIV = human immunodeficiency virus; e-diary = electronic diary.
b. The visit may be conducted across 2 consecutive days; if so, all steps from assessing the inclusion and exclusion criteria onwards must be conducted on the
same day.
c. Including, if indicated, a physical examination.
d. 20 mL is to be collected from participants ≥16 years of age; 10 mL is to be collected from participants 12 to 15 years of age.
e. Reactogenicity subset participants only.
f. Any AEs occurring up to 48 hours after the blood draw must be recorded (see Section 8.3.1).
CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014086
Page 33
Protocol C4591001
2. INTRODUCTION
The BNT162 RNA-based COVID-19 vaccines are currently being investigated for
prevention of COVID-19 in healthy individuals.
2.1. Study Rationale

The purpose of the study is to rapidly describe the safety, tolerability, and immunogenicity of
2 BNT162 RNA-based COVID-19 vaccine candidates against COVID-19, and the efficacy
of 1 candidate, in healthy individuals. There are currently no licensed vaccines to prevent
infection with SARS-CoV-2 or COVID-19. Given the global crisis of COVID-19 and fast
expansion of the disease in the United States and elsewhere, the rapid development of an
effective vaccine is of utmost importance.
2.2. Background
In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China.
In January 2020, it became clear that a novel coronavirus (2019-nCoV) was the underlying
cause. Later in January, the genetic sequence of the 2019-nCoV became available to the
World Health Organization (WHO) and public (MN908947.3), and the virus was categorized
in the Betacoronavirus subfamily. By sequence analysis, the phylogenetic tree revealed a
closer relationship to severe acute respiratory syndrome (SARS) virus isolates than to another
coronavirus infecting humans, the Middle East respiratory syndrome (MERS) virus.
SARS-CoV-2 infections and the resulting disease, COVID-19, have spread globally,
affecting a growing number of countries.
On 11 March 2020, the WHO characterized the COVID-19 outbreak as a pandemic.1

The WHO Situation Update Report dated 30 March 2020 noted 693,224 confirmed cases
with 33,106 deaths globally, including 142,081 confirmed cases with 2457 deaths in the
Americas.2 The United States currently has the most reported cases globally. At the time of
this communication, the number of confirmed cases continues to rise globally. There are
currently no vaccines or effective antiviral drugs to treat SARS-CoV-2 infections or the
disease it causes, COVID-19.3
A prophylactic, RNA-based SARS-CoV-2 vaccine provides one of the most flexible and
fastest approaches available to immunize against the emerging virus.4,5
The development of an RNA-based vaccine encoding a viral antigen, which is then expressed
by the vaccine recipient as a protein capable of eliciting protective immune responses,
provides significant advantages over more traditional vaccine approaches. Unlike live
attenuated vaccines, RNA vaccines do not carry the risks associated with infection and may
be given to people who cannot be administered live virus (eg, pregnant women and
immunocompromised persons). RNA-based vaccines are manufactured via a cell-free in
vitro transcription process, which allows an easy and rapid production and the prospect of
producing high numbers of vaccination doses within a shorter time period than achieved with
CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014087
Page 34
Protocol C4591001
traditional vaccine approaches. This capability is pivotal to enable the most effective
response in outbreak scenarios.
Two SARS-CoV-2–RNA lipid nanoparticle (RNA-LNP) vaccines based on a platform of

nucleoside-modified messenger RNA (modRNA, BNT162b) will be evaluated in this study.
Each vaccine candidate expresses 1 of 2 antigens: the SARS-CoV-2 full-length, P2 mutant,
prefusion spike glycoprotein (P2 S) (version 9) or a trimerized SARS-CoV-2 spike
glycoprotein-receptor binding domain (RBD) (version 5). The 2 SARS-CoV-2 vaccine
candidates that will be tested in this study are therefore:
 BNT162b1 (variant RBP020.3): nucleoside-modified messenger RNA (modRNA)

with blunted innate immune sensor–activating capacity and augmented expression
encoding the RBD.
 BNT162b2 (variant RBP020.2): nucleoside-modified messenger RNA (modRNA) as

above, but encoding P2 S.
The vaccine candidate selected for Phase 2/3 evaluation is BNT162b2.
2.2.1. Clinical Overview

Prior to this study, given clinical data from other similarly formulated uRNA liposomal
vaccines from BioNTech in oncology trials6 and recent published results from clinical trials
using modRNA influenza vaccines by Moderna,7 the BNT162 vaccines were expected to
have a favorable safety profile with mild, localized, and transient effects. BNT162 vaccines
based on modRNA have now been administered to humans for the first time in this study and
the BNT162-01 study conducted in Germany by BioNTech, at doses between 1 µg and
100 µg. The currently available safety and immunogenicity data are presented in the BNT162
IB.
2.3. Benefit/Risk Assessment

There is an ongoing global pandemic of COVID-19 with no preventative or therapeutic
options available. While there were no data available from clinical trials on the use of
BNT162 vaccines in humans at the outset of this study, available nonclinical data with these
vaccines, and data from nonclinical studies and clinical trials with the same or related RNA
components, or antigens, supported a favorable risk/benefit profile. Anticipated AEs after
vaccination were expected to be manageable using routine symptom-driven standard of care
as determined by the investigators and, as a result, the profile of these vaccine candidates
supported initiation of this Phase 1/2/3 clinical study.
Updates as part of protocol amendment 6:
 In order for the overall Phase 3 study population to be as representative and

diverse as possible, the inclusion of participants with known chronic stable HIV,
HCV, or HBV infection is permitted. Individuals with chronic viral diseases are at
increased risk for COVID-19 complications and severe disease. In addition, with
CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014088
Page 35
Protocol C4591001
the currently available therapies for their treatment, many individuals with chronic
stable HIV, HCV, and HBV infections are unlikely to be at higher safety risk as a
participant in this vaccine study than individuals with other chronic stable medical
conditions.
 All participants with chronic stable HIV disease will be included in the
reactogenicity subset (see Section 8.2.2).
 The minimum age for inclusion in Phase 3 is lowered to 12 years, therefore

allowing the inclusion of participants 12 to 15 years of age.
 For individuals 12 to 15 years of age, the immune responses in this age group may
be higher and reactogenicity is expected to be similar to younger adults 18 to 25
years of age. Inclusion of individuals 12 to 15 years of age was based upon a
satisfactory blinded safety profile in participants 18 to 25 years of age.
 All participants 12 to 15 years of age will be included in the reactogenicity subset

(see Section 8.2.2).
More detailed information about the known and expected benefits and risks and reasonably
expected AEs of BNT162 RNA-based COVID-19 vaccines may be found in the IB, which is
the SRSD for this study.
CONFIDENTIAL
Page 36
FDA-CBER-2021-5683-0014089
Page 36
Protocol C4591001
2.3.1. Risk Assessment

Potential Risk of Clinical Summary of Data/Rationale for Risk Mitigation Strategy
Significance
Study Intervention: BNT162 RNA-Based COVID-19 Vaccine
Potential for local reactions (injection These are common adverse reactions seen The Phase 1 study design includes the use of controlled vaccination and
site redness, injection site swelling, with other vaccines, as noted in the FDA dose escalation to closely monitor and limit the rate of enrollment to ensure
and injection site pain) and systemic Center for Biologics Evaluation and participant safety. The study employs the use of a reactogenicity e-diary to
events (fever, fatigue, headache, Research (CBER) guidelines on toxicity monitor local reactions and systemic events in real time. Stopping rules are
chills, vomiting, diarrhea, muscle grading scales for healthy adult volunteers also in place. The first 5 participants in each group in Phase 1 will be
pain, and joint pain) following enrolled in preventive vaccine clinical observed for 4 hours after vaccination to assess any immediate AEs. All
vaccination. trials.8 other participants will be observed for at least 30 minutes after vaccination.
Unknown AEs and laboratory This study is one of the first 2 The Phase 1 study design includes the use of controlled vaccination and
abnormalities with a novel vaccine. parallel-running clinical studies with the dose escalation to closely monitor and limit the rate of enrollment to ensure
BNT162 vaccine candidates and as such participant safety. An IRC (in Phase 1) and DMC (throughout the study)
there are no clinical data available for this will also review safety data. Stopping rules are also in place. The first 5
vaccine. participants in each group in Phase 1 will be observed for 4 hours after
vaccination to assess any immediate AEs. All other participants will be
observed for at least 30 minutes after vaccination.
Potential for COVID-19 Disease enhancement has been seen Phase 1 excludes participants with likely previous or current COVID-19. In
enhancement. following vaccination with respiratory Phase 2/3, temporary delay criteria defer vaccination of participants with
syncytial virus (RSV), feline coronavirus, symptoms of potential COVID-19. All participants are followed for any
and Dengue virus vaccines. potential COVID-19 illness, including markers of severity, and have blood
samples taken for potential measurement of SARS-CoV-2 antigen-specific
antibody and SARS-CoV-2 neutralizing titers.
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014090
Page 37
Protocol C4591001

Significance
Study Procedures
Participants will be required to attend Without appropriate social distancing and Pfizer will work with sites to ensure an appropriate COVID-19 prevention
healthcare facilities during the global PPE, there is a potential for increased strategy. Potential COVID-19 illness visits can be conducted via telehealth,
SARS-CoV-2 pandemic. exposure to SARS-CoV-2. without the need for an in-person visit, if required, with the participant
performing a self-swab.
Venipuncture will be performed There is the risk of bleeding, bruising, Only appropriately qualified personnel would obtain the blood draw.
during the study. hematoma formation, and infection at the
venipuncture site.
CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014091
Page 38
Protocol C4591001
2.3.2. Benefit Assessment

Benefits to individual participants may include:
 Receipt of a potentially efficacious COVID-19 vaccine during a global pandemic
 Access to COVID-19 diagnostic testing
 Contributing to research to help others in a time of global pandemic
2.3.3. Overall Benefit/Risk Conclusion

Taking into account the measures taken to minimize risk to participants participating in this
study, the potential risks identified in association with BNT162 RNA-based COVID-19
vaccine are justified by the anticipated benefits that may be afforded to healthy participants.
3. OBJECTIVES, ESTIMANDS, AND ENDPOINTS

3.1. For Phase 1
dose  SAEs

after Dose 2
CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014092
Page 39
Protocol C4591001

intervention: 7 and 21 days after Dose
1; 7 and 14 days and 1, 6, 12, and 24
months after Dose 2
each time point
vaccination
 Geometric mean concentrations S1-binding IgG levels and RBD-

(GMCs) at each time point binding IgG levels
 GMFR from prior to first dose of
study intervention to each
subsequent time point

estimated by the ratio of the
geometric mean of SARS-CoV-2  S1-binding IgG levels
neutralizing titers to the geometric  RBD-binding IgG levels
mean of binding IgG levels at
each time point
CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014093
Page 40
Protocol C4591001
3.2. For Phase 2/3

Primary Efficacy
infection
Primary Safety

the second dose  AEs
after the second dose fatigue, headache, chills,
after the second dose worsened muscle pain, and
after the second dose  AEs
 SAEs from Dose 1 to 6  SAEs
months after the second dose
CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014094
Page 41
Protocol C4591001

Secondary Efficacy
infection
confirmed severe COVID-19 participants) follow-up in participants with no
occurring from 7 days and from 14  at least 7 days serological or virological evidence (up
days after the second dose in and to 7 days and up to 14 days after
participants without evidence of  at least 14 days receipt of the second dose) of past
infection before vaccination after receipt of the second dose of SARS-CoV-2 infection
study intervention:

vaccine to placebo]
confirmed severe COVID-19 participants) follow-up
occurring from 7 days and from 14  at least 7 days
days after the second dose in and
participants with and without  at least 14 days
evidence of infection before after receipt of the second dose of
vaccination study intervention:
vaccine to placebo]
the CDC-defined symptoms)  at least 7 days confirmed NAAT in participants with
occurring from 7 days and from 14 and no serological or virological evidence
days after the second dose in  at least 14 days (up to 7 days and up to 14 days after
participants without evidence of after receipt of the second dose of receipt of the second dose) of past
infection before vaccination study intervention: SARS-CoV-2 infection
vaccine to placebo]
the CDC-defined symptoms)  at least 7 days confirmed NAAT
occurring from 7 days and from 14 and
days after the second dose in  at least 14 days
participants with and without after receipt of the second dose of
evidence of infection before study intervention:
vaccine to placebo]
CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014095
Page 42
Protocol C4591001

vaccination
Exploratory
vaccination
study

confirmed COVID-19
individuals with confirmed stable
HIV disease
“Process 2”b
b. See Section 6.1.1 for description of the manufacturing process.
This protocol will use a group of internal case reviewers to determine whether certain
investigator-reported events meet the definition of disease-related efficacy endpoints, using
predefined endpoint criteria.
For those AEs that are handled as disease-related efficacy endpoints (which may include
death), a DMC will conduct unblinded reviews on a regular basis throughout the trial
(see Section 9.6).
CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014096
Page 43
Protocol C4591001
Any AE that is determined by the internal case reviewers NOT to meet endpoint criteria is
reported back to the investigator site of incidence. Refer to Section 8.3.1.1 for instructions
on how to report any such AE that meets the criteria for seriousness to Pfizer Safety.
4. STUDY DESIGN
4.1. Overall Design
This is a multicenter, multinational, Phase 1/2/3, randomized, placebo-controlled,
individuals.
The study consists of 2 parts. Phase 1: to identify preferred vaccine candidate(s) and dose

The study is observer-blinded, as the physical appearance of the investigational vaccine

candidates and the placebo may differ. The participant, investigator, study coordinator, and
other site staff will be blinded. At the study site, only the dispenser(s)/administrator(s) are
unblinded.
To facilitate rapid review of data in real time, sponsor staff will be unblinded to vaccine
allocation for the participants in Phase 1.
4.1.1. Phase 1
Each group (vaccine candidate/dose level/age group) will comprise 15 participants;
12 participants will be randomized to receive active vaccine and 3 to receive placebo.
For each vaccine candidate/dose level/age group, the following apply:
 Additional safety assessments (see Section 8.2)
CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014097
Page 44
Protocol C4591001
 Controlled enrollment (required only for the first candidate and/or dose level studied):
 No more than 5 participants (4 active, 1 placebo) can be vaccinated on the first

day
 The first 5 participants must be observed by blinded site staff for at least 4 hours
after vaccination for any acute reactions
 Vaccination of the remaining participants will commence no sooner than 24 hours

after the fifth participant received his or her vaccination
 Application of stopping rules
 IRC review of safety data to determine escalation to the next dose level in the 18- to
55-year age cohort:
 Escalation between dose levels will be based on IRC review of at least 7-day
post–Dose 1 safety data in this study and/or the BioNTech study conducted in
Germany (BNT162-01)
 Note that, since both candidates are based upon the same RNA platform, dose
escalation for the second candidate studied may be based upon the safety profile
of the first candidate studied being deemed acceptable at the same, or a higher,
dose level by the IRC
Groups of participants 65 to 85 years of age will not be started until safety data for the RNA
platform have been deemed acceptable at the same, or a higher, dose level in the 18- to
55-year age cohort by the IRC.
In this phase, 13 groups will be studied, corresponding to a total of 195 participants.
The IRC will select 1 vaccine candidate that, in Phase 1, has an established dose level per age
group based on induction of a post–Dose 2 immune response, including neutralizing
antibodies, which is expected to be associated with protection against COVID-19, for
progression into Phase 2/3.
4.1.2. Phase 2/3

On the basis of safety and/or immunogenicity data generated during the course of this study,
and/or the BioNTech study conducted in Germany (BNT162-01), 1 vaccine candidate was
selected to proceed into Phase 2/3. Participants in this phase will be ≥12 years of age,
stratified as follows: 12 to 15 years, 16 to 55 years, or >55 years. The 12- to 15-year stratum
will comprise up to approximately 2000 participants enrolled at selected investigational sites.
It is intended that a minimum of 40% of participants will be in the >55-year stratum.
Commencement of each age stratum will be based upon satisfactory post–Dose 2 safety and
immunogenicity data from the 18- to 55-year and 65- to 85-year age groups in Phase 1,
CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014098
Page 45
Protocol C4591001
respectively. The vaccine candidate selected for Phase 2/3 evaluation is BNT162b2 at a dose
of 30 µg.
Phase 2/3 is event-driven. Under the assumption of a true VE rate of ≥60%, after the second
dose of investigational product, a target of 164 primary-endpoint cases of confirmed
COVID-19 due to SARS-CoV-2 occurring at least 7 days following the second dose of the
primary series of the candidate vaccine will be sufficient to provide 90% power to conclude
true VE >30% with high probability. The total number of participants enrolled in Phase 2/3
may vary depending on the incidence of COVID-19 at the time of the enrollment, the true
underlying VE, and a potential early stop for efficacy or futility.
Assuming a COVID-19 attack rate of 1.3% per year in the placebo group, accrual of 164 first
primary-endpoint cases within 6 months, an estimated 20% nonevaluable rate, and 1:1
randomization, the BNT162b2 vaccine candidate selected for Phase 2/3 is expected to
comprise approximately 21,999 vaccine recipients. This is the number of participants
initially targeted for Phase 2/3 and may be adjusted based on advice from DMC analyses of
case accumulation and the percentage of participants who are seropositive at baseline.
Dependent upon the evolution of the pandemic, it is possible that the COVID-19 attack rate
may be much higher, in which case accrual would be expected to be more rapid, enabling the
study’s primary endpoint to be evaluated much sooner.
The first 360 participants enrolled (180 to active vaccine and 180 to placebo, stratified
equally between 18 to 55 years and >55 to 85 years) will comprise the “Phase 2” portion.
Safety data through 7 days after Dose 2 and immunogenicity data through 1 month after
Dose 2 from these 360 participants will be analyzed by the unblinded statistical team,
reviewed by the DMC, and submitted to appropriate regulatory authorities for review.
Enrollment may continue during this period and these participants would be included in the
efficacy evaluation in the “Phase 3” portion of the study.
In Phase 3, up to approximately 2000 participants, enrolled at selected sites, are anticipated

to be 12 to 15 years of age. Noninferiority of immune response to prophylactic BNT162b2
in participants 12 to 15 years of age to response in participants 16 to 25 years of age will be
assessed based on the GMR of SARS-CoV-2 neutralizing titers using a 1.5-fold margin. A
sample size of 200 evaluable participants (or 250 vaccine recipients) per age group will
provide a power of 90.8% to declare the noninferiority in terms of GMR (lower limit of 95%
CI for GMR >0.67). A random sample of 250 participants from each of the 2 age groups
(12 to 15 years and 16 to 25 years) will be selected as an immunogenicity subset for the
noninferiority assessment.
The initial BNT162b2 was manufactured using “Process 1”; however, “Process 2” was
developed to support an increased scale of manufacture. In the study, each lot of
“Process 2”-manufactured BNT162b2 will be administered to approximately 250 participants
16 to 55 years of age. The safety and immunogenicity of prophylactic BNT162b2 in
individuals 16 to 55 years of age vaccinated with “Process 1” and each lot of “Process 2”
study intervention will be described. A random sample of 250 participants from those
CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014099
Page 46
Protocol C4591001
vaccinated with study intervention produced by manufacturing “Process 1” will be selected

for this descriptive analysis.

4.2. Scientific Rationale for Study Design

Additional surveillance for COVID-19 will be conducted as part of the study, given the
potential risk of disease enhancement. If a participant experiences symptoms, as detailed in
Section 8.13, a COVID-19 illness and subsequent convalescent visit will occur. As part of
these visits, samples (nasal [midturbinate] swab and blood) will be taken for antigen and
antibody assessment as well as recording of COVID-19–related clinical and laboratory
information (including local diagnosis).
Human reproductive safety data are not available for BNT162 RNA-based COVID-19
vaccines, but there is no suspicion of human teratogenicity based on the intended mechanism
of action of the compound. Therefore, the use of a highly effective method of contraception
is required (see Appendix 4).
4.3. Justification for Dose

Because of the requirement for a rapid response to the newly emerged COVID-19 pandemic,
sufficient data were not available to experimentally validate the dose selection and initial
starting dose. Therefore, the original planned starting dose of 10 µg (for both BNT162b1 and
BNT162b2) in this study was based on nonclinical experience with the same RNAs encoding
other viral antigens (such as influenza and HIV antigens). The general safety and
effectiveness of uRNA and modRNA platforms have been demonstrated in oncological
clinical trials with different administration routes (NCT02410733, NCT03871348). Doses of
up to 400 µg total uRNA have been administered IV as RNA lipoplex (RNA-LPX) and doses
of up to 1000 µg total naked modRNA have been administered intratumorally, both without
signs of unpredictable overstimulation of the immune system.
Based on nonclinical data of the RNA components, with other liposomes or in conjunction
with the lipid nanoparticles as will be tested clinically in this study, it was expected that
doses in the 1- to 5-µg range would be immunogenic and induce neutralizing antibodies;
however, it was anticipated that 3- to 10-fold higher doses would likely be required to elicit a
stronger antibody response. Based on previous clinical and nonclinical experience, it was
expected that doses of up to 100 µg would be well tolerated.
Update as part of protocol amendment 2: preliminary experience in this study and the
BioNTech study conducted in Germany (BNT162-01) suggests that, for vaccine candidates
based on the modRNA platform, a dose level between 30 µg and 100 µg warrants
consideration. Therefore, a 50-µg dose level is formally included for BNT162b1 and
BNT162b2.
CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014100
Page 47
Protocol C4591001
Update as part of protocol amendment 3: as data have become available from this study and
the BNT162-01 study in Germany, it was decided:
 To not study the BNT162a1 and BNT162c2 vaccine candidates at this time, so these
candidates have been removed from the protocol; and
 That lower dose levels of BNT162b1 and BNT162b2 warrant consideration.

Therefore, a 20-µg dose level is formally included for both candidates.
Update as part of protocol amendment 4: the 50-µg dose level for BNT162b1 and BNT162b2
is removed and the 100-µg dose level for BNT162b2 is removed; similar dose levels of
BNT162b3 may be studied as for BNT162b1 and BNT162b2.
Update as part of protocol amendment 5: the vaccine candidate selected for Phase 2/3
evaluation is BNT162b2 at a dose of 30 µg. BNT162b3 will not be studied.
4.4. End of Study Definition

A participant is considered to have completed the study if he/she has completed all phases of
the study, including the last visit. Note that participants enrolled in Phase 1 in groups that do
not proceed to Phase 2/3 may be followed for fewer than 24 months (but no less than
6 months after the last vaccination).
The end of the study is defined as the date of last visit of the last participant in the study.
5. STUDY POPULATION
This study can fulfill its objectives only if appropriate participants are enrolled. The
following eligibility criteria are designed to select participants for whom participation in the
study is considered appropriate. All relevant medical and nonmedical conditions should be
taken into consideration when deciding whether a particular participant is suitable for this
protocol.
Prospective approval of protocol deviations to recruitment and enrollment criteria, also

known as protocol waivers or exemptions, is not permitted.
5.1. Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
1. Male or female participants between the ages of 18 and 55 years, inclusive, and 65 and
85 years, inclusive (Phase 1), or ≥12 years (Phase 2/3), at randomization. Note that
participants <18 years of age cannot be enrolled in the EU.
 Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female
(Section 10.4.2) participants.
CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014101
Page 48
Protocol C4591001
Type of Participant and Disease Characteristics:
2. Participants who are willing and able to comply with all scheduled visits, vaccination
plan, laboratory tests, lifestyle considerations, and other study procedures.
3. Healthy participants who are determined by medical history, physical examination

(if required), and clinical judgment of the investigator to be eligible for inclusion in the
study.
Note: Healthy participants with preexisting stable disease, defined as disease not
requiring significant change in therapy or hospitalization for worsening disease during
the 6 weeks before enrollment, can be included. Specific criteria for Phase 3 participants
with known stable infection with human immunodeficiency virus (HIV), hepatitis C virus
(HCV), or hepatitis B virus (HBV) can be found in Section 10.8.
4. Phase 2/3 only: Participants who, in the judgment of the investigator, are at higher risk
for acquiring COVID-19 (including, but not limited to, use of mass transportation,
relevant demographics, and frontline essential workers).
Informed Consent:
5. Capable of giving personal signed informed consent/have parent(s)/legal guardian

capable of giving signed informed consent as described in Appendix 1, which includes
compliance with the requirements and restrictions listed in the ICD and in this protocol.
5.2. Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
1. Other medical or psychiatric condition including recent (within the past year) or active
suicidal ideation/behavior or laboratory abnormality that may increase the risk of study
participation or, in the investigator’s judgment, make the participant inappropriate for the
study.
2. Phases 1 and 2 only: Known infection with human immunodeficiency virus (HIV),
hepatitis C virus (HCV), or hepatitis B virus (HBV).
3. History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the study intervention(s).
4. Receipt of medications intended to prevent COVID-19.
5. Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT

result was not available) or microbiological (based on COVID-19 symptoms/signs and a
positive SARS-CoV-2 NAAT result) diagnosis of COVID-19.
CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014102
Page 49
Protocol C4591001
6. Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of
the following risk factors:
 Hypertension
 Diabetes mellitus
 Chronic pulmonary disease
 Asthma
 Current vaping or smoking
 History of chronic smoking within the prior year
 Chronic liver disease
 Stage 3 or worse chronic kidney disease (glomerular filtration rate
<60 mL/min/1.73 m2)
 Resident in a long-term facility
 BMI >30 kg/m2
 Anticipating the need for immunosuppressive treatment within the next 6 months
7. Phase 1 only: Individuals currently working in occupations with high risk of exposure to
SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
8. Immunocompromised individuals with known or suspected immunodeficiency, as

determined by history and/or laboratory/physical examination.
9. Phase 1 only: Individuals with a history of autoimmune disease or an active autoimmune

disease requiring therapeutic intervention, including but not limited to: systemic or
cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré
syndrome, multiple sclerosis, Sjögren’s syndrome, idiopathic thrombocytopenia purpura,
glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis),
psoriasis, and insulin-dependent diabetes mellitus (type 1).
10. Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.
11. Women who are pregnant or breastfeeding.
Prior/Concomitant Therapy:
12. Previous vaccination with any coronavirus vaccine.
13. Individuals who receive treatment with immunosuppressive therapy, including cytotoxic
agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned
receipt throughout the study. If systemic corticosteroids have been administered short
CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014103
Page 50
Protocol C4591001
term (<14 days) for treatment of an acute illness, participants should not be enrolled into
the study until corticosteroid therapy has been discontinued for at least 28 days before
study intervention administration. Inhaled/nebulized (except for participants in
Phase 1 – see exclusion criterion 14), intra-articular, intrabursal, or topical (skin or eyes)
corticosteroids are permitted.
14. Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids.
15. Receipt of blood/plasma products or immunoglobulin, from 60 days before study

intervention administration or planned receipt throughout the study.
Prior/Concurrent Clinical Study Experience:
16. Participation in other studies involving study intervention within 28 days prior to study
entry and/or during study participation.
17. Previous participation in other studies involving study intervention containing lipid
nanoparticles.
Diagnostic Assessments:
18. Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at
the screening visit.
19. Phase 1 only: Any screening hematology and/or blood chemistry laboratory value that
meets the definition of a ≥ Grade 1 abnormality.
Note: With the exception of bilirubin, participants with any stable Grade 1 abnormalities
(according to the toxicity grading scale) may be considered eligible at the discretion of
the investigator. (Note: A “stable” Grade 1 laboratory abnormality is defined as a report
of Grade 1 on an initial blood sample that remains ≤ Grade 1 upon repeat testing on a
second sample from the same participant.)
20. Phase 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B
core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening
visit.
21. Phase 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of
study intervention.
Other Exclusions:
22. Investigator site staff or Pfizer/BioNTech employees directly involved in the conduct of
the study, site staff otherwise supervised by the investigator, and their respective family
members.
CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014104
Page 51
Protocol C4591001
5.3. Lifestyle Considerations

5.3.1. Contraception
The investigator or his or her designee, in consultation with the participant, will confirm that
the participant has selected an appropriate method of contraception for the individual
participant and his or her partner(s) from the permitted list of contraception methods
(see Appendix 4, Section 10.4.4) and will confirm that the participant has been instructed in
its consistent and correct use. At time points indicated in the SoA, the investigator or
designee will inform the participant of the need to use highly effective contraception
consistently and correctly and document the conversation and the participant’s affirmation in
the participant’s chart (participants need to affirm their consistent and correct use of at least 1
of the selected methods of contraception). In addition, the investigator or designee will
instruct the participant to call immediately if the selected contraception method is
discontinued or if pregnancy is known or suspected in the participant or partner.
5.4. Screen Failures

Screen failures are defined as participants who consent to participate in the clinical study but
are not subsequently randomly assigned to study intervention. A minimal set of screen
failure information is required to ensure transparent reporting of screen failure participants to
meet the CONSORT publishing requirements and to respond to queries from regulatory
authorities. Minimal information includes demography, screen failure details, eligibility

criteria, and any SAE.
Individuals who do not meet the criteria for participation in this study (screen failure) may be
rescreened under a different participant number.
5.5. Criteria for Temporarily Delaying Enrollment/Randomization/Study Intervention

Administration
The following conditions are temporary or self-limiting and a participant may be vaccinated
once the condition(s) has/have resolved and no other exclusion criteria are met.
1. Current febrile illness (body temperature ≥100.4°F [≥38°C]) or other acute illness within
48 hours before study intervention administration. This includes current symptoms that
could represent a potential COVID-19 illness:
 New or increased cough;
 New or increased shortness of breath;
 Chills;
 New or increased muscle pain;
 New loss of taste/smell;
CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014105
Page 52
Protocol C4591001
 Sore throat;
 Diarrhea;
 Vomiting.
2. Receipt of any seasonal or pandemic influenza vaccine within 14 days, or any other
nonstudy vaccine within 28 days, before study intervention administration.
3. Anticipated receipt of any seasonal or pandemic influenza vaccine within 14 days, or any
other nonstudy vaccine within 28 days, after study intervention administration.
4. Receipt of short-term (<14 days) systemic corticosteroids. Study intervention

administration should be delayed until systemic corticosteroid use has been discontinued
for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or
eyes) corticosteroids are permitted.
6. STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s),
placebo, medical device(s), or study procedure(s) intended to be administered to a study
participant according to the study protocol.
COVID-19 in 3 age groups (18 to 55 years of age, 65 to 85 years of age, and ≥12 years of
age [stratified as 12-15, 16-55, or >55 years of age]).
These 2 investigational RNA vaccine candidates, with the addition of saline placebo, are the
3 potential study interventions that may be administered to a study participant:
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg
 Normal saline (0.9% sodium chloride solution for injection)
CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014106
Page 53
Protocol C4591001
6.1. Study Intervention(s) Administered

Intervention Name BNT162b1 BNT162b2 Saline Placebo
(BNT162 RNA-LNP (BNT162 RNA-LNP
vaccine utilizing vaccine utilizing
modRNA) modRNA)
Type Vaccine Vaccine Placebo
Dose Formulation modRNA modRNA Normal saline (0.9%
sodium chloride solution
for injection)
Unit Dose Strength(s) 250 µg/0.5 mL 250 µg/0.5 mL N/A
Dosage Level(s)a 10-, 20-, 30-, 100-µg 10-, 20-, 30-µg N/A
Route of Administration Intramuscular injection Intramuscular injection Intramuscular injection
Use Experimental Experimental Placebo
IMP or NIMP IMP IMP IMP
Sourcing Provided centrally by the Provided centrally by the Provided centrally by the
sponsor sponsor sponsor
Packaging and Labeling Study intervention will be Study intervention will be Study intervention will be
provided in a glass vial as provided in a glass vial as provided in a glass or
open-label supply. Each open-label supply. Each plastic vial as open-label
vial will be labeled as vial will be labeled as supply. Each vial will be
required per country required per country labeled as required per
requirement requirement country requirement
a. Dependent upon safety and/or immunogenicity data generated during the course of this study, or the
BioNTech study conducted in Germany (BNT162-01), it is possible that groups may be started at the next
highest dose, groups may not be started, groups may be terminated early, and/or groups may be added
with dose levels below the lowest stated dose or intermediate between the lowest and highest stated doses.
6.1.1. Manufacturing Process

The scale of the BNT162b2 manufacturing has been increased to support future supply.
BNT162b2 generated using the manufacturing process supporting an increased supply
(“Process 2”) will be administered to approximately 250 participants 16 to 55 years of age,
per lot, in the study. The safety and immunogenicity of prophylactic BNT162b2 in
individuals 16 to 55 years of age vaccinated with material generated using the existing
manufacturing process “Process 1,” and with material from lots generated using the
manufacturing process supporting increased supply, “Process 2,” will be described.
In brief, the process changes relate to the method of production for the DNA template that
RNA drug substance is transcribed from, and the RNA drug substance purification method.
The BNT162b2 drug product is then produced using a scaled-up LNP manufacturing process.
6.1.2. Administration
Participants will receive 1 dose of study intervention as randomized at each vaccination visit
(Visits 1 and 4 for Phase 1 participants, Visits 1 and 2 for Phase 2/3 participants) in
accordance with the study’s SoA. The volume to be administered may vary by vaccine
candidate and dose level; full details are described in the IP manual.
CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014107
Page 54
Protocol C4591001
Study intervention should be administered intramuscularly into the deltoid muscle, preferably
of the nondominant arm, by an unblinded administrator.
Standard vaccination practices must be observed and vaccine must not be injected into blood
vessels. Appropriate medication and other supportive measures for management of an acute
hypersensitivity reaction should be available in accordance with local guidelines for standard
immunization practices.
Administration of study interventions should be performed by an appropriately qualified,

GCP-trained, and vaccine-experienced member of the study staff (eg, physician, nurse,
physician’s assistant, nurse practitioner, pharmacist, or medical assistant) as allowed by
local, state, and institutional guidance.
Study intervention administration details will be recorded on the CRF.
6.2. Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have been
maintained during transit for all study interventions received and any discrepancies are
reported and resolved before use of the study intervention.
2. Only participants enrolled in the study may receive study intervention and only
authorized site staff may supply or administer study intervention. All study interventions
must be stored in a secure, environmentally controlled, and monitored (manual or
automated recording) area in accordance with the labeled storage conditions with access
limited to the investigator and authorized site staff. At a minimum, daily minimum and
maximum temperatures for all site storage locations must be documented and available
upon request. Data for nonworking days must indicate the minimum and maximum
temperatures since previously documented for all site storage locations upon return to
business.
3. Any excursions from the study intervention label storage conditions should be reported to
Pfizer upon discovery along with any actions taken. The site should actively pursue
options for returning the study intervention to the storage conditions described in the
labeling, as soon as possible. Once an excursion is identified, the study intervention must
be quarantined and not used until Pfizer provides permission to use the study
intervention. Specific details regarding the definition of an excursion and information the
site should report for each excursion will be provided to the site in the IP manual.
4. Any storage conditions stated in the SRSD will be superseded by the storage conditions
stated on the label.
5. Study interventions should be stored in their original containers.
6. See the IP manual for storage conditions of the study intervention.
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014108
Page 55
Protocol C4591001
7. The investigator, institution, or the head of the medical institution (where applicable) is
responsible for study intervention accountability, reconciliation, and record maintenance
(ie, receipt, reconciliation, and final disposition records), such as the IPAL or
sponsor-approved equivalent. All study interventions will be accounted for using a study
intervention accountability form/record.
8. Further guidance and information for the final disposition of unused study interventions
are provided in the IP manual. All destruction must be adequately documented. If
destruction is authorized to take place at the investigator site, the investigator must ensure
that the materials are destroyed in compliance with applicable environmental regulations,
institutional policy, and any special instructions provided by Pfizer.
Upon identification of a product complaint, notify the sponsor within 1 business day of
discovery as described in the IP manual.
6.2.1. Preparation and Dispensing
See the IP manual for instructions on how to prepare the study intervention for
administration. Study intervention should be prepared and dispensed by an appropriately
qualified and experienced member of the study staff (eg, physician, nurse, physician’s
assistant, nurse practitioner, pharmacy assistant/technician, or pharmacist) as allowed by

local, state, and institutional guidance. A second staff member will verify the dispensing.
Study intervention and placebo will be prepared by qualified unblinded site personnel
according to the IP manual. The study intervention will be administered in such a way to
ensure the participants remain blinded.
6.3. Measures to Minimize Bias: Randomization and Blinding

6.3.1. Allocation to Study Intervention
Allocation (randomization) of participants to vaccine groups will proceed through the use of
an IRT system (IWR). The site personnel (study coordinator or specified designee) will be
required to enter or select information including but not limited to the user’s ID and
password, the protocol number, and the participant number. The site personnel will then be
provided with a vaccine assignment and randomization number. The IRT system will
provide a confirmation report containing the participant number, randomization number, and
study intervention allocation assigned. The confirmation report must be stored in the site’s
files.
The study-specific IRT reference manual and IP manual will provide the contact information
and further details on the use of the IRT system.
6.3.2. Blinding of Site Personnel

In this observer blinded study, the study staff receiving, storing, dispensing, preparing, and
administering the study interventions will be unblinded. All other study and site personnel,
CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014109
Page 56
Protocol C4591001
including the investigator, investigator staff, and participants, will be blinded to study
intervention assignments. In particular, the individuals who evaluate participant safety will
be blinded. Because the BNT162 RNA-based COVID-19 vaccine candidates and placebo
are different in physical appearance, the study intervention syringes will be administered in a
manner that prevents the study participants from identifying the study intervention type based
on its appearance.
The responsibility of the unblinded dispenser and administrator must be assigned to an

individual or individuals who will not participate in the evaluation of any study participants.
Contact between the unblinded dispenser and study participants and unblinded administrator
and study participants should be kept to a minimum. The remaining site personnel must not
know study intervention assignments.
6.3.3. Blinding of the Sponsor

To facilitate rapid review of data in real time, sponsor staff will be unblinded to study
intervention allocation for the participants in Phase 1. The majority of sponsor staff will be
blinded to study intervention allocation in Phase 2/3. All laboratory testing personnel
performing serology assays will remain blinded to study intervention assigned/received
throughout the study. The following sponsor staff, who will have no part in the blinded
conduct of the study, will be unblinded in Phase 2/3 (further details will be provided in a data
blinding plan):
 Those study team members who are involved in ensuring that protocol requirements
for study intervention preparation, handling, allocation, and administration are
fulfilled at the site will be unblinded for the duration of the study (eg, unblinded study
manager, unblinded clinical research associate).
 Unblinded clinician(s), who are not direct members of the study team and will not
participate in any other study-related activities, will review unblinded protocol
deviations.
 An unblinded team supporting interactions with, and analyses for, the DMC
(see Section 9.6). This will comprise a statistician, programmer(s), a clinical
scientist, and a medical monitor who will review cases of severe COVID-19 as they
are received, and will review AEs at least weekly for additional potential cases of
severe COVID-19 (see Section 8.2.3).
 An unblinded submissions team will be responsible for preparing unblinded analyses

and documents to support regulatory activities that may be required while the study is
ongoing. This team will only be unblinded at the group level and not have access to
individual participant assignments. The programs that produce the summary tables
will be developed and validated by the blinded study team, and these programs will
be run by the unblinded DMC team. The submissions team will not have access to
unblinded COVID-19 cases unless efficacy is achieved in either an interim analysis or
the final analysis, as determined by the DMC.
CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014110
Page 57
Protocol C4591001
6.3.4. Breaking the Blind

The IRT will be programmed with blind-breaking instructions. In case of an emergency, the
investigator has the sole responsibility for determining if unblinding of a participant’s study
intervention assignment is warranted. Participant safety must always be the first
consideration in making such a determination. If the investigator decides that unblinding is
warranted, the investigator should make every effort to contact the sponsor prior to
unblinding a participant’s vaccine assignment unless this could delay further management of
the participant. If a participant’s vaccine assignment is unblinded, the sponsor must be
notified within 24 hours after breaking the blind. The date and reason that the blind was
broken must be recorded in the source documentation and CRF.
6.4. Study Intervention Compliance

When participants are dosed at the site, they will receive study intervention directly from the
investigator or designee, under medical supervision. The date and time of each dose
administered in the clinic will be recorded in the source documents and recorded in the CRF.
The dose of study intervention and study participant identification will be confirmed at the
time of dosing by a member of the study site staff other than the person administering the
study intervention.
6.5. Concomitant Therapy

The following concomitant medications and vaccinations will be recorded in the CRF:
 All vaccinations received from 28 days prior to study enrollment until the 6-month
follow-up visit (Visit 8 for Phase 1 participants, and Visit 4 for Phase 2/3
participants).
 Prohibited medications listed in Section 6.5.1 will be recorded, to include start and
stop dates, name of the medication, dose, unit, route, and frequency.
 In addition, for participants enrolled in Phase 1, all current medication at baseline will
be recorded, to include start date, name of the medication, dose, unit, route, and
frequency.
6.5.1. Prohibited During the Study

Receipt of the following vaccines and medications during the time periods listed below may
exclude a participant from the per-protocol analysis from that point onwards, and may
require vaccinations to be discontinued in that participant; however, it is anticipated that the
participant would not be withdrawn from the study (see Section 7). Medications should not
be withheld if required for a participant’s medical care.
CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014111
Page 58
Protocol C4591001
Unless considered medically necessary, no vaccines other than study intervention should be
administered within 28 days before and 28 days after each study vaccination. One exception
to this is that seasonal and pandemic influenza vaccine can be given at least 14 days after, or
at least 14 days prior to, the administration of study intervention.
Receipt of chronic systemic treatment with known immunosuppressant medications, or

radiotherapy, within 60 days before enrollment through conclusion of the study.
Receipt of systemic corticosteroids (≥20 mg/day of prednisone or equivalent) for ≥14 days is
prohibited from 28 days prior to enrollment to Visit 7 for Phase 1 participants, and Visit 3 for
Phase 2/3 participants).
Receipt of inhaled/nebulized corticosteroids from 28 days prior to enrollment to Visit 7

(1-month follow-up visit) for Phase 1 participants.
Receipt of blood/plasma products or immunoglobulins within 60 days before enrollment

through conclusion of the study.
Receipt of any other (nonstudy) coronavirus vaccine at any time prior to or during study
participation is prohibited.
Prophylactic antipyretics and other pain medication to prevent symptoms associated with
study intervention administration are not permitted. However, if a participant is taking a
medication for another condition, even if it may have antipyretic or pain-relieving properties,
it should not be withheld prior to study vaccination.
6.5.2. Permitted During the Study

The use of antipyretics and other pain medication to treat symptoms associated with study
intervention administration or ongoing conditions is permitted.
Medication other than that described as prohibited in Section 6.5.1 required for treatment of
preexisting stable conditions is permitted.
Inhaled (except in Phase 1 participants – see Section 6.5.1), topical, or localized injections of
corticosteroids (eg, intra-articular or intrabursal administration) are permitted.
6.6. Dose Modification

This protocol allows some alteration of vaccine dose for individual participants and/or dose
groups from the currently outlined dosing schedule. For reasons of reactogenicity,
tolerability, or safety, the IRC may recommend to reduce the second dose of study
intervention and/or increase the interval between doses.
If, due to a medication error, a participant receives 1 dose of BNT162b2 at Visit 1 and 1 dose
of placebo at Visit 2 (or vice versa), the participant should be offered the possibility to
receive a second dose of BNT162b2 at an unscheduled visit. In this situation:
CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014112
Page 59
Protocol C4591001
 Obtain informed consent for administration of the additional dose.
 Measure the participant’s body temperature.
 Perform urine pregnancy test on WOCBP as described in Section 8.2.6.
 Discuss contraceptive use as described in Section 10.4.
 Ensure that the participant meets none of the temporary delay criteria as described in
Section 5.5.
 Unblinded site staff member(s) will dispense/administer 1 dose of study intervention

into the deltoid muscle of the preferably nondominant arm. Please refer to the IP
manual for further instruction on this process.
 Blinded site staff must observe the participant for at least 30 minutes after study
intervention administration for any acute reactions. Record any acute reactions
(including time of onset) in the participant’s source documents and on the AE page of
the CRF, and on an SAE form as applicable.
 The participant should continue to adhere to the normal visit schedule but must be
followed for nonserious AEs for 1 month and SAEs for 6 months after the second
dose of BNT162b2. This will require AEs to be elicited either by unscheduled
telephone contact(s) and/or in-person visit(s).
6.7. Intervention After the End of the Study

No intervention will be provided to study participants at the end of the study.

DISCONTINUATION/WITHDRAWAL
7.1. Discontinuation of Study Intervention
In rare instances, it may be necessary for a participant to permanently discontinue study
intervention (definitive discontinuation). Reasons for definitive discontinuation of study
intervention may include the following: AEs; participant request; investigator request;
pregnancy; protocol deviation (including no longer meeting all the inclusion criteria, or
meeting 1 or more exclusion criteria). In general, unless the investigator considers it unsafe
to administer the second dose, or the participant does not wish to receive it, it is preferred
that the second dose be administered. Note that a positive SARS-CoV-2 NAAT result
without symptoms does not meet exclusion criterion 5 and should not result in
discontinuation of study intervention, whereas a COVID-19 diagnosis does meet exclusion
criterion 5 and should result in discontinuation of study intervention (see Section 8.15).
Note that discontinuation of study intervention does not represent withdrawal from the study.
Per the study estimands, if study intervention is definitively discontinued, the participant will
CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014113
Page 60
Protocol C4591001
remain in the study to be evaluated for safety, immunogenicity, and efficacy. See the SoA
for data to be collected at the time of discontinuation of study intervention and follow-up for
any further evaluations that need to be completed.
In the event of discontinuation of study intervention, it must be documented on the

appropriate CRF/in the medical records whether the participant is discontinuing further
receipt of study intervention or also from study procedures, posttreatment study follow-up,
and/or future collection of additional information.
7.2. Participant Discontinuation/Withdrawal From the Study

A participant may withdraw from the study at any time at his/her own request. Reasons for
discontinuation from the study may include the following:
 Refused further follow-up;

 Lost to follow-up;
 Death;
 Study terminated by sponsor;
 AEs;
 Participant request;
 Investigator request;
 Protocol deviation.
If a participant does not return for a scheduled visit, every effort should be made to contact
the participant. All attempts to contact the participant and information received during
contact attempts must be documented in the participant’s source document. In any
circumstance, every effort should be made to document participant outcome, if possible.
The investigator or his or her designee should capture the reason for withdrawal in the CRF
for all participants.
If a participant withdraws from the study, he/she may request destruction of any remaining
samples taken and not tested, and the investigator must document any such requests in the
site study records and notify the sponsor accordingly.
If the participant withdraws from the study and also withdraws consent (see Section 7.2.1)
for disclosure of future information, no further evaluations should be performed and no
additional data should be collected. The sponsor may retain and continue to use any data
collected before such withdrawal of consent.
Lack of completion of all or any of the withdrawal/early termination procedures will not be
viewed as protocol deviations so long as the participant’s safety was preserved.
CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014114
Page 61
Protocol C4591001
7.2.1. Withdrawal of Consent

Participants who request to discontinue receipt of study intervention will remain in the study
and must continue to be followed for protocol-specified follow-up procedures. The only
exception to this is when a participant specifically withdraws consent for any further contact
with him or her or persons previously authorized by the participant to provide this
information. Participants should notify the investigator in writing of the decision to
withdraw consent from future follow-up, whenever possible. The withdrawal of consent
should be explained in detail in the medical records by the investigator, as to whether the
withdrawal is only from further receipt of study intervention or also from study procedures
and/or posttreatment study follow-up, and entered on the appropriate CRF page. In the event
that vital status (whether the participant is alive or dead) is being measured, publicly
available information should be used to determine vital status only as appropriately directed
in accordance with local law.
7.3. Lost to Follow-up

A participant will be considered lost to follow-up if he or she repeatedly fails to return for
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to attend a required study visit:
 The site must attempt to contact the participant and reschedule the missed visit as
soon as possible and counsel the participant on the importance of maintaining the
assigned visit schedule and ascertain whether or not the participant wishes to and/or
should continue in the study;
 Before a participant is deemed lost to follow-up, the investigator or designee must

make every effort to regain contact with the participant (where possible, 3 telephone
calls and, if necessary, a certified letter to the participant’s last known mailing
address or local equivalent methods). These contact attempts should be documented
in the participant’s medical record;
 Should the participant continue to be unreachable, he/she will be considered to have

withdrawn from the study.
8. STUDY ASSESSMENTS AND PROCEDURES

The investigator (or an appropriate delegate at the investigator site) must obtain a signed and
dated ICD before performing any study-specific procedures.
The full date of birth will be collected to critically evaluate the immune response and safety
profile by age.
Study procedures and their timing are summarized in the SoA. Protocol waivers or
exemptions are not allowed.
CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014115
Page 62
Protocol C4591001
Safety issues should be discussed with the sponsor immediately upon occurrence or
awareness to determine whether the participant should continue or discontinue study
intervention.
Adherence to the study design requirements, including those specified in the SoA, is essential
and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential
participants meet all eligibility criteria. The investigator will maintain a screening log to
record details of all participants screened and to confirm eligibility or record reasons for
screening failure, as applicable.
Every effort should be made to ensure that protocol-required tests and procedures are
completed as described. However, it is anticipated that from time to time there may be
circumstances outside the control of the investigator that may make it unfeasible to perform
the test. In these cases, the investigator must take all steps necessary to ensure the safety and
well-being of the participant. When a protocol-required test cannot be performed, the
investigator will document the reason for the missed test and any corrective and preventive
actions that he or she has taken to ensure that required processes are adhered to as soon as
possible. The study team must be informed of these incidents in a timely manner.
For samples being collected and shipped, detailed collection, processing, storage, and
shipment instructions and contact information will be provided to the investigator site prior
to initiation of the study.
The total blood sampling volume for individual participants in this study is approximately up
to: 515 mL for participants in Phase 1, 110 mL for Phase 2/3 participants ≥16 years of age,
and 50 mL for participants in the 12- to 15-year age stratum. Additionally, 20 mL of blood
for participants ≥16 years of age and 10 mL for participants in the 12- to 15-year age stratum
will be taken at an unplanned convalescent visit at any time a participant develops respiratory
symptoms indicating a potential COVID-19 infection. Select participants in Phase 1 will also
be asked to provide an additional blood sample of approximately 170 mL at either Visit 5, 6,
or 7. These participants would therefore have a total blood sampling volume of 700 mL
during the 24-month study period. Other additional blood samples may be taken for safety
assessments at times specified by Pfizer, provided the total volume taken during the study
does not exceed 550 mL during any period of 60 consecutive days.
8.1. Efficacy and/or Immunogenicity Assessments

Efficacy will be assessed throughout a participant’s involvement in the study through
surveillance for potential cases of COVID-19. If, at any time, a participant develops acute
respiratory illness (see Section 8.13), for the purposes of the study he or she will be
considered to potentially have COVID-19 illness.9 In this circumstance, the participant
should contact the site, an in-person or telehealth visit should occur, and assessments should
be conducted as specified in the SoA. The assessments will include a nasal (midturbinate)
swab, which will be tested at a central laboratory using a reverse transcription–polymerase
CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014116
Page 63
Protocol C4591001
chain reaction (RT-PCR) test (Cepheid; FDA approved under EUA), or other equivalent
nucleic acid amplification–based test (ie, NAAT), to detect SARS-CoV-2. In addition,
clinical information and results from local standard-of-care tests (as detailed in Section 8.13)
will be assessed. The central laboratory NAAT result will be used for the case definition,
unless no result is available from the central laboratory, in which case a local NAAT result
may be used if it was obtained using 1 of the following assays:
 Cepheid Xpert Xpress SARS-CoV-2
 Roche cobas SARS-CoV-2 real-time RT-PCR test (EUA200009/A001)
 Abbott Molecular/RealTime SARS-CoV-2 assay (EUA200023/A001)
Two definitions of SARS-CoV-2–related cases, and SARS-CoV-2–related severe cases, will

be considered (for both, the onset date of the case will be the date that symptoms were first
experienced by the participant; if new symptoms are reported within 4 days after resolution
of all previous symptoms, they will be considered as part of a single illness):
 Confirmed COVID-19: presence of at least 1 of the following symptoms and

SARS-CoV-2 NAAT-positive during, or within 4 days before or after, the
symptomatic period, either at the central laboratory or at a local testing facility (using
an acceptable test):
 Fever;
 Chills;
 New loss of taste or smell;
 Sore throat;
 Diarrhea;
 Vomiting.
The second definition, which may be updated as more is learned about COVID-19, will
include the following additional symptoms defined by the CDC (listed at
https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html):
 Fatigue;
CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014117
Page 64
Protocol C4591001
 Headache;
 Nasal congestion or runny nose;
 Nausea.
 Confirmed severe COVID-19: confirmed COVID-19 and presence of at least 1 of the

following:
 Clinical signs at rest indicative of severe systemic illness (RR ≥30 breaths per
minute, HR ≥125 beats per minute, SpO2 ≤93% on room air at sea level, or
PaO2/FiO2 <300 mm Hg);
 Respiratory failure (defined as needing high-flow oxygen, noninvasive

ventilation, mechanical ventilation, or ECMO);
 Evidence of shock (SBP <90 mm Hg, DBP <60 mm Hg, or requiring

vasopressors);
 Significant acute renal, hepatic, or neurologic dysfunction*;

 Admission to an ICU;
 Death.
The DMC may recommend modification of the definition of severe disease according to
emerging information.
* Three blinded case reviewers (medically qualified Pfizer staff members) will review all
potential COVID-19 illness events. If a NAAT-confirmed case in Phase 2/3 may be
considered severe, or not, solely on the basis of this criterion, the blinded data will be
reviewed by the case reviewers to assess whether the criterion is met; the majority opinion
will prevail.
In addition, a serological definition will be used for participants without clinical presentation
of COVID-19:
 Confirmed seroconversion to SARS-CoV-2 without confirmed COVID-19: positive

N-binding antibody result in a participant with a prior negative N-binding antibody
result
Serum samples will be obtained for immunogenicity testing at the visits specified in the SoA.
The following assays will be performed:
 SARS-CoV-2 neutralization assay
CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014118
Page 65
Protocol C4591001
 S1-binding IgG level assay
 RBD-binding IgG level assay
 N-binding antibody assay
Note that all immunogenicity analyses will be based upon samples analyzed at the central
laboratory; the rapid test will only be performed at screening by all sites recruiting
participants in Phase 1 (see Section 8.11.1.1) to determine eligibility.
Serum obtained from the additional ~170-mL blood sample from select participants in Phase
1 at either Visit 5, 6, or 7 will be used for exploratory COVID-19 research, intended to
establish a surrogate endpoint that is reasonably likely to predict clinical benefit.
8.1.1. Biological Samples

Blood and nasal swab samples will be used only for scientific research. Each sample will be
labeled with a code so that the laboratory personnel testing the samples will not know the
participant’s identity. Samples that remain after performing assays outlined in the protocol
may be stored by Pfizer. Unless a time limitation is required by local regulations or ethical
requirements, the samples will be stored for up to 15 years after the end of the study and then
destroyed. If allowed by the ICD, stored samples may be used for additional testing to better
understand the immune responses to the vaccine(s) under study in this protocol, to inform the
development of other products, and/or for vaccine-related assay work supporting vaccine
programs. No testing of the participant’s DNA will be performed.
The participant may request that his or her samples, if still identifiable, be destroyed at any
time; however, any data already collected from those samples will still be used for this
research. The biological samples may be shared with other researchers as long as
confidentiality is maintained and no testing of the participant’s DNA is performed.
8.2. Safety Assessments

Planned time points for all safety assessments are provided in the SoA. Unscheduled clinical
laboratory measurements may be obtained at any time during the study to assess any
perceived safety issues.
A clinical assessment, including medical history, will be performed on all participants at

his/her first visit to establish a baseline. Significant medical history and observations from
any physical examination, if performed, will be documented in the CRF.
AEs and SAEs are collected, recorded, and reported as defined in Section 8.3.
Acute reactions within the first 4 hours after administration of the study intervention (for the
first 5 participants vaccinated in each Phase 1 group), and within the first 30 minutes (for the
remainder of participants), will be assessed and documented in the AE CRF.
CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014119
Page 66
Protocol C4591001
The safety parameters also include reactogenicity e-diary reports of local reactions and
systemic events (including fever), and use of antipyretic medication that occur in the 7 days
after administration of the study intervention in a subset of participants. These prospectively
self-collected occurrences of local reactions and systemic events are graded as described in
Section 8.2.2. For participants who are not in the reactogenicity subset, these local reactions
and systemic events should be detected and reported as AEs, in accordance with
Section 8.3.2.
8.2.1. Clinical Safety Laboratory Assessments (Phase 1 Participants Only)

See Appendix 2 for the list of clinical safety laboratory tests to be performed and the SoA for
the timing and frequency. All protocol-required laboratory assessments, as defined in
Appendix 2, must be conducted in accordance with the laboratory manual and the SoA.
Unscheduled clinical laboratory measurements may be obtained at any time during the study
to assess any perceived safety issues.
The investigator must review the laboratory report, document this review, and record any
clinically relevant changes occurring during the study in the AE section of the CRF. See
Appendix 2 for the grading scale for assessment of clinically significant abnormal laboratory
findings. Clinically significant abnormal laboratory findings are those which are not
associated with the underlying disease, unless judged by the investigator to be more severe
than expected for the participant's condition.
All laboratory tests with values considered clinically significantly abnormal during
participation in the study or within 28 days after the last dose of study intervention should be
repeated until the values return to normal or baseline or are no longer considered clinically
significant by the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by
the investigator, the etiology should be identified and the sponsor notified.
See Appendix 5 for suggested actions and follow-up assessments in the event of potential
drug-induced liver injury (DILI).
8.2.2. Electronic Diary

Participants will be required to complete a reactogenicity e-diary through an application
(see Section 8.14) installed on a provisioned device or on the participant’s own personal
device. All participants in Phase 1, and a subset of at least the first 6000 randomized in
Phase 2/3, will be asked to monitor and record local reactions, systemic events, and
antipyretic medication usage for 7 days following administration of the study intervention.
All participants in Phase 3 who are HIV-positive or 12 to 15 years of age will be included in
this subset. In addition, participants 16 through 17 years of age enrolled under protocol
amendment 9 and onwards will be included in the reactogenicity subset. The reactogenicity
e-diary allows recording of these assessments only within a fixed time window, thus
providing the accurate representation of the participant’s experience at that time. Data on
local reactions and systemic events reported in the reactogenicity e-diary will be transferred
CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014120
Page 67
Protocol C4591001
electronically to a third-party vendor, where they will be available for review by investigators
and the Pfizer clinicians at all times via an internet-based portal.
At intervals agreed to by the vendor and Pfizer, these data will be transferred electronically
into Pfizer's database for analysis and reporting. These data do not need to be reported by the
investigator in the CRF as AEs.
Investigators (or designee) will be required to review the reactogenicity e-diary data online at
frequent intervals as part of the ongoing safety review.
The investigator or designee must obtain stop dates from the participant for any ongoing
local reactions, systemic events, or use of antipyretic medication on the last day that the
reactogenicity e-diary was completed. The stop dates should be documented in the source
documents and the information entered in the CRF.
8.2.2.1. Grading Scales

The grading scales used in this study to assess local reactions and systemic events as
described below are derived from the FDA Center for Biologics Evaluation and Research
(CBER) guidelines on toxicity grading scales for healthy adult volunteers enrolled in
preventive vaccine clinical trials.8
8.2.2.2. Local Reactions

During the reactogenicity e-diary reporting period, participants will be asked to assess
redness, swelling, and pain at the injection site and to record the symptoms in the
reactogenicity e-diary. If a local reaction persists beyond the end of the reactogenicity
e-diary period following vaccination, the participant will be requested to report that
information. The investigator will enter this additional information in the CRF.
Redness and swelling will be measured and recorded in measuring device units
(range: 1 to 21) and then categorized during analysis as absent, mild, moderate, or severe
based on the grading scale in Table 1. Measuring device units can be converted to
centimeters according to the following formula: 1 measuring device unit = 0.5 cm. Pain at
the injection site will be assessed by the participant as absent, mild, moderate, or severe
according the grading scale in Table 1.
If a Grade 3 local reaction is reported in the reactogenicity e-diary, a telephone contact

should occur to ascertain further details and determine whether a site visit is clinically
indicated. Only an investigator or medically qualified person is able to classify a
participant’s local reaction as Grade 4. If a participant experiences a confirmed Grade 4 local
reaction, the investigator must immediately notify the sponsor and, if it is determined to be
related to the administration of the study intervention, further vaccinations will be
discontinued in that participant.
CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014121
Page 68
Protocol C4591001
Table 1. Local Reaction Grading Scale

Mild Moderate Severe Potentially Life
(Grade 1) (Grade 2) (Grade 3) Threatening
(Grade 4)
Pain at the Does not interfere Interferes with Prevents daily activity Emergency room visit
injection site with activity activity or hospitalization for
severe pain
Redness >2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis or
(5 to 10 measuring (11 to 20 measuring (≥21 measuring exfoliative dermatitis
device units) device units) device units)
Swelling >2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis
(5 to 10 measuring (11 to 20 measuring (≥21 measuring
8.2.2.3. Systemic Events

vomiting, diarrhea, headache, fatigue, chills, new or worsened muscle pain, and new or
worsened joint pain and to record the symptoms in the reactogenicity e-diary. The symptoms
will be assessed by the participant as absent, mild, moderate, or severe according to the
grading scale in Table 2.
If a Grade 3 systemic event is reported in the reactogenicity e-diary, a telephone contact

participant’s systemic event as Grade 4. If a participant experiences a confirmed Grade 4
systemic event, the investigator must immediately notify the sponsor and, if it is determined
to be related to the administration of the study intervention, further vaccinations will be
Table 2. Systemic Event Grading Scale

(Grade 4)
Vomiting 1-2 times in >2 times in Requires IV Emergency room visit or
24 hours 24 hours hydration hospitalization for
hypotensive shock
Diarrhea 2 to 3 loose stools 4 to 5 loose stools 6 or more loose Emergency room visit or
in 24 hours in 24 hours stools in 24 hours hospitalization for severe
diarrhea
Headache Does not interfere Some interference Prevents daily Emergency room visit or
with activity with activity routine activity hospitalization for severe
headache
Fatigue/ Does not interfere Some interference Prevents daily Emergency room visit or
tiredness with activity with activity routine activity hospitalization for severe
fatigue
CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014122
Page 69
Protocol C4591001

(Grade 4)
Chills Does not interfere Some interference Prevents daily Emergency room visit or
chills
New or Does not interfere Some interference Prevents daily Emergency room visit or
worsened with activity with activity routine activity hospitalization for severe
muscle pain new or worsened muscle
pain
joint pain new or worsened joint pain
Abbreviation: IV = intravenous.
8.2.2.4. Fever
In order to record information on fever, a thermometer will be given to participants with
instructions on how to measure oral temperature at home. Temperature will be collected in
the reactogenicity e-diary in the evening daily during the reactogenicity e-diary reporting
period. It will also be collected at any time during the reactogenicity e-diary data collection
periods when fever is suspected. Fever is defined as an oral temperature of ≥38.0°C
(100.4°F). The highest temperature for each day will be recorded in the reactogenicity
e-diary. Temperature will be measured and recorded to 1 decimal place and then categorized
during analysis according to the scale shown in Table 3.
If a fever of ≥39.0°C (102.1°F) is reported in the reactogenicity e-diary, a telephone contact

indicated. Only an investigator or medically qualified person is able to confirm a
participant’s fever as >40.0°C (>104.0°F). If a participant experiences a confirmed fever
>40.0°C (>104.0°F), the investigator must immediately notify the sponsor and, if it is
determined to be related to the administration of the study intervention, further vaccinations
will be discontinued in that participant.
Table 3. Scale for Fever

≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)
CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014123
Page 70
Protocol C4591001
8.2.2.5. Antipyretic Medication

The use of antipyretic medication to treat symptoms associated with study intervention
administration will be recorded in the reactogenicity e-diary daily during the reporting period
(Day 1 to Day 7).
8.2.3. Phase 1 Stopping Rules

The following stopping rules are in place for all Phase 1 participants, based on review of AE
data and e-diary reactogenicity data, until the start of Phase 2/3 or 30 days after the last dose
of study intervention in Phase 1, whichever is later. These data will be monitored on an
ongoing basis by the investigator (or medically qualified designee) and sponsor in order to
promptly identify and flag any event that potentially contributes to a stopping rule.
The sponsor study team will be unblinded during Phase 1, so will be able to assess whether
or not a stopping rule has been met on the basis of a participant’s individual study
intervention allocation.
In the event that sponsor personnel confirm that a stopping rule is met, the following actions
will commence:
 The IRC will review all appropriate data.

 The stopping rule will PAUSE randomization and study intervention administration
for the impacted vaccine candidate all dose levels and age groups.
 The DMC will review all appropriate data.
 For all participants vaccinated, all other routine study conduct activities, including
ongoing data entry, reporting of AEs, participant reactogenicity e-diary completion,
blood sample collection, and participant follow-up, will continue during the pause.
A stopping rule is met if any of the following rules occur after administration of
investigational BNT162 vaccine; data from placebo recipients will not contribute to the
stopping rules. Reactogenicity e-diary data confirmed by the investigator as being entered by
the participant in error will not contribute toward a stopping rule.
The BNT162b RNA platform will be evaluated for contribution to stopping rules overall;
vaccine candidate dose levels within the platform and age groups will contribute to stopping
rules together. However, it is possible that the recommendations may include halting or
continuing randomization with any of the BNT162 vaccine candidates.
Stopping Rule Criteria for Each BNT162 Vaccine Candidate:
1. If any participant vaccinated with the BNT162 candidate (at any dose level) develops an
SAE that is assessed by the investigator as possibly related, or for which there is no
alternative, plausible, attributable cause.
CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014124
Page 71
Protocol C4591001
2. If any participant vaccinated with the BNT162 candidate (at any dose level) develops a
Grade 4 local reaction or systemic event after vaccination (see Section 8.2.2) that is
assessed as possibly related by the investigator, or for which there is no alternative,
plausible, attributable cause.
fever >40.0°C (>104.0°F) for at least 1 daily measurement after vaccination
(see Section 8.2.2.4) that is assessed as possibly related by the investigator, or for which
there is no alternative, plausible, attributable cause.
4. If any 2 participants vaccinated with the BNT162 candidate (at any dose level) report the
same or similar severe (Grade 3) AE (including laboratory abnormalities) after
vaccination, assessed as possibly related by the investigator, or for which there is no
5. If any participant dies or requires ICU admission due to SARS-CoV-2 infection; if this
stopping rule is met, all available clinical and preclinical safety and immunogenicity data
should be reviewed to evaluate for enhanced COVID-19.
8.2.4. Surveillance of Events That Could Represent Enhanced COVID-19 and Phase 2/3
Stopping Rule
Participants in all phases of the study will be surveilled for potential COVID-19 illness from
Visit 1 onwards (see Section 8.13).
As this is a sponsor open-label study during Phase 1, the sponsor will conduct unblinded
reviews of the data during the course of the study, including for the purpose of safety
assessment. All NAAT-confirmed cases in Phase 1 will be reviewed contemporaneously by
the IRC and the DMC (see Section 9.6).
In Phase 2/3, the unblinded team supporting the DMC, including an unblinded medical
monitor, will review cases of severe COVID-19 as they are received and will review AEs at
least weekly for additional potential cases of severe COVID-19. At any point, the unblinded
team may discuss with the DMC chair whether the DMC should review cases for an adverse
imbalance of cases of COVID-19 and/or severe COVID-19 between the vaccine and placebo
groups.
The purpose of these reviews will be to identify whether any features of each case appear
unusual, in particular greater in severity, compared to available information at the time of
review. Indicators of severity may include accelerated deterioration, need for hospitalization,
need for ventilation, or death. Observed rates of these indicators will be compared with what
could be expected in a similar population to the study participants based upon available
information at the time of review.
Stopping and alert rules will be applied as follows. The stopping rule will be triggered when
the 1-sided probability of observing the same or a more extreme case split is 5% or less when
the true incidence of severe disease is the same for vaccine and placebo participants, and alert
CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014125
Page 72
Protocol C4591001
criteria are triggered when this probability is less than 11%. In addition, when the total
number of severe cases is low (15 or less), the unblinded team supporting the DMC will
implement the alert rule when a reverse case split of 2:1 or worse is observed. For example,
at 3 cases 2:1, at 4 cases 3:1, etc. Below 15 cases, this rule is more rigorous than requiring
the probability of an observed adverse split or worse be <11%. Further details can be found
in Section 10.7.
8.2.5. Randomization and Vaccination After a Stopping Rule Is Met

Once the IRC (if in Phase 1) and DMC (all phases) have reviewed the safety data and
provided guidance, a notification will be sent from the sponsor to the sites with guidance on
how to proceed.
8.2.6. Pregnancy Testing

Pregnancy tests may be urine or serum tests, but must have a sensitivity of at least
25 mIU/mL. Pregnancy tests will be performed in WOCBP at the times listed in the SoA,
immediately before the administration of each vaccine dose. A negative pregnancy test result
will be required prior to the participant’s receiving the study intervention. Pregnancy tests
may also be repeated if requested by IRBs/ECs or if required by local regulations. In the
case of a positive confirmed pregnancy, the participant will be withdrawn from
administration of study intervention but may remain in the study.
8.3. Adverse Events and Serious Adverse Events

The definitions of an AE and an SAE can be found in Appendix 3.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or
the participant's parent(s)/legal guardian).
The investigator and any qualified designees are responsible for detecting, documenting, and
recording events that meet the definition of an AE or SAE and remain responsible to pursue
and obtain adequate information both to determine the outcome and to assess whether the
event meets the criteria for classification as an SAE or caused the participant to discontinue
the study intervention (see Section 7.1).
Each participant/parent(s)/legal guardian will be questioned about the occurrence of AEs in a

nonleading manner.
In addition, the investigator may be requested by Pfizer Safety to obtain specific follow-up
information in an expedited fashion.
8.3.1. Time Period and Frequency for Collecting AE and SAE Information
The time period for actively eliciting and collecting AEs and SAEs (“active collection
period”) for each participant begins from the time the participant/parent(s)/legal guardian
provides informed consent, which is obtained before the participant’s participation in the
study (ie, before undergoing any study-related procedure and/or receiving study
CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014126
Page 73
Protocol C4591001
intervention), through and including Visit 7 for Phase 1 participants, and Visit 3 for Phase
2/3 participants. In addition, any AEs occurring up to 48 hours after each subsequent blood
draw must be recorded on the CRF.
SAEs will be collected from the time the participant/parent(s)/legal guardian provides
informed consent to approximately 6 months after the last dose of study intervention (Visit 8
for Phase 1 participants, and Visit 4 for Phase 2/3 participants).
Follow-up by the investigator continues throughout and after the active collection period and
until the AE or SAE or its sequelae resolve or stabilize at a level acceptable to the
investigator and Pfizer concurs with that assessment.
For participants who are screen failures, the active collection period ends when screen failure
status is determined.
If the participant withdraws from the study and also withdraws consent for the collection of
future information, the active collection period ends when consent is withdrawn.
If a participant definitively discontinues or temporarily discontinues study intervention

because of an AE or SAE, the AE or SAE must be recorded on the CRF and the SAE
reported using the Vaccine SAE Report Form.
Investigators are not obligated to actively seek AEs or SAEs after the participant has
concluded study participation. However, if the investigator learns of any SAE, including a
death, at any time after a participant has completed the study, and he/she considers the event
to be reasonably related to the study intervention, the investigator must promptly report the
SAE to Pfizer using the Vaccine SAE Report Form.
8.3.1.1. Reporting SAEs to Pfizer Safety

All SAEs occurring in a participant during the active collection period as described in
Section 8.3.1 are reported to Pfizer Safety on the Vaccine SAE Report Form immediately
upon awareness and under no circumstance should this exceed 24 hours, as indicated in
Appendix 3. The investigator will submit any updated SAE data to the sponsor within
24 hours of it being available.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF

All nonserious AEs and SAEs occurring in a participant during the active collection period,
which begins after obtaining informed consent as described in Section 8.3.1, will be recorded
on the AE section of the CRF.
The investigator is to record on the CRF all directly observed and all spontaneously reported
AEs and SAEs reported by the participant.
CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014127
Page 74
Protocol C4591001
8.3.2. Method of Detecting AEs and SAEs

The method of recording, evaluating, and assessing causality of AEs and SAEs and the
procedures for completing and transmitting SAE reports are provided in Appendix 3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and
nonleading verbal questioning of the participant is the preferred method to inquire about
AE occurrences.
8.3.3. Follow-up of AEs and SAEs

After the initial AE/SAE report, the investigator is required to proactively follow each
participant at subsequent visits/contacts. For each event, the investigator must pursue and
obtain adequate information until resolution, stabilization, the event is otherwise explained,
or the participant is lost to follow-up (as defined in Section 7.3).
In general, follow-up information will include a description of the event in sufficient detail to
allow for a complete medical assessment of the case and independent determination of
possible causality. Any information relevant to the event, such as concomitant medications
and illnesses, must be provided. In the case of a participant death, a summary of available
autopsy findings must be submitted as soon as possible to Pfizer Safety.
Further information on follow-up procedures is given in Appendix 3.
8.3.4. Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of an SAE is essential so that legal
obligations and ethical responsibilities towards the safety of participants and the safety of a
study intervention under clinical investigation are met.
The sponsor has a legal responsibility to notify both the local regulatory authority and other
regulatory agencies about the safety of a study intervention under clinical investigation. The
sponsor will comply with country-specific regulatory requirements relating to safety
reporting to the regulatory authority, IRBs/ECs, and investigators.
Investigator safety reports must be prepared for SUSARs according to local regulatory
requirements and sponsor policy and forwarded to investigators as necessary.
An investigator who receives SUSARs or other specific safety information (eg, summary or
listing of SAEs) from the sponsor will review and then file it along with the SRSD(s) for the
study and will notify the IRB/EC, if appropriate according to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure

Exposure to the study intervention under study during pregnancy or breastfeeding and
occupational exposure are reportable to Pfizer Safety within 24 hours of investigator
awareness.
CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014128
Page 75
Protocol C4591001
8.3.5.1. Exposure During Pregnancy

An EDP occurs if:
 A female participant is found to be pregnant while receiving or after discontinuing

study intervention.
 A male participant who is receiving or has discontinued study intervention exposes a

female partner prior to or around the time of conception.
 A female is found to be pregnant while being exposed or having been exposed to

study intervention due to environmental exposure. Below are examples of
environmental exposure during pregnancy:
 A female family member or healthcare provider reports that she is pregnant after
having been exposed to the study intervention by inhalation or skin contact.
 A male family member or healthcare provider who has been exposed to the study
intervention by inhalation or skin contact then exposes his female partner prior to
or around the time of conception.
The investigator must report EDP to Pfizer Safety within 24 hours of the investigator’s
awareness, irrespective of whether an SAE has occurred. The initial information submitted
should include the anticipated date of delivery (see below for information related to
termination of pregnancy).
 If EDP occurs in a participant or a participant’s partner, the investigator must report

this information to Pfizer Safety on the Vaccine SAE Report Form and an EDP
Supplemental Form, regardless of whether an SAE has occurred. Details of the
pregnancy will be collected after the start of study intervention and until 6 months
after the last dose of study intervention.
 If EDP occurs in the setting of environmental exposure, the investigator must report
information to Pfizer Safety using the Vaccine SAE Report Form and EDP
Supplemental Form. Since the exposure information does not pertain to the
participant enrolled in the study, the information is not recorded on a CRF; however,
a copy of the completed Vaccine SAE Report Form is maintained in the investigator
site file.
Follow-up is conducted to obtain general information on the pregnancy and its outcome for
all EDP reports with an unknown outcome. The investigator will follow the pregnancy until
completion (or until pregnancy termination) and notify Pfizer Safety of the outcome as a
follow-up to the initial EDP Supplemental Form. In the case of a live birth, the structural
integrity of the neonate can be assessed at the time of birth. In the event of a termination, the
reason(s) for termination should be specified and, if clinically possible, the structural
integrity of the terminated fetus should be assessed by gross visual inspection (unless
CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014129
Page 76
Protocol C4591001
preprocedure test findings are conclusive for a congenital anomaly and the findings are
reported).
Abnormal pregnancy outcomes are considered SAEs. If the outcome of the pregnancy meets
the criteria for an SAE (ie, ectopic pregnancy, spontaneous abortion, intrauterine fetal
demise, neonatal death, or congenital anomaly), the investigator should follow the procedures
for reporting SAEs. Additional information about pregnancy outcomes that are reported to
Pfizer Safety as SAEs follows:
 Spontaneous abortion including miscarriage and missed abortion;
 Neonatal deaths that occur within 1 month of birth should be reported, without regard
to causality, as SAEs. In addition, infant deaths after 1 month should be reported as
SAEs when the investigator assesses the infant death as related or possibly related to
exposure to the study intervention.
Additional information regarding the EDP may be requested by the sponsor. Further
follow-up of birth outcomes will be handled on a case-by-case basis (eg, follow-up on
preterm infants to identify developmental delays). In the case of paternal exposure, the
investigator will provide the participant with the Pregnant Partner Release of Information
Form to deliver to his partner. The investigator must document in the source documents that
the participant was given the Pregnant Partner Release of Information Form to provide to his
partner.
8.3.5.2. Exposure During Breastfeeding

An exposure during breastfeeding occurs if:
 A female participant is found to be breastfeeding while receiving or after

discontinuing study intervention.
 A female is found to be breastfeeding while being exposed or having been exposed to

study intervention (ie, environmental exposure). An example of environmental
exposure during breastfeeding is a female family member or healthcare provider who
reports that she is breastfeeding after having been exposed to the study intervention
by inhalation or skin contact.
The investigator must report exposure during breastfeeding to Pfizer Safety within 24 hours
of the investigator’s awareness, irrespective of whether an SAE has occurred. The
information must be reported using the Vaccine SAE Report Form. When exposure during
breastfeeding occurs in the setting of environmental exposure, the exposure information does
not pertain to the participant enrolled in the study, so the information is not recorded on a
CRF. However, a copy of the completed Vaccine SAE Report Form is maintained in the
investigator site file.
CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014130
Page 77
Protocol C4591001
An exposure during breastfeeding report is not created when a Pfizer drug specifically
approved for use in breastfeeding women (eg, vitamins) is administered in accord with
authorized use. However, if the infant experiences an SAE associated with such a drug, the
SAE is reported together with the exposure during breastfeeding.
8.3.5.3. Occupational Exposure

An occupational exposure occurs when a person receives unplanned direct contact with the
study intervention, which may or may not lead to the occurrence of an AE. Such persons
may include healthcare providers, family members, and other roles that are involved in the
trial participant’s care.
The investigator must report occupational exposure to Pfizer Safety within 24 hours of the
investigator’s awareness, regardless of whether there is an associated SAE. The information
must be reported using the Vaccine SAE Report Form. Since the information does not
pertain to a participant enrolled in the study, the information is not recorded on a CRF;
however, a copy of the completed Vaccine SAE Report Form is maintained in the
8.3.6. Cardiovascular and Death Events

Not applicable.
8.3.7. Disease-Related Events and/or Disease-Related Outcomes Not Qualifying as AEs

or SAEs
Potential COVID-19 illnesses and their sequelae that are consistent with the clinical endpoint
definition should not be recorded as AEs. These data will be captured as efficacy assessment
data only on the relevant pages of the CRF, as these are expected endpoints.
Potential COVID-19 illnesses and their sequelae will not be reported according to the
standard process for expedited reporting of SAEs, even though the event may meet the
definition of an SAE. These events will be recorded on the COVID-19 illness pages in the
participant’s CRF within 1 day.
NOTE: However, if either of the following conditions applies, then the event must be
recorded and reported as an SAE (instead of a disease-related event):
The event is, in the investigator’s opinion, of greater intensity, frequency, or duration than
expected for the individual participant.
OR
The investigator considers that there is a reasonable possibility that the event was related to
study intervention.
Potential COVID-19 illness events and their sequelae will be reviewed by a group of internal
blinded case reviewers. Any SAE that is determined by the internal case reviewers NOT to
CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014131
Page 78
Protocol C4591001
meet endpoint criteria is reported back to the investigator site of incidence. The investigator
must report the SAE to Pfizer Safety within 24 hours of being made aware that the SAE did
not meet endpoint criteria. The investigator’s SAE awareness date is the date on which the
investigator site of incidence receives the SAE back from the internal case reviewers.
8.3.8. Adverse Events of Special Interest

Not applicable.
8.3.8.1. Lack of Efficacy

Lack of efficacy is reportable to Pfizer Safety only if associated with an SAE.
8.3.9. Medical Device Deficiencies

Not applicable.
8.3.10. Medication Errors

Medication errors may result from the administration or consumption of the study
intervention by the wrong participant, or at the wrong time, or at the wrong dosage strength.
Exposures to the study intervention under study may occur in clinical trial settings, such as
medication errors.
Safety Event Recorded on the CRF Reported on the Vaccine SAE Report
Form to Pfizer Safety Within 24 Hours
of Awareness
Medication errors All (regardless of whether Only if associated with an SAE

associated with an AE)
Medication errors include:
 Medication errors involving participant exposure to the study intervention;
 Potential medication errors or uses outside of what is foreseen in the protocol that do
or do not involve the study participant;
 The administration of expired study intervention;
 The administration of an incorrect study intervention;
 The administration of an incorrect dosage;
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014132
Page 79
Protocol C4591001
 The administration of study intervention that has undergone temperature excursion

from the specified storage range, unless it is determined by the sponsor that the study
intervention under question is acceptable for use.
Such medication errors occurring to a study participant are to be captured on the medication
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the sponsor should be notified within 24 hours.
Whether or not the medication error is accompanied by an AE, as determined by the

investigator, the medication error is recorded on the medication error page of the CRF and, if
applicable, any associated AE(s), serious and nonserious, are recorded on the AE page of the
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccine SAE
Report Form only when associated with an SAE.
8.4. Treatment of Overdose

For this study, any dose of study intervention greater than 1 dose of study intervention within
a 24-hour time period will be considered an overdose.
Pfizer does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator should:
1. Contact the medical monitor within 24 hours.
2. Closely monitor the participant for any AEs/SAEs.
3. Document the quantity of the excess dose as well as the duration of the overdose in the
CRF.
4. Overdose is reportable to Safety only when associated with an SAE.
Decisions regarding dose interruptions or modifications will be made by the investigator in

consultation with the medical monitor based on the clinical evaluation of the participant.
8.5. Pharmacokinetics
Pharmacokinetic parameters are not evaluated in this study.
8.6. Pharmacodynamics
Pharmacodynamic parameters are not evaluated in this study.
8.7. Genetics
Genetics (specified analyses) are not evaluated in this study.
CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014133
Page 80
Protocol C4591001
8.8. Biomarkers
Biomarkers are not evaluated in this study.
8.9. Immunogenicity Assessments

Immunogenicity assessments are described in Section 8.1.
8.10. Health Economics

Health economics/medical resource utilization and health economics parameters are not
evaluated in this study.
8.11. Study Procedures

8.11.1. Phase 1
8.11.1.1. Screening: (0 to 28 Days Before Visit 1)
Before enrollment and before any study-related procedures are performed, voluntary, written
study-specific informed consent will be obtained from the participant. Each signature on the
ICD must be personally dated by the signatory. The investigator or his or her designee will
also sign the ICD. A copy of the signed and dated ICD must be given to the participant. The
source data must reflect that the informed consent was obtained before participation in the
study.
It is anticipated that the procedures below will be conducted in a stepwise manner; however,
the visit can occur over more than 1 day.
 Assign a single participant number using the IRT system.
 Obtain the participant’s demography (including date of birth, sex, race, and ethnicity).
The full date of birth will be collected to critically evaluate the immune response and
safety profile by age.
 Obtain any medical history of clinical significance.
 Obtain details of any medications currently taken.
 Perform physical examination including vital signs (weight, height, body temperature,
pulse rate, and seated blood pressure), evaluating any clinically significant
abnormalities within the following body systems: general appearance; skin; head,
eyes, ears, nose, and throat; heart; lungs; abdomen; musculoskeletal; extremities;
neurological; and lymph nodes.
 Collect a blood sample (approximately 20 mL) for potential future serological

assessment and to perform a rapid test for prior COVID-19 infection.
CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014134
Page 81
Protocol C4591001
 Collect a blood sample (approximately 10 mL) for hematology and chemistry

laboratory tests as described in Section 10.2.
 Collect a blood sample (approximately 10 mL) for HIV, HBsAg, HBc Ab, and HCV
Ab tests.
 Record nonstudy vaccinations as described in Section 6.5.
 Ensure and document that all of the inclusion criteria and none of the exclusion
criteria are met.
 Record AEs as described in Section 8.3. AEs that occur prior to dosing should be
noted on the Medical History CRF.
 Ask the participant to contact the site staff or investigator immediately if any
significant illness or hospitalization occurs.
 Ask the participant to contact the site staff or investigator immediately if he or she
experiences any respiratory symptoms as detailed in Section 8.13.
 Schedule an appointment for the participant to return for the next study visit.
 Complete the source documents.
 Complete the CRF.
8.11.1.2. Visit 1 – Vaccination 1: (Day 1)

It is anticipated that the procedures below will be conducted in a stepwise manner; ensure
that procedures listed prior to administration of the vaccine are conducted prior to
vaccination.
 Record AEs as described in Section 8.3.
 Measure vital signs (body temperature, pulse rate, and seated blood pressure), and, if
indicated by any change in the participant’s health since the previous visit, perform a
physical examination, evaluating any clinically significant abnormalities within the
following body systems: general appearance; skin; head, eyes, ears, nose, and throat;
heart; lungs; abdomen; musculoskeletal; extremities; neurological; and lymph nodes.
CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014135
Page 82
Protocol C4591001
 Review screening laboratory results (hematology and chemistry, and HIV, HBsAg,
HBc Ab, and HCV Ab tests).
 Obtain 2 nasal (midturbinate) swabs (collected by site staff). One will be tested
(if possible at the site, otherwise at the central laboratory) within 24 hours and
vaccination will proceed only if it is NAAT-negative for SARS-CoV-2 genomes.
The second will be sent to the central laboratory for potential later testing.
criteria are met.
Section 5.5.
 Obtain the participant’s randomization number and study intervention allocation

using the IRT system. Only an unblinded site staff member may obtain this
information.
 Collect a blood sample (approximately 50 mL) for immunogenicity testing.

 The first 5 participants vaccinated in each group must be observed by blinded site
staff for any acute reactions for at least 4 hours after vaccination. For participants
enrolled thereafter, blinded site staff must observe the participant for at least 30
minutes after study intervention administration for any acute reactions. Record any
acute reactions (including time of onset) in the participant’s source documents and on
the AE page of the CRF, and on an SAE form as applicable.
 Issue a measuring device to measure local reactions at the injection site and a
thermometer for recording daily temperatures and provide instructions on their use.
 Explain the e-diary technologies available for this study (see Section 8.14), and assist
the participant in downloading the study application onto the participant’s own device
or issue a provisioned device if required. Provide instructions on e-diary completion
and ask the participant to complete the reactogenicity e-diary from Day 1 to Day 7,
with Day 1 being the day of vaccination and, if utilized, the COVID-19 illness e-diary
(to be completed if the participant is diagnosed with COVID-19 or has possible new
or increased symptoms, and when he/she receives a reminder, at least weekly).
CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014136
Page 83
Protocol C4591001
experiences any of the following from Day 1 to Day 7 after vaccination (where Day 1
is the day of vaccination) to determine if an unscheduled reactogenicity visit is
required:
 Fever ≥39.0°C (≥102.1°F).
 Redness or swelling at the injection site measuring greater than 10 cm

(>20 measuring device units).
 Severe pain at the injection site.
 Any severe systemic event.
 Ask the participant to contact the site staff or investigator if a medically attended
event (eg, doctor’s visit, emergency room visit) or hospitalization occurs.
 Ask the participant to contact the site staff or investigator (this could be via the
COVID-19 illness e-diary) immediately if he or she experiences any respiratory
symptoms as detailed in Section 8.13.
 Remind the participant to bring the e-diary to the next visit.
 The investigator or an authorized designee completes the CRFs and an unblinded

dispenser/administrator updates the study intervention accountability records.
 The investigator or appropriately qualified designee reviews the reactogenicity

e-diary data online following vaccination to evaluate participant compliance and as
part of the ongoing safety review. Daily review is optimal during the active diary
period.
8.11.1.3. Visit 2 – Next-Day Follow-up Visit (Vaccination 1): (1 to 3 Days After Visit 1)
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014137
Page 84
Protocol C4591001

 Record details of any of the prohibited medications specified in Section 6.5.1

received by the participant if required for his or her clinical care.
required:
 Fever ≥39.0°C (≥102.1°F).

 The investigator or an authorized designee completes the CRFs.
 The investigator or appropriately qualified designee reviews the reactogenicity e-

diary data online following vaccination to evaluate participant compliance and as part
of the ongoing safety review. Daily review is optimal during the active diary period.
CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014138
Page 85
Protocol C4591001
8.11.1.4. Visit 3 – 1-Week Follow-up Visit (Vaccination 1): (6 to 8 Days After Visit 1)
 Review hematology and chemistry laboratory results and record any AEs in
accordance with Appendix 2.


required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014139
Page 86
Protocol C4591001

8.11.1.5. Visit 4 – Vaccination 2: (19 to 23 Days After Visit 1)

vaccination.
 Review the participant’s reactogenicity e-diary data. Collect stop dates of any
reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary
was completed and record stop dates in the CRF if required.

 Obtain 2 nasal (midturbinate) swabs (collected by site staff). One will be tested (if
possible at the site, otherwise at the central laboratory) within 24 hours and
vaccination will only proceed if it is NAAT-negative for SARS-CoV-2 genomes.
CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014140
Page 87
Protocol C4591001
criteria are met. If not, the participant should not receive further study intervention
but will remain in the study to be evaluated for safety, immunogenicity, and efficacy
(see Section 7.1).
Section 5.5.


 Ensure the participant has a measuring device to measure local reactions at the
injection site and a thermometer for recording daily temperatures.
 Ensure the participant remains comfortable with his or her chosen e-diary platform,
confirm instructions on e-diary completion, and ask the participant to complete the
reactogenicity e-diary from Day 1 to Day 7, with Day 1 being the day of vaccination.
required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014141
Page 88
Protocol C4591001


period.


 If the participant (select participants only, details will be provided by the sponsor)
consents, collect an additional 170 mL blood sample for exploratory COVID-19
research.
CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014142
Page 89
Protocol C4591001
required:
 Fever ≥39.0°C (≥102.1°F).


period.
CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014143
Page 90
Protocol C4591001


 If not collected at Visit 5, and the participant (select participants only, details will be
provided by the sponsor) consents, collect an additional 170-mL blood sample for
exploratory COVID-19 research.
 Ask the participant to contact the site staff or investigator immediately (this could be
via the COVID-19 illness e-diary) if he or she experiences any respiratory symptoms
as detailed in Section 8.13.
8.11.1.8. Visit 7 – 1-Month Follow-up Visit: (28 to 35 Days After Visit 4)


 If not collected at Visit 5 or 6, and the participant (select participants only, details will
be provided by the sponsor) consents, collect an additional 170-mL blood sample for
CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014144
Page 91
Protocol C4591001
 Record SAEs as described in Section 8.3.

 Record any AEs that occur within the 48 hours after the blood draw as described in
Section 8.3.

CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014145
Page 92
Protocol C4591001
Section 8.3.

 Collect the participant’s e-diary or assist the participant to remove the study
application from his or her own personal device.
Section 8.3.
8.11.2. Phase 2/3

Before enrollment and before any study-related procedures are performed, voluntary, written,
study-specific informed consent will be obtained from the participant or his/her
parent(s)/legal guardian, as appropriate. Each signature on the ICD must be personally dated
by the signatory. The investigator or his or her designee will also sign the ICD. A copy of
the signed and dated ICD must be given to the participant/participant’s parent(s)/legal
guardian. The source data must reflect that the informed consent was obtained before
participation in the study.
It is anticipated that the procedures below will be conducted in a stepwise manner. The visit
may be conducted across 2 consecutive days; if so, all steps from assessing the inclusion and
exclusion criteria onwards must be conducted on the same day.
CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014146
Page 93
Protocol C4591001
 Obtain any medical history of clinical significance. For participants who are
HIV-positive, record HIV viral load and CD4 count results from the most recent test
performed in the previous 6 months.
 Perform a clinical assessment. If the clinical assessment indicates that a physical

examination is necessary to comprehensively evaluate the participant, perform a
physical examination and record any findings in the source documents and, if
clinically significant, record on the medical history CRF.
 Measure the participant’s height and weight.

criteria are met.
Section 5.5.
 Collect a blood sample (approximately 20 mL for participants ≥16 years of age and
approximately 10 mL for participants in the 12- to 15-year age stratum) for
immunogenicity testing.
 Obtain a nasal (midturbinate) swab (collected by site staff).

number using the IRT system. Only an unblinded site staff member may obtain this
information.

CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014147
Page 94
Protocol C4591001
 For participants in the reactogenicity subset, issue a measuring device to measure

local reactions at the injection site and a thermometer for recording daily
temperatures and provide instructions on their use.
 For participants not in the reactogenicity subset, issue a thermometer to monitor for
fever (for COVID-19 surveillance) and provide instructions on its use.
the participant or his/her parent(s)/legal guardian, as appropriate, in downloading the
study application onto the participant’s own device or issue a provisioned device if
required.
 For participants in the reactogenicity subset, provide instructions on

reactogenicity e-diary completion and ask the participant or his/her parent(s)/legal
guardian, as appropriate, to complete the reactogenicity e-diary from Day 1 to
Day 7, with Day 1 being the day of vaccination.
 For all participants, provide instructions on COVID-19 illness e-diary completion

and ask the participant or his/her parent(s)/legal guardian, as appropriate, to
complete the COVID-19 illness e-diary if the participant is diagnosed with
COVID-19 or has possible new or increased symptoms, and when he/she receives
a reminder, at least weekly. See Section 8.14 for further details.
 If the participant is part of the reactogenicity subset, ask the participant or his/her
parent(s)/legal guardian, as appropriate, to contact the site staff or investigator
immediately if the participant experiences any of the following from Day 1 to Day 7
after vaccination (where Day 1 is the day of vaccination) to determine if an
unscheduled reactogenicity visit is required:
 Fever ≥39.0°C (≥102.1°F).

 Ask the participant or his/her parent(s)/legal guardian, as appropriate, to contact the

site staff or investigator if a medically attended event (eg, doctor’s visit, emergency
room visit) or hospitalization occurs.
CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014148
Page 95
Protocol C4591001

site staff or investigator (this could be via the COVID-19 illness e-diary) immediately
if he or she experiences any respiratory symptoms as detailed in Section 8.13.
 Remind the participant or his/her parent(s)/legal guardian, as appropriate, to bring the

e-diary to the next visit.

If the participant is part of the reactogenicity subset, the investigator or appropriately

qualified designee reviews the reactogenicity e-diary data online following vaccination to
evaluate participant compliance and as part of the ongoing safety review. Daily review is
optimal during the active diary period.

vaccination.
 If the participant is part of the reactogenicity subset, review the participant’s

reactogenicity e-diary data. Collect stop dates of any reactogenicity e-diary events
ongoing on the last day that the reactogenicity e-diary was completed and record stop
dates in the CRF if required.

criteria are met. If not, the participant may not receive further study intervention but
will remain in the study to be evaluated for safety, immunogenicity, and efficacy
(see Section 7.1).
CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014149
Page 96
Protocol C4591001
Section 5.5.

 Ensure the participant or his/her parent(s)/legal guardian, as appropriate, has a

measuring device to measure local reactions at the injection site and a thermometer
for recording daily temperatures.
 Ensure the participant or his/her parent(s)/legal guardian, as appropriate, remains

comfortable with the chosen e-diary platform, confirm instructions on e-diary
completion, and, if the participant is part of the reactogenicity subset, ask the
participant or his/her parent(s)/legal guardian, as appropriate, to complete the
 Fever ≥39.0°C (≥102.1°F).


CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014150
Page 97
Protocol C4591001

if the participant experiences any respiratory symptoms as detailed in Section 8.13.



8.11.2.3. Visit 3 – 1-Month Follow-up Visit (After Vaccination 2): (28 to 35 Days After
Visit 2)
 Review the participant’s reactogenicity e-diary data. If the participant is part of the
reactogenicity subset, review the participant’s reactogenicity e-diary data. Collect
stop dates of any reactogenicity e-diary events ongoing on the last day that the
reactogenicity e-diary was completed and record stop dates in the CRF if required.

 For participants who are HIV-positive, record HIV viral load and CD4 count results
from the most recent test performed since Visit 1 (if any).
 Collect a blood sample (approximately 20 mL for participants ≥16 years of age, and

CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014151
Page 98
Protocol C4591001



Section 8.3.

CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014152
Page 99
Protocol C4591001

Section 8.3.

Section 8.3.
8.12. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction

If a Grade 3 local reaction (Section 8.2.2.2), systemic event (Section 8.2.2.3), or fever
(Section 8.2.2.4) is reported in the reactogenicity e-diary, a telephone contact should occur to
ascertain further details and determine whether a site visit is clinically indicated. If suspected
Grade 4 local reaction (Section 8.2.2.2), systemic event (Section 8.2.2.3), or fever
(Section 8.2.2.4) is reported in the reactogenicity e-diary, a telephone contact or site visit
should occur to confirm whether the event meets the criteria for Grade 4.
CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014153
Page 100
Protocol C4591001
A site visit must be scheduled as soon as possible to assess the participant unless any of the
following is true:
 The participant is unable to attend the unscheduled visit.
 The local reaction/systemic event is no longer present at the time of the telephone
contact.
 The participant or his/her parent(s)/legal guardian, as appropriate, recorded an

incorrect value in the reactogenicity e-diary (confirmation of a reactogenicity e-diary
data entry error).
 The PI or authorized designee determined it was not needed.
This telephone contact will be recorded in the participant’s source documentation and the
CRF.
If the participant is unable to attend the unscheduled visit, or the PI or authorized designee
determined it was not needed, any ongoing local reactions/systemic events must be assessed
at the next study visit.
During the unscheduled visit, the reactions should be assessed by the investigator or a
medically qualified member of the study staff such as a study physician or a study nurse, as
applicable to the investigator’s local practice, who will:
 Measure body temperature (°F/°C).
 Measure minimum and maximum diameters of redness (if present).
 Measure minimum and maximum diameters of swelling (if present).
 Assess injection site pain (if present) in accordance with the grades provided in
Section 8.2.2.2.
 Assess systemic events (if present) in accordance with the grades provided in
Section 8.2.2.3.
 Assess for other findings associated with the reaction and record on the AE page of
the CRF, if appropriate.
The investigator or an authorized designee will complete the unscheduled visit assessment
page of the CRF.
8.13. COVID-19 Surveillance (All Participants)

If a participant experiences any of the following (irrespective of perceived etiology or
clinical significance), he or she is instructed to contact the site immediately and, if
CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014154
Page 101
Protocol C4591001
confirmed, participate in an in-person or telehealth visit as soon as possible, optimally within

3 days of symptom onset (and at the latest 4 days after symptom resolution). Note that:
 If new symptoms are reported within 4 days after resolution of all previous symptoms,
they will be considered as part of a single illness and a second illness visit is not required;
 Surveillance of potential COVID-19 symptoms should continue even if a participant has

a positive SARS-CoV-2 test earlier in the study.
During the 7 days following each vaccination, potential COVID-19 symptoms that overlap
with specific systemic events (ie, fever, chills, new or increased muscle pain, diarrhea,
vomiting) should not trigger a potential COVID-19 illness visit unless, in the investigator’s
opinion, the clinical picture is more indicative of a possible COVID-19 illness than vaccine
reactogenicity. If, in the investigator’s opinion, the symptoms are considered more likely to
be vaccine reactogenicity, but a participant is required to demonstrate that they are
SARS-CoV-2–negative, a local SARS-CoV-2 test may be performed: if positive, the
symptoms should be recorded as a potential COVID-19 illness; if not, the symptoms should
be recorded as AEs (unless already captured in the reactogenicity e-diary).
Participants may utilize a COVID-19 illness e-diary through an application (see Section 8.14)
installed on a provisioned device or on the participant’s own personal device to prompt

him/her to report any symptoms. Note that this does not substitute for a participant’s routine
medical care. Therefore, participants should be encouraged to seek care, if appropriate, from
their usual provider.
 A diagnosis of COVID-19;
 Fever;
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014155
Page 102
Protocol C4591001
8.13.1. Potential COVID-19 Illness Visit: (Optimally Within 3 Days After Potential
COVID-19 Illness Onset)
This visit may be conducted as an in-person or telehealth visit; a telehealth visit involves the
sharing of healthcare information and services via telecommunication technologies
(eg, audio, video, video-conferencing software) remotely, thus allowing the participant and
investigator to communicate on aspects of clinical care.
As a participant’s COVID-19 illness may evolve over time, several contacts may be required
to obtain the following information:
 Record AEs, as appropriate as described in Section 8.3. Note: Potential COVID-19

illnesses that are consistent with the clinical endpoint definition should not be
recorded as AEs. These data will be captured as efficacy assessment data only on the
relevant pages of the CRF, as these are expected endpoints.

 If the visit is conducted in person, obtain a nasal (midturbinate) swab (collected by

site staff). Alternatively, if conducted by telehealth, instruct the participant to
self-collect a nasal (midturbinate) swab and ship for assessment at the central
laboratory.
 Collect COVID-19–related standard-of-care clinical and laboratory information. This

includes, but is not limited to:
 Symptoms and signs, including
PaO2/FiO2 <300 mm Hg)

vasopressors)
 Significant acute renal, hepatic, or neurologic dysfunction

ventilation, mechanical ventilation, or ECMO)
 Clinical diagnosis
 Local laboratory SARS-CoV-2 test result(s). Note that if it is routine practice to

perform a repeat local SARS-CoV-2 test for any reason, then a repeat nasal
CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014156
Page 103
Protocol C4591001
(midturbinate) swab should also be obtained and shipped for assessment at the
central laboratory.
 Full blood count
 Blood chemistry, specifically creatinine, urea, liver function tests, and C-reactive
protein
 Imaging results (eg, CT or MRI scan) to document neurologic dysfunction
 Number and type of any healthcare contact; duration of hospitalization and ICU
stay
 Death
 Schedule an appointment for the participant to return for the potential COVID-19
convalescent visit once he or she has recovered.

The investigator or an authorized designee completes the CRFs.
8.13.2. Potential COVID-19 Convalescent Visit: (28 to 35 Days After Potential

COVID-19 Illness Visit)

 Collect/update COVID-19–related clinical and laboratory information (detailed in

Section 8.13.1).
Section 8.3.
CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014157
Page 104
Protocol C4591001
8.14. Communication and Use of Technology

In a study of this nature that requires illness events to be reported outside of scheduled study
visits, it is vital that communication between the study site and the participant or his/her
parent(s)/legal guardian, as appropriate, is maintained to ensure that endpoint events are not
missed. This study will employ various methods, tailored to the individual participant, to
ensure that communication is maintained and study information can be transmitted securely.
Using appropriate technology, such as a study application, a communication pathway
between the participant or his/her parent(s)/legal guardian, as appropriate, and the study site
staff will be established. The participant or his/her parent(s)/legal guardian, as appropriate,
may be able to utilize his or her own devices to access this technology, or use a device
provided by the sponsor. Traditional methods of telephone communication will also be
available. The technology solution may facilitate the following:
 Contact with the investigator, including the ability of the participant or his/her
parent(s)/legal guardian, as appropriate, to report whether or not the participant has
experienced symptoms that could represent a potential COVID-19 illness (COVID-19
illness e-diary; see Section 8.13).
 An alert in the event that the participant is hospitalized.

 Visit reminders.
 Messages of thanks and encouragement from the study team.
 A platform for recording local reactions and systemic events (reactogenicity e-diary)
– see Section 8.2.2.
If a participant or his/her parent(s)/legal guardian, as appropriate, is not actively completing

either the reactogenicity or COVID-19 illness e-diary, the investigator or designee is required
to contact the participant or his/her parent(s)/legal guardian, as appropriate, to ascertain why
and also to obtain details of any missed events.
8.15. SARS-CoV-2 NAAT Results From Visits 1 and 2 and Potential COVID-19 Illness
Visits
Nasal (midturbinate) swabs for SARS-CoV-2 NAAT are obtained at:
 Visits 1 and 2: To determine whether a participant will be included in efficacy analyses

of those with no serological or virological evidence (up to 7 or 14 days after receipt of the
second dose, depending on the objective) of past SARS-CoV-2 infection.
 Potential COVID-19 illness visits: To determine whether symptoms experienced by the

participant fulfill the COVID-19 case definition.
Research laboratory–generated positive results from the Visit 1 and Visit 2 swabs, and all
results from the illness visit swabs, will be provided to the site once available, but this will
CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014158
Page 105
Protocol C4591001
not be in real time and cannot be relied upon to direct clinical care. Therefore, the participant
should be directed to seek additional testing through his/her primary healthcare providers at a
licensed clinical laboratory when exhibiting potential COVID-19 symptoms or otherwise
receiving a positive result and counseled on whether to take any precautionary measures
pending confirmatory testing.
Participants who have a positive SARS-CoV-2 NAAT result prior to Visit 2 should be
handled as follows:
 Positive SARS-CoV-2 test with no symptoms, either at Visit 1 or any time between Visit
1 and Visit 2: A positive test in an asymptomatic participant does not meet exclusion
criterion 5; therefore, Vaccination 2 should proceed as normal.
 Confirmed COVID-19 (ie, symptoms and positive SARS-CoV-2 test): This meets
exclusion criterion 5; therefore, Vaccination 2 should not be given but the participant
should remain in the study.
9. STATISTICAL CONSIDERATIONS
Methodology for summary and statistical analyses of the data collected in this study is
described here and further detailed in a statistical analysis plan (SAP), which will be
maintained by the sponsor. The SAP may modify what is outlined in the protocol where
appropriate; however, any major modifications of the primary endpoint definitions or their
analyses will also be reflected in a protocol amendment.
9.1. Estimands and Statistical Hypotheses

9.1.1. Estimands
The estimand corresponding to each primary, secondary, and tertiary/exploratory objective is
described in the table in Section 3.
In the primary safety objective evaluations, missing reactogenicity e-diary data will not be
imputed. Missing AE dates will be imputed according to Pfizer safety rules. No other
missing information will be imputed in the safety analysis.
The estimands to evaluate the immunogenicity objectives are based on evaluable populations
for immunogenicity (Section 9.3). These estimands estimate the vaccine effect in the
hypothetical setting where participants follow the study schedules and protocol requirements
as directed. Missing antibody results will not be imputed. Immunogenicity results that are
below the LLOQ will be set to 0.5 × LLOQ in the analysis; this may be adjusted once
additional data on the assay characteristics become available.
The estimands to evaluate the efficacy objectives are based on evaluable populations for
efficacy (Section 9.3). These estimands estimate the vaccine effect in the hypothetical
setting where participants follow the study schedules and protocol requirements as directed.
In addition, VE will also be analyzed by all-available efficacy population. Missing laboratory
CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014159
Page 106
Protocol C4591001
results will not be imputed for the primary analysis, but missing data imputation for the
efficacy endpoint may be performed as a sensitivity analysis.
9.1.2. Statistical Hypotheses

9.1.2.1. Statistical Hypothesis Evaluation for Efficacy
Phase 2/3 of the study has 2 primary efficacy endpoints evaluating VE, which is defined as
VE = 100 × (1 – IRR). IRR is calculated as the ratio of first confirmed COVID-19 illness rate
in the vaccine group to the corresponding illness rate in the placebo group. In Phase 2/3, the
assessment of VE will be based on posterior probabilities of VE1 > 30% and VE2 > 30%.
VE1 represents VE for prophylactic BNT162b2 against confirmed COVID-19 in participants
without evidence of infection before vaccination, and VE2 represents VE for prophylactic
BNT162b2 against confirmed COVID-19 in all participants after vaccination.
For participants with multiple confirmed cases, only the first case will contribute to the VE
calculation for each hypothesis. VE1 and VE2 will be evaluated sequentially to control the
overall type I error to the desired level of 2.5%. VE is demonstrated if there is sufficient
evidence (posterior probability) that either VE1 >30% or both VE1 and VE2 are >30%. The
assessment for the primary analysis will be based on posterior probability using a Bayesian
model.
9.1.2.2. Statistical Hypothesis Evaluation for Immunogenicity

One of the secondary objectives in the Phase 3 part of the study is to evaluate noninferiority
of the immune response to prophylactic BNT162b2 in participants 12 to 15 years of age
compared to the response in participants 16 to 25 years of age at 1 month after Dose 2. The
(Dose 2) evaluable immunogenicity population will be used for the following hypothesis
testing:
H0: ln(µ2) – ln(µ1) ≤ ln(0.67)
where ln (0.67) corresponds to a 1.5-fold margin for noninferiority, ln(µ2) and ln(µ1) are the
natural log of the geometric mean of SARS-CoV-2 neutralizing titers from BNT162b2
recipients 12 to 15 years of age and 16 to 25 years of age, respectively, measured 1 month
after Dose 2. If the lower limit of the 95% CI for the GMR (12-15 years of age to 16-25
years of age) is >0.67, the noninferiority objective is met.
9.2. Sample Size Determination

The study sample size for Phase 1 of the study is not based on any statistical hypothesis
testing. Phase 1 comprises 15 participants (randomization ratio of 4:1 so that 12 receive
active vaccine and 3 receive placebo) per group; 13 vaccine groups are studied,
corresponding to a total of 195 participants.
For Phase 2/3, with assumptions of a true VE of 60% after the second dose of investigational
product, a total of approximately 164 first confirmed COVID-19 illness cases will provide
90% power to conclude true VE >30% with high probability, allowing early stopping for
CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014160
Page 107
Protocol C4591001
efficacy at the IA. This would be achieved with 17,600 evaluable participants per group or
21,999 vaccine recipients randomized in a 1:1 ratio with placebo, for a total sample size of
43,998, based on the assumption of a 1.3% illness rate per year in the placebo group, accrual
of 164 first primary-endpoint cases within 6 months, and 20% of the participants being
nonevaluable or having serological evidence of prior infection with SARS-CoV-2,
potentially making them immune to further infection. Dependent upon the evolution of the
pandemic, it is possible that the COVID-19 attack rate may be much higher, in which case
accrual would be expected to be more rapid, enabling the study’s primary endpoint to be
evaluated much sooner. The total number of participants enrolled in Phase 2/3 may vary
depending on the incidence of COVID-19 at the time of the enrollment, the true underlying
VE, and a potential early stop for efficacy or futility.
In Phase 3, approximately 2000 participants are anticipated to be 12 to 15 years of age. A

random sample of 250 participants will be selected for each of the 2 age groups (12 to 15
years and 16 to 25 years) as an immunogenicity subset for the noninferiority assessment.
With the standard deviation and observed GMT difference assumed in the power analysis
below, a sample size of 200 evaluable participants (or 250 vaccine recipients) per age group
will provide a power of 90.8% to declare the noninferiority of adolescents to 16- to
25-year-olds in terms of neutralizing antibody GMR, 1 month after the second dose
(see Table 4).
Table 4. Power Analysis for Noninferiority Assessment

Criteria Standard Assumed Number of Powerb
Deviation Observed GMT Evaluable
(Log Value)a Difference (Log Participants per
Scale) Age Group
Lower limit of 95% 0.623 -0.2 200 90.8%
CI for GMR
(12-15/16-25)
>0.67
Abbreviation: GMR = geometric mean ratio.
a. Reference: 1 month after Dose 2, BNT162b2 (30 µg), 18- to 55-year age group (C4591001 Phase 1,
N=12). Calculation may be updated if additional information becomes available to better estimate the
standard deviation.
b. At 0.05 alpha level (2-sided).
For safety outcomes, Table 5 shows the probability of observing at least 1 AE for a given
true event rate of a particular AE, for various sample sizes. For example, if the true AE rate
is 10%, with 12 participants in a vaccine group, there is 72% probability of observing at least
1 AE.
CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014161
Page 108
Protocol C4591001
Table 5. Probability of Observing at Least 1 AE by Assumed True Event Rates

With Different Sample Sizes
Assumed N=12 N=45 N=180 N=1000 N=3000 N=6000 N=9000 N=15000
True Event
Rate of an
AE
0.01% 0.00 0.00 0.02 0.10 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.18 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.33 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.45 0.83 0.97 0.99 >0.99
0.08% 0.01 0.04 0.13 0.55 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.63 0.95 0.99 0.99 >0.99
0.15% 0.02 0.07 0.24 0.78 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 0.86 >0.99 >0.99 >0.99 >0.99
0.25% 0.03 0.11 0.36 0.92 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 0.95 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 0.97 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 0.99 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99

10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
Note: N = number in sample.
9.3. Analysis Sets

For purposes of analysis, the following populations are defined:
Population Description
Enrolled All participants who have a signed ICD.
Randomized All participants who are assigned a randomization number in
the IWR system.
Dose 1 evaluable For Phase 1 only, all eligible randomized participants who
immunogenicity receive the vaccine to which they are randomly assigned at the
first dose, have at least 1 valid and determinate
immunogenicity result after Dose 1, have blood collection
within an appropriate window after Dose 1, and have no other
important protocol deviations as determined by the clinician.
Dose 2 evaluable All eligible randomized participants who receive 2 doses of
immunogenicity the vaccine to which they are randomly assigned, within the
predefined window, have at least 1 valid and determinate
CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014162
Page 109
Protocol C4591001
Dose 1 all-available For Phase 1 only: all randomized participants who receive at
immunogenicity least 1 dose of the study intervention with at least 1 valid and
determinate immunogenicity result after Dose 1 but before
Dose 2.
Dose 2 all-available All randomized participants who receive at least 1 dose of the
immunogenicity study intervention with at least 1 valid and determinate
immunogenicity result after Dose 2.
Evaluable efficacy All eligible randomized participants who receive all
vaccination(s) as randomized within the predefined window
and have no other important protocol deviations as determined
by the clinician.
All-available efficacy 1. All randomized participants who receive at least
1 vaccination.
2. All randomized participants who complete 2 vaccination
doses.
Safety All randomized participants who receive at least 1 dose of the
study intervention.
9.4. Statistical Analyses

The SAP will be developed and finalized before database lock for any of the planned
analyses in Section 9.5.1. It will describe the participant populations to be included in the
analyses and the procedures for accounting for missing, unused, and spurious data. This
section provides a summary of the planned statistical analyses of the primary, secondary, and
tertiary/exploratory endpoints.
9.4.1. Immunogenicity Analyses

Immunogenicity samples will be drawn for all participants. Immunogenicity analyses will be
based upon results from appropriately sized subsets of samples, according to the purpose.
The statistical analysis of immunogenicity results will be primarily based on the evaluable
immunogenicity populations as defined in Section 9.3. Serology data after a postbaseline
positive SARS-CoV-2 test result will not be included in the analysis based on the evaluable
immunogenicity populations.
An additional analysis will be performed based on the all-available populations if there is a

large enough difference in sample size between the all-available immunogenicity population
and the evaluable immunogenicity population. Participants will be summarized according to
the vaccine group to which they were randomized.
CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014163
Page 110
Protocol C4591001
Endpoint Statistical Analysis Methods

Secondary Geometric mean titers/concentrations (GMTs/GMCs) of
immunogenicity SARS-CoV-2 neutralizing titers, S1-binding IgG level, and
RBD-binding IgG level
For SARS-CoV-2 neutralizing titers, S1-binding IgG levels, and

RBD-binding IgG levels, GMTs/GMCs and 2-sided 95% CIs will be
provided for each investigational product within each group before
vaccination and at each of the following time points:
 Phase 1: 7 and 21 days after Dose 1; 7 and 14 days and 1, 6, 12

and 24 months after Dose 2
Geometric means will be calculated as the mean of the assay results

after making the logarithm transformation and then exponentiating the
mean to express results on the original scale. Two-sided 95% CIs will
be obtained by taking natural log transforms of concentrations/titers,
calculating the 95% CI with reference to the t-distribution, and then
exponentiating the confidence limits.
GMFRs of SARS-CoV-2 neutralizing titers, S1-binding IgG level,

and RBD-binding IgG level

RBD-binding IgG levels, the GMFRs and 2-sided 95% CIs will be
provided for each investigational product within each group at each of
the following time points:
 Phase 1: 7 and 21 days after Dose 1; 7 and 14 days and 1, 6, 12,

GMFRs will be limited to participants with nonmissing values prior to

the first dose and at the postvaccination time point. The GMFR will be
calculated as the mean of the difference of logarithmically transformed
assay results (later time point – earlier time point) and exponentiating
the mean. The associated 2-sided CIs will be obtained by calculating
CIs using Student’s t-distribution for the mean difference of the
logarithmically transformed assay results and exponentiating the
confidence limits.
Percentage of participants with ≥4-fold rise in SARS-CoV-2

neutralizing titers, S1-binding IgG level, and RBD-binding IgG
level

RBD-binding IgG levels, percentages (and 2-sided 95% CIs) of
CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014164
Page 111
Protocol C4591001

participants with ≥4-fold rise will be provided for each investigational
product within each group at each of the following time points:

The Clopper-Pearson method will be used to calculate the CIs.
GMR of SARS-CoV-2 neutralizing titer to S1-binding IgG level

and to RBD-binding IgG level

RBD-binding IgG levels, the GMRs and 2-sided 95% CIs will be

GMRs will be limited to participants with nonmissing values for both

SARS-CoV-2 neutralizing titers and S1-binding IgG level/RBD-

binding IgG level at each time point. The GMR will be calculated as
the mean of the difference of logarithmically transformed assay results
(eg, SARS-CoV-2 neutralizing titers minus S1-binding IgG level for
each participant) and exponentiating the mean. Two-sided CIs will be
obtained by calculating CIs using Student’s t-distribution for the mean
difference of the logarithmically transformed assay results and
For all the immunogenicity endpoints, the analysis will be based on the
Dose 1 and Dose 2 evaluable immunogenicity populations. An
additional analysis will be performed based on the all-available
immunogenicity populations if there is a large enough difference in
sample size between the all-available immunogenicity populations and
the evaluable immunogenicity populations. Participants will be
summarized according to the vaccine group to which they were
randomized. Missing serology data will not be imputed.
Secondary GMR of SARS-CoV-2 neutralizing titers in participants 12 to 15

immunogenicity years of age to those 16 to 25 years of age
(noninferiority in
the 12- to 15-year For participants with no serological or virological evidence (up to
age group 1 month after receipt of the second dose) of past SARS-CoV-2
compared to the infection, the GMR of SARS-CoV-2 neutralizing titers in participants
12 to 15 years of age to those in participants 16 to 25 years of age and
CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014165
Page 112
Protocol C4591001

16- to 25-year age 2-sided 95% CIs will be provided at 1 month after Dose 2 for
group) noninferiority assessment.
The GMR and its 2-sided 95% CI will be derived by calculating

differences in means and CIs on the natural log scale of the titers based
on the Student’s t-distribution and then exponentiating the results. The
difference in means on the natural log scale will be 12 to 15 years
minus 16 to 25 years. Noninferiority will be declared if the lower
bound of the 2-sided 95% CI for the GMR is greater than 0.67.
This analysis will be based on Dose 2 evaluable immunogenicity

populations. An additional analysis may be performed based on the
Dose 2 all-available immunogenicity population if needed.
Participants will be summarized according to the vaccine group to
which they were randomized. Missing serology data will not be
imputed.
Exploratory Geometric mean titers/concentrations (GMTs/GMCs) of


vaccination and at each of the following time points in Phase 2/3:
 1, 6, 12, and 24 months after completion of vaccination in

participants with and without serological or virological
evidence of SARS-CoV-2 infection before vaccination



the following time points in Phase 2/3:
CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014166
Page 113
Protocol C4591001


confidence limits.
Percentage of participants with antibody levels ≥ predefined

threshold(s) for SARS-CoV-2 serological parameters
For SARS-CoV-2 neutralizing titers, S1-binding IgG levels and/or

RBD-binding IgG levels, N-binding antibody, and SARS-CoV-2
detection by NAAT, percentages (and 2-sided 95% CIs) of participants
with antibody levels ≥ predefined threshold(s) will be provided for

each investigational product within each group at baseline and each of

Percentage of participants with the immune response (non-S) to

SARS-CoV-2 for N-binding antibody at the time points when data
are available
For all of the immunogenicity endpoints, the analysis will be based on

the Dose 1 and Dose 2 evaluable immunogenicity populations. An
CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014167
Page 114
Protocol C4591001

RCDCs for immunogenicity results
Empirical RCDCs will be provided for SARS-CoV-2 neutralizing

titers, S1-binding IgG level, and RBD-binding IgG level after Dose 1
and after Dose 2.
9.4.2. Efficacy Analyses

The evaluable efficacy population will be the primary analysis population for all efficacy
analyses. Additional analyses based on the all-available efficacy population will be
performed.

Primary efficacy Ratio of confirmed COVID-19 illness from 7 days after the second
dose per 1000 person-years of follow-up in participants without
evidence of infection (prior to 7 days after receipt of the second
dose) for the active vaccine group to the placebo group
VE will be estimated by 100 × (1 – IRR), where IRR is the calculated

ratio of confirmed COVID-19 illness per 1000 person-years follow-up
in the active vaccine group to the corresponding illness rate in the
placebo group from 7 days after the second dose. VE will be analyzed
using a beta-binomial model.
After the above objective is met, the second primary endpoint will be
evaluated as below.
Ratio of confirmed COVID-19 illness from 7 days after the second

dose per 1000 person-years of follow-up in participants with and
without evidence of infection (prior to 7 days after receipt of the
second dose) for the active vaccine group to the placebo group

placebo group from 7 days after the second dose. VE will be analyzed
The efficacy analysis for the first primary objective evaluation will be
based on the participants without evidence of infection before
vaccination and included in the evaluable efficacy population and in
the all-available efficacy population.
CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014168
Page 115
Protocol C4591001

The efficacy analysis for the second primary objective evaluation will
be based on all participants included in the evaluable efficacy
population and in the all-available efficacy population.
For the primary endpoint analysis, missing efficacy data will not be
imputed. A sensitivity analysis will be performed by imputing missing
values with the assumption of MAR. A missing efficacy endpoint may
be imputed based on predicted probability using the fully conditional
specification method. Other imputation methods without the MAR
assumption may be explored. The details will be provided in the SAP.
Secondary First: Ratio of confirmed COVID-19 illness from 14 days after the
second dose per 1000 person-years of follow-up in participants
without evidence of infection (prior to 14 days after receipt of the
Second: Ratio of confirmed COVID-19 illness from 14 days after

the second dose per 1000 person-years of follow-up in participants
with and without evidence of infection (prior to 14 days after
receipt of the second dose) for the active vaccine group to the
placebo group
Third and fourth: Ratios of confirmed severe COVID-19 illness

from 7 days and from 14 days after the second dose per 1000
person-years of follow-up in participants without evidence of
infection (prior to 7 days or 14 days after receipt of the second
dose) for the active vaccine group to the placebo group
Fifth and sixth: Ratios of confirmed severe COVID-19 illness from

7 days and from 14 days after the second dose per 1000
person-years of follow-up in participants with and without
evidence of infection (prior to 7 days or 14 days after receipt of the
These secondary efficacy objectives will be evaluated sequentially in

the order specified above after the primary objectives are met. The
analysis will be based on the evaluable efficacy population and the all-
available efficacy population. The analysis methodology used for the
primary efficacy endpoints will be applied for the analysis of the above
secondary efficacy endpoints.
The following secondary efficacy endpoints will be evaluated

descriptively with 95% CIs.
CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014169
Page 116
Protocol C4591001

Ratios of confirmed COVID-19 illness (according to the
CDC-defined symptoms) from 7 days and from 14 days after the
without evidence of infection (prior to 7 days or 14 days after
receipt of the second dose) for the active vaccine group to the
placebo group
Ratios of confirmed COVID-19 illness (according to the

CDC-defined symptoms) from 7 days and from 14 days after the
with and without evidence of infection (prior to 7 days or 14 days
after receipt of the second dose) for the active vaccine group to the
placebo group
VE = 100 × (1 – IRR) will be estimated with confirmed COVID-19

illness according to the CDC-defined symptoms from 7 days or from
14 days after the second dose. The 2-sided 95% CI for VE will be
derived using the Clopper-Pearson method as described by Agresti.9
Missing efficacy data will not be imputed.
9.4.3. Safety Analyses

Primary Descriptive statistics will be provided for each reactogenicity endpoint
for each dose and vaccine group. Local reactions and systemic events
from Day 1 through Day 7 after each vaccination will be presented by
severity and cumulatively across severity levels. Descriptive
summary statistics will include counts and percentages of participants
with the indicated endpoint and the associated Clopper-Pearson 95%
CIs.
For Phase 1, descriptive statistics will be provided for abnormal

hematology and chemistry laboratory values at 1 and 7 days after
Dose 1 and 7 days after Dose 2, including grading shifts in
hematology and chemistry laboratory assessments between baseline
and 1 and 7 days after Dose 1, and before Dose 2 and 7 days after
Dose 2. Descriptive summary statistics will include counts and
percentages of participants with the indicated endpoint and the
associated Clopper-Pearson 2-sided 95% CIs.
AEs will be categorized according to the Medical Dictionary for

Regulatory Activities (MedDRA) terms. A 3-tier approach will be
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014170
Page 117
Protocol C4591001

used to summarize AEs in Phase 2/3. Under this approach AEs are
classified into 1 of 3 tiers: (1) Tier 1 events are prespecified events of
clinical importance and are identified in a list in the product’s safety
review plan; (2) Tier 2 events are those that are not Tier 1 but are
considered “relatively common”; a MedDRA preferred term is defined
as a Tier 2 event if there are at least 1% of participants in at least 1
vaccine group reporting the event; and (3) Tier 3 events are those that
are neither Tier 1 nor Tier 2 events. For both Tier 1 and Tier 2 events,
2-sided 95% CIs for the difference between the vaccine and placebo
groups in the percentage of participants reporting the events based on
the Miettinen and Nurminen method10 will be provided. In addition,
for Tier 1 events, the asymptotic p-values will also be presented for
the difference between groups in the percentage of participants
reporting the events, based on the same test statistic and under the
assumption that the test statistic is asymptotically normally
distributed.
Descriptive summary statistics (counts, percentages, and associated

Clopper-Pearson 95% CIs) will be provided for any AE events for
each vaccine group.
SAEs will be categorized according to MedDRA terms. Counts,

percentages, and the associated Clopper-Pearson 95% CIs of SAEs
from Dose 1 to 6 months after the last dose will be provided for each
vaccine group.
The safety analyses are based on the safety population. Participants

will be summarized by vaccine group according to the investigational
products they actually received. Missing reactogenicity e-diary data
will not be imputed; missing AE dates will be handled according to
the Pfizer safety rules.
Secondary Not applicable (N/A)
Exploratory N/A
9.4.4. Other Analyses

The ratios of (GMFR A to GMFR B) and (GMFR A to GMFR C) may be explored, where
GMFR A is the geometric mean of the ratio of the SARS-CoV-2 neutralizing titer at the
postvaccination time point to the corresponding titer at the prevaccination time point,
GFMR B is the geometric mean of the ratio of the S1-binding IgG level at the
postvaccination time point to the corresponding IgG level at the prevaccination time point,
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014171
Page 118
Protocol C4591001
and GMFR C is the geometric mean of the ratio of the RBD-binding IgG level at the
postvaccination time point to the corresponding antibody level at the prevaccination time
point.
The safety data and immunogenicity results for individuals with confirmed stable HIV
disease will be summarized descriptively. Furthermore, VE may be assessed if there is a
sufficient number of COVID-19 cases in this group of participants.
The safety and immunogenicity results for individuals 16 to 55 years of age vaccinated with
study intervention produced by manufacturing “Process 1” and each lot of “Process 2” will
be summarized descriptively. A random sample of 250 participants from those vaccinated
with study intervention produced by manufacturing “Process 1” will be selected randomly for
the analysis.
9.5. Interim Analyses

As this is a sponsor open-label study during Phase 1, the sponsor may conduct unblinded
reviews of the data during the course of the study for the purpose of safety assessment,
facilitating dose escalation decisions, and/or supporting clinical development.
During Phase 2/3, 4 IAs were planned to be performed by an unblinded statistical team after
accrual of at least 32, 62, 92, and 120 cases. However, for operational reasons, the first
planned IA was not performed. Consequently, 3 IAs are now planned to be performed after
accrual of at least 62, 92, and 120 cases. At these IAs, futility and VE with respect to the
first primary endpoint will be assessed as follows:
 VE for the first primary objective will be evaluated. Overwhelming efficacy will be
declared if the first primary study objective is met. The criteria for success at an
interim analysis are based on the posterior probability (ie, P[VE >30%|data]) at the
current number of cases. Overwhelming efficacy will be declared if the posterior
probability is higher than the success threshold. The success threshold for each
interim analysis will be calibrated to protect overall type I error at 2.5%. Additional
details about the success threshold or boundary calculation at each interim analysis
will be provided in the SAP.
 The study will stop for lack of benefit (futility) if the predicted probability of success
at the final analysis or study success is <5%. The posterior predictive POS will be
calculated using a beta-binomial model. The futility assessment will be performed
for the first primary endpoint and the futility boundary may be subject to change to
reflect subsequent program-related decisions by the sponsor.
 Efficacy and futility boundaries will be applied in a nonbinding way.
Bayesian approaches require specification of a prior distribution for the possible values of the
unknown vaccine effect, thereby accounting for uncertainty in its value. A minimally
informative beta prior, beta (0.700102, 1), is proposed for θ = (1-VE)/(2-VE). The prior is
CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014172
Page 119
Protocol C4591001
centered at θ = 0.4118 (VE=30%) which can be considered pessimistic. The prior allows
considerable uncertainty; the 95% interval for θ is (0.005, 0.964) and the corresponding 95%
interval for VE is (-26.2, 0.995).
Table 6 illustrates the boundary for efficacy and futility if, for example, IAs are performed
after accrual of 32, 62, 92, and 120 cases in participants without evidence of infection before
vaccination. Note that although the first IA was not performed, the statistical criterion for
demonstrating success (posterior probability threshold) at the interim (>0.995) and final
(>0.986) analyses remains unchanged. Similarly, the futility boundaries are not changed.
Table 6. Interim Analysis Plan and Boundaries for Efficacy and Futility
Analysis Number of Success Criteriaa Futility Boundary
Cases VE Point Estimate VE Point Estimate
(Case Split) (Case Split)
IA1 32 76.9% (6:26) 11.8% (15:17)
IA2 62 68.1% (15:47) 27.8% (26:36)
IA3 92 62.7% (25:67) 38.6% (35:57)
IA4 120 58.8% (35:85) N/A
Final 164 52.3% (53:111)
Abbreviations: IA = interim analysis; N/A = not applicable; VE = vaccine efficacy.
Note: Case split = vaccine : placebo.

a. Interim efficacy claim: P(VE >30%|data) > 0.995; success at the final analysis: P(VE >30%|data)
> 0.986.
Additional design operating characteristics (the boundary based on the number of cases
observed in the vaccine group; the probabilities for efficacy and futility given assumed
various VEs with a 1:1 randomization ratio) are listed in Table 7 and Table 8, for IAs
conducted at 32, 62, 92, and 120 cases and the final analysis at 164 cases. Although the IA at
32 cases was not performed, the overall Type I error (overall probability of success when true
VE=30%) will still be strictly controlled at 0.025 with the originally proposed success/futility
boundaries.
CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014173
Page 120
Protocol C4591001
Table 7. Statistical Design Operating Characteristics: Probability of Success or

Failure for Interim Analyses
Vaccine Interim Analysis 1 Interim Analysis 2 Interim Analysis 3 Interim
Efficacy (Total Cases = 32) (Total Cases = 62) (Total Cases = 92) Analysis 4
(%) (Total Cases
= 120)
Probability Probability Probability Probability Probability Probability Probability of
of Success of Failure of Success of Failure of Success of Failure Success
(Cases in (Cases in (Cases in (Cases in (Cases in (Cases in (Cases
Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine Vaccine
Group ≤6) Group ≥15) Group ≤15) Group ≥26) Group ≤25) Group ≥35) Group ≤35)
30 0.006 0.315 0.003 0.231 0.002 0.239 0.002
50 0.054 0.078 0.051 0.056 0.063 0.103 0.075
60 0.150 0.021 0.160 0.010 0.175 0.019 0.160
70 0.368 0.003 0.310 <0.001 0.195 0.001 0.085
80 0.722 <0.001 0.238 <0.001 0.037 <0.001 0.003
Table 8. Statistical Design Operating Characteristics: Probability of Success for

Final Analysis and Overall
Vaccine Efficacy (%) Final Analysis Overall Probability of Success
(Total Cases = 164)

Probability of Success (Cases in Vaccine
Group ≤53)
30 0.007 0.021
50 0.196 0.439
60 0.220 0.866
70 0.036 >0.999
80 <0.001 >0.999
If neither success nor futility has been declared after all IAs, the final analysis will be
performed and the first primary objective will have been met if there are 53 or fewer cases
observed in the vaccine group out of a total of 164 first confirmed cases from 7 days after
receipt of the second dose of investigational product onwards.
Only the first primary endpoint will be analyzed at IA. If the first primary objective is met,
the second primary objective will be evaluated at the final analysis. After the primary
objectives are met, the first 6 secondary VE endpoints (confirmed COVID-19 occurring from
14 days after the second dose in participants without evidence of infection and in all
participants, confirmed severe COVID-19 occurring from 7 days and from 14 days after the
second dose in participants without evidence of infection and in all participants) will be
evaluated sequentially in the stated order, by the same method used for the evaluation of
primary VE endpoints. Success thresholds for secondary VE endpoints will be appropriately
chosen to control overall Type I error at 2.5%. Further details will be provided in the SAP.
The remaining secondary VE endpoints will be evaluated descriptively to calculate the
observed VE with 95% CIs.
CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014174
Page 121
Protocol C4591001
9.5.1. Analysis Timing

Statistical analyses will be carried out when the following data are available:
 Complete safety and immunogenicity analysis approximately 1 month after Dose 2

for Phase 1.
 Safety data through 7 days after Dose 2 and immunogenicity data through 1 month
after Dose 2 from the first 360 participants enrolled (180 to active vaccine and 180 to
placebo, stratified equally between 18 to 55 years and >55 to 85 years) in Phase 2/3.
 Safety data through 1 month after Dose 2 from at least 6000 participants enrolled
(3000 to active vaccine and 3000 to placebo) in Phase 2/3. Additional analyses of
safety data (with longer follow-up and/or additional participants) may be conducted if
required for regulatory purposes.
 IAs for efficacy after accrual of at least 62, 92, and 120 cases and futility after accrual
of at least 62 and 92 cases.
 Safety data through 1 month after Dose 2 and noninferiority comparison of

SARS-CoV-2 neutralizing titers in participants 12 to 15 years of age compared to
those in participants 16 to 25 years of age, 1 month after Dose 2.
 Descriptive analysis of immunogenicity and safety of “Process 1” and “Process 2”

material, 1 month after Dose 2.
 Complete safety and immunogenicity analysis approximately 6 months after Dose 2

for all participants in Phase 2/3.
 Complete efficacy and persistence-of-immunogenicity analysis after complete data

are available or at the end of the study.
All analyses conducted on Phase 2/3 data while the study is ongoing will be performed by an
unblinded statistical team.
9.6. Data Monitoring Committee or Other Independent Oversight Committee

This study will use an IRC, a DMC, and a group of internal case reviewers. The IRC is
independent of the study team and includes only internal members. The DMC is independent
of the study team and includes only external members. The IRC and DMC charters describe
the role of the IRC and DMC in more detail.
The responsibilities of the IRC are only in Phase 1 and will include:
 Review of safety data to permit dose escalations in the 18- to 55-year age cohort
 Review of safety data in the case of a stopping rule being met
CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014175
Page 122
Protocol C4591001
 Review of safety and/or immunogenicity data to:
 Allow groups of participants of 65 to 85 years of age to proceed
 Select vaccine candidate/dose level(s) to proceed into Phase 2/3. Data supporting
the selection, including results for both binding antibody levels and neutralizing
titers, and the ratio between them, will also be submitted to the FDA for review
 Review of any available safety and/or immunogenicity data generated during the
course of this study, or the BioNTech study conducted in Germany, to determine:
 Whether any groups may not be started
 Whether any groups may be terminated early
 Whether any groups may be added with dose levels below the lowest stated dose
or intermediate between the lowest and highest stated doses
 Contemporaneous review of all NAAT-confirmed COVID-19 illnesses in Phase 1

The DMC will be responsible for ongoing monitoring of the safety of participants in the
study according to the charter. This may include, but is not limited to:
 Contemporaneous review of related AEs up to 1 month after completion of the

vaccination schedule
 Contemporaneous review of all SAEs up to 6 months after completion of the

 At the time of the planned IAs, and ad hoc if requested by the unblinded team, review
of cases of COVID-19 for an adverse imbalance of cases of COVID-19 and/or severe
COVID-19 between the vaccine and placebo groups
The recommendations made by the DMC to alter the conduct of the study will be forwarded
to the appropriate Pfizer personnel for final decision. Pfizer will forward such decisions,
which may include summaries of aggregate analyses of safety data, to regulatory authorities,
as appropriate.
Three blinded case reviewers (medically qualified Pfizer staff members) will review all
considered severe, or not, solely on the basis of “significant acute renal, hepatic, or
neurologic dysfunction,” the blinded data will be reviewed by the case reviewers to assess
whether the criterion is met; the majority opinion will prevail.
CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014176
Page 123
Protocol C4591001
10. SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS

10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study will be conducted in accordance with the protocol and with the following:
 Consensus ethical principles derived from international guidelines including the

Declaration of Helsinki and CIOMS International Ethical Guidelines;
 Applicable ICH GCP guidelines;
 Applicable laws and regulations, including applicable privacy laws.
The protocol, protocol amendments, ICD, SRSD(s), and other relevant documents
(eg, advertisements) must be reviewed and approved by the sponsor and submitted to an
IRB/EC by the investigator and reviewed and approved by the IRB/EC before the study is
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of
changes made to the study design, except for changes necessary to eliminate an immediate
hazard to study participants.
The investigator will be responsible for the following:
 Providing written summaries of the status of the study to the IRB/EC annually or
more frequently in accordance with the requirements, policies, and procedures
established by the IRB/EC;
 Notifying the IRB/EC of SAEs or other significant safety findings as required by

IRB/EC procedures;
 Providing oversight of the conduct of the study at the site and adherence to
requirements of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014
for clinical studies (if applicable), and all other applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GCP
In the event of any prohibition or restriction imposed (ie, clinical hold) by an applicable
regulatory authority in any area of the world, or if the investigator is aware of any new
information that might influence the evaluation of the benefits and risks of the study
intervention, Pfizer should be informed immediately.
In addition, the investigator will inform Pfizer immediately of any urgent safety measures
taken by the investigator to protect the study participants against any immediate hazard, and
of any serious breaches of this protocol or of ICH GCP that the investigator becomes aware
of.
CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014177
Page 124
Protocol C4591001
10.1.2. Informed Consent Process

The investigator or his/her representative will explain the nature of the study to the
participant or his or her parent(s)/legal guardian and answer all questions regarding the study.
The participant or his or her parent(s)/legal guardian should be given sufficient time and
opportunity to ask questions and to decide whether or not to participate in the trial.
Participants must be informed that their participation is voluntary. Participants or their

parent(s)/legal guardian will be required to sign a statement of informed consent that meets
the requirements of 21 CFR 50, local regulations, ICH guidelines, HIPAA requirements,
where applicable, and the IRB/EC or study center.
The investigator must ensure that each study participant or his or her parent(s)/legal guardian
is fully informed about the nature and objectives of the study, the sharing of data related to
the study, and possible risks associated with participation, including the risks associated with
the processing of the participant’s personal data.
The participant must be informed that his/her personal study-related data will be used by the
sponsor in accordance with local data protection law. The level of disclosure must also be
explained to the participant.
The participant must be informed that his/her medical records may be examined by Clinical
Quality Assurance auditors or other authorized personnel appointed by the sponsor, by
appropriate IRB/EC members, and by inspectors from regulatory authorities.
The investigator further must ensure that each study participant or his or her parent(s)/legal
guardian is fully informed about his or her right to access and correct his or her personal data
and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained
before the participant was enrolled in the study and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the ICD.
Participants must be reconsented to the most current version of the ICD(s) during their
A copy of the ICD(s) must be provided to the participant or his or her parent(s)/legal
guardian. Participants who are rescreened are required to sign a new ICD.
Unless prohibited by local requirements or IRB/EC decision, the ICD will contain a separate
section that addresses the use of samples for optional additional research. The optional
additional research does not require the collection of any further samples. The investigator
or authorized designee will explain to each participant the objectives of the additional
research. Participants will be told that they are free to refuse to participate and may
withdraw their consent at any time and for any reason during the storage period.
CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014178
Page 125
Protocol C4591001
10.1.3. Data Protection

All parties will comply with all applicable laws, including laws regarding the implementation
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study site in encrypted electronic and/or paper
form and will be password protected or secured in a locked room to ensure that only
authorized study staff have access. The study site will implement appropriate technical and
organizational measures to ensure that the personal data can be recovered in the event of
disaster. In the event of a potential personal data breach, the study site will be responsible
for determining whether a personal data breach has in fact occurred and, if so, providing
breach notifications as required by law.
To protect the rights and freedoms of participants with regard to the processing of personal
data, participants will be assigned a single, participant-specific numerical code. Any
participant records or data sets that are transferred to the sponsor will contain the numerical
code; participant names will not be transferred. All other identifiable data transferred to the
sponsor will be identified by this single, participant-specific code. The study site will
maintain a confidential list of participants who participated in the study, linking each
participant’s numerical code to his or her actual identity and medical record identification. In
case of data transfer, the sponsor will protect the confidentiality of participants’ personal data
consistent with the clinical study agreement and applicable privacy laws.
10.1.4. Dissemination of Clinical Study Data

Pfizer fulfills its commitment to publicly disclose clinical study results through posting the
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the EudraCT, and/or
www.pfizer.com, and other public registries in accordance with applicable local
laws/regulations. In addition, Pfizer reports study results outside of the requirements of local
laws/regulations pursuant to its SOPs.
In all cases, study results are reported by Pfizer in an objective, accurate, balanced, and
complete manner and are reported regardless of the outcome of the study or the country in
which the study was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial results on www.clinicaltrials.gov for Pfizer-sponsored interventional

studies (conducted in patients) that evaluate the safety and/or efficacy of a product,
regardless of the geographical location in which the study is conducted. These results are
submitted for posting in accordance with the format and timelines set forth by US law.
EudraCT
Pfizer posts clinical trial results on EudraCT for Pfizer-sponsored interventional studies in
accordance with the format and timelines set forth by EU requirements.
CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014179
Page 126
Protocol C4591001
www.pfizer.com
Pfizer posts public disclosure synopses (CSR synopses in which any data that could be used
to identify individual participants have been removed) on www.pfizer.com for
Pfizer-sponsored interventional studies at the same time the corresponding study results are
posted to www.clinicaltrials.gov.
Documents within marketing authorization packages/submissions
Pfizer complies with the European Union Policy 0070, the proactive publication of clinical
data to the EMA website. Clinical data, under Phase 1 of this policy, includes clinical
overviews, clinical summaries, CSRs, and appendices containing the protocol and protocol
amendments, sample CRFs, and statistical methods. Clinical data, under Phase 2 of this
policy, includes the publishing of individual participant data. Policy 0070 applies to new
marketing authorization applications submitted via the centralized procedure since
01 January 2015 and applications for line extensions and for new indications submitted via
the centralized procedure since 01 July 2015.
Data Sharing
Pfizer provides researchers secure access to patient-level data or full CSRs for the purposes
of “bona-fide scientific research” that contributes to the scientific understanding of the

disease, target, or compound class. Pfizer will make available data from these trials
24 months after study completion. Patient-level data will be anonymized in accordance with
applicable privacy laws and regulations. CSRs will have personally identifiable information
redacted.
Data requests are considered from qualified researchers with the appropriate competencies to
perform the proposed analyses. Research teams must include a biostatistician. Data will not
be provided to applicants with significant conflicts of interest, including individuals
requesting access for commercial/competitive or legal purposes.
10.1.5. Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic CRF unless
transmitted to the sponsor or designee electronically (eg, laboratory data). The investigator is
responsible for verifying that data entries are accurate and correct by physically or
electronically signing the CRF.
The investigator must maintain accurate documentation (source data) that supports the
information entered in the CRF.
The investigator must ensure that the CRFs are securely stored at the study site in encrypted
electronic and/or paper form and are password protected or secured in a locked room to
prevent access by unauthorized third parties.
CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014180
Page 127
Protocol C4591001
The investigator must permit study-related monitoring, audits, IRB/EC review, and
regulatory agency inspections and provide direct access to source data documents. This
verification may also occur after study completion. It is important that the investigator(s)
and their relevant personnel are available during the monitoring visits and possible audits or
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy (eg, risk-based initiatives in operations and quality
such as risk management and mitigation strategies and analytical risk-based monitoring),
methods, responsibilities, and requirements, including handling of noncompliance issues and
monitoring techniques (central, remote, or on-site monitoring), are provided in the
monitoring plan.
The sponsor or designee is responsible for the data management of this study, including
quality checking of the data.
Study monitors will perform ongoing source data verification to confirm that data entered
into the CRF by authorized site personnel are accurate, complete, and verifiable from source
documents; that the safety and rights of participants are being protected; and that the study is
being conducted in accordance with the currently approved protocol and any other study
agreements, ICH GCP, and all applicable regulatory requirements.
Records and documents, including signed ICDs, pertaining to the conduct of this study must
be retained by the investigator for 15 years after study completion unless local regulations or
institutional policies require a longer retention period. No records may be destroyed during
the retention period without the written approval of the sponsor. No records may be
transferred to another location or party without written notification to the sponsor. The
investigator must ensure that the records continue to be stored securely for as long as they are
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such
data are promptly and irrevocably deleted from all systems.
The investigator(s) will notify the sponsor or its agents immediately of any regulatory
inspection notification in relation to the study. Furthermore, the investigator will cooperate
with the sponsor or its agents to prepare the investigator site for the inspection and will allow
the sponsor or its agent, whenever feasible, to be present during the inspection. The
investigator site and investigator will promptly resolve any discrepancies that are identified
between the study data and the participant's medical records. The investigator will promptly
provide copies of the inspection findings to the sponsor or its agent. Before response
submission to the regulatory authorities, the investigator will provide the sponsor or its
agents with an opportunity to review and comment on responses to any such findings.
CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014181
Page 128
Protocol C4591001
10.1.6. Source Documents

Source documents provide evidence for the existence of the participant and substantiate the
integrity of the data collected. Source documents are filed at the investigator site.
Data reported on the CRF or entered in the eCRF that are from source documents must be
consistent with the source documents or the discrepancies must be explained. The
investigator may need to request previous medical records or transfer records, depending on
the study. Also, current medical records must be available.
Definition of what constitutes source data can be found in the study monitoring plan.
Description of the use of computerized system is documented in the Data Management Plan.
10.1.7. Study and Site Start and Closure

The study start date is the date on which the clinical study will be open for recruitment of
participants.
The first act of recruitment is the date of the first participant’s first visit and will be the study
start date.
The sponsor designee reserves the right to close the study site or terminate the study at any
time for any reason at the sole discretion of the sponsor. Study sites will be closed upon
study completion. A study site is considered closed when all required documents and study
supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time upon notification to the sponsor
or designee if requested to do so by the responsible IRB/EC or if such termination is required
to protect the health of study participants.
Reasons for the early closure of a study site by the sponsor may include but are not limited
to:
 Failure of the investigator to comply with the protocol, the requirements of the
IRB/EC or local health authorities, the sponsor's procedures, or GCP guidelines;
 Inadequate recruitment of participants by the investigator;
 Discontinuation of further study intervention development.
If the study is prematurely terminated or suspended, the sponsor shall promptly inform the
investigators, the ECs/IRBs, the regulatory authorities, and any CRO(s) used in the study of
the reason for termination or suspension, as specified by the applicable regulatory
requirements. The investigator shall promptly inform the participant and should assure
appropriate participant therapy and/or follow-up.
CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014182
Page 129
Protocol C4591001
Study termination is also provided for in the clinical study agreement. If there is any conflict
between the contract and this protocol, the contract will control as to termination rights.
10.1.8. Sponsor’s Qualified Medical Personnel

The contact information for the sponsor's appropriately qualified medical personnel for the
study is documented in the study contact list located in the supporting study documentation.
To facilitate access to appropriately qualified medical personnel on study-related medical

questions or problems, participants are provided with a contact card at the time of informed
consent. The contact card contains, at a minimum, protocol and study intervention
identifiers, participant numbers, contact information for the investigator site, and contact
details for a contact center in the event that the investigator site staff cannot be reached to
provide advice on a medical question or problem originating from another healthcare
professional not involved in the participant’s participation in the study. The contact number
can also be used by investigator staff if they are seeking advice on medical questions or
problems; however, it should be used only in the event that the established communication
pathways between the investigator site and the study team are not available. It is therefore
intended to augment, but not replace, the established communication pathways between the
investigator site and the study team for advice on medical questions or problems that may
arise during the study. The contact number is not intended for use by the participant directly,
and if a participant calls that number, he or she will be directed back to the investigator site.
CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014183
Page 130
Protocol C4591001
10.2. Appendix 2: Clinical Laboratory Tests

The following safety laboratory tests will be performed at times defined in the SoA section of
this protocol. Additional laboratory results may be reported on these samples as a result of
the method of analysis or the type of analyzer used by the clinical laboratory, or as derived
from calculated values. These additional tests would not require additional collection of
blood. Unscheduled clinical laboratory measurements may be obtained at any time during
the study to assess any perceived safety issues.
Hematology Chemistry Other

Hemoglobin BUN and creatinine  Urine pregnancy test (β-hCG)
Hematocrit AST, ALT At screening only:
RBC count Total bilirubin  Hepatitis B core antibody
MCV Alkaline phosphatase  Hepatitis B surface antigen
MCH  Hepatitis C antibody
MCHC  Human immunodeficiency virus
Platelet count
WBC count
Total neutrophils (Abs)
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)
Investigators must document their review of each laboratory safety report.
Clinically significant abnormal laboratory findings should be recorded in the AE CRF in

accordance with the following grading scale (Table 9).
Table 9. Laboratory Abnormality Grading Scale

Hematology Mild (Grade 1) Moderate Severe (Grade 3) Potentially Life
(Grade 2) Threatening
(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
decrease - cells/mm3
Neutrophils decrease 1,500 – 2,000 1,000 – 1,499 500 – 999 <500
- cells/mm3
Eosinophils - 650 – 1500 1501 - 5000 >5000 Hypereosinophilic
cells/mm3
Platelets decreased - 125,000 – 140,000 100,000 – 124,000 25,000 – 99,000 <25,000
cells/mm3
CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014184
Page 131
Protocol C4591001

Chemistry Mild (Grade 1) Moderate Severe Potentially Life
(Grade 2) (Grade 3) Threatening
(Grade 4)
BUN - mg/dL 23 – 26 27 – 31 > 31 Requires dialysis
Creatinine – mg/dL 1.5 – 1.7 1.8 – 2.0 2.1 – 2.5 > 2.5 or requires
dialysis
Alkaline 1.1 – 2.0 x ULN 2.1 – 3.0 x ULN 3.1 – 10 x ULN >10 x ULN
phosphate –
increase by factor
Liver function tests 1.1 – 2.5 x ULN 2.6 – 5.0 x ULN 5.1 – 10 x ULN >10 x ULN
– ALT, AST
increase by factor
Bilirubin – when 1.1 – 1.25 x ULN 1.26 – 1.5 x ULN 1.51 – 1.75 x ULN >1.75 x ULN
accompanied
by any increase in
liver function test -
increase by factor
liver function test is
normal - increase by
factor
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen;
ULN = upper limit of normal; WBC = white blood cell.
CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014185
Page 132
Protocol C4591001

Evaluating, Follow-up, and Reporting
10.3.1. Definition of AE
AE Definition
 An AE is any untoward medical occurrence in a patient or clinical study participant,
temporally associated with the use of study intervention, whether or not considered
related to the study intervention.
 NOTE: An AE can therefore be any unfavorable and unintended sign (including an

abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally
associated with the use of study intervention.
Events Meeting the AE Definition

 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis)
or other safety assessments (eg, ECG, radiological scans, vital sign measurements),
including those that worsen from baseline, considered clinically significant in the
medical and scientific judgment of the investigator Any abnormal laboratory test
results that meet any of the conditions below must be recorded as an AE:
 Is associated with accompanying symptoms.
 Requires additional diagnostic testing or medical/surgical intervention.
 Leads to a change in study dosing (outside of any protocol-specified dose

adjustments) or discontinuation from the study, significant additional
concomitant drug treatment, or other therapy.
 Exacerbation of a chronic or intermittent preexisting condition including either an

increase in frequency and/or intensity of the condition.
 New conditions detected or diagnosed after study intervention administration even

though it may have been present before the start of the study.
 Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study

intervention or a concomitant medication. Overdose per se will not be reported as
an AE/SAE unless it is an intentional overdose taken with possible
suicidal/self-harming intent. Such overdoses should be reported regardless of
sequelae.
CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014186
Page 133
Protocol C4591001
Events NOT Meeting the AE Definition

 Any clinically significant abnormal laboratory findings or other abnormal safety
assessments which are associated with the underlying disease, unless judged by the
investigator to be more severe than expected for the participant’s condition.
 The disease/disorder being studied or expected progression, signs, or symptoms of

the disease/disorder being studied, unless more severe than expected for the
participant’s condition.
 Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that

leads to the procedure is the AE.
 Situations in which an untoward medical occurrence did not occur (social and/or
convenience admission to a hospital).
 Anticipated day-to-day fluctuations of preexisting disease(s) or condition(s) present

or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE

If an event is not an AE per definition above, then it cannot be an SAE even if serious
conditions are met (eg, hospitalization for signs/symptoms of the disease under study, death
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life-threatening
The term “life-threatening” in the definition of “serious” refers to an event in which the
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically might have caused death if it were more severe.
c. Requires inpatient hospitalization or prolongation of existing hospitalization

In general, hospitalization signifies that the participant has been detained (usually involving
at least an overnight stay) at the hospital or emergency ward for observation and/or
treatment that would not have been appropriate in the physician’s office or outpatient
setting. Complications that occur during hospitalization are AEs. If a complication
prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in
doubt as to whether “hospitalization” occurred or was necessary, the AE should be
considered serious.
CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014187
Page 134
Protocol C4591001
Hospitalization for elective treatment of a preexisting condition that did not worsen from
baseline is not considered an AE.
d. Results in persistent disability/incapacity

 The term disability means a substantial disruption of a person’s ability to conduct
normal life functions.
 This definition is not intended to include experiences of relatively minor medical

significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza,
and accidental trauma (eg, sprained ankle) which may interfere with or prevent
everyday life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
 Medical or scientific judgment should be exercised in deciding whether SAE
reporting is appropriate in other situations such as important medical events that
may not be immediately life-threatening or result in death or hospitalization but may
jeopardize the participant or may require medical or surgical intervention to prevent
one of the other outcomes listed in the above definition. These events should
usually be considered serious.
 Examples of such events include invasive or malignant cancers, intensive treatment

in an emergency room or at home for allergic bronchospasm, blood dyscrasias or
convulsions that do not result in hospitalization, or development of drug dependency
or drug abuse.
 Suspected transmission via a Pfizer product of an infectious agent, pathogenic or

nonpathogenic, is considered serious. The event may be suspected from clinical
symptoms or laboratory findings indicating an infection in a patient exposed to a
Pfizer product. The terms “suspected transmission” and “transmission” are
considered synonymous. These cases are considered unexpected and handled as
serious expedited cases by pharmacovigilance personnel. Such cases are also
considered for reporting as product defects, if appropriate.
CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014188
Page 135
Protocol C4591001
10.3.3. Recording/Reporting and Follow-up of AEs and/or SAEs
AE and SAE Recording/Reporting
The table below summarizes the requirements for recording adverse events on the CRF and
for reporting serious adverse events on the Vaccine SAE Report Form to Pfizer Safety.
These requirements are delineated for 3 types of events: (1) SAEs; (2) nonserious adverse
events (AEs); and (3) exposure to the study intervention under study during pregnancy or
breastfeeding, and occupational exposure.
It should be noted that the Vaccine SAE Report Form for reporting of SAE information is
not the same as the AE page of the CRF. When the same data are collected, the forms must
be completed in a consistent manner. AEs should be recorded using concise medical
terminology and the same AE term should be used on both the CRF and the Vaccine SAE
Report Form for reporting of SAE information.
Safety Event Recorded on the CRF Reported on the Vaccine

SAE Report Form to
Pfizer Safety Within 24
Hours of Awareness
SAE All All

Nonserious AE All None
Exposure to the study All AEs/SAEs associated All (and EDP supplemental
intervention under study with exposure during form for EDP)
during pregnancy or pregnancy or breastfeeding Note: Include all SAEs
breastfeeding, and associated with exposure
occupational exposure
Occupational exposure is not during pregnancy or
recorded. breastfeeding. Include all
AEs/SAEs associated with
occupational exposure.
 When an AE/SAE occurs, it is the responsibility of the investigator to review all

documentation (eg, hospital progress notes, laboratory reports, and diagnostic
reports) related to the event.
 The investigator will then record all relevant AE/SAE information in the CRF.
 It is not acceptable for the investigator to send photocopies of the participant’s

medical records to Pfizer Safety in lieu of completion of the Vaccine SAE Report
Form/AE/SAE CRF page.
 There may be instances when copies of medical records for certain cases are
requested by Pfizer Safety. In this case, all participant identifiers, with the
CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014189
Page 136
Protocol C4591001
exception of the participant number, will be redacted on the copies of the medical
records before submission to Pfizer Safety.
 The investigator will attempt to establish a diagnosis of the event based on signs,
symptoms, and/or other clinical information. Whenever possible, the diagnosis
(not the individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported during
the study and assign it to 1 of the following categories:
GRADE If required on the AE page of the CRF, the investigator will use the
adjectives MILD, MODERATE, SEVERE, or LIFE-THREATENING to
describe the maximum intensity of the AE. For purposes of consistency,
these intensity grades are defined as follows:
1 MILD Does not interfere with participant's usual

function.
2 MODERATE Interferes to some extent with participant's usual

function.
3 SEVERE Interferes significantly with participant's usual

function.
4 LIFE-THREATENING Life-threatening consequences; urgent

intervention indicated.
Assessment of Causality
 The investigator is obligated to assess the relationship between study intervention
and each occurrence of each AE/SAE.
 A “reasonable possibility” of a relationship conveys that there are facts, evidence,

and/or arguments to suggest a causal relationship, rather than a relationship cannot
be ruled out.
 The investigator will use clinical judgment to determine the relationship.
 Alternative causes, such as underlying disease(s), concomitant therapy, and other

risk factors, as well as the temporal relationship of the event to study intervention
administration, will be considered and investigated.
CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014190
Page 137
Protocol C4591001
 The investigator will also consult the IB and/or product information, for marketed
products, in his/her assessment.
 For each AE/SAE, the investigator must document in the medical notes that he/she
has reviewed the AE/SAE and has provided an assessment of causality.
 There may be situations in which an SAE has occurred and the investigator has
minimal information to include in the initial report to the sponsor. However, it is
very important that the investigator always make an assessment of causality for
every event before the initial transmission of the SAE data to the sponsor.
 The investigator may change his/her opinion of causality in light of follow-up

information and send an SAE follow-up report with the updated causality
assessment.
 The causality assessment is one of the criteria used when determining regulatory
reporting requirements.
 If the investigator does not know whether or not the study intervention caused the
event, then the event will be handled as “related to study intervention” for reporting
purposes, as defined by the sponsor. In addition, if the investigator determines that

an SAE is associated with study procedures, the investigator must record this causal
relationship in the source documents and CRF, and report such an assessment in the
dedicated section of the Vaccine SAE Report Form and in accordance with the SAE
Follow-up of AEs and SAEs

 The investigator is obligated to perform or arrange for the conduct of supplemental
measurements and/or evaluations as medically indicated or as requested by the
sponsor to elucidate the nature and/or causality of the AE or SAE as fully as
possible. This may include additional laboratory tests or investigations,
histopathological examinations, or consultation with other healthcare providers.
 If a participant dies during participation in the study or during a recognized

follow-up period, the investigator will provide Pfizer Safety with a copy of any
postmortem findings including histopathology.
 New or updated information will be recorded in the originally completed CRF.
 The investigator will submit any updated SAE data to the sponsor within 24 hours of
receipt of the information.
CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014191
Page 138
Protocol C4591001
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via Vaccine SAE Report Form

 Facsimile transmission of the Vaccine SAE Report Form is the preferred method to
transmit this information to Pfizer Safety.
 In circumstances when the facsimile is not working, notification by telephone is

acceptable with a copy of the Vaccine SAE Report Form sent by overnight mail or
courier service.
 Initial notification via telephone does not replace the need for the investigator to
complete and sign the Vaccine SAE Report Form pages within the designated
reporting time frames.
CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014192
Page 139
Protocol C4591001
10.4. Appendix 4: Contraceptive Guidance

10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they agree to the following requirements during
the intervention period and for at least 28 days after the last dose of study intervention, which
corresponds to the time needed to eliminate reproductive safety risk of the study
intervention(s):
 Refrain from donating sperm.
PLUS either:
 Be abstinent from heterosexual intercourse with a female of childbearing potential as

their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and
agree to remain abstinent.
OR
 Must agree to use a male condom when engaging in any activity that allows for
passage of ejaculate to another person.
 In addition to male condom use, a highly effective method of contraception may be

considered in WOCBP partners of male participants (refer to the list of highly
effective methods below in Section 10.4.4).
10.4.2. Female Participant Reproductive Inclusion Criteria

A female participant is eligible to participate if she is not pregnant or breastfeeding, and at
least 1 of the following conditions applies:
 Is not a WOCBP (see definitions below in Section 10.4.3).
OR
 Is a WOCBP and using an acceptable contraceptive method as described below

during the intervention period (for a minimum of 28 days after the last dose of study
intervention). The investigator should evaluate the effectiveness of the contraceptive
method in relationship to the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent
sexual activity to decrease the risk for inclusion of a woman with an early undetected
pregnancy.
CONFIDENTIAL
Page 140
FDA-CBER-2021-5683-0014193
Page 140
Protocol C4591001
10.4.3. Woman of Childbearing Potential

A woman is considered fertile following menarche and until becoming postmenopausal
unless permanently sterile (see below).
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot
be confirmed before the first dose of study intervention, additional evaluation should be
considered.
Women in the following categories are not considered WOCBP:
1. Premenarchal.
2. Premenopausal female with 1 of the following:
 Documented hysterectomy;
 Documented bilateral salpingectomy;
 Documented bilateral oophorectomy.

For individuals with permanent infertility due to an alternate medical cause other than the
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be
applied to determining study entry.
Note: Documentation for any of the above categories can come from the site personnel’s
review of the participant’s medical records, medical examination, or medical history
interview. The method of documentation should be recorded in the participant’s medical
record for the study.
3. Postmenopausal female:
 A postmenopausal state is defined as no menses for 12 months without an alternative

medical cause. In addition, a
 high FSH level in the postmenopausal range must be used to confirm a

postmenopausal state in women under 60 years of age and not using hormonal
contraception or HRT.
 Female on HRT and whose menopausal status is in doubt will be required to use
one of the nonestrogen hormonal highly effective contraception methods if they
wish to continue their HRT during the study. Otherwise, they must discontinue
HRT to allow confirmation of postmenopausal status before study enrollment.
CONFIDENTIAL
Page 141
FDA-CBER-2021-5683-0014194
Page 141
Protocol C4591001
10.4.4. Contraception Methods

Contraceptive use by men or women should be consistent with local availability/regulations
regarding the use of contraceptive methods for those participating in clinical trials.
1. Implantable progestogen-only hormone contraception associated with inhibition of

ovulation.
2. Intrauterine device.
3. Intrauterine hormone-releasing system.
4. Bilateral tubal occlusion.
5. Vasectomized partner:
 Vasectomized partner is a highly effective contraceptive method provided that the

partner is the sole sexual partner of the woman of childbearing potential and the
absence of sperm has been confirmed. If not, an additional highly effective method
of contraception should be used. The spermatogenesis cycle is approximately
90 days.
6. Combined (estrogen- and progestogen-containing) hormonal contraception associated

with inhibition of ovulation:
 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
7. Progestogen-only hormone contraception associated with inhibition of ovulation:
 Oral;
 Injectable.
8. Sexual abstinence:
 Sexual abstinence is considered a highly effective method only if defined as

refraining from heterosexual intercourse during the entire period of risk associated
with the study intervention. The reliability of sexual abstinence needs to be evaluated
in relation to the duration of the study and the preferred and usual lifestyle of the
participant.
CONFIDENTIAL
Page 142
FDA-CBER-2021-5683-0014195
Page 142
Protocol C4591001
9. Progestogen-only oral hormonal contraception where inhibition of ovulation is not the

primary mode of action.
10. Male or female condom with or without spermicide.
11. Cervical cap, diaphragm, or sponge with spermicide.
12. A combination of male condom with either cervical cap, diaphragm, or sponge with
spermicide (double-barrier methods).
CONFIDENTIAL
Page 143
FDA-CBER-2021-5683-0014196
Page 143
Protocol C4591001
10.5. Appendix 5: Liver Safety: Suggested Actions and Follow-up Assessments

Potential Cases of Drug-Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury (as determined by elevations in
transaminases) are termed “tolerators,” while those who show transient liver injury, but adapt
are termed “adaptors.” In some participants, transaminase elevations are a harbinger of a
more serious potential outcome. These participants fail to adapt and therefore are
"susceptible" to progressive and serious liver injury, commonly referred to as DILI.
Participants who experience a transaminase elevation above 3 × ULN should be monitored
more frequently to determine if they are an “adaptor” or are “susceptible.”
LFTs are not required as a routine safety monitoring procedure for all participants in this
study. However, should an investigator deem it necessary to assess LFTs because a
participant presents with clinical signs/symptoms, such LFT results should be managed and
followed as described below.
In the majority of DILI cases, elevations in AST and/or ALT precede TBili elevations
(>2 × ULN) by several days or weeks. The increase in TBili typically occurs while
AST/ALT is/are still elevated above 3 × ULN (ie, AST/ALT and TBili values will be
elevated within the same laboratory sample). In rare instances, by the time TBili elevations
are detected, AST/ALT values might have decreased. This occurrence is still regarded as a
potential DILI. Therefore, abnormal elevations in either AST OR ALT in addition to TBili
that meet the criteria outlined below are considered potential DILI (assessed per Hy’s law
criteria) cases and should always be considered important medical events, even before all
other possible causes of liver injury have been excluded.
The threshold of laboratory abnormalities for a potential DILI case depends on the
participant’s individual baseline values and underlying conditions. Participants who present
with the following laboratory abnormalities should be evaluated further as potential DILI
(Hy’s law) cases to definitively determine the etiology of the abnormal laboratory values:
 Participants with AST/ALT and TBili baseline values within the normal range who
subsequently present with AST OR ALT values >3 × ULN AND a TBili value
>2 × ULN with no evidence of hemolysis and an alkaline phosphatase value
<2 × ULN or not available.
 For participants with baseline AST OR ALT OR TBili values above the ULN, the
following threshold values are used in the definition mentioned above, as needed,
depending on which values are above the ULN at baseline:
 Preexisting AST or ALT baseline values above the normal range: AST or ALT
values >2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is
smaller).
CONFIDENTIAL
Page 144
FDA-CBER-2021-5683-0014197
Page 144
Protocol C4591001
 Preexisting values of TBili above the normal range: TBili level increased from
baseline value by an amount of at least 1 × ULN or if the value reaches
>3 × ULN (whichever is smaller).
Rises in AST/ALT and TBili separated by more than a few weeks should be assessed
individually based on clinical judgment; any case where uncertainty remains as to whether it
represents a potential Hy’s law case should be reviewed with the sponsor.
The participant should return to the investigator site and be evaluated as soon as possible,
preferably within 48 hours from awareness of the abnormal results. This evaluation should
include laboratory tests, detailed history, and physical assessment.
In addition to repeating measurements of AST and ALT and TBili for suspected cases of
Hy’s law, additional laboratory tests should include albumin, CK, direct and indirect
bilirubin, GGT, PT/INR, total bile acids, and alkaline phosphatase. Consideration should
also be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood
for further testing, as needed, for further contemporaneous analyses at the time of the
recognized initial abnormalities to determine etiology. A detailed history, including relevant
information, such as review of ethanol, acetaminophen/paracetamol (either by itself or as a
coformulated product in prescription or over-the-counter medications), recreational drug,
supplement (herbal) use and consumption, family history, sexual history, travel history,
history of contact with a jaundiced person, surgery, blood transfusion, history of liver or
allergic disease, and potential occupational exposure to chemicals, should be collected.
Further testing for acute hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary
tract) and collection of serum samples for acetaminophen/paracetamol drug and/or protein
adduct levels may be warranted.
All cases demonstrated on repeat testing as meeting the laboratory criteria of AST/ALT and
TBili elevation defined above should be considered potential DILI (Hy’s law) cases if no
other reason for the LFT abnormalities has yet been found. Such potential DILI (Hy’s law)
cases are to be reported as SAEs, irrespective of availability of all the results of the
investigations performed to determine etiology of the LFT abnormalities.
A potential DILI (Hy’s law) case becomes a confirmed case only after all results of
reasonable investigations have been received and have excluded an alternative etiology.
CONFIDENTIAL
Page 145
FDA-CBER-2021-5683-0014198
Page 145
Protocol C4591001
10.6. Appendix 6: Abbreviations

The following is a list of abbreviations that may be used in the protocol.
Abbreviation Term
2019-nCoV novel coronavirus 2019
Abs absolute (in Appendix 2)
AE adverse event
ALT alanine aminotransferase
AST aspartate aminotransferase
-hCG beta-human chorionic gonadotropin
BMI body mass index
BUN blood urea nitrogen
CBER Center for Biologics Evaluation and Research
CDC Centers for Disease Control and Prevention (United States)
CFR Code of Federal Regulations
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CLIA Clinical Laboratory Improvement Amendments
CONSORT Consolidated Standards of Reporting Trials
COVID-19 coronavirus disease 2019

CRF case report form
CRO contract research organization
CSR clinical study report
CT computed tomography
DBP diastolic blood pressure
DILI drug-induced liver injury
DMC data monitoring committee
DNA deoxyribonucleic acid
DU dosing unit
EC ethics committee
ECMO extracorporeal membrane oxygenation
ECG electrocardiogram
eCRF electronic case report form
e-diary electronic diary
EDP exposure during pregnancy
EMA European Medicines Agency
EU European Union
EUA emergency use authorization
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FiO2 fraction of inspired oxygen
FSH follicle-stimulating hormone
GCP Good Clinical Practice
CONFIDENTIAL
Page 146
FDA-CBER-2021-5683-0014199
Page 146
Protocol C4591001
Abbreviation Term
GGT gamma-glutamyl transferase
GMC geometric mean concentration
GMFR geometric mean fold rise
GMR geometric mean ratio
GMT geometric mean titer
HBc Ab hepatitis B core antibody
HBe hepatitis B e
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HCV Ab hepatitis C virus antibody
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
HR heart rate
HRT hormone replacement therapy
IA interim analysis
IB investigator’s brochure
ICD informed consent document

ICH International Council for Harmonisation
ICU intensive care unit
ID identification
Ig immunoglobulin
IgG immunoglobulin G
IgM immunoglobulin M
IMP investigational medicinal product
IND investigational new drug
INR international normalized ratio
IP manual investigational product manual
IPAL Investigational Product Accountability Log
IRB institutional review board
IRC internal review committee
IRR illness rate ratio
IRT interactive response technology
ISO International Organization for Standardization
IV intravenous(ly)
IWR interactive Web-based response
LFT liver function test
LL lower limit
LLOQ lower limit of quantitation
LNP lipid nanoparticle
LPX lipoplex
CONFIDENTIAL
Page 147
FDA-CBER-2021-5683-0014200
Page 147
Protocol C4591001
Abbreviation Term
MAR missing at random
MCH mean corpuscular hemoglobin
MCHC mean corpuscular hemoglobin concentration
MCV mean corpuscular volume
MedDRA Medical Dictionary for Regulatory Activities
MERS Middle East respiratory syndrome
MIS-C multisystem inflammatory syndrome in children
modRNA nucleoside-modified messenger ribonucleic acid
MRI magnetic resonance imaging
N SARS-CoV-2 nucleoprotein
N/A not applicable
NAAT nucleic acid amplification test
non-S nonspike protein
P2 S SARS-CoV-2 full-length, P2 mutant, prefusion spike glycoprotein
PaO2 partial pressure of oxygen, arterial
PCR polymerase chain reaction
PI principal investigator
POS probability of success
PPE personal protective equipment

PT prothrombin time
RBC red blood cell
RBD receptor-binding domain
RCDC reverse cumulative distribution curve
RNA ribonucleic acid
RR respiratory rate
RSV respiratory syncytial virus
RT-PCR reverse transcription–polymerase chain reaction
S1 spike protein S1 subunit
SAE serious adverse event
SAP statistical analysis plan
saRNA self-amplifying messenger ribonucleic acid
SARS severe acute respiratory syndrome
SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
SBP systolic blood pressure
SoA schedule of activities
SOP standard operating procedure
SpO2 oxygen saturation as measured by pulse oximetry
SRSD single reference safety document
SUSAR suspected unexpected serious adverse reaction
TBD to be determined
TBili total bilirubin
ULN upper limit of normal
CONFIDENTIAL
Page 148
FDA-CBER-2021-5683-0014201
Page 148
Protocol C4591001
Abbreviation Term
uRNA unmodified messenger ribonucleic acid
US United States
vax vaccination
VE vaccine efficacy
WBC white blood cell
WHO World Health Organization
WOCBP woman/women of childbearing potential
CONFIDENTIAL
Page 149
FDA-CBER-2021-5683-0014202
Page 149
Protocol C4591001
10.7. Appendix 7: Stopping and Alert Rules for Enhanced COVID-19

In Phase 2/3, the unblinded team supporting the DMC (reporting team), including an
unblinded medical monitor, will review cases of severe COVID-19 as they are received, and
will review AEs at least weekly for additional potential cases of severe COVID-19 and will
contact the DMC in the event that the stopping rule or an alert is met. Specifically, the
unblinded reporting team will contact the DMC chair, who will then convene the full DMC
as soon as possible. The DMC will review all available safety and/or efficacy data at the
time of the review. The DMC will make one of the following recommendations to Pfizer:
withhold final recommendation until further information/data are provided, continue the
study as designed, modify the study and continue, or stop the study. The final decision to
accept or reject the committee’s recommendation resides with Pfizer management and will be
communicated to the committee chairperson in writing.
At any point the unblinded team may discuss with the DMC chair whether the DMC should
review cases for an adverse imbalance of cases of COVID-19 and/or severe COVID-19
between the vaccine and placebo groups (see Section 9.6). In addition, at the time of the IAs
after accrual of at least 62, 92, and 120 cases, the number of severe COVID-19 cases in the
vaccine and placebo groups will be assessed.
the probability of an observed adverse split or worse be <11%.
The stopping rule and alert rules are illustrated in Table 10 and Table 11, respectively, when
the total number of severe cases is 20 or less. For example, when there are 7 severe cases,
the adverse split has to be 7:0 to stop the study, but a split of 5:2 would trigger the alert rule.
Similarly, when there is a total of 9 severe cases, an adverse split of 9:0 triggers the stopping
rule, while a split of 6:3 or worse triggers the alert rule. The alert rule may be triggered with
as few as 2 cases, with a split of 2:0.
CONFIDENTIAL
Page 150
FDA-CBER-2021-5683-0014203
Page 150
Protocol C4591001
Table 10. Stopping Rule: Enrollment Is Stopped if the Number of Severe Cases in
the Vaccine Group Is Greater Than or Equal to the Prespecified Stopping
Rule Value (S)
Total Severe Cases Prespecified Stopping Rule Value If the True Ratio of Severe Cases
(S): Number of Severe Cases in the Between Vaccine and Placebo
Vaccine Group to Stop Groups Is 1:1, Probability of S or
More Being Observed in the Vaccine
Group
4 4 N/A
5 5 3.13%
6 6 1.56%
7 7 0.78%
8 7 3.52%
9 8 1.95%
10 9 1.07%
11 9 3.27%
12 10 1.93%
13 10 4.61%
14 11 2.87%
15 12 1.76%
16 12 3.84%
17 13 2.45%
18 13 4.81%
19 14 3.18%
20 15 2.07%
Abbreviation: N/A = not applicable.
CONFIDENTIAL
Page 151
FDA-CBER-2021-5683-0014204
Page 151
Protocol C4591001
Table 11. Alert Rule: Further Action Is Taken if the Number of Severe Cases in the
Vaccine Group Is Greater Than or Equal to the Prespecified Alert Rule
Value (A)
Total Prespecifie If the True If the True If the True If the True If the True
Severe d Alert Ratio of Ratio of Ratio of Ratio of Ratio of
Cases Rule Value Severe Cases Severe Cases Severe Cases Severe Cases Severe Cases
(A): Between the Between the Between the Between the Between the
Number of Vaccine and Vaccine and Vaccine and Vaccine and Vaccine and
Severe Placebo Placebo Placebo Placebo Placebo
Cases in the Groups Is Groups Is Groups Is Groups Is Groups Is
Vaccine 1:1, 1:1, 2:1, 3:1, 4:1,
Group to Probability Probability Probability Probability Probability
Trigger of A Being of A or More of A or More of A or More of A or More
Further Observed in Being Being Being Being
Action the Vaccine Observed in Observed in Observed in Observed in
Group the Vaccine the Vaccine the Vaccine the Vaccine
Group Group Group Group
2 2 25.00% 25.00% 44.49% 56.25% 64.00%
3 2 37.50% 50.00% 74.12% 84.38% 89.60%
4 3 25.00% 31.25% 59.32% 73.83% 81.92%
5 4 15.63% 18.75% 46.16% 63.28% 73.73%
6 4 23.44% 34.38% 68.10% 83.06% 90.11%
7 5 16.41% 22.66% 57.14% 75.64% 85.20%

8 6 10.94% 14.45% 46.90% 67.85% 79.69%
9 6 16.41% 25.39% 65.11% 83.43% 91.44%
10 7 11.72% 17.19% 56.02% 77.59% 87.91%
11 8 8.06% 11.33% 47.35% 71.33% 83.89%
12 8 12.08% 19.38% 63.25% 84.24% 92.74%
13 9 8.73% 13.34% 55.31% 79.40% 90.09%
14 10 6.11% 8.98% 47.66% 74.15% 87.02%
15 10 9.16% 15.09% 61.94% 85.16% 93.89%
16 11 6.67% 10.51% 54.81% 81.03% 91.83%
17 12 4.72% 7.17% 47.88% 76.53% 89.43%
18 13 3.27% 4.81% 41.34% 71.75% 86.71%
19 13 5.18% 8.35% 54.43% 82.51% 93.24%
20 14 3.70% 5.77% 48.06% 78.58% 91.33%
CONFIDENTIAL
Page 152
FDA-CBER-2021-5683-0014205
Page 152
Protocol C4591001
10.8. Appendix 8: Criteria for Allowing Inclusion of Participants With Chronic Stable
HIV, HCV, or HBV Infection
Potential participants with chronic stable HIV, HCV, or HBV infection may be considered
for inclusion if they fulfill the following respective criteria.
Known HIV infection
 Confirmed stable HIV disease defined as documented viral load <50 copies/mL and
CD4 count >200 cells/mm3 within 6 months before enrollment, and on stable
antiretroviral therapy for at least 6 months.
Known HCV infection
 History of chronic HCV with evidence of sustained virological response (defined as

undetectable HCV RNA) for ≥12 weeks following HCV treatment or without
evidence of HCV RNA viremia (undetectable HCV viral load).
Known HBV infection
Confirmed inactive chronic HBV infection, defined as HBsAg present for ≥6 months and the
following:
 HBeAg negative, anti-HBe positive
 Serum HBV DNA <2000 IU/mL
 Persistently normal ALT and/or AST levels
 In those who have had a liver biopsy performed, findings that confirm the absence of
significant necroinflammation.
CONFIDENTIAL
Page 153
FDA-CBER-2021-5683-0014206
Page 153
Protocol C4591001
11. REFERENCES
1
World Health Organization. WHO Director-General's opening remarks at the media
briefing on COVID-19. Available from: https://www.who.int/dg/speeches/detail/
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---
11-march-2020. Published: 11 Mar 2020. Accessed: 01 Apr 2020.
2
World Health Organization. Coronavirus disease 2019 (COVID-19) situation report - 70.
In: Data as reported by national authorities by 10:00 CET 30 March 2020. Geneva,
Switzerland: World Health Organization; 2020.
3
Centers for Disease Control and Prevention. Coronavirus disease 2019 (COVID-19):
information for clinicians on investigational therapeutics for patients with COVID-19.
Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-
options.html. Updated: 25 Apr 2020. Accessed: 26 Jun 2020.
4
Rauch S, Jasny E, Schmidt KE, et al. New vaccine technologies to combat outbreak
situations. Front Immunol 2018;9:1963.
5
Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of
drugs. Nat Rev Drug Discov 2014;13(10):759-80.

6
BioNTech RNA Pharmaceuticals GmbH. CorVAC/BNT162 Investigator’s Brochure.
Mainz, Germany: BioNTech RNA Pharmaceuticals GmbH; 25 Mar 2020.
7
Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9
influenza viruses of pandemic potential are immunogenic and well tolerated in healthy
adults in phase 1 randomized clinical trials. Vaccine 2019;37(25):3326-34.
8
US Food and Drug Administration. Guidance for industry: toxicity grading scale for
healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials.
Rockville, MD: Center for Biologics Evaluation and Research; September 2007.
9
Agresti A. Introduction: distributions and inference for categorical data. In: Agresti A,
ed. Categorical data analysis. 2nd ed. Hoboken, NJ: John Wiley & Sons; 2002:1-35.
10
Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med
1985;4(2):213-26.
CONFIDENTIAL
Page 154
FDA-CBER-2021-5683-0014207
Page 154
Document Approval Record
Document Name:
Document Title: ! "#$%&'""( '%()*+( #',

'$#"*%( ($-*%(*%. &/(0 & ,"/& & -&0 &
"'#*"*&0 *))/%.%**&0 %( --*0 - '$,$
'% ,*% %(*(& .*%& ,*($ *% "&0 *
%(*,*(/"
Signed By: Date(GMT) Signing Capacity
"12 2 3 ! $$ !4!4 #35 55 " 6

73 7 2 ! $$ !4 4 - 6
FDA-CBER-2021-5683-0014208
Page 155
Protocol C4591001


090177e195444379\Approved\Approved On: 16-Oct-2020 06:36 (GMT)

Phase: 1/2/3
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014209
Page 156
Protocol C4591001
Document History

Protocol amendment 8 15 October 2020  Removed “N-binding antibody” and
“SARS-CoV-2 detection by NAAT” as
endpoints from the third exploratory objective,
as these results are used for the determination of
the population, and are not endpoints.
 Clarified that the “Process 1” participants
included in the descriptive analysis of
“Process 1”- and “Process 2”-manufactured
study interventions will be selected randomly.
 Clarified that surveillance of potential
COVID-19 symptoms should continue even if a
participant has a positive SARS-CoV-2 test
earlier in the study.
 Further modified the circumstances in which a
local NAAT result may be used in the
COVID-19 case definition.
 Clarified that for participants who are not in the
reactogenicity subset, local reactions and

systemic events following vaccination should be
detected and reported as AEs.
 Clarified that premenarchal females are not
WOCBP.
Section 7.1.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014210
Page 157
Protocol C4591001
Document History

case definition.
single illness.

25 years of age.
Section 9.5.1.
EU.
Vaccination 2.
~43,998.
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014211
Page 158
Protocol C4591001
Document History


AEs.
30 µg.
phase of the study.
In addition:
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014212
Page 159
Protocol C4591001
Document History

to the purpose.
evaluated.

added to Section 3.





CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014213
Page 160
Protocol C4591001
Document History

template.





protocol.
BNT162b2.
intervention.



CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014214
Page 161
Protocol C4591001
Document History


illness e-diary.

In addition:

(BNT162-01):
BNT162c2
Additionally:
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014215
Page 162
Protocol C4591001
Document History

after Dose 1 or 2
escalation
antigen to BNT162c2
subunit

will be directed
candidate
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014216
Page 163
Protocol C4591001
Document History

CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014217
Page 164
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................15
1.1. Synopsis ..................................................................................................................17
1.2. Schema ....................................................................................................................24
1.3.1. Phase 1 ........................................................................................................25
1.3.2. Phase 2/3.....................................................................................................30
2. INTRODUCTION ...............................................................................................................33
2.1. Study Rationale .......................................................................................................33
2.2. Background .............................................................................................................33
2.3.1. Risk Assessment .........................................................................................36

3.1. For Phase 1 ..............................................................................................................38
3.2. For Phase 2/3 ...........................................................................................................40
4. STUDY DESIGN.................................................................................................................42
4.1. Overall Design.........................................................................................................42
4.1.1. Phase 1 ........................................................................................................43
4.1.2. Phase 2/3.....................................................................................................44
5.3.1. Contraception..............................................................................................50
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014218
Page 165
Protocol C4591001
5.4. Screen Failures ........................................................................................................50

6.1.2. Administration ............................................................................................53

7.3. Lost to Follow-up ....................................................................................................60
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014219
Page 166
Protocol C4591001
8.2.2.1. Grading Scales...........................................................................66

8.2.2.2. Local Reactions .........................................................................66
8.2.2.3. Systemic Events ........................................................................67
8.2.2.4. Fever..........................................................................................68

Exposure ..........................................................................................................74
8.3.8.1. Lack of Efficacy ........................................................................77
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014220
Page 167
Protocol C4591001
8.7. Genetics ...................................................................................................................79

8.8. Biomarkers ..............................................................................................................79
8.11.1. Phase 1 ......................................................................................................79
8 Days After Visit 1) .........................................................................84
8 Days After Visit 4) .........................................................................87

16 Days After Visit 4) .......................................................................89
Visit 4) ...............................................................................................90
After Visit 4)......................................................................................90
After Visit 4)......................................................................................91
After Visit 4)......................................................................................91
8.11.2. Phase 2/3...................................................................................................92
After Visit 2)......................................................................................97
After Visit 2)......................................................................................98
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014221
Page 168
Protocol C4591001

After Visit 2)......................................................................................98
8.12. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction ........................99
8.13. COVID-19 Surveillance (All Participants) .........................................................100
Illness Visits ............................................................................................................104
9.1.1. Estimands..................................................................................................105

9.3. Analysis Sets .........................................................................................................108
9.4.3. Safety Analyses ........................................................................................115
9.4.4. Other Analyses..........................................................................................117
9.5.1. Analysis Timing........................................................................................120
CONSIDERATIONS ........................................................................................................122
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014222
Page 169
Protocol C4591001

10.1.3. Data Protection .......................................................................................124
10.3.1. Definition of AE .....................................................................................131

11. REFERENCES ................................................................................................................152
LIST OF TABLES
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014223
Page 170
Protocol C4591001

CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014224
Page 171
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale


importance.
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014225
Page 172
Protocol C4591001
For Phase 1

dose  SAEs
after Dose 2

intervention:

Dose 2

each time point
vaccination
CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014226
Page 173
Protocol C4591001

 Geometric mean concentrations S1-binding IgG levels and
(GMCs) at each time point RBD-binding IgG levels
vaccination
time point
For Phase 2/3

Primary Efficacy
confirmed COVID-19 in participants participants) at least 7 days after central laboratory or locally
without evidence of infection before receipt of the second dose of study confirmed NAAT in participants with
vaccination intervention: no serological or virological evidence
100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the
infection
with and without evidence of receipt of the second dose of study confirmed NAAT
infection before vaccination intervention:
vaccine to placebo]
Primary Safety
the last dose  AEs
after the last dose
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014227
Page 174
Protocol C4591001

after the last dose fatigue, headache, chills,
after the last dose worsened muscle pain, and
after the last dose  AEs
after the last dose
Secondary Efficacy
confirmed severe COVID-19 in participants) at least 7 days after follow-up in participants with no
participants without evidence of receipt of the second dose of study serological or virological evidence of
infection before vaccination intervention: past SARS-CoV-2 infection
vaccine to placebo]
confirmed severe COVID-19 in participants) at least 7 days after follow-up
participants with and without receipt of the second dose of study
evidence of infection before intervention:
vaccine to placebo]
confirmed COVID-19 (according to participants) at least 7 days after central laboratory or locally
the CDC-defined symptoms) in receipt of the second dose of study confirmed NAAT in participants with
infection
the CDC-defined symptoms) in receipt of the second dose of study confirmed NAAT
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014228
Page 175
Protocol C4591001

vaccination
Exploratory
vaccination
study

confirmed COVID-19
disease
“Process 2”b
Overall Design
This is a Phase 1/2/3, multicenter, multinational, randomized, placebo-controlled,

individuals.
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014229
Page 176
Protocol C4591001

195 participants.
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg
CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014230
Page 177
Protocol C4591001

Statistical Methods

CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014231
Page 178
Protocol C4591001

1.2. Schema
Age: 18-55 y Age: 65-85 y

after Dose 1)

after Dose 1)

after Dose 1)


analyses)
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014232
Page 179
Protocol C4591001

protocol.
1.3.1. Phase 1

(Vax 1)
Illness
Onset
currently taken
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014233
Page 180
Protocol C4591001

(Vax 1)
Illness
Onset
laboratory testsb
COVID-19 infection
(if appropriate)
swab(s)c
information
use
chemistry results
criteria
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014234
Page 181
Protocol C4591001

(Vax 1)
Illness
Onset
(if appropriate)
allocation
~170 mL ~170 mL ~170 mL
device, if required
measuring device
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014235
Page 182
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
dates
appropriate
application
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014236
Page 183
Protocol C4591001

(Vax 1)
Illness
Onset
Collection of X X
COVID-19–related clinical
and laboratory information
CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014237
Page 184
Protocol C4591001
1.3.2. Phase 2/3

MIS-C.

Visit
Potential COVID-19
Illness Onset
c X
CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014238
Page 185
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
application
CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014239
Page 186
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
same day.
CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014240
Page 187
Protocol C4591001
2. INTRODUCTION

2.2. Background

CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014241
Page 188
Protocol C4591001


encoding the RBD.


IB.


CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014242
Page 189
Protocol C4591001
conditions.


CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014243
Page 190
Protocol C4591001

Significance
Unknown AEs and laboratory This study is one of the first 2 The Phase 1 study design includes the use of controlled vaccination and
abnormalities with a novel vaccine. parallel-running clinical studies with the dose escalation to closely monitor and limit the rate of enrollment to ensure
BNT162 vaccine candidates and as such participant safety. An IRC (in Phase 1) and DMC (throughout the study)
there are no clinical data available for this will also review safety data. Stopping rules are also in place. The first 5
vaccine. participants in each group in Phase 1 will be observed for 4 hours after
CONFIDENTIAL
Page 36
FDA-CBER-2021-5683-0014244
Page 191
Protocol C4591001

Significance
Study Procedures
venipuncture site.
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014245
Page 192
Protocol C4591001



3.1. For Phase 1
dose  SAEs

after Dose 2
CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014246
Page 193
Protocol C4591001

1; 7 and 14 days and 1, 6, 12, and 24
months after Dose 2
each time point
vaccination


each time point
CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014247
Page 194
Protocol C4591001
3.2. For Phase 2/3

Primary Efficacy
infection
vaccine to placebo]
Primary Safety

after the last dose
months after the last dose
CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014248
Page 195
Protocol C4591001

Secondary Efficacy
vaccine to placebo]
vaccine to placebo]
infection
vaccination
Exploratory
vaccination
study
confirmed COVID-19
CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014249
Page 196
Protocol C4591001

HIV disease
“Process 2”b
(see Section 9.6).
4. STUDY DESIGN
4.1. Overall Design
This is a multicenter, multinational, Phase 1/2/3, randomized, placebo-controlled,
individuals.
CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014250
Page 197
Protocol C4591001

unblinded.
4.1.1. Phase 1


day

55-year age cohort:
Germany (BNT162-01)
CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014251
Page 198
Protocol C4591001
4.1.2. Phase 2/3

of 30 µg.
Assuming a COVID-19 attack rate of 1.3% per year in the placebo group, accrual of 164
CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014252
Page 199
Protocol C4591001

developed to support an increased scale of manufacture. In the study, each lot of
“Process 2”-manufactured BNT162b2 will be administered to approximately 250 participants
16 to 55 years of age. The safety and immunogenicity of prophylactic BNT162b2 in
individuals 16 to 55 years of age vaccinated with “Process 1” and each lot of “Process 2”
study intervention will be described. A random sample of 250 participants from those
vaccinated with study intervention produced by manufacturing “Process 1” will be selected

for this descriptive analysis.



CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014253
Page 200
Protocol C4591001
BNT162b2.


CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014254
Page 201
Protocol C4591001
5. STUDY POPULATION
protocol.


Age and Sex:

study.
Informed Consent:

CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014255
Page 202
Protocol C4591001

Medical Conditions:
study.

 Hypertension
 Asthma
<60 mL/min/1.73 m2)
 BMI >30 kg/m2
CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014256
Page 203
Protocol C4591001



nanoparticles.
CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014257
Page 204
Protocol C4591001
visit.
study intervention.
Other Exclusions:
members.


CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014258
Page 205
Protocol C4591001

Administration
 Chills;

 Sore throat;
 Diarrhea;
 Vomiting.

CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014259
Page 206
Protocol C4591001
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg


modRNA) modRNA)
for injection)
CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014260
Page 207
Protocol C4591001


CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014261
Page 208
Protocol C4591001
business.
CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014262
Page 209
Protocol C4591001

files.

on its appearance.


blinding plan):
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014263
Page 210
Protocol C4591001
deviations.
(see Section 9.6). This will comprise a statistician, programmer(s), and a medical
monitor who will review cases of severe COVID-19 as they are received, and will
review AEs at least weekly for additional potential cases of severe COVID-19

individual subject assignments. The programs that produce the summary tables will
be developed and validated by the blinded study team, and these programs will be run
by the unblinded DMC team. The submissions team will not have access to


study intervention.
CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014264
Page 211
Protocol C4591001

participants).
frequency.




CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014265
Page 212
Protocol C4591001


Section 5.5.

CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014266
Page 213
Protocol C4591001






 Death;
 AEs;
CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014267
Page 214
Protocol C4591001


CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014268
Page 215
Protocol C4591001



profile by age.
intervention.
CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014269
Page 216
Protocol C4591001

may be used if it was obtained using 1 of the following assays:
 Cepheid Xpert Xpress SARS-CoV-2
 Roche cobas SARS-CoV-2 real-time RT-PCR test (EUA200009/A001)
 Abbott Molecular/RealTime SARS-CoV-2 assay (EUA200023/A001)


 Fever;
CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014270
Page 217
Protocol C4591001
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
 Fatigue;
 Headache;
 Nausea.

following:


vasopressors);
 Death.
CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014271
Page 218
Protocol C4591001
will prevail.
of COVID-19:

result


CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014272
Page 219
Protocol C4591001


after administration of the study intervention in a subset of participants. These prospectively
self-collected occurrences of local reactions and systemic events are graded as described in
Section 8.2.2. For participants who are not in the reactogenicity subset, these local reactions
and systemic events should be detected and reported as AEs, in accordance with
Section 8.3.2.

CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014273
Page 220
Protocol C4591001

this subset. The reactogenicity e-diary allows recording of these assessments only within a
fixed time window, thus providing the accurate representation of the participant’s experience
at that time. Data on local reactions and systemic events reported in the reactogenicity
e-diary will be transferred electronically to a third-party vendor, where they will be available
for review by investigators and the Pfizer clinicians at all times via an internet-based portal.


CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014274
Page 221
Protocol C4591001



(Grade 4)
severe pain


CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014275
Page 222
Protocol C4591001


(Grade 4)
hypotensive shock
diarrhea
headache
fatigue
chills
pain
8.2.2.4. Fever

CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014276
Page 223
Protocol C4591001


≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)

(Day 1 to Day 7).


will commence:
CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014277
Page 224
Protocol C4591001
Stopping Rule
groups.
CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014278
Page 225
Protocol C4591001
in Section 10.7.

how to proceed.

CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014279
Page 226
Protocol C4591001


nonleading manner.

reported using the Vaccines SAE Report Form.
CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014280
Page 227
Protocol C4591001
SAE to Pfizer using the Vaccines SAE Report Form.

Section 8.3.1 are reported to Pfizer Safety on the Vaccines SAE Report Form immediately


AE occurrences.

CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014281
Page 228
Protocol C4591001


awareness.

An EDP occurs if:

study intervention.


CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014282
Page 229
Protocol C4591001

this information to Pfizer Safety on the Vaccines SAE Report Form and an EDP
information to Pfizer Safety using the Vaccines SAE Report Form and EDP
a copy of the completed Vaccines SAE Report Form is maintained in the investigator
site file.
reported).
partner.
CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014283
Page 230
Protocol C4591001



information must be reported using the Vaccines SAE Report Form. When exposure during
CRF. However, a copy of the completed Vaccines SAE Report Form is maintained in the

must be reported using the Vaccines SAE Report Form. Since the information does not
however, a copy of the completed Vaccines SAE Report Form is maintained in the

Not applicable.
CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014284
Page 231
Protocol C4591001

or SAEs
OR
study intervention.

Not applicable.


Not applicable.

medication errors.
CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014285
Page 232
Protocol C4591001
Safety Event Recorded on the CRF Reported on the Vaccines SAE Report
of Awareness




CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a Vaccines SAE

CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014286
Page 233
Protocol C4591001
CRF.

8.7. Genetics
8.8. Biomarkers



8.11.1. Phase 1
study.
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014287
Page 234
Protocol C4591001


Ab tests.
criteria are met.
CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014288
Page 235
Protocol C4591001

vaccination.

criteria are met.
Section 5.5.

information.

CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014289
Page 236
Protocol C4591001

required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014290
Page 237
Protocol C4591001





required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014291
Page 238
Protocol C4591001



required:
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014292
Page 239
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).




vaccination.
CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014293
Page 240
Protocol C4591001

(see Section 7.1).
Section 5.5.


CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014294
Page 241
Protocol C4591001
required:
 Fever ≥39.0°C (≥102.1°F).



CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014295
Page 242
Protocol C4591001


research.
required:
 Fever ≥39.0°C (≥102.1°F).


CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014296
Page 243
Protocol C4591001
period.


CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014297
Page 244
Protocol C4591001




CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014298
Page 245
Protocol C4591001
Section 8.3.

Section 8.3.

Section 8.3.
CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014299
Page 246
Protocol C4591001
8.11.2. Phase 2/3

 Obtain any medical history of clinical significance. For participants who are
HIV-positive, record HIV viral load and CD4 count results from the most recent test

criteria are met.
Section 5.5.
CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014300
Page 247
Protocol C4591001

information.


required.


CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014301
Page 248
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).







vaccination.

CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014302
Page 249
Protocol C4591001

(see Section 7.1).
Section 5.5.



CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014303
Page 250
Protocol C4591001

 Fever ≥39.0°C (≥102.1°F).






Visit 2)
CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014304
Page 251
Protocol C4591001





CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014305
Page 252
Protocol C4591001
Section 8.3.


Section 8.3.

CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014306
Page 253
Protocol C4591001
Section 8.3.

following is true:
contact.

data entry error).
CRF.
CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014307
Page 254
Protocol C4591001
Section 8.2.2.2.
Section 8.2.2.3.
page of the CRF.

3 days of symptom onset (and at the latest 4 days after symptom resolution). Note that:
 If new symptoms are reported within 4 days after resolution of all previous symptoms,
they will be considered as part of a single illness and a second illness visit is not required;
 Surveillance of potential COVID-19 symptoms should continue even if a participant has

a positive SARS-CoV-2 test earlier in the study.
with specific systemic events (ie, fever, chills, new or increased muscle pain, diarrhea,
be vaccine reactogenicity, but a participant is required to demonstrate that they are
SARS-CoV-2–negative, a local SARS-CoV-2 test may be performed: if positive, the
symptoms should be recorded as a potential COVID-19 illness; if not, the symptoms should
be recorded as AEs (unless already captured in the reactogenicity e-diary).
 Fever;
CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014308
Page 255
Protocol C4591001
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
sharing of healthcare information and services via telecommunication technologies
(eg, audio, video, video-conferencing software) remotely, thus allowing the participant and



site staff). Alternatively, if conducted by telehealth, instruct the participant to
self-collect a nasal (midturbinate) swab and ship for assessment at the central
laboratory.

CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014309
Page 256
Protocol C4591001

vasopressors)


central laboratory.

protein
stay
 Death

CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014310
Page 257
Protocol C4591001


Section 8.13.1).
Section 8.3.

CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014311
Page 258
Protocol C4591001

Visits

of those with no serological or virological evidence (up to 7 days after receipt of the
second dose) of past SARS-CoV-2 infection.


handled as follows:
CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014312
Page 259
Protocol C4591001

9.1.1. Estimands
In addition, VE will be analyzed by all--available efficacy population. Missing laboratory


model.

CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014313
Page 260
Protocol C4591001
testing:
H0: ln(µ2) – ln(µ1) ≤ ln(0.67)

of 164 primary-endpoint cases within 6 months, and 20% of the participants being

(see Table 4).
CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014314
Page 261
Protocol C4591001

Scale) Age Group
Lower limit of 95% 0.623 -0.2 200 90.8%
CI for GMR
(12-15/16-25)
>0.67
standard deviation.
1 AE.

True Event
Rate of an
AE
0.01% 0.00 0.00 0.02 0.10 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.18 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.33 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.45 0.83 0.97 0.99 >0.99
0.08% 0.01 0.04 0.13 0.55 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.63 0.95 0.99 0.99 >0.99
0.15% 0.02 0.07 0.24 0.78 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 0.86 >0.99 >0.99 >0.99 >0.99
0.25% 0.03 0.11 0.36 0.92 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 0.95 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 0.97 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 0.99 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014315
Page 262
Protocol C4591001
9.3. Analysis Sets

the IWR system.
Dose 2.
by the clinician.
1 vaccination.
doses.
study intervention.

CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014316
Page 263
Protocol C4591001

immunogenicity populations as defined in Section 9.3.









CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014317
Page 264
Protocol C4591001

confidence limits.

level







CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014318
Page 265
Protocol C4591001


(noninferiority in
16- to 25-year age 12 to 15 years of age to those in participants 16 to 25 years of age and
group) 2-sided 95% CIs will be provided at 1 month after Dose 2 for



imputed.




CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014319
Page 266
Protocol C4591001





confidence limits.




are available
CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014320
Page 267
Protocol C4591001



and after Dose 2.
CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014321
Page 268
Protocol C4591001

The statistical analysis of efficacy will be based on the evaluable efficacy population
(primary analysis) and the all-available efficacy population as defined in Section 9.3.

Primary efficacy Ratio of confirmed COVID-19 illness per 1000 person-years of
follow-up in participants without evidence of infection before
vaccination for the active vaccine group to the placebo group

placebo group 7 days after the second dose. VE will be analyzed using
a beta-binomial model.
evaluated as below.
Ratio of confirmed COVID-19 illness per 1000 person-years of

follow-up in participants with and without evidence of infection
before vaccination for the active vaccine group to the placebo

group

placebo group after 7 days after the second dose. VE will be analyzed
CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014322
Page 269
Protocol C4591001

Secondary Ratio of confirmed severe COVID-19 illness per 1000 person-years
of follow-up in participants without evidence of infection before
Ratio of confirmed severe COVID-19 illness per 1000 person-years

of follow-up for the active vaccine group to the placebo group
These secondary efficacy objectives will be evaluated after the primary

objectives are met. The analysis will be based on the evaluable
efficacy population and the all-available efficacy population. The
analysis methodology used for the primary efficacy endpoints will be
applied for the analysis of the above secondary efficacy endpoints.

Ratio of confirmed COVID-19 illness (according to the

CDC-defined symptoms) per 1000 person-years of follow-up in
participants without evidence of infection before vaccination for
the active vaccine group to the placebo group

participants with and without evidence of infection before

illness according to the CDC-defined symptoms after 7 days after the
second dose. The 2-sided 95% CI for VE will be derived using the
Clopper-Pearson method as described by Agresti.9

severity cumulatively across severity levels. Descriptive summary
statistics will include counts and percentages of participants with the
indicated endpoint and the associated Clopper-Pearson 95% CIs.
CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014323
Page 270
Protocol C4591001


distributed.

each vaccine group.

from Dose 1 to 6 months after last dose will be provided for each
vaccine group.

CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014324
Page 271
Protocol C4591001

Exploratory N/A

point.
study intervention produced by manufacturing “Process 1” and each lot of “Process 2” will
be summarized descriptively. A random sample of 250 participants from those vaccinated
with study intervention produced by manufacturing “Process 1” will be selected randomly for
the analysis.

During Phase 2/3, 4 IAs are planned and will be performed by an unblinded statistical team
after accrual of 32, 62, 92, and 120 cases. At each IA:
 VE for the first primary objective will be evaluated. Overwhelming efficacy will be
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014325
Page 272
Protocol C4591001
Table 6 illustrates the boundary for efficacy and futility if IAs are performed after accrual of
32 62, 92, and 120 cases in participants without evidence of infection before vaccination.
Cases VE Point Estimate VE Point Estimate
IA1 32 76.9% (6:26) 11.8% (15:17)
IA2 62 68.1% (15:47) 27.8% (26:36)

IA3 92 62.7% (25:67) 38.6% (35:57)
IA4 120 58.8% (35:85) N/A
Final 164 52.3% (53:111)
> 0.986.
various VEs with a 1:1 randomization ratio) are listed in Table 7 and Table 8.
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014326
Page 273
Protocol C4591001

(%) (Total Cases
= 120)
30 0.006 0.315 0.003 0.231 0.002 0.239 0.002
50 0.054 0.078 0.051 0.056 0.063 0.103 0.075
60 0.150 0.021 0.160 0.010 0.175 0.019 0.160
70 0.368 0.003 0.310 <0.001 0.195 0.001 0.085
80 0.722 <0.001 0.238 <0.001 0.037 <0.001 0.003

(Total Cases = 164)

Group ≤53)
30 0.007 0.021
50 0.196 0.439
60 0.220 0.866
70 0.036 >0.999
80 <0.001 >0.999
After the primary objectives are met, the secondary VE endpoints (confirmed severe
COVID-19 in participants without evidence of infection before vaccination and confirmed
severe COVID-19 in all participants) will be evaluated sequentially, by the same method
used for the primary VE endpoint evaluation. Success thresholds for secondary VE will be
appropriately chosen to control overall Type I error at 2.5%. Further details will be provided
in the SAP. The remaining secondary VE endpoints will be evaluated descriptively to
calculate the observed VE with 95% CIs.
CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014327
Page 274
Protocol C4591001


for Phase 1.
 IAs for efficacy at 32, 62, 92, and 120 cases and futility at 32, 62, and 92 cases.
 Safety data through 1 month after Dose 2 and noninferiority comparison of

SARS-CoV-2 neutralizing titers in participants 12 to 15 years of age compared to
those in participants 16 to 25 years of age, 1 month after Dose 2

material, 1 month after Dose 2



CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014328
Page 275
Protocol C4591001



as appropriate.
CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014329
Page 276
Protocol C4591001


initiated.

IRB/EC procedures;
of.
CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014330
Page 277
Protocol C4591001


CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014331
Page 278
Protocol C4591001



EudraCT
CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014332
Page 279
Protocol C4591001
www.pfizer.com
Data Sharing

redacted.

CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014333
Page 280
Protocol C4591001
monitoring plan.
maintained.
CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014334
Page 281
Protocol C4591001


participants.
start date.
to:
CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014335
Page 282
Protocol C4591001


CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014336
Page 283
Protocol C4591001


Platelet count
WBC count
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)


(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
- cells/mm3
cells/mm3
cells/mm3
CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014337
Page 284
Protocol C4591001

(Grade 4)
dialysis
phosphate –
increase by factor
– ALT, AST
increase by factor
accompanied
by any increase in
increase by factor
factor
CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014338
Page 285
Protocol C4591001

AE Definition






sequelae.
CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014339
Page 286
Protocol C4591001





a. Results in death

considered serious.
CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014340
Page 287
Protocol C4591001



or drug abuse.

CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014341
Page 288
Protocol C4591001
for reporting serious adverse events on the Vaccines SAE Report Form to Pfizer Safety.
It should be noted that the Vaccines SAE Report Form for reporting of SAE information is
terminology and the same AE term should be used on both the CRF and the Vaccines SAE
Safety Event Recorded on the CRF Reported on the Vaccines

SAE Report Form to
Hours of Awareness
SAE All All



medical records to Pfizer Safety in lieu of completion of the Vaccines SAE Report
CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014342
Page 289
Protocol C4591001

function.

function.

function.


be ruled out.

CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014343
Page 290
Protocol C4591001

assessment.

dedicated section of the Vaccines SAE Report Form and in accordance with the
SAE reporting requirements.


CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014344
Page 291
Protocol C4591001
SAE Reporting to Pfizer Safety via Vaccines SAE Report Form

 Facsimile transmission of the Vaccines SAE Report Form is the preferred method to

acceptable with a copy of the Vaccines SAE Report Form sent by overnight mail or
courier service.
complete and sign the Vaccines SAE Report Form pages within the designated
CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014345
Page 292
Protocol C4591001

intervention(s):
PLUS either:

OR


OR

pregnancy.
CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014346
Page 293
Protocol C4591001

considered.
1. Premenarchal.



CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014347
Page 294
Protocol C4591001


ovulation.

90 days.

 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
 Oral;
 Injectable.

participant.
CONFIDENTIAL
Page 140
FDA-CBER-2021-5683-0014348
Page 295
Protocol C4591001

CONFIDENTIAL
Page 141
FDA-CBER-2021-5683-0014349
Page 296
Protocol C4591001

smaller).
CONFIDENTIAL
Page 142
FDA-CBER-2021-5683-0014350
Page 297
Protocol C4591001
CONFIDENTIAL
Page 143
FDA-CBER-2021-5683-0014351
Page 298
Protocol C4591001

Abbreviation Term
AE adverse event
BMI body mass index

DU dosing unit
EC ethics committee
EU European Union
CONFIDENTIAL
Page 144
FDA-CBER-2021-5683-0014352
Page 299
Protocol C4591001
Abbreviation Term
HBe hepatitis B e
HR heart rate
IA interim analysis

ID identification
Ig immunoglobulin
IV intravenous(ly)
LL lower limit
LPX lipoplex
CONFIDENTIAL
Page 145
FDA-CBER-2021-5683-0014353
Page 300
Protocol C4591001
Abbreviation Term
N/A not applicable

PT prothrombin time
RBC red blood cell
RR respiratory rate
CONFIDENTIAL
Page 146
FDA-CBER-2021-5683-0014354
Page 301
Protocol C4591001
Abbreviation Term
US United States
vax vaccination
VE vaccine efficacy
CONFIDENTIAL
Page 147
FDA-CBER-2021-5683-0014355
Page 302
Protocol C4591001

at 32, 62, 92, and 120 cases, the number of severe COVID-19 cases in the vaccine and
placebo groups will be assessed.
CONFIDENTIAL
Page 148
FDA-CBER-2021-5683-0014356
Page 303
Protocol C4591001
Rule Value (S)
Group
4 4 N/A
5 5 3.13%
6 6 1.56%
7 7 0.78%
8 7 3.52%
9 8 1.95%
10 9 1.07%
11 9 3.27%
12 10 1.93%
13 10 4.61%
14 11 2.87%
15 12 1.76%
16 12 3.84%
17 13 2.45%
18 13 4.81%
19 14 3.18%
20 15 2.07%
CONFIDENTIAL
Page 149
FDA-CBER-2021-5683-0014357
Page 304
Protocol C4591001
Value (A)
Vaccine 1:1, 1:1, 2:1, 3:1, 4:1,
2 2 25.00% 25.00% 44.49% 56.25% 64.00%
3 2 37.50% 50.00% 74.12% 84.38% 89.60%
4 3 25.00% 31.25% 59.32% 73.83% 81.92%
5 4 15.63% 18.75% 46.16% 63.28% 73.73%
6 4 23.44% 34.38% 68.10% 83.06% 90.11%
7 5 16.41% 22.66% 57.14% 75.64% 85.20%

8 6 10.94% 14.45% 46.90% 67.85% 79.69%
9 6 16.41% 25.39% 65.11% 83.43% 91.44%
10 7 11.72% 17.19% 56.02% 77.59% 87.91%
11 8 8.06% 11.33% 47.35% 71.33% 83.89%
12 8 12.08% 19.38% 63.25% 84.24% 92.74%
13 9 8.73% 13.34% 55.31% 79.40% 90.09%
14 10 6.11% 8.98% 47.66% 74.15% 87.02%
15 10 9.16% 15.09% 61.94% 85.16% 93.89%
16 11 6.67% 10.51% 54.81% 81.03% 91.83%
17 12 4.72% 7.17% 47.88% 76.53% 89.43%
18 13 3.27% 4.81% 41.34% 71.75% 86.71%
19 13 5.18% 8.35% 54.43% 82.51% 93.24%
20 14 3.70% 5.77% 48.06% 78.58% 91.33%
CONFIDENTIAL
Page 150
FDA-CBER-2021-5683-0014358
Page 305
Protocol C4591001
Known HIV infection
Known HCV infection

Known HBV infection
following:
CONFIDENTIAL
Page 151
FDA-CBER-2021-5683-0014359
Page 306
Protocol C4591001
11. REFERENCES
1
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---
11-march-2020. Published: 11 Mar 2020. Accessed: 01 Apr 2020.
2
3
4
5

6
7
8
9
10
1985;4(2):213-26.
CONFIDENTIAL
Page 152
FDA-CBER-2021-5683-0014360
Page 307
Document Name:
Document Title: !!" # $%&'(## ) (&)*+, ) $ (-

(%$#+&) ) %.+&)+&/ '0)1 ' -#0' ' . '1 '
# ($+#+'1 +**0&/ &++'1 &) ..+1 . (%-%
(& -+& &)+)' /+&' -+)% +& #'1 +
&)+-+)0#
23 2 4 %% "55 . 6

#74 4 3 8%% 85"85 $39 99 # 6
FDA-CBER-2021-5683-0014361
Page 308
Protocol C4591001


090177e1951cd87d\Approved\Approved On: 07-Oct-2020 08:40 (GMT)

Phase: 1/2/3
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014362
Page 309
Protocol C4591001
Document History


Section 7.1.
case definition.
single illness.
25 years of age.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014363
Page 310
Protocol C4591001
Document History

Section 9.5.1.
EU.
Vaccination 2.

~43,998.
AEs.
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014364
Page 311
Protocol C4591001
Document History

30 µg.
phase of the study.
In addition:

to the purpose.
evaluated.
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014365
Page 312
Protocol C4591001
Document History

added to Section 3.






template.




protocol.
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014366
Page 313
Protocol C4591001
Document History

BNT162b2.
intervention.





illness e-diary.
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014367
Page 314
Protocol C4591001
Document History

In addition:


(BNT162-01):
BNT162c2
Additionally:
after Dose 1 or 2
escalation
antigen to BNT162c2
subunit
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014368
Page 315
Protocol C4591001
Document History

will be directed

candidate
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014369
Page 316
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................14
1.1. Synopsis ..................................................................................................................16
1.2. Schema ....................................................................................................................23
1.3.1. Phase 1 ........................................................................................................24
1.3.2. Phase 2/3.....................................................................................................29
2. INTRODUCTION ...............................................................................................................32
2.1. Study Rationale .......................................................................................................32
2.2. Background .............................................................................................................32
2.3.1. Risk Assessment .........................................................................................35

3.1. For Phase 1 ..............................................................................................................37
3.2. For Phase 2/3 ...........................................................................................................39
4. STUDY DESIGN.................................................................................................................41
4.1. Overall Design.........................................................................................................41
4.1.1. Phase 1 ........................................................................................................42
4.1.2. Phase 2/3.....................................................................................................43
5.3.1. Contraception..............................................................................................49
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014370
Page 317
Protocol C4591001
5.4. Screen Failures ........................................................................................................49

6.1.2. Administration ............................................................................................52

7.3. Lost to Follow-up ....................................................................................................59
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014371
Page 318
Protocol C4591001
8.2.2.1. Grading Scales...........................................................................65

8.2.2.2. Local Reactions .........................................................................65
8.2.2.3. Systemic Events ........................................................................66
8.2.2.4. Fever..........................................................................................67

Exposure ..........................................................................................................73
8.3.8.1. Lack of Efficacy ........................................................................76
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014372
Page 319
Protocol C4591001
8.7. Genetics ...................................................................................................................78

8.8. Biomarkers ..............................................................................................................78
8.11.1. Phase 1 ......................................................................................................78
8 Days After Visit 1) .........................................................................83
8 Days After Visit 4) .........................................................................86

16 Days After Visit 4) .......................................................................88
Visit 4) ...............................................................................................89
After Visit 4)......................................................................................89
After Visit 4)......................................................................................90
After Visit 4)......................................................................................90
8.11.2. Phase 2/3...................................................................................................91
After Visit 2)......................................................................................96
After Visit 2)......................................................................................97
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014373
Page 320
Protocol C4591001

After Visit 2)......................................................................................97
8.13. COVID-19 Surveillance (All Participants) ...........................................................99
Illness Visits ............................................................................................................103
9.1.1. Estimands..................................................................................................103

9.3. Analysis Sets .........................................................................................................107
9.4.3. Safety Analyses ........................................................................................114
9.4.4. Other Analyses..........................................................................................116
9.5.1. Analysis Timing........................................................................................119
CONSIDERATIONS ........................................................................................................121
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014374
Page 321
Protocol C4591001

10.1.3. Data Protection .......................................................................................123
10.3.1. Definition of AE .....................................................................................130

11. REFERENCES ................................................................................................................151
LIST OF TABLES
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014375
Page 322
Protocol C4591001

CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014376
Page 323
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale


importance.
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014377
Page 324
Protocol C4591001
For Phase 1

dose  SAEs
after Dose 2

intervention:

Dose 2

each time point
vaccination
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014378
Page 325
Protocol C4591001

vaccination
time point
For Phase 2/3

Primary Efficacy
infection
vaccine to placebo]
Primary Safety
after the last dose
CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014379
Page 326
Protocol C4591001

after the last dose
Secondary Efficacy
vaccine to placebo]
vaccine to placebo]
infection
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014380
Page 327
Protocol C4591001

vaccination
Exploratory
vaccination
study
 Confirmed COVID-19  N-binding antibody
 Confirmed severe COVID-19 
SARS-CoV-2 detection by
 SARS-CoV-2 infection without NAAT
confirmed COVID-19
disease
“Process 2”b
Overall Design
This is a Phase 1/2/3, multicenter, multinational, randomized, placebo-controlled, observer-

blind, dose-finding, vaccine candidate–selection, and efficacy study in healthy individuals.
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014381
Page 328
Protocol C4591001

195 participants.
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014382
Page 329
Protocol C4591001

Statistical Methods

CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014383
Page 330
Protocol C4591001

1.2. Schema
Age: 18-55 y Age: 65-85 y

after Dose 1)

after Dose 1)

after Dose 1)


analyses)
CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014384
Page 331
Protocol C4591001

protocol.
1.3.1. Phase 1

(Vax 1)
Illness
Onset
currently taken
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014385
Page 332
Protocol C4591001

(Vax 1)
Illness
Onset
laboratory testsb
COVID-19 infection
(if appropriate)
swab(s)c
information
use
chemistry results
criteria
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014386
Page 333
Protocol C4591001

(Vax 1)
Illness
Onset
(if appropriate)
allocation
~170 mL ~170 mL ~170 mL
device, if required
measuring device
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014387
Page 334
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
dates
appropriate
application
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014388
Page 335
Protocol C4591001

(Vax 1)
Illness
Onset
Collection of COVID-19– X X
related clinical and laboratory
information (including local
diagnosis)
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014389
Page 336
Protocol C4591001
1.3.2. Phase 2/3

MIS-C.

Visit
Potential COVID-19
Illness Onset
c X
CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014390
Page 337
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
application
CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014391
Page 338
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
same day.
CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014392
Page 339
Protocol C4591001
2. INTRODUCTION

2.2. Background

CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014393
Page 340
Protocol C4591001


encoding the RBD.


IB.


CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014394
Page 341
Protocol C4591001
conditions.


CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014395
Page 342
Protocol C4591001

Significance
Unknown AEs and laboratory This study is one of the first 2 parallel- The Phase 1 study design includes the use of controlled vaccination and
abnormalities with a novel vaccine. running clinical studies with the BNT162 dose escalation to closely monitor and limit the rate of enrollment to ensure
vaccine candidates and as such there are no participant safety. An IRC (in Phase 1) and DMC (throughout the study)
clinical data available for this vaccine. will also review safety data. Stopping rules are also in place. The first 5
participants in each group in Phase 1 will be observed for 4 hours after
CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014396
Page 343
Protocol C4591001

Significance
Study Procedures
venipuncture site.
CONFIDENTIAL
CT02-GSOP Clinical Pro o o Template Phase 1 2 3 4 (05 December 2019)
Page 36
FDA-CBER-2021-5683-0014397
Page 344
Protocol C4591001



3.1. For Phase 1
dose  SAEs

after Dose 2
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014398
Page 345
Protocol C4591001

1; 7 and 14 days and 1, 6, 12, and 24
months after Dose 2
each time point
vaccination


each time point
CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014399
Page 346
Protocol C4591001
3.2. For Phase 2/3

Primary Efficacy
infection
vaccine to placebo]
Primary Safety

after the last dose
months after the last dose
CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014400
Page 347
Protocol C4591001

Secondary Efficacy
vaccine to placebo]
vaccine to placebo]
infection
vaccination
Exploratory
vaccination
study
 Confirmed severe COVID-19  SARS-CoV-2 detection by
confirmed COVID-19
CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014401
Page 348
Protocol C4591001

HIV disease
“Process 2”b
(see Section 9.6).
4. STUDY DESIGN
4.1. Overall Design
This is a multicenter, multinational, Phase 1/2/3, randomized, placebo-controlled, observer-
CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014402
Page 349
Protocol C4591001

unblinded.
4.1.1. Phase 1


day

55-year age cohort:
Germany (BNT162-01)
CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014403
Page 350
Protocol C4591001
4.1.2. Phase 2/3

of 30 µg.
CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014404
Page 351
Protocol C4591001

developed to support an increased scale of manufacture. In the study, each lot of “Process
2,” manufactured BNT162b2 will be administered to approximately 250 participants 16 to 55
years of age. The safety and immunogenicity of prophylactic BNT162b2 in individuals 16 to
55 years of age vaccinated with “Process 1” and each lot of “Process 2” study intervention
will be described.



CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014405
Page 352
Protocol C4591001

BNT162b2.


CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014406
Page 353
Protocol C4591001
5. STUDY POPULATION
protocol.


Age and Sex:

study.
Informed Consent:

CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014407
Page 354
Protocol C4591001

Medical Conditions:
study.

 Hypertension
 Asthma
<60 mL/min/1.73 m2)
 BMI >30 kg/m2
CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014408
Page 355
Protocol C4591001



nanoparticles.
CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014409
Page 356
Protocol C4591001
visit.
study intervention.
Other Exclusions:
members.


CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014410
Page 357
Protocol C4591001

Administration
 Chills;

 Sore throat;
 Diarrhea;
 Vomiting.

CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014411
Page 358
Protocol C4591001
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg


modRNA) modRNA)
for injection)
CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014412
Page 359
Protocol C4591001


CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014413
Page 360
Protocol C4591001
business.
CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014414
Page 361
Protocol C4591001

files.

on its appearance.


blinding plan):
CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014415
Page 362
Protocol C4591001
deviations.
monitor who will review cases of severe COVID-19 as they are received, and will
review AEs at least weekly for additional potential cases of severe COVID-19

individual subject assignments. The programs that produce the summary tables will
be developed and validated by the blinded study team, and these programs will be run
by the unblinded DMC team. The submissions team will not have access to


study intervention.
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014416
Page 363
Protocol C4591001

participants).
frequency.




CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014417
Page 364
Protocol C4591001


Section 5.5.

CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014418
Page 365
Protocol C4591001






 Death;
 AEs;
CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014419
Page 366
Protocol C4591001


CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014420
Page 367
Protocol C4591001



profile by age.
intervention.
CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014421
Page 368
Protocol C4591001

may be used if:
It was obtained using:
 An FDA-cleared assay; or an assay that is not FDA-cleared but was conducted in a

laboratory that is currently CLIA-certified; or an assay performed by a laboratory
accredited according to the ISO 15189 standard by a national or regional accreditation
body;
AND
 The assay is deemed acceptable by Pfizer.


CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014422
Page 369
Protocol C4591001
 Fever;
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
 Fatigue;
 Headache;
 Nausea.

following:


vasopressors);
CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014423
Page 370
Protocol C4591001
 Death.
will prevail.
of COVID-19:

result

CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014424
Page 371
Protocol C4591001


after administration of the study intervention. These prospectively self-collected occurrences
of local reactions and systemic events are graded as described in Section 8.2.2.

CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014425
Page 372
Protocol C4591001

this subset. The reactogenicity e-diary allows recording of these assessments only within a
fixed time window, thus providing the accurate representation of the participant’s experience
at that time. Data on local reactions and systemic events reported in the reactogenicity
e-diary will be transferred electronically to a third-party vendor, where they will be available
for review by investigators and the Pfizer clinicians at all times via an internet-based portal.


CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014426
Page 373
Protocol C4591001



(Grade 4)
severe pain


CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014427
Page 374
Protocol C4591001


(Grade 4)
hypotensive shock
diarrhea
headache
fatigue
chills
pain
8.2.2.4. Fever

CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014428
Page 375
Protocol C4591001


≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)

(Day 1 to Day 7).


will commence:
CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014429
Page 376
Protocol C4591001
Stopping Rule
groups.
CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014430
Page 377
Protocol C4591001
in Section 10.7.

how to proceed.

CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014431
Page 378
Protocol C4591001


nonleading manner.

CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014432
Page 379
Protocol C4591001



AE occurrences.

CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014433
Page 380
Protocol C4591001


awareness.

An EDP occurs if:

study intervention.


CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014434
Page 381
Protocol C4591001

this information to Pfizer Safety on the Vaccines SAE Report Form and an EDP
a copy of the completed Vaccines SAE Report Form is maintained in the investigator
site file.
reported).
partner.
CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014435
Page 382
Protocol C4591001





Not applicable.
CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014436
Page 383
Protocol C4591001

or SAEs
OR
study intervention.

Not applicable.


Not applicable.

medication errors.
CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014437
Page 384
Protocol C4591001
of Awareness




CRF.

CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014438
Page 385
Protocol C4591001
CRF.

8.7. Genetics
8.8. Biomarkers



8.11.1. Phase 1
study.
CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014439
Page 386
Protocol C4591001


Ab tests.
criteria are met.
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014440
Page 387
Protocol C4591001

vaccination.

criteria are met.
Section 5.5.

information.

CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014441
Page 388
Protocol C4591001

required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014442
Page 389
Protocol C4591001





required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014443
Page 390
Protocol C4591001



required:
CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014444
Page 391
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).




vaccination.
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014445
Page 392
Protocol C4591001

(see Section 7.1).
Section 5.5.


CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014446
Page 393
Protocol C4591001
required:
 Fever ≥39.0°C (≥102.1°F).



CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014447
Page 394
Protocol C4591001


research.
required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014448
Page 395
Protocol C4591001


CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014449
Page 396
Protocol C4591001




CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014450
Page 397
Protocol C4591001
Section 8.3.

Section 8.3.

Section 8.3.
CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014451
Page 398
Protocol C4591001
8.11.2. Phase 2/3

 Obtain any medical history of clinical significance. For participants who are HIV-
positive, record HIV viral load and CD4 count results from the most recent test

criteria are met.
Section 5.5.
CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014452
Page 399
Protocol C4591001

information.


required.


CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014453
Page 400
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).







vaccination.

CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014454
Page 401
Protocol C4591001

(see Section 7.1).
Section 5.5.



CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014455
Page 402
Protocol C4591001

 Fever ≥39.0°C (≥102.1°F).






Visit 2)
CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014456
Page 403
Protocol C4591001





CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014457
Page 404
Protocol C4591001
Section 8.3.


Section 8.3.

CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014458
Page 405
Protocol C4591001
Section 8.3.

following is true:
contact.

data entry error).
CRF.
CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014459
Page 406
Protocol C4591001
Section 8.2.2.2.
Section 8.2.2.3.
page of the CRF.

3 days of symptom onset (and at the latest 4 days after symptom resolution). Note that if
new symptoms are reported within 4 days after resolution of all previous symptoms, they will
be considered as part of a single illness and a second illness visit is not required.
with solicited systemic events (ie, fever, chills, new or increased muscle pain, diarrhea,
be vaccine reactogenicity, but a participant is required to demonstrate that they are SARS-
CoV-2–negative, a local SARS-CoV-2 test may be performed: if positive, the symptoms
should be recorded as a potential COVID-19 illness; if not, the symptoms should be recorded
as AEs (unless already captured in the reactogenicity e-diary).
 Fever;
CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014460
Page 407
Protocol C4591001
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
sharing of healthcare information and services via telecommunication technologies (eg,
audio, video, video-conferencing software) remotely, thus allowing the participant and



site staff). Alternatively, if conducted by telehealth, instruct the participant to self-
collect a nasal (midturbinate) swab and ship for assessment at the central laboratory.


vasopressors)
CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014461
Page 408
Protocol C4591001


central laboratory.
protein
stay
 Death


CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014462
Page 409
Protocol C4591001

Section 8.13.1).
Section 8.3.



CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014463
Page 410
Protocol C4591001
Visits

of those with no serological or virological evidence (up to 7 days after receipt of the
second dose) of past SARS-CoV-2 infection.

handled as follows:

9.1.1. Estimands
CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014464
Page 411
Protocol C4591001

model.

testing:
H0: ln(µ2) – ln(µ1) ≤ ln(0.67)
CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014465
Page 412
Protocol C4591001


(see Table 4).
CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014466
Page 413
Protocol C4591001

Scale) Age Group
Lower limit of 95% 0.623 -0.2 200 90.8%
CI for GMR
(12-15/16-25)
>0.67
standard deviation.
1 AE.

True Event
Rate of an
AE
0.01% 0.00 0.00 0.02 0.10 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.18 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.33 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.45 0.83 0.97 0.99 >0.99
0.08% 0.01 0.04 0.13 0.55 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.63 0.95 0.99 0.99 >0.99
0.15% 0.02 0.07 0.24 0.78 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 0.86 >0.99 >0.99 >0.99 >0.99
0.25% 0.03 0.11 0.36 0.92 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 0.95 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 0.97 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 0.99 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99 >0.99
CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014467
Page 414
Protocol C4591001
9.3. Analysis Sets

the IWR system.
Dose 2.
by the clinician.
1 vaccination.
doses.
study intervention.

CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014468
Page 415
Protocol C4591001










CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014469
Page 416
Protocol C4591001

confidence limits.

level







CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014470
Page 417
Protocol C4591001


(noninferiority in
16- to 25-year age 12 to 15 years of age to those in participants 16 to 25 years of age and
group) 2-sided 95% CIs will be provided at 1 month after Dose 2 for



imputed.




CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014471
Page 418
Protocol C4591001





confidence limits.




are available
CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014472
Page 419
Protocol C4591001



and after Dose 2.
CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014473
Page 420
Protocol C4591001



placebo group 7 days after the second dose. VE will be analyzed using
a beta-binomial model.
evaluated as below.


group

placebo group after 7 days after the second dose. VE will be analyzed
CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014474
Page 421
Protocol C4591001



objectives are met. The analysis will be based on the evaluable efficacy
population and the all-available efficacy population. The analysis
methodology used for the primary efficacy endpoints will be applied
for the analysis of the above secondary efficacy endpoints.




second dose. The 2-sided 95% CI for VE will be derived using the

CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014475
Page 422
Protocol C4591001


distributed.

each vaccine group.

vaccine group.

CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014476
Page 423
Protocol C4591001

Exploratory N/A

point.
study intervention produced by manufacturing “Process 1” or “Process 2” will be

summarized descriptively.

 VE for the first primary objective will be evaluated . Overwhelming efficacy will be
CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014477
Page 424
Protocol C4591001
Cases
VE Point Estimate VE Point Estimate
IA1 32 76.9% (6:26) 11.8% (15:17)
IA2 62 68.1% (15:47) 27.8% (26:36)
IA3 92 62.7% (25:67) 38.6% (35:57)
IA4 120 58.8% (35:85) N/A

Final 164 52.3% (53:111)
> 0.986.
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014478
Page 425
Protocol C4591001

(%) (Total Cases
= 120)
30 0.006 0.315 0.003 0.231 0.002 0.239 0.002
50 0.054 0.078 0.051 0.056 0.063 0.103 0.075
60 0.150 0.021 0.160 0.010 0.175 0.019 0.160
70 0.368 0.003 0.310 <0.001 0.195 0.001 0.085
80 0.722 <0.001 0.238 <0.001 0.037 <0.001 0.003

(Total Cases = 164)

Group ≤53)
30 0.007 0.021
50 0.196 0.439
60 0.220 0.866
70 0.036 >0.999
80 <0.001 >0.999
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014479
Page 426
Protocol C4591001


for Phase 1.
 Safety data through 1 month after Dose 2 and noninferiority comparison of SARS-
CoV-2 neutralizing titers in participants 12 to 15 years of age compared to those in
participants 16 to 25 years of age, 1 month after Dose 2

material, 1 month after Dose 2



CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014480
Page 427
Protocol C4591001



as appropriate.
CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014481
Page 428
Protocol C4591001


initiated.

IRB/EC procedures;
of.
CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014482
Page 429
Protocol C4591001


CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014483
Page 430
Protocol C4591001



EudraCT
CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014484
Page 431
Protocol C4591001
www.pfizer.com
Data Sharing

redacted.

CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014485
Page 432
Protocol C4591001
monitoring plan.
maintained.
CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014486
Page 433
Protocol C4591001


participants.
start date.
to:
CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014487
Page 434
Protocol C4591001


CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014488
Page 435
Protocol C4591001


Platelet count
WBC count
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)


(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
- cells/mm3
cells/mm3
cells/mm3
CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014489
Page 436
Protocol C4591001

(Grade 4)
dialysis
phosphate –
increase by factor
– ALT, AST
increase by factor
accompanied
by any increase in
increase by factor
factor
CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014490
Page 437
Protocol C4591001

AE Definition






sequelae.
CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014491
Page 438
Protocol C4591001





a. Results in death

considered serious.
CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014492
Page 439
Protocol C4591001



or drug abuse.

CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014493
Page 440
Protocol C4591001

SAE Report Form to
Hours of Awareness
SAE All All



CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014494
Page 441
Protocol C4591001

function.

function.

function.


be ruled out.

CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014495
Page 442
Protocol C4591001

assessment.



CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014496
Page 443
Protocol C4591001


courier service.
CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014497
Page 444
Protocol C4591001

intervention(s):
PLUS either:

OR


OR

pregnancy.
CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014498
Page 445
Protocol C4591001

considered.


CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014499
Page 446
Protocol C4591001


ovulation.

90 days.

 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
 Oral;
 Injectable.

participant.
CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014500
Page 447
Protocol C4591001

CONFIDENTIAL
Page 140
FDA-CBER-2021-5683-0014501
Page 448
Protocol C4591001

smaller).
CONFIDENTIAL
Page 141
FDA-CBER-2021-5683-0014502
Page 449
Protocol C4591001
CONFIDENTIAL
Page 142
FDA-CBER-2021-5683-0014503
Page 450
Protocol C4591001

Abbreviation Term
AE adverse event
BMI body mass index

DU dosing unit
EC ethics committee
EU European Union
CONFIDENTIAL
Page 143
FDA-CBER-2021-5683-0014504
Page 451
Protocol C4591001
Abbreviation Term
HBe hepatitis B e
HR heart rate
IA interim analysis

ID identification
Ig immunoglobulin
IV intravenous(ly)
LL lower limit
LPX lipoplex
CONFIDENTIAL
Page 144
FDA-CBER-2021-5683-0014505
Page 452
Protocol C4591001
Abbreviation Term
N/A not applicable

PT prothrombin time
RBC red blood cell
RR respiratory rate
CONFIDENTIAL
Page 145
FDA-CBER-2021-5683-0014506
Page 453
Protocol C4591001
Abbreviation Term
US United States
vax vaccination
VE vaccine efficacy
CONFIDENTIAL
Page 146
FDA-CBER-2021-5683-0014507
Page 454
Protocol C4591001

CONFIDENTIAL
Page 147
FDA-CBER-2021-5683-0014508
Page 455
Protocol C4591001
Rule Value (S)
Group
4 4 N/A
5 5 3.13%
6 6 1.56%
7 7 0.78%
8 7 3.52%
9 8 1.95%
10 9 1.07%
11 9 3.27%
12 10 1.93%
13 10 4.61%
14 11 2.87%
15 12 1.76%
16 12 3.84%
17 13 2.45%
18 13 4.81%
19 14 3.18%
20 15 2.07%
CONFIDENTIAL
Page 148
FDA-CBER-2021-5683-0014509
Page 456
Protocol C4591001
Value (A)
Vaccine 1:1, 1:1, 2:1, 3:1, 4:1,
2 2 25.00% 25.00% 44.49% 56.25% 64.00%
3 2 37.50% 50.00% 74.12% 84.38% 89.60%
4 3 25.00% 31.25% 59.32% 73.83% 81.92%
5 4 15.63% 18.75% 46.16% 63.28% 73.73%
6 4 23.44% 34.38% 68.10% 83.06% 90.11%
7 5 16.41% 22.66% 57.14% 75.64% 85.20%

8 6 10.94% 14.45% 46.90% 67.85% 79.69%
9 6 16.41% 25.39% 65.11% 83.43% 91.44%
10 7 11.72% 17.19% 56.02% 77.59% 87.91%
11 8 8.06% 11.33% 47.35% 71.33% 83.89%
12 8 12.08% 19.38% 63.25% 84.24% 92.74%
13 9 8.73% 13.34% 55.31% 79.40% 90.09%
14 10 6.11% 8.98% 47.66% 74.15% 87.02%
15 10 9.16% 15.09% 61.94% 85.16% 93.89%
16 11 6.67% 10.51% 54.81% 81.03% 91.83%
17 12 4.72% 7.17% 47.88% 76.53% 89.43%
18 13 3.27% 4.81% 41.34% 71.75% 86.71%
19 13 5.18% 8.35% 54.43% 82.51% 93.24%
20 14 3.70% 5.77% 48.06% 78.58% 91.33%
CONFIDENTIAL
Page 149
FDA-CBER-2021-5683-0014510
Page 457
Protocol C4591001
Known HIV infection
Known HCV infection

Known HBV infection
following:
CONFIDENTIAL
Page 150
FDA-CBER-2021-5683-0014511
Page 458
Protocol C4591001
11. REFERENCES
1
who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-
2020. Published: 11 Mar 2020. Accessed: 01 Apr 2020.
2
3
4
5

6
7
8
9
10
1985;4(2):213-26.
CONFIDENTIAL
Page 151
FDA-CBER-2021-5683-0014512
Page 459
Document Name:
Document Title: ! ""# $!%&'()$$!* )'*+,-!* % !).

!)&%$,'* * !&/,'*,'0 (1*2 ( !.$1(! (! /!(2 (
$!)%,$,(2 ,++1'0!',,(2 '* !//,2 / ) &.&
)' .,'! '*,*(! 0,' ( .,*& ,' !$(2 ,
'*,.,*1$
34 3 5 && 676 / 8

$95 5 4 && 76 6 %4: :: $ 8
FDA-CBER-2021-5683-0014513
Page 460
Protocol C4591001
Protocol Amendment 6, 08 September 2020


090177e194dca764\Approved\Approved On: 08-Sep-2020 23:40 (GMT)

Phase: 1/2/3
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014514
Page 461
Protocol C4591001
Document History

Vaccination 2.
~43,998.

AEs.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014515
Page 462
Protocol C4591001
Document History

30 µg.
phase of the study.
In addition:

to the purpose.
evaluated.
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014516
Page 463
Protocol C4591001
Document History

added to Section 3.





template.




protocol.
BNT162b2.
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014517
Page 464
Protocol C4591001
Document History

intervention.





illness e-diary.
In addition:
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014518
Page 465
Protocol C4591001
Document History


(BNT162-01):
BNT162c2
Additionally:
after Dose 1 or 2
escalation
antigen to BNT162c2
subunit
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014519
Page 466
Protocol C4591001
Document History

will be directed

candidate
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014520
Page 467
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................13
1.1. Synopsis ..................................................................................................................15
1.2. Schema ....................................................................................................................22
1.3.1. Phase 1 ........................................................................................................23
1.3.2. Phase 2/3.....................................................................................................28
2. INTRODUCTION ...............................................................................................................30
2.1. Study Rationale .......................................................................................................30
2.2. Background .............................................................................................................30
2.3.1. Risk Assessment .........................................................................................33

3.1. For Phase 1 ..............................................................................................................34
3.2. For Phase 2/3 ...........................................................................................................36
4. STUDY DESIGN.................................................................................................................38
4.1. Overall Design.........................................................................................................38
4.1.1. Phase 1 ........................................................................................................39
4.1.2. Phase 2/3.....................................................................................................40
5.3.1. Contraception..............................................................................................45
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014521
Page 468
Protocol C4591001
5.4. Screen Failures ........................................................................................................46

6.1.1. Administration ............................................................................................48

7.3. Lost to Follow-up ....................................................................................................54
8.2.2.1. Grading Scales...........................................................................60
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014522
Page 469
Protocol C4591001
8.2.2.2. Local Reactions .........................................................................60

8.2.2.3. Systemic Events ........................................................................61
8.2.2.4. Fever..........................................................................................62

Exposure ..........................................................................................................68
8.3.8.1. Lack of Efficacy ........................................................................71
8.7. Genetics ...................................................................................................................73
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014523
Page 470
Protocol C4591001
8.8. Biomarkers ..............................................................................................................73

8.11.1. Phase 1 ......................................................................................................73
8 Days After Visit 1) .........................................................................78
8 Days After Visit 4) .........................................................................81
16 Days After Visit 4) .......................................................................82

Visit 4) ...............................................................................................83
After Visit 4)......................................................................................84
After Visit 4)......................................................................................85
After Visit 4)......................................................................................85
8.11.2. Phase 2/3...................................................................................................86
After Visit 2)......................................................................................91
After Visit 2)......................................................................................91
After Visit 2)......................................................................................92
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014524
Page 471
Protocol C4591001

Potential COVID-19 Illness Onset) .................................................................94
Potential COVID-19 Illness Visit)..................................................................96
8.14. Communication and Use of Technology...............................................................97
9. STATISTICAL CONSIDERATIONS ................................................................................97
9.1. Estimands and Statistical Hypotheses .....................................................................97
9.1.1. Estimands....................................................................................................97
9.1.2. Statistical Hypotheses.................................................................................98
9.2. Sample Size Determination.....................................................................................98
9.3. Analysis Sets ...........................................................................................................99

9.4.3. Safety Analyses ........................................................................................106
9.4.4. Other Analyses..........................................................................................108
9.5.1. Analysis Timing........................................................................................111
CONSIDERATIONS ........................................................................................................113
10.1.3. Data Protection .......................................................................................115
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014525
Page 472
Protocol C4591001

10.3.1. Definition of AE .....................................................................................122

11. REFERENCES ................................................................................................................143
LIST OF TABLES
Rates With Different Sample Sizes ..........................................................99
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014526
Page 473
Protocol C4591001

CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014527
Page 474
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale


importance.
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014528
Page 475
Protocol C4591001
For Phase 1

dose  SAEs
after Dose 2

intervention:

Dose 2

each time point
vaccination
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014529
Page 476
Protocol C4591001

vaccination
time point
For Phase 2/3

Primary Efficacy
without evidence of infection before receipt of the last dose of study confirmed NAAT in participants with
100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
vaccine to placebo] dose) of past SARS-CoV-2 infection
with and without evidence of receipt of the last dose of study confirmed NAAT
vaccine to placebo]
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014530
Page 477
Protocol C4591001

Primary Safety
after the last dose
Secondary Efficacy
participants without evidence of receipt of the last dose of study serological or virological evidence of
vaccine to placebo]
participants with and without receipt of the last dose of study
vaccine to placebo]
the CDC-defined symptoms) in receipt of the last dose of study confirmed NAAT in participants with
infection before vaccination 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
the CDC-defined symptoms) in receipt of the last dose of study confirmed NAAT
CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014531
Page 478
Protocol C4591001

Exploratory
vaccination
study
confirmed COVID-19
disease
Overall Design
This is a Phase 1/2/3, multicenter, multinational, randomized, placebo-controlled, observer-

years of age [stratified as ≤55 or >55 years of age]).
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014532
Page 479
Protocol C4591001
195 participants.
21,999 vaccine recipients. It is intended that a minimum of 40% of participants will be in the
>55-year stratum. An equal number of participants will receive placebo, ie, randomized in a
1:1 ratio.
≥16 years of age [stratified as ≤55 or >55 years of age]):
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg

Statistical Methods
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014533
Page 480
Protocol C4591001
The immunogenicity objectives will be evaluated descriptively by GMT, GMC, GMFR,

percentage of participants with ≥4-fold rise, percentage of participants with ≥ specified
threshold, and GMC ratio, and the associated 95% confidence intervals (CIs), for
SARS-CoV-2 neutralizing titers, S1-binding IgG levels, and RBD-binding IgG levels at the
various time points.
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014534
Page 481
Protocol C4591001
1.2. Schema
Age: 18-55 y Age: 65-85 y

after Dose 1)

after Dose 1)

after Dose 1)


Phase 2 data (first 360 participants) (Stratified 16-55 or >55)
analyses)
CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014535
Page 482
Protocol C4591001

protocol.
1.3.1. Phase 1

(Vax 1)
Illness
Onset
currently taken
CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014536
Page 483
Protocol C4591001

(Vax 1)
Illness
Onset
laboratory testsb
COVID-19 infection
(if appropriate)
swab(s)c
information
use
chemistry results
criteria
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014537
Page 484
Protocol C4591001

(Vax 1)
Illness
Onset
(if appropriate)
allocation
~170 mL ~170 mL ~170 mL
device, if required
measuring device
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014538
Page 485
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
dates
appropriate
application
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014539
Page 486
Protocol C4591001

(Vax 1)
Illness
Onset
diagnosis)
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014540
Page 487
Protocol C4591001
1.3.2. Phase 2/3



Visit
Potential COVID-19
Illness Onset
c X
For participants who are HIV positive, record latest X X X X X
Collect blood sample for immunogenicity ~20 mL ~20 mL ~20 mL ~20 mL ~20 mL ~20 mL
assessmentd
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014541
Page 488
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
optimal during the active diary period)d
and obtain stop datesd
Collect AEs and SAEs as appropriate X X X Xe Xe Xe X Xe
application
same day.
d. Reactogenicity subset participants only.
e. Any AEs occurring up to 48 hours after the blood draw must be recorded (see Section 8.3.1).
CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014542
Page 489
Protocol C4591001
2. INTRODUCTION

2.2. Background

CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014543
Page 490
Protocol C4591001

 BNT162b1 (variant RBP020.3): nucleoside-modified messenger RNA (modRNA) with

blunted innate immune sensor–activating capacity and augmented expression encoding
the RBD.


IB.

 In order for the overall Phase 3 study population to be as representative and diverse as
possible, the inclusion of participants with known chronic stable HIV, HCV, or HBV
infection is permitted. Individuals with chronic viral diseases are at increased risk for
COVID-19 complications and severe disease. In addition, with the currently available
CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014544
Page 491
Protocol C4591001
therapies for their treatment, many individuals with chronic stable HIV, HCV, and HBV
infections are unlikely to be at higher safety risk as a participant in this vaccine study
than individuals with other chronic stable medical conditions.
 All participants with chronic stable HIV disease will be included in the reactogenicity
subset (see Section 8.2.2).
CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014545
Page 492
Protocol C4591001

Significance
syncytial virus (RSV), feline coronavirus, possible current clinical COVID-19. All participants are followed for
and Dengue virus vaccines. SARS-CoV-2 antigen-specific antibody and SARS-CoV-2 neutralizing
titers, and COVID-19 illness, including markers of severity.
Study Procedures
venipuncture site.
CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014546
Page 493
Protocol C4591001

 Access to COVID-19 diagnostic and antibody testing


3.1. For Phase 1
dose  SAEs

after Dose 2
CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014547
Page 494
Protocol C4591001

1; 7 and 14 days and 1, 6, 12, and 24
months after Dose 2
each time point
vaccination


each time point
CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014548
Page 495
Protocol C4591001
3.2. For Phase 2/3

Primary Efficacy
vaccine to placebo]
Primary Safety

after the last dose

Secondary Efficacy
vaccine to placebo]
CONFIDENTIAL
Page 36
FDA-CBER-2021-5683-0014549
Page 496
Protocol C4591001

vaccine to placebo]
Exploratory
and persistence of immune response defined threshold(s), at baseline and
 SARS-CoV-2 neutralizing titers

vaccination
study
confirmed COVID-19
HIV disease
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014550
Page 497
Protocol C4591001
(see Section 9.6).
4. STUDY DESIGN
4.1. Overall Design
This is a multicenter, multinational, Phase 1/2/3, randomized, placebo-controlled, observer-

unblinded.
CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014551
Page 498
Protocol C4591001
4.1.1. Phase 1
 No more than 5 participants (4 active, 1 placebo) can be vaccinated on the first day
 The first 5 participants must be observed by blinded site staff for at least 4 hours after
vaccination for any acute reactions


55-year age cohort:
Germany (BNT162-01)
escalation for the second candidate studied may be based upon the safety profile of
the first candidate studied being deemed acceptable at the same, or a higher, dose
level by the IRC
CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014552
Page 499
Protocol C4591001
4.1.2. Phase 2/3

stratified as follows: 16 to 55 years or >55 years. It is intended that a minimum of 40% of
participants will be in the >55-year stratum. Commencement of each age stratum will be
based upon satisfactory post–Dose 2 safety and immunogenicity data from the 18- to 55-year
and 65- to 85-year age groups in Phase 1, respectively. The vaccine candidate selected for
Phase 2/3 evaluation is BNT162b2 at a dose of 30 µg.
Phase 2/3 is event-driven. Under the assumption of a true VE rate of ≥60%, after the last
COVID-19 due to SARS-CoV-2 occurring at least 7 days following the last dose of the


CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014553
Page 500
Protocol C4591001


BNT162b2.
 That lower dose levels of BNT162b1 and BNT162b2 warrant consideration. Therefore, a
20-µg dose level is formally included for both candidates.
CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014554
Page 501
Protocol C4591001

5. STUDY POPULATION
protocol.


Age and Sex:
85 years, inclusive (Phase 1), or ≥16 years (Phase 2/3), at randomization.

study.
CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014555
Page 502
Protocol C4591001
Informed Consent:
5. Capable of giving personal signed informed consent as described in Appendix 1, which

includes compliance with the requirements and restrictions listed in the ICD and in this
protocol.

Medical Conditions:
study.
5. Previous clinical or microbiological diagnosis of COVID-19.
 Hypertension
 Asthma
CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014556
Page 503
Protocol C4591001

<60 mL/min/1.73 m2)
 BMI >30 kg/m2



CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014557
Page 504
Protocol C4591001
nanoparticles.
visit.
study intervention.
Other Exclusions:
members.

CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014558
Page 505
Protocol C4591001



Administration
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014559
Page 506
Protocol C4591001

age [stratified as ≤55 or >55 years of age]).
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg

modRNA) modRNA)
for injection)
a
Dosage Level(s) 10-, 20-, 30-, 100-µg 10-, 20-, 30-µg N/A
CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014560
Page 507
Protocol C4591001

modRNA) modRNA)

CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014561
Page 508
Protocol C4591001
business.
CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014562
Page 509
Protocol C4591001

files.

on its appearance.


blinding plan):
 Those study team members who are involved in ensuring that protocol requirements for
study intervention preparation, handling, allocation, and administration are fulfilled at the
site will be unblinded for the duration of the study (eg, unblinded study manager,
unblinded clinical research associate).
CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014563
Page 510
Protocol C4591001
deviations.
monitor who will review cases of severe COVID-19 as they are received, and will review
AEs at least weekly for additional potential cases of severe COVID-19
 An unblinded submissions team will be responsible for preparing unblinded analyses and
documents to support regulatory activities that may be required while the study is
ongoing. All statistical analyses conducted on Phase 2/3 data while the study is ongoing,
that are not in support of the DMC, will be performed by this team. This team will not
have access to unblinded COVID-19 cases unless efficacy is achieved in either an interim
analysis or the final analysis, as determined by the DMC.



study intervention.

follow-up visit (Visit 8 for Phase 1 participants, and Visit 4 for Phase 2/3 participants).
CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014564
Page 511
Protocol C4591001
 Prohibited medications listed in Section 6.5.1 will be recorded, to include start and stop
dates, name of the medication, dose, unit, route, and frequency.
 In addition, for participants enrolled in Phase 1, all current medication at baseline will be
recorded, to include start date, name of the medication, dose, unit, route, and frequency.





CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014565
Page 512
Protocol C4591001



meeting 1 or more exclusion criteria). Note that a positive SARS-CoV-2 NAAT result
without symptoms should not result in discontinuation of study intervention.



 Death;
 AEs;
CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014566
Page 513
Protocol C4591001


CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014567
Page 514
Protocol C4591001
 The site must attempt to contact the participant and reschedule the missed visit as soon as
possible and counsel the participant on the importance of maintaining the assigned visit
schedule and ascertain whether or not the participant wishes to and/or should continue in
the study;
 Before a participant is deemed lost to follow-up, the investigator or designee must make
every effort to regain contact with the participant (where possible, 3 telephone calls and,
if necessary, a certified letter to the participant’s last known mailing address or local
equivalent methods). These contact attempts should be documented in the participant’s
medical record;


profile by age.
intervention.
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014568
Page 515
Protocol C4591001
to 515 mL for participants in Phase 1, and approximately up to 110 mL for Phase 2/3
participants. Additionally, 20 mL of blood will be taken at an unplanned convalescent visit
at any time a participant develops respiratory symptoms indicating a potential COVID-19
infection. Select participants in Phase 1 will also be asked to provide an additional blood
sample of approximately 170 mL at either Visit 5, 6, or 7. These participants would
therefore have a total blood sampling volume of 700 mL during the 24-month study period.
Other additional blood samples may be taken for safety assessments at times specified by
Pfizer, provided the total volume taken during the study does not exceed 550 mL during any
period of 60 consecutive days.

will be assessed. A local NAAT result will be considered acceptable if it was obtained using:
 An FDA-cleared (including Emergency Use Authorization) assay; or
 An assay that is not FDA-cleared but was conducted in a laboratory that is currently
CLIA-certified; or
 An assay performed by a laboratory accredited according to the ISO 15189 standard by a

national or regional accreditation body.

experienced by the participant):

SARS-CoV-2 NAAT positive during, or within 4 days before or after, the symptomatic
period, either at the central laboratory or at a local testing facility (using an acceptable
test):
CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014569
Page 516
Protocol C4591001
 Fever;
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
 Fatigue;
 Headache;
 Nausea.

following:
 Clinical signs at rest indicative of severe systemic illness (RR ≥30 breaths per minute,
HR ≥125 beats per minute, SpO2 ≤93% on room air at sea level, or PaO2/FiO2
<300 mm Hg);
 Respiratory failure (defined as needing high-flow oxygen, noninvasive ventilation,

mechanical ventilation, or ECMO);
 Evidence of shock (SBP <90 mm Hg, DBP <60 mm Hg, or requiring vasopressors);
CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014570
Page 517
Protocol C4591001
 Death.
will prevail.
of COVID-19:

N-binding antibody result in a participant with a prior negative N-binding antibody result


CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014571
Page 518
Protocol C4591001



CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014572
Page 519
Protocol C4591001

All participants in Phase 3 who are HIV positive will be included in this subset. The
reactogenicity e-diary allows recording of these assessments only within a fixed time
window, thus providing the accurate representation of the participant’s experience at that
time. Data on local reactions and systemic events reported in the reactogenicity e-diary will
be transferred electronically to a third-party vendor, where they will be available for review
by investigators and the Pfizer clinicians at all times via an internet-based portal.


CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014573
Page 520
Protocol C4591001


(Grade 4)

severe pain


CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014574
Page 521
Protocol C4591001

(Grade 4)
hypotensive shock
diarrhea
headache
fatigue
chills
pain
8.2.2.4. Fever

CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014575
Page 522
Protocol C4591001

≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)

(Day 1 to Day 7).

will commence:
 The stopping rule will PAUSE randomization and study intervention administration for
the impacted vaccine candidate all dose levels and age groups.
CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014576
Page 523
Protocol C4591001

Stopping Rule
groups.
CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014577
Page 524
Protocol C4591001
in Section 10.7.

how to proceed.

CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014578
Page 525
Protocol C4591001

the participant's legally authorized representative).
Each participant will be questioned about the occurrence of AEs in a nonleading manner.
period”) for each participant begins from the time the participant provides informed consent,
which is obtained before the participant’s participation in the study (ie, before undergoing
any study-related procedure and/or receiving study intervention), through and including
Visit 7 for Phase 1 participants, and Visit 3 for Phase 2/3 participants. In addition, any AEs
occurring up to 48 hours after each subsequent blood draw must be recorded on the CRF.
SAEs will be collected from the time the participant provides informed consent to
approximately 6 months after the last dose of study intervention (Visit 8 for Phase 1
participants, and Visit 4 for Phase 2/3 participants).

CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014579
Page 526
Protocol C4591001



AE occurrences.

CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014580
Page 527
Protocol C4591001


awareness.

An EDP occurs if:
 A female participant is found to be pregnant while receiving or after discontinuing study

intervention.

 A female is found to be pregnant while being exposed or having been exposed to study
intervention due to environmental exposure. Below are examples of environmental
exposure during pregnancy:
intervention by inhalation or skin contact then exposes his female partner prior to or
around the time of conception.
CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014581
Page 528
Protocol C4591001
 If EDP occurs in a participant or a participant’s partner, the investigator must report this
information to Pfizer Safety on the Vaccines SAE Report Form and an EDP
pregnancy will be collected after the start of study intervention and until 6 months after
the last dose of study intervention.
Supplemental Form. Since the exposure information does not pertain to the participant
enrolled in the study, the information is not recorded on a CRF; however, a copy of the
completed Vaccines SAE Report Form is maintained in the investigator site file.
reported).
 Neonatal deaths that occur within 1 month of birth should be reported, without regard to
causality, as SAEs. In addition, infant deaths after 1 month should be reported as SAEs
when the investigator assesses the infant death as related or possibly related to exposure
to the study intervention.
partner.
CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014582
Page 529
Protocol C4591001

 A female participant is found to be breastfeeding while receiving or after discontinuing

study intervention.

study intervention (ie, environmental exposure). An example of environmental exposure
during breastfeeding is a female family member or healthcare provider who reports that
she is breastfeeding after having been exposed to the study intervention by inhalation or
skin contact.


Not applicable.
CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014583
Page 530
Protocol C4591001

or SAEs

Not applicable.


Not applicable.

medication errors.
of Awareness

CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014584
Page 531
Protocol C4591001
 Potential medication errors or uses outside of what is foreseen in the protocol that do or
do not involve the study participant;
 The administration of study intervention that has undergone temperature excursion from
the specified storage range, unless it is determined by the sponsor that the study

CRF.

CRF.
CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014585
Page 532
Protocol C4591001

8.7. Genetics
8.8. Biomarkers



8.11.1. Phase 1
study.
CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014586
Page 533
Protocol C4591001
pulse rate, and seated blood pressure), evaluating any clinically significant abnormalities
within the following body systems: general appearance; skin; head, eyes, ears, nose, and
throat; heart; lungs; abdomen; musculoskeletal; extremities; neurological; and lymph
nodes.
 Collect a blood sample (approximately 20 mL) for potential future serological assessment
and to perform a rapid test for prior COVID-19 infection.
 Collect a blood sample (approximately 10 mL) for hematology and chemistry laboratory
tests as described in Section 10.2.
 Collect a blood sample (approximately 10 mL) for HIV, HBsAg, HBc Ab, and HCV Ab
tests.

 Ensure and document that all of the inclusion criteria and none of the exclusion criteria
are met.
 Record AEs as described in Section 8.3. AEs that occur prior to dosing should be noted
on the Medical History CRF.
 Ask the participant to contact the site staff or investigator immediately if any significant
illness or hospitalization occurs.

vaccination.
CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014587
Page 534
Protocol C4591001
are met.
Section 5.5.
 Obtain the participant’s randomization number and study intervention allocation using
the IRT system. Only an unblinded site staff member may obtain this information.
 Unblinded site staff member(s) will dispense/administer 1 dose of study intervention into
the deltoid muscle of the preferably nondominant arm. Please refer to the IP manual for
further instruction on this process.
 The first 5 participants vaccinated in each group must be observed by blinded site staff
for any acute reactions for at least 4 hours after vaccination. For participants enrolled
thereafter, blinded site staff must observe the participant for at least 30 minutes after
study intervention administration for any acute reactions. Record any acute reactions
(including time of onset) in the participant’s source documents and on the AE page of the
CRF, and on an SAE form as applicable.
CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014588
Page 535
Protocol C4591001
 Explain the e-diary technologies available for this study (see Section 8.14), and assist the
participant in downloading the study application onto the participant’s own device or
issue a provisioned device if required. Provide instructions on e-diary completion and
ask the participant to complete the reactogenicity e-diary from Day 1 to Day 7, with
Day 1 being the day of vaccination and, if utilized, the COVID-19 illness e-diary (to be
completed if the participant is diagnosed with COVID-19 or has possible new or
increased symptoms, and when he/she receives a reminder, at least weekly).
experiences any of the following from Day 1 to Day 7 after vaccination (where Day 1 is
the day of vaccination) to determine if an unscheduled reactogenicity visit is required:
 Fever ≥39.0°C (≥102.1°F).


 Ask the participant to contact the site staff or investigator if a medically attended event
(eg, doctor’s visit, emergency room visit) or hospitalization occurs.

 The investigator or appropriately qualified designee reviews the reactogenicity e-diary

data online following vaccination to evaluate participant compliance and as part of the
ongoing safety review. Daily review is optimal during the active diary period.
CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014589
Page 536
Protocol C4591001
 Record details of any of the prohibited medications specified in Section 6.5.1 received by
the participant if required for his or her clinical care.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014590
Page 537
Protocol C4591001

 Review hematology and chemistry laboratory results and record any AEs in accordance
with Appendix 2.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014591
Page 538
Protocol C4591001


vaccination.
reactogenicity e-diary events ongoing on the last day that the reactogenicity e-diary was
completed and record stop dates in the CRF if required.
with Appendix 2.
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014592
Page 539
Protocol C4591001
possible at the site, otherwise at the central laboratory) within 24 hours and vaccination
will only proceed if it is NAAT-negative for SARS-CoV-2 genomes. The second will be
sent to the central laboratory for potential later testing.
are met. If not, the participant should not receive further study intervention but will
remain in the study to be evaluated for safety, immunogenicity, and efficacy
(see Section 7.1).
Section 5.5.
 Ensure the participant has a measuring device to measure local reactions at the injection
site and a thermometer for recording daily temperatures.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014593
Page 540
Protocol C4591001


with Appendix 2.
CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014594
Page 541
Protocol C4591001
consents, collect an additional 170 mL blood sample for exploratory COVID-19 research.
 Fever ≥39.0°C (≥102.1°F).


with Appendix 2.
CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014595
Page 542
Protocol C4591001
 Ask the participant to contact the site staff or investigator immediately (this could be via
the COVID-19 illness e-diary) if he or she experiences any respiratory symptoms as
detailed in Section 8.13.

CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014596
Page 543
Protocol C4591001
 If not collected at Visit 5 or 6, and the participant (select participants only, details will be
Section 8.3.
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014597
Page 544
Protocol C4591001
Section 8.3.
 Collect the participant’s e-diary or assist the participant to remove the study application
from his or her own personal device.
Section 8.3.
CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014598
Page 545
Protocol C4591001
8.11.2. Phase 2/3

study.
 Obtain any medical history of clinical significance. For participants who are HIV
positive, record HIV viral load and CD4 count results from the most recent test

examination is necessary to comprehensively evaluate the participant, perform a physical
examination and record any findings in the source documents and, if clinically
significant, record on the medical history CRF.
are met.
Section 5.5.
CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014599
Page 546
Protocol C4591001
 Obtain the participant’s randomization number and study intervention allocation number
using the IRT system. Only an unblinded site staff member may obtain this information.
 For participants in the reactogenicity subset, issue a measuring device to measure local
reactions at the injection site and a thermometer for recording daily temperatures and
provide instructions on their use.
 For participants not in the reactogenicity subset, issue a thermometer to monitor for fever
(for COVID-19 surveillance) and provide instructions on its use.
issue a provisioned device if required.
 For participants in the reactogenicity subset, provide instructions on reactogenicity

e-diary completion and ask the participant to complete the reactogenicity e-diary from
Day 1 to Day 7, with Day 1 being the day of vaccination.
 For all participants, provide instructions on COVID-19 illness e-diary completion and
ask the participant to complete the COVID-19 illness e-diary if he/she is diagnosed
with COVID-19 or has possible new or increased symptoms, and when he/she
receives a reminder, at least weekly. See Section 8.14 for further details.
 If the participant is part of the reactogenicity subset, ask the participant to contact the site
staff or investigator immediately if he or she experiences any of the following from Day
1 to Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if an
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014600
Page 547
Protocol C4591001



vaccination.

CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014601
Page 548
Protocol C4591001
are met. If not, the participant may not receive further study intervention but will remain
in the study to be evaluated for safety, immunogenicity, and efficacy
(see Section 7.1).
Section 5.5.
confirm instructions on e-diary completion, and, if the participant is part of the
reactogenicity subset, ask the participant to complete the reactogenicity e-diary from
staff or investigator immediately if he or she experiences any of the following from
Day 1 to Day 7 after vaccination (where Day 1 is the day of vaccination) to determine if
an unscheduled reactogenicity visit is required:
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014602
Page 549
Protocol C4591001


Visit 2)
reactogenicity subset, review the participant’s reactogenicity e-diary data. Collect stop
dates of any reactogenicity e-diary events ongoing on the last day that the reactogenicity
e-diary was completed and record stop dates in the CRF if required.
 For participants who are HIV positive, record HIV viral load and CD4 count results from
the most recent test performed since Visit 1 (if any).
CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014603
Page 550
Protocol C4591001

Section 8.3.
CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014604
Page 551
Protocol C4591001
Section 8.3.
Section 8.3.

following is true:
contact.
CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014605
Page 552
Protocol C4591001
 The participant recorded an incorrect value in the reactogenicity e-diary (confirmation of

a reactogenicity e-diary data entry error).
CRF.

Section 8.2.2.2.
Section 8.2.2.3.
 Assess for other findings associated with the reaction and record on the AE page of the
CRF, if appropriate.
page of the CRF.
CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014606
Page 553
Protocol C4591001

3 days of symptom onset (and at the latest 4 days after symptom resolution). During the
7 days following each vaccination, potential COVID-19 symptoms that overlap with solicited
systemic events (ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should
not trigger a potential COVID-19 illness visit unless, in the investigator’s opinion, the
clinical picture is more indicative of a possible COVID-19 illness than vaccine
reactogenicity. Participants may utilize a COVID-19 illness e-diary through an application
device to prompt him/her to report any symptoms. Note that this does not substitute for a
participant’s routine medical care. Therefore, participants should be encouraged to seek care,
if appropriate, from their usual provider.
 Fever;

 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.
CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014607
Page 554
Protocol C4591001

illnesses that are consistent with the clinical endpoint definition should not be recorded as
AEs. These data will be captured as efficacy assessment data only on the relevant pages
of the CRF, as these are expected endpoints.
 If the visit is conducted in person, obtain a nasal (midturbinate) swab (collected by site
staff). Alternatively, if conducted by telehealth, instruct the participant to self-collect a
nasal (midturbinate) swab and ship for assessment at the central laboratory. The result
from this swab will be provided to the site once it is available, but this will not be in real
time, and cannot be relied upon to direct clinical care. Therefore, the participant should
be encouraged to seek care, if appropriate, from his or her usual provider.



vasopressors)

 Local laboratory COVID-19 test result
protein
 Number and type of any healthcare contact; duration of hospitalization and ICU stay
 Death
CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014608
Page 555
Protocol C4591001

illnesses that are consistent with the clinical endpoint definition should not be recorded as
AEs. These data will be captured as efficacy assessment data only on the relevant pages
of the CRF, as these are expected endpoints.

Section 8.13.1).
Section 8.3.
CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014609
Page 556
Protocol C4591001

visits, it is vital that communication between the study site and the participant is maintained
to ensure that endpoint events are not missed. This study will employ various methods,
tailored to the individual participant, to ensure that communication is maintained and study
information can be transmitted securely. Using appropriate technology, such as a study
application, a communication pathway between the participant and the study site staff will be
established. The participant may be able to utilize his or her own devices to access this
technology, or use a device provided by the sponsor. Traditional methods of telephone
communication will also be available. The technology solution may facilitate the following:
 Contact with the investigator, including the ability of the participant to report whether or
not he or she has experienced symptoms that could represent a potential COVID-19
illness (COVID-19 illness e-diary; see Section 8.13).

 A platform for recording local reactions and systemic events (reactogenicity e-diary) –
see Section 8.2.2.
If a participant is not actively completing either the reactogenicity or COVID-19 illness

e-diary, the investigator or designee is required to contact the participant to ascertain why

9.1.1. Estimands
CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014610
Page 557
Protocol C4591001

model.

For Phase 2/3, with assumptions of a true VE of 60% after the last dose of investigational
CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014611
Page 558
Protocol C4591001
1 AE.

Assumed N=12 N=45 N=180 N=3000 N=6000 N=9000 N=15000
True Event
Rate of an
AE
0.01% 0.00 0.00 0.02 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.83 0.97 0.99 >0.99

0.08% 0.01 0.04 0.13 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.95 0.99 0.99 >0.99
0.15% 0.02 0.07 0.24 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 >0.99 >0.99 >0.99 >0.99
0.25% 0.03 0.11 0.36 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99
10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99
9.3. Analysis Sets

the IWR system.
CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014612
Page 559
Protocol C4591001
major protocol deviations as determined by the clinician.
Dose 1 all-available For Phase 1 only: all participants who receive at least 1 dose
immunogenicity of the study intervention with at least 1 valid and determinate
immunogenicity result after Dose 1 but before Dose 2.
Dose 2 all-available All participants who receive at least 1 dose of the study
immunogenicity intervention with at least 1 valid and determinate
and have no other major protocol deviations as determined by
the clinician.
All-available efficacy 1. All eligible randomized participants who receive at least
1 vaccination.
2. All eligible randomized participants who complete

2 vaccination doses.

study intervention.


CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014613
Page 560
Protocol C4591001









confidence limits.
CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014614
Page 561
Protocol C4591001

level







CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014615
Page 562
Protocol C4591001



participants with and without serological or virological evidence of
SARS-CoV-2 infection before vaccination





confidence limits.

CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014616
Page 563
Protocol C4591001



are available



and after Dose 2.
CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014617
Page 564
Protocol C4591001



placebo group 7 days after the last dose. VE will be analyzed using a
beta-binomial model.
evaluated as below.


group

placebo group after 7 days after the last dose. VE will be analyzed
CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014618
Page 565
Protocol C4591001







last dose. The 2-sided 95% CI for VE will be derived using the

CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014619
Page 566
Protocol C4591001


distributed.

each vaccine group.

vaccine group.

CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014620
Page 567
Protocol C4591001

Exploratory N/A

point.

declared if the first primary study objective is met. The criteria for success at an interim
analysis are based on the posterior probability (ie, P[VE >30%|data]) at the current
number of cases. Overwhelming efficacy will be declared if the posterior probability is
higher than the success threshold. The success threshold for each interim analysis will be
calibrated to protect overall type I error at 2.5%. Additional details about the success
threshold or boundary calculation at each interim analysis will be provided in the SAP.
 The study will stop for lack of benefit (futility) if the predicted probability of success at
the final analysis or study success is <5%. The posterior predictive POS will be
calculated using a beta-binomial model. The futility assessment will be performed for the
first primary endpoint and the futility boundary may be subject to change to reflect
subsequent program-related decisions by the sponsor.
CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014621
Page 568
Protocol C4591001
Cases
IA1 32 76.9% (6:26) 11.8% (15:17)
IA2 62 68.1% (15:47) 27.8% (26:36)
IA3 92 62.7% (25:67) 38.6% (35:57)
IA4 120 58.8% (35:85) N/A
Final 164 52.3% (53:111)
> 0.986.
CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014622
Page 569
Protocol C4591001

(%) (Total Cases
= 120)
30 0.006 0.315 0.003 0.231 0.002 0.239 0.002
50 0.054 0.078 0.051 0.056 0.063 0.103 0.075
60 0.150 0.021 0.160 0.010 0.175 0.019 0.160
70 0.368 0.003 0.310 <0.001 0.195 0.001 0.085
80 0.722 <0.001 0.238 <0.001 0.037 <0.001 0.003

(Total Cases = 164)

Group ≤53)
30 0.007 0.021
50 0.196 0.439
60 0.220 0.866
70 0.036 >0.999
80 <0.001 >0.999
receipt of the last dose of investigational product onwards.
CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014623
Page 570
Protocol C4591001

 Complete safety and immunogenicity analysis approximately 1 month after Dose 2 for
Phase 1.
 Safety data through 7 days after Dose 2 and immunogenicity data through 1 month after
Dose 2 from the first 360 participants enrolled (180 to active vaccine and 180 to placebo,
stratified equally between 18 to 55 years and >55 to 85 years) in Phase 2/3.
 Safety data through 1 month after Dose 2 from the first 6000 participants enrolled (3000
to active vaccine and 3000 to placebo) in Phase 2/3.
 Complete safety and immunogenicity analysis approximately 6 months after Dose 2 for
all participants in Phase 2/3.
 Complete efficacy and persistence-of-immunogenicity analysis after complete data are

available at the end of the study.

 Select vaccine candidate/dose level(s) to proceed into Phase 2/3. Data supporting the
selection, including results for both binding antibody levels and neutralizing titers,
and the ratio between them, will also be submitted to the FDA for review
CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014624
Page 571
Protocol C4591001
 Review of any available safety and/or immunogenicity data generated during the course
of this study, or the BioNTech study conducted in Germany, to determine:
 Whether any groups may be added with dose levels below the lowest stated dose or
intermediate between the lowest and highest stated doses

 Contemporaneous review of all SAEs up to 6 months after completion of the vaccination

schedule
 At the time of the planned IAs, and ad hoc if requested by the unblinded team, review of
cases of COVID-19 for an adverse imbalance of cases of COVID-19 and/or severe
as appropriate.
CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014625
Page 572
Protocol C4591001


initiated.
 Providing written summaries of the status of the study to the IRB/EC annually or more
frequently in accordance with the requirements, policies, and procedures established by
the IRB/EC;
 Notifying the IRB/EC of SAEs or other significant safety findings as required by IRB/EC
procedures;
 Providing oversight of the conduct of the study at the site and adherence to requirements
of 21 CFR, ICH guidelines, the IRB/EC, European regulation 536/2014 for clinical
studies (if applicable), and all other applicable local regulations.
of.
CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014626
Page 573
Protocol C4591001

participant and answer all questions regarding the study. The participant should be given
sufficient time and opportunity to ask questions and to decide whether or not to participate in
the trial.
Participants must be informed that their participation is voluntary. Participants will be

required to sign a statement of informed consent that meets the requirements of 21 CFR 50,
local regulations, ICH guidelines, HIPAA requirements, where applicable, and the IRB/EC
or study center.
The investigator must ensure that each study participant is fully informed about the nature
and objectives of the study, the sharing of data related to the study, and possible risks
associated with participation, including the risks associated with the processing of the
participant’s personal data.
The investigator further must ensure that each study participant is fully informed about his or
her right to access and correct his or her personal data and to withdraw consent for the
processing of his or her personal data.
A copy of the ICD(s) must be provided to the participant. Participants who are rescreened are
required to sign a new ICD.
CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014627
Page 574
Protocol C4591001



EudraCT
CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014628
Page 575
Protocol C4591001
www.pfizer.com
Data Sharing

redacted.

CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014629
Page 576
Protocol C4591001
monitoring plan.
maintained.
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014630
Page 577
Protocol C4591001


participants.
start date.
to:
 Failure of the investigator to comply with the protocol, the requirements of the IRB/EC
or local health authorities, the sponsor's procedures, or GCP guidelines;
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014631
Page 578
Protocol C4591001


CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014632
Page 579
Protocol C4591001


Platelet count
WBC count
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)


(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
- cells/mm3
cells/mm3
cells/mm3
CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014633
Page 580
Protocol C4591001

(Grade 4)
dialysis
phosphate –
increase by factor
– ALT, AST
increase by factor
accompanied
by any increase in
increase by factor
factor
CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014634
Page 581
Protocol C4591001

AE Definition






an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-
harming intent. Such overdoses should be reported regardless of sequelae.
CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014635
Page 582
Protocol C4591001





a. Results in death

considered serious.
CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014636
Page 583
Protocol C4591001



or drug abuse.

CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014637
Page 584
Protocol C4591001

SAE Report Form to
Hours of Awareness
SAE All All



CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014638
Page 585
Protocol C4591001

function.

function.

function.


be ruled out.

CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014639
Page 586
Protocol C4591001

assessment.



CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014640
Page 587
Protocol C4591001


courier service.
CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014641
Page 588
Protocol C4591001

intervention(s):
PLUS either:

OR
 Must agree to use a male condom when engaging in any activity that allows for passage
of ejaculate to another person.

considered in WOCBP partners of male participants (refer to the list of highly effective
methods below in Section 10.4.4).

OR
 Is a WOCBP and using an acceptable contraceptive method as described below during

the intervention period (for a minimum of 28 days after the last dose of study
pregnancy.
CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014642
Page 589
Protocol C4591001

considered.


CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014643
Page 590
Protocol C4591001


ovulation.

90 days.

 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
 Oral;
 Injectable.

participant.
CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014644
Page 591
Protocol C4591001

CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014645
Page 592
Protocol C4591001

subsequently present with AST OR ALT values >3 × ULN AND a TBili value >2 × ULN
with no evidence of hemolysis and an alkaline phosphatase value <2 × ULN or not
available.
 Preexisting AST or ALT baseline values above the normal range: AST or ALT values
>2 times the baseline values AND >3 × ULN; or >8 × ULN (whichever is smaller).
CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014646
Page 593
Protocol C4591001
baseline value by an amount of at least 1 × ULN or if the value reaches >3 × ULN
(whichever is smaller).
CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014647
Page 594
Protocol C4591001

Abbreviation Term
AE adverse event
BMI body mass index

DU dosing unit
EC ethics committee
EU European Union
EUA emergency use application
CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014648
Page 595
Protocol C4591001
Abbreviation Term
HBe hepatitis B e
HR heart rate
IA interim analysis

ID identification
Ig immunoglobulin
IV intravenous(ly)
LL lower limit
LPX lipoplex
CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014649
Page 596
Protocol C4591001
Abbreviation Term
N/A not applicable
PT prothrombin time
RBC red blood cell
RR respiratory rate
CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014650
Page 597
Protocol C4591001
Abbreviation Term
US United States
vax vaccination
VE vaccine efficacy
CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014651
Page 598
Protocol C4591001

CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014652
Page 599
Protocol C4591001

Rule Value (S)
Group
4 4 N/A
5 5 3.13%
6 6 1.56%
7 7 0.78%
8 7 3.52%
9 8 1.95%
10 9 1.07%
11 9 3.27%
12 10 1.93%
13 10 4.61%
14 11 2.87%
15 12 1.76%
16 12 3.84%
17 13 2.45%
18 13 4.81%
19 14 3.18%
20 15 2.07%
CONFIDENTIAL
Page 140
FDA-CBER-2021-5683-0014653
Page 600
Protocol C4591001
Value (A)
Vaccine 1:1, 1:1, 2:1, 3:1, 4:1,
2 2 25.00% 25.00% 44.49% 56.25% 64.00%
3 2 37.50% 50.00% 74.12% 84.38% 89.60%
4 3 25.00% 31.25% 59.32% 73.83% 81.92%
5 4 15.63% 18.75% 46.16% 63.28% 73.73%
6 4 23.44% 34.38% 68.10% 83.06% 90.11%
7 5 16.41% 22.66% 57.14% 75.64% 85.20%

8 6 10.94% 14.45% 46.90% 67.85% 79.69%
9 6 16.41% 25.39% 65.11% 83.43% 91.44%
10 7 11.72% 17.19% 56.02% 77.59% 87.91%
11 8 8.06% 11.33% 47.35% 71.33% 83.89%
12 8 12.08% 19.38% 63.25% 84.24% 92.74%
13 9 8.73% 13.34% 55.31% 79.40% 90.09%
14 10 6.11% 8.98% 47.66% 74.15% 87.02%
15 10 9.16% 15.09% 61.94% 85.16% 93.89%
16 11 6.67% 10.51% 54.81% 81.03% 91.83%
17 12 4.72% 7.17% 47.88% 76.53% 89.43%
18 13 3.27% 4.81% 41.34% 71.75% 86.71%
19 13 5.18% 8.35% 54.43% 82.51% 93.24%
20 14 3.70% 5.77% 48.06% 78.58% 91.33%
CONFIDENTIAL
Page 141
FDA-CBER-2021-5683-0014654
Page 601
Protocol C4591001
Known HIV infection
 Confirmed stable HIV disease defined as documented viral load <50 copies/mL and CD4
count >200 cells/mm3 within 6 months before enrollment, and on stable antiretroviral
therapy for at least 6 months.
Known HCV infection

undetectable HCV RNA) for ≥12 weeks following HCV treatment or without evidence
of HCV RNA viremia (undetectable HCV viral load).
Known HBV infection
Confirmed inactive chronic HBV infection, defined as HBsAg present for ≥6 months and
the following:
CONFIDENTIAL
Page 142
FDA-CBER-2021-5683-0014655
Page 602
Protocol C4591001
11. REFERENCES
1
briefing on COVID-19. Available from: https://www.who.int/dg/speeches/detail/who-
director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-
2
3
4
5

6
7
8
9
10
1985;4(2):213-26.
CONFIDENTIAL
Page 143
FDA-CBER-2021-5683-0014656
Page 603
Document Name:
Document Title: !!" # $%&%'()%## * )'*%+,- * %$ ).

)&$#,'* *% &/,'*,'0 (1*2 (% .#1( ( / (2 (
%# )$,#,(2 ,++1'%0 ',,(2 '* //,2 %/ )&%.&
)' .,' '*,*( 0,'( %.,*& ,' #(2 ,
'*,.,*1#
#34 4 5 && 6 6"7 $58 88 # 9

:5 : 4 && "6 6" / 9
FDA-CBER-2021-5683-0014657
Page 604
Protocol C4591001
Protocol Amendment 5, 24 July 2020

CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS

090177e1947b6a02\Approved\Approved On: 24-Jul-2020 13:05 (GMT)

Phase: 1/2/3
Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014658
Page 605
Protocol C4591001
Document History

30 µg.
phase of the study.
In addition:
to the purpose.
evaluated.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014659
Page 606
Protocol C4591001
Document History

added to Section 3.





template.




CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014660
Page 607
Protocol C4591001
Document History

protocol.
BNT162b2.
intervention.





illness e-diary.
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014661
Page 608
Protocol C4591001
Document History

In addition:

(BNT162-01):
BNT162c2
Additionally:
after Dose 1 or 2
escalation
antigen to BNT162c2
subunit
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014662
Page 609
Protocol C4591001
Document History

will be directed

candidate
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014663
Page 610
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................12
1.1. Synopsis ..................................................................................................................14
1.2. Schema ....................................................................................................................21
1.3.1. Phase 1 ........................................................................................................22
1.3.2. Phase 2/3.....................................................................................................27
2. INTRODUCTION ...............................................................................................................29
2.1. Study Rationale .......................................................................................................29
2.2. Background .............................................................................................................29
2.3.1. Risk Assessment .........................................................................................31

3.1. For Phase 1 ..............................................................................................................32
3.2. For Phase 2/3 ...........................................................................................................34
4. STUDY DESIGN.................................................................................................................36
4.1. Overall Design.........................................................................................................36
4.1.1. Phase 1 ........................................................................................................36
4.1.2. Phase 2/3.....................................................................................................37
5.3.1. Contraception..............................................................................................43
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014664
Page 611
Protocol C4591001
5.4. Screen Failures ........................................................................................................43

6.1.1. Administration ............................................................................................45

7.3. Lost to Follow-up ....................................................................................................52
8.2.2.1. Grading Scales...........................................................................58
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014665
Page 612
Protocol C4591001
8.2.2.2. Local Reactions .........................................................................58

8.2.2.3. Systemic Events ........................................................................59
8.2.2.4. Fever..........................................................................................60

Exposure ..........................................................................................................66
8.3.8.1. Lack of Efficacy ........................................................................69
8.7. Genetics ...................................................................................................................71
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014666
Page 613
Protocol C4591001
8.8. Biomarkers ..............................................................................................................71

8.11.1. Phase 1 ......................................................................................................71
8 Days After Visit 1) .........................................................................76
8 Days After Visit 4) .........................................................................79
16 Days After Visit 4) .......................................................................80

Visit 4) ...............................................................................................81
After Visit 4)......................................................................................82
After Visit 4)......................................................................................83
After Visit 4)......................................................................................83
8.11.2. Phase 2/3...................................................................................................84
After Visit 2)......................................................................................89
After Visit 2)......................................................................................89
After Visit 2)......................................................................................90
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014667
Page 614
Protocol C4591001

Potential COVID-19 Illness Onset) .................................................................92
Potential COVID-19 Illness Visit)..................................................................93
8.14. Communication and Use of Technology...............................................................94
9. STATISTICAL CONSIDERATIONS ................................................................................94
9.1. Estimands and Statistical Hypotheses .....................................................................94
9.1.1. Estimands....................................................................................................94
9.1.2. Statistical Hypotheses.................................................................................95
9.2. Sample Size Determination.....................................................................................95
9.3. Analysis Sets ...........................................................................................................96
9.4. Statistical Analyses .................................................................................................97
9.4.1. Immunogenicity Analyses ..........................................................................98

9.4.3. Safety Analyses ........................................................................................104
9.4.4. Other Analyses..........................................................................................105
9.5.1. Analysis Timing........................................................................................108
CONSIDERATIONS ........................................................................................................110
10.1.3. Data Protection .......................................................................................112
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014668
Page 615
Protocol C4591001

10.3.1. Definition of AE .....................................................................................119

11. REFERENCES ................................................................................................................139
LIST OF TABLES
Rates With Different Sample Sizes ..........................................................96
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014669
Page 616
Protocol C4591001
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014670
Page 617
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale


importance.
the SARS-CoV-2 full-length, P2 mutant, “heads up,” prefusion spike glycoprotein (P2 S)
(version 9) or a trimerized SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD)
(version 5). The 2 SARS-CoV-2 vaccine candidates that will be tested in this study are
therefore:
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014671
Page 618
Protocol C4591001
For Phase 1

profiles of prophylactic BNT162 of study intervention and having safety injection site, redness, and
vaccines in healthy adults after 1 or 2 data reported after any vaccination, the swelling)
doses percentage of participants reporting:  Systemic events (fever, fatigue,
 Local reactions for up to 7 days headache, chills, vomiting,
following each dose diarrhea, new or worsened muscle
 Systemic events for up to 7 days pain, and new or worsened joint
following each dose pain)
 Adverse events (AEs) from  AEs
Dose 1 to 1 month after the last  SAEs
dose
after Dose 2

intervention:

Dose 2
 Geometric mean titers (GMTs) at SARS-CoV-2 serum neutralizing titers

each time point
vaccination
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014672
Page 619
Protocol C4591001

 Geometric mean concentrations SARS-CoV-2 anti-S1 binding antibody
(GMCs) at each time point levels and anti-RBD binding antibody
 GMFR from before vaccination to levels
vaccination
 Geometric mean ratio (GMR),  SARS-CoV-2 serum neutralizing
estimated by the ratio of the titers
geometric mean of SARS-CoV-2  SARS-CoV-2 anti-S1 binding
serum neutralizing titers to the antibody levels
geometric mean of SARS-CoV-2–  SARS-CoV-2 anti-RBD binding
binding antibody levels at each antibody levels
time point
For Phase 2/3

Primary Efficacy
vaccine to placebo]
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014673
Page 620
Protocol C4591001

Primary Safety
prophylactic BNT162b2 in the first dose of study intervention and having injection site, redness, and
360 participants randomized (Phase 2) safety data reported after any swelling)
vaccination, the percentage of  Systemic events (fever, fatigue,
participants reporting: headache, chills, vomiting,
 Local reactions for up to 7 days diarrhea, new or worsened
 Systemic events for up to 7 days worsened joint pain)
following each dose  AEs
 AEs from Dose 1 to 1 month  SAEs
after the last dose
 SAEs from Dose 1 to 6 months
after the last dose
prophylactic BNT162b2 in all 1 dose of study intervention and  SAEs
participants randomized in Phase 2/3 having safety data reported after any  In a subset of at least 6000
vaccination, the percentage of participants:
participants reporting: o Local reactions (pain at the
 Local reactions for up to 7 days injection site, redness, and
 Systemic events for up to 7 days o Systemic events (fever,
following each dose fatigue, headache, chills,
 AEs from Dose 1 to 1 month vomiting, diarrhea, new or
 SAEs from Dose 1 to 6 months new or worsened joint pain)

after the last dose
Secondary Efficacy
vaccine to placebo]
vaccine to placebo]
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014674
Page 621
Protocol C4591001

Exploratory
To evaluate the immune response GMC/GMT, GMFR, and percentage  SARS-CoV-2 anti-S1 binding
over time to prophylactic BNT162b2 of participants with titers greater than antibody levels and/or anti-RBD
and persistence of immune response defined threshold(s), at baseline and binding antibody levels
in participants with and without 1, 6, 12, and 24 months after  SARS-CoV-2 serum neutralizing
serological or virological evidence of completion of vaccination titers
vaccination
To evaluate the immune response  SARS-CoV-2 NVA-specific
(non-S) to SARS-CoV-2 in binding antibody
study
To describe the serological responses  SARS-CoV-2 anti-S1 binding
to the BNT vaccine candidate in cases antibody levels and/or anti-RBD
of: binding antibody levels
 Confirmed COVID-19  SARS-CoV-2 serum neutralizing
 Confirmed severe COVID-19 titers
 SARS-CoV-2 infection without  SARS-CoV-2 NVA-specific
confirmed COVID-19 binding antibody
 SARS-CoV-2 detection by
NAAT
Overall Design
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine

candidate–selection, and efficacy study in healthy adults.
 In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: 18 to 85

CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014675
Page 622
Protocol C4591001
195 participants.
14,643 vaccine recipients. It is intended that a minimum of 40% of participants will be in the
56- to 85-year stratum. An equal number of participants will receive placebo, ie, randomized
in a 1:1 ratio.
18 to 85 years of age [stratified as ≤55 or >55 years of age]):
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg

Statistical Methods
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014676
Page 623
Protocol C4591001
placebo group, and 20% of the participants being nonevaluable. If the attack rate is much
higher, case accrual would be expected to be more rapid, enabling the study’s primary
endpoint to be evaluated much sooner. The total number of participants enrolled in Phase 2/3
The immunogenicity objectives will be evaluated descriptively by GMT, GMC, GMFR,

percentage of participants with ≥4-fold rise, and GMC ratio, and the associated 95%
confidence intervals (CIs), for SARS-CoV-2 serum neutralizing titers, SARS-CoV-2 anti-S1
binding antibody levels, and anti-RBD binding antibody levels at the various time points.
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014677
Page 624
Protocol C4591001
1.2. Schema
Age: 18-55 y Age: 65-85 y

IRC (safety) IRC (safety
after Dose 1)
IRC (safety
IRC (safety) Mid-dose-level 2-dose group (n=15)
after Dose 1)
IRC (safety
after Dose 1)


Safety and immunogenicity analysis of Age: 18-85
Phase 2 data (first 360 participants) (Stratified 18-55 or 56-85)
by unblinded team (these participants
BNT162b2 30 µg or placebo 2 doses
will also be included in Phase 3
(n~14,643 per group, total n~29,286)
analyses)
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014678
Page 625
Protocol C4591001

protocol.
1.3.1. Phase 1

(Vax 1)
Illness
Onset
currently taken
CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014679
Page 626
Protocol C4591001

(Vax 1)
Illness
Onset
laboratory testsb
COVID-19 infection
(if appropriate)
swab(s)c
information
use
chemistry results
criteria
CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014680
Page 627
Protocol C4591001

(Vax 1)
Illness
Onset
(if appropriate)
allocation
~170 mL ~170 mL ~170 mL
device, if required
measuring device
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014681
Page 628
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
dates
appropriate
application
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014682
Page 629
Protocol C4591001

(Vax 1)
Illness
Onset
diagnosis)
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014683
Page 630
Protocol C4591001
1.3.2. Phase 2/3



Visit
Potential COVID-19
Illness Onset
c X
assessment
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014684
Page 631
Protocol C4591001

Visit

Potential COVID-19
Illness Onset
Provide a thermometer (all participants) and X X
measuring device (reactogenicity subset
participants only)
Collect AEs and SAEs as appropriate X X X X X X X X
application
Abbreviation: e-diary = electronic diary.
same day.
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014685
Page 632
Protocol C4591001
2. INTRODUCTION
prevention of COVID-19 in healthy adults.

of 1 candidate, in healthy adults. There are currently no licensed vaccines to prevent
2.2. Background

CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014686
Page 633
Protocol C4591001

“heads up,” prefusion spike glycoprotein (P2 S) (version 9) or a trimerized SARS-CoV-2
spike glycoprotein-receptor binding domain (RBD) (version 5). The 2 SARS-CoV-2 vaccine

the RBD.


the BNT162-01 study conducted in Germany by BioNTech, at doses between 1 µg and 100
µg. The currently available safety and immunogenicity data are presented in the BNT162 IB.

CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014687
Page 634
Protocol C4591001

Significance
syncytial virus (RSV), feline coronavirus, possible current clinical COVID-19. All participants are followed for
and Dengue virus vaccines. SARS-CoV-2 antigen-specific antibody and SARS-CoV-2 serum
neutralizing titers, and COVID-19 illness, including markers of severity.
Study Procedures
venipuncture site.
CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014688
Page 635
Protocol C4591001



3.1. For Phase 1
dose

after Dose 2
CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014689
Page 636
Protocol C4591001

1; 7 and 14 days and 1, 6, 12, and 24
months after Dose 2
each time point
vaccination

 GMFR from prior to first dose of levels

geometric mean of SARS-CoV-2
serum neutralizing titers to the  SARS-CoV-2 anti-S1 binding
geometric mean of SARS-CoV-2 antibody levels
binding antibody levels at each  SARS-CoV-2 anti-RBD binding
time point antibody levels
CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014690
Page 637
Protocol C4591001
3.2. For Phase 2/3

Primary Efficacy
vaccine to placebo]
Primary Safety
prophylactic BNT162b2 in the first dose of study intervention and having injection site, redness, and
360 participants randomized (Phase 2) safety data reported after any swelling)
vaccination, the percentage of  Systemic events (fever, fatigue,

after the last dose
after the last dose
prophylactic BNT162b2 in all 1 dose of study intervention and  SAEs
participants randomized in Phase 2/3 having safety data reported after any  In a subset of at least 6000
vaccination, the percentage of participants:
after the last dose
Secondary Efficacy
vaccine to placebo]
CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014691
Page 638
Protocol C4591001

vaccine to placebo]
Exploratory
To evaluate the immune response GMC/GMT, GMFR, and percentage  SARS-CoV-2 anti-S1 binding
over time to prophylactic BNT162b2 of participants with titers greater than antibody levels and/or anti-RBD
and persistence of immune response defined threshold(s), at baseline and
binding antibody levels

in participants with and without 1, 6, 12, and 24 months after  SARS-CoV-2 serum neutralizing
serological or virological evidence of completion of vaccination titers
vaccination
study
NAAT
(see Section 9.6).
CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014692
Page 639
Protocol C4591001
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine
candidate–selection, and efficacy study in healthy adults.

 In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: 18 to 85


unblinded.
4.1.1. Phase 1
CONFIDENTIAL
Page 36
FDA-CBER-2021-5683-0014693
Page 640
Protocol C4591001

55-year age cohort:
Germany (BNT162-01)
escalation for the second candidate studied may be based upon the safety profile of
the first candidate studied being deemed acceptable at the same, or a higher, dose
level by the IRC
4.1.2. Phase 2/3

selected to proceed into Phase 2/3. Participants in this phase will be 18 to 85 years of age,
stratified as follows: 18 to 55 years or 56 to 85 years. It is intended that a minimum of 40%
of participants will be in the 56- to 85-year stratum. Commencement of each age stratum
will be based upon satisfactory post–Dose 2 safety and immunogenicity data from the 18- to
55-year and 65- to 85-year age groups in Phase 1, respectively. The vaccine candidate
selected for Phase 2/3 evaluation is BNT162b2 at a dose of 30 µg.
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014694
Page 641
Protocol C4591001
Phase 2/3 is event-driven. Under the assumption of a true VE rate of ≥60%, after the last
COVID-19 due to SARS-CoV-2 occurring at least 7 days following the last dose of the
Assuming a COVID-19 attack rate of 1.0% per year in the placebo group, an estimated 20%
nonevaluable rate, and 1:1 randomization, the BNT162b2 vaccine candidate selected for
Phase 2/3 is expected to comprise approximately 14,643 vaccine recipients. This is the
number of participants initially targeted for Phase 2/3 and may be adjusted based on advice
from DMC analyses of case accumulation and the percentage of participants who are
seropositive at baseline. Dependent upon the evolution of the pandemic, it is possible that
the COVID-19 attack rate may be much higher, in which case accrual would be expected to
be more rapid, enabling the study’s primary endpoint to be evaluated much sooner.
The first 360 participants enrolled (180 to active vaccine and 180 to placebo) will comprise
the “Phase 2” portion. Safety data through 7 days after Dose 2 and immunogenicity data
through 1 month after Dose 2 from these 360 participants will be analyzed by the unblinded
statistical team, reviewed by the DMC, and submitted to appropriate regulatory authorities
for review. Enrollment may continue during this period and these participants would be
included in the efficacy evaluation in the “Phase 3” portion of the study.



CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014695
Page 642
Protocol C4591001
BNT162b2.

CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014696
Page 643
Protocol C4591001
5. STUDY POPULATION
protocol.


Age and Sex:
1. Male or female participants between the ages of 18 and 55 years, inclusive, 65 and
85 years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon
study phase).

study.
the 6 weeks before enrollment, can be included.
4. Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19.
Informed Consent:

protocol.
CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014697
Page 644
Protocol C4591001

Medical Conditions:
study.
2. Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
hepatitis B virus (HBV).
5. Previous clinical or microbiological diagnosis of COVID-19.

 Hypertension
 Asthma
<60 mL/min/1.73 m2)
 BMI >30 kg/m2

CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014698
Page 645
Protocol C4591001



nanoparticles.
CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014699
Page 646
Protocol C4591001
visit.
study intervention.
Other Exclusions:
22. Investigator site staff or Pfizer employees directly involved in the conduct of the study,
site staff otherwise supervised by the investigator, and their respective family members.


CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014700
Page 647
Protocol C4591001

Administration
 Chills;
 Sore throat;
 Diarrhea;
 Vomiting.

COVID-19 in 3 age groups (18 to 55 years of age, 65 to 85 years of age, and 18 to 85 years
of age [stratified as ≤55 or >55 years of age]).
CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014701
Page 648
Protocol C4591001
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg

Intervention Name BNT162b1 BNT162b2 Saline placebo
modRNA) modRNA)
for injection)
a
Dosage Level(s) 10-, 20-, 30-, 100-µg 10-, 20-, 30-µg N/A
CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014702
Page 649
Protocol C4591001

business.
CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014703
Page 650
Protocol C4591001


files.
CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014704
Page 651
Protocol C4591001

on its appearance.


blinding plan):
 Those study team members who are involved in ensuring that protocol requirements for
study intervention preparation, handling, allocation, and administration are fulfilled at the
site will be unblinded for the duration of the study (eg, unblinded study manager,
unblinded clinical research associate).
deviations.
monitor who will review cases of severe COVID-19 as they are received, and will review
AEs at least weekly for additional potential cases of severe COVID-19
 An unblinded submissions team will be responsible for preparing unblinded analyses and
documents to support regulatory activities that may be required while the study is
ongoing. All statistical analyses conducted on Phase 2/3 data while the study is ongoing,
that are not in support of the DMC, will be performed by this team. This team will not
CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014705
Page 652
Protocol C4591001
have access to unblinded COVID-19 cases unless efficacy is achieved in either an interim
analysis or the final analysis, as determined by the DMC.


study intervention.

follow-up visit (Visit 8 for Phase 1 participants, and Visit 4 for Phase 2/3 participants).
 In addition, for participants enrolled in Phase 1, all current medication at baseline will be
recorded, to include start date, name of the medication, dose, unit, route, and frequency.

CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014706
Page 653
Protocol C4591001






CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014707
Page 654
Protocol C4591001

meeting 1 or more exclusion criteria).



 Death;
 AEs;
CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014708
Page 655
Protocol C4591001


the study;
medical record;

CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014709
Page 656
Protocol C4591001

profile by age.
intervention.
The total blood sampling volume for individual participants in this study is approximately
530 mL for participants in Phase 1 and 125 mL for Phase 2/3 participants. Additionally,
50 mL of blood will be taken at an unplanned convalescent visit at any time a participant
develops respiratory symptoms indicating a potential COVID-19 infection. Select
participants in Phase 1 will also be asked to provide an additional blood sample of
approximately 170 mL at either Visit 5, 6, or 7. These participants would therefore have a
total blood sampling volume of 700 mL during the 24-month study period. Other additional
blood samples may be taken for safety assessments at times specified by Pfizer, provided the
total volume taken during the study does not exceed 550 mL during any period of
60 consecutive days.
CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014710
Page 657
Protocol C4591001

 An assay that is not FDA-cleared but was conducted in a laboratory that is currently
CLIA-certified; or



SARS-CoV-2 NAAT positive at central laboratory or at a local testing facility (using an
acceptable test):
 Fever;
 Chills;
 Sore throat;
 Diarrhea;
CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014711
Page 658
Protocol C4591001
 Vomiting.
 Fatigue;
 Headache;
 Nausea.

following:
<300 mm Hg);

 Death.
will prevail.
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014712
Page 659
Protocol C4591001
of COVID-19:

SARS-CoV-2 NVA-binding antibody result in a participant with a prior negative
SARS-CoV-2 NVA-binding antibody result
 SARS-CoV-2 serum neutralization assay
 SARS-CoV-2 anti-S1 IgG direct Luminex immunoassay
 SARS-CoV-2 anti-RBD IgG direct Luminex immunoassay
 Nonvaccine antigen (NVA) Ig direct Luminex immunoassay. The NVA will include a
SARS-CoV-2 target antigen that is not derived from the S glycoprotein, most likely an
antigen derived from the SARS-CoV-2 nucleoprotein.

CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014713
Page 660
Protocol C4591001



CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014714
Page 661
Protocol C4591001

device. All participants in Phase 1, and a subset of at least 6000 in Phase 2/3, will be asked
to monitor and record local reactions, systemic events, and antipyretic medication usage for
7 days following administration of the study intervention. The reactogenicity e-diary allows
recording of these assessments only within a fixed time window, thus providing the accurate
representation of the participant’s experience at that time. Data on local reactions and
systemic events reported in the reactogenicity e-diary will be transferred electronically to a
third-party vendor, where they will be available for review by investigators and the Pfizer
clinicians at all times via an internet-based portal.


CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014715
Page 662
Protocol C4591001


(Grade 4)
severe pain
Redness 2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis or
Swelling 2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis


CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014716
Page 663
Protocol C4591001

(Grade 4)
hypotensive shock
diarrhea
headache
fatigue
chills
pain
8.2.2.4. Fever

CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014717
Page 664
Protocol C4591001

≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)

(Day 1 to Day 7).

will commence:
CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014718
Page 665
Protocol C4591001

Stopping Rule
groups.
CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014719
Page 666
Protocol C4591001
in Section 10.7.

how to proceed.

CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014720
Page 667
Protocol C4591001

Visit 7 for Phase 1 participants, and Visit 3 for Phase 2/3 participants. In addition, any AEs
occurring up to 48 hours after each subsequent blood draw must be recorded on the CRF.
approximately 6 months after the last dose of study intervention (Visit 8 for Phase 1
participants, and Visit 4 for Phase 2/3 participants).

CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014721
Page 668
Protocol C4591001



AE occurrences.

CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014722
Page 669
Protocol C4591001


awareness.

An EDP occurs if:

intervention.

CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014723
Page 670
Protocol C4591001
reported).
partner.
CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014724
Page 671
Protocol C4591001


study intervention.

skin contact.


Not applicable.
CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014725
Page 672
Protocol C4591001

or SAEs
Potential COVID-19 illness will not be reported according to the standard process for
expedited reporting of SAEs, even though the event may meet the definition of an SAE.
These events will be recorded on the COVID-19 illness pages in the participant’s CRF within
1 day.
Potential COVID-19 illness events will be reviewed by a group of internal blinded case
reviewers. Any SAE that is determined by the internal case reviewers NOT to meet endpoint
criteria is reported back to the investigator site of incidence. The investigator must report the
SAE to Pfizer Safety within 24 hours of being made aware that the SAE did not meet
endpoint criteria. The investigator’s SAE awareness date is the date on which the

Not applicable.


Not applicable.

medication errors.
of Awareness

CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014726
Page 673
Protocol C4591001

CRF.

CRF.

CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014727
Page 674
Protocol C4591001
8.7. Genetics
8.8. Biomarkers



8.11.1. Phase 1
study.
CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014728
Page 675
Protocol C4591001
nodes.
tests.

are met.

vaccination.
CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014729
Page 676
Protocol C4591001
are met.
Section 5.5.
 The first 5 participants vaccinated in each group must be observed by blinded site staff
for any acute reactions for at least 4 hours after vaccination. For participants enrolled
thereafter, blinded site staff must observe the participant for at least 30 minutes after
study intervention administration for any acute reactions. Record any acute reactions
CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014730
Page 677
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).




CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014731
Page 678
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014732
Page 679
Protocol C4591001

with Appendix 2.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014733
Page 680
Protocol C4591001


vaccination.
with Appendix 2.
CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014734
Page 681
Protocol C4591001
(see Section 7.1).
Section 5.5.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014735
Page 682
Protocol C4591001


with Appendix 2.
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014736
Page 683
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).


with Appendix 2.
CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014737
Page 684
Protocol C4591001

CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014738
Page 685
Protocol C4591001
Section 8.3.
CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014739
Page 686
Protocol C4591001
Section 8.3.
Section 8.3.
CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014740
Page 687
Protocol C4591001
8.11.2. Phase 2/3

study.

are met.
Section 5.5.
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014741
Page 688
Protocol C4591001
(for COVID-19 surveillance) and provide instructions on its use.

 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014742
Page 689
Protocol C4591001



vaccination.

CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014743
Page 690
Protocol C4591001

(see Section 7.1).
Section 5.5.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014744
Page 691
Protocol C4591001


Visit 2)
CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014745
Page 692
Protocol C4591001
Section 8.3.
CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014746
Page 693
Protocol C4591001
Section 8.3.

following is true:
contact.

CRF.
CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014747
Page 694
Protocol C4591001
Section 8.2.2.2.
Section 8.2.2.3.
page of the CRF.

If a participant experiences any of the following, he or she is instructed to contact the site
immediately and, if confirmed, participate in an in-person or telehealth visit as soon as
possible, optimally within 3 days of symptom onset. During the 7 days following each
vaccination, potential COVID-19 symptoms that overlap with solicited systemic events
(ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a
potential COVID-19 illness visit unless, in the investigator’s opinion, the clinical picture is
more indicative of a possible COVID-19 illness than vaccine reactogenicity. Participants may
utilize a COVID-19 illness e-diary through an application (see Section 8.14) installed on a
provisioned device or on the participant’s own personal device to prompt him/her to report
any symptoms. Note that this does not substitute for a participant’s routine medical care.
Therefore, participants should be encouraged to seek care, if appropriate, from their usual
provider.
 Fever;
 Chills;
CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014748
Page 695
Protocol C4591001
 Sore throat;
 Diarrhea;
 Vomiting.
 Record AEs, as appropriate as described in Section 8.3.
 If the visit is conducted in person, obtain a nasal (midturbinate) swab (collected by site
staff). Alternatively, if conducted by telehealth, instruct the participant to self-collect a
nasal (midturbinate) swab and ship for assessment at the central laboratory. The result
from this swab will be provided to the site once it is available, but this will not be in real
time, and cannot be relied upon to direct clinical care. Therefore, the participant should
be encouraged to seek care, if appropriate, from his or her usual provider.


vasopressors)
CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014749
Page 696
Protocol C4591001

protein
 Death


Section 8.13.1).
CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014750
Page 697
Protocol C4591001


see Section 8.2.2.


9.1.1. Estimands
CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014751
Page 698
Protocol C4591001

model.

For Phase 2/3, with assumptions of a true VE of 60% after the last dose of investigational
29,286, based on the assumption of a 1.0% illness rate per year in the placebo group, and
20% of the participants being nonevaluable or having serological evidence of prior infection
with SARS-CoV-2, potentially making them immune to further infection. Dependent upon
the evolution of the pandemic, it is possible that the COVID-19 attack rate may be much
CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014752
Page 699
Protocol C4591001
higher, in which case accrual would be expected to be more rapid, enabling the study’s
primary endpoint to be evaluated much sooner. The total number of participants enrolled in
Phase 2/3 may vary depending on the incidence of COVID-19 at the time of the enrollment,
the true underlying VE, and a potential early stop for efficacy or futility.
1 AE.

Assumed True N=12 N=45 N=180 N=3000 N=6000 N=9000 N=15000
Event Rate of
an AE
0.01% 0.00 0.00 0.02 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.83 0.97 0.99 >0.99
0.08% 0.01 0.04 0.13 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.95 0.99 0.99 >0.99

0.15% 0.02 0.07 0.24 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 >0.99 >0.99 >0.99 >0.99
0.25% 0.03 0.11 0.36 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99
10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99
9.3. Analysis Sets

the IWR system.
Dose 1 evaluable All eligible randomized participants who receive the vaccine
immunogenicity to which they are randomly assigned at the first dose, have at
least 1 valid and determinate immunogenicity result 21 days
after Dose 1, have blood collection within an appropriate
CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014753
Page 700
Protocol C4591001
window after Dose 1, and have no other major protocol
deviations as determined by the clinician.
vaccination(s) as randomized within the predefined window,
have the efficacy measurement after the last dose of study
intervention, and have no other major protocol deviations as
determined by the clinician. A major protocol deviation will
exclude a participant from the evaluable efficacy population

from the date that it occurs through the participant’s remaining
follow-up.
All-available efficacy All eligible randomized participants who receive at least
1 vaccination and have the efficacy measurement at any time
after Dose 1.
All eligible randomized participants who complete

2 vaccination doses and have the efficacy measurement at any
time after Dose 2.

study intervention.

CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014754
Page 701
Protocol C4591001



immunogenicity SARS-CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1
binding antibody and anti-RBD binding antibody
For SARS-CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1

binding antibody levels and anti-RBD binding antibody levels,
GMTs/GMCs and 2-sided 95% CIs will be provided for each
investigational product within each group before vaccination and at

each of the following time points:


GMFRs of SARS-CoV-2 serum neutralizing titers and

SARS-CoV-2 anti-S1 binding antibody and anti-RBD binding
antibody

binding antibody levels and anti-RBD binding antibody levels, the
GMFRs and 2-sided 95% CIs will be provided for each investigational

CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014755
Page 702
Protocol C4591001

confidence limits.
Percentage of participants with ≥4-fold rise in SARS-CoV-2 serum

neutralizing titers and SARS-CoV-2 anti-S1 binding antibody and
anti-RBD binding antibody

percentages (and 2-sided 95% CIs) of participants with ≥4-fold rise
will be provided for each investigational product within each group at

GMR of SARS-CoV-2 serum neutralizing titer to SARS-CoV-2

anti-S1 binding antibody and SARS-CoV-2 anti-RBD binding
antibody

GMRs and 2-sided 95% CIs will be provided for each investigational


SARS-CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1
binding antibody/SARS-CoV-2 anti-RBD binding antibody at each
time point. The GMR will be calculated as the mean of the difference
of logarithmically transformed assay results (eg, SARS-CoV-2 serum
neutralizing titers minus SARS-CoV-2 anti-S1 binding antibody for
CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014756
Page 703
Protocol C4591001

Exploratory Geometric mean titers/concentrations (GMTs/GMCs) of SARS-

immunogenicity CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1 binding
antibody and anti-RBD binding antibody


each of the following time points in Phase 2/3:


GMFRs of SARS-CoV-2 serum neutralizing titers and SARS-CoV-

2 anti-S1 binding antibody and anti-RBD binding antibody

product within each group at each of the following time points in Phase
2/3:
CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014757
Page 704
Protocol C4591001


confidence limits.

For SARS-CoV-2 serum neutralizing titers, SARS-CoV-2 anti-S1

binding antibody levels and/or anti-RBD binding antibody levels,
SARS-CoV-2 NVA-specific binding antibody, and SARS-CoV-2



SARS-CoV-2 for SARS-CoV-2 NVA-specific binding antibody at
the time points when data are available

CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014758
Page 705
Protocol C4591001

Empirical RCDCs will be provided for SARS-CoV-2 serum

neutralizing titers, SARS-CoV-2 S1-specific binding antibody, and
RBD-specific binding antibody after Dose 1 and after Dose 2.




evaluated as below.

group

CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014759
Page 706
Protocol C4591001

values; details will be provided in the SAP.







CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014760
Page 707
Protocol C4591001



distributed.

each vaccine group.

CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014761
Page 708
Protocol C4591001

vaccine group.

Exploratory N/A

GMFR A is the geometric mean of the ratio of the SARS-CoV-2 serum neutralizing titer at
the postvaccination time point to the corresponding titer at the prevaccination time point,
GFMR B is the geometric mean of the ratio of the SARS-CoV-2 S1-specific binding
antibody level at the postvaccination time point to the corresponding antibody level at the
prevaccination time point, and GMFR C is the geometric mean of the ratio of the
SARS-CoV-2 RBD-specific binding antibody level at the postvaccination time point to the
corresponding antibody level at the prevaccination time point.

declared if the first primary study objective is met. The criteria for success at an interim
analysis are based on the posterior probability (ie, P[VE >30%|data]) at the current
number of cases. Overwhelming efficacy will be declared if the posterior probability is
higher than the success threshold. The success threshold for each interim analysis will be
calibrated to protect overall type I error at 2.5%. Additional details about the success
threshold or boundary calculation at each interim analysis will be provided in the SAP.
calculated using a beta-binomial model. The futility assessment will be performed for the
CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014762
Page 709
Protocol C4591001
first primary endpoint and the futility boundary may be subject to change to reflect
Cases
IA1 32 76.9% (6:26) 11.8% (15:17)

IA2 62 68.1% (15:47) 27.8% (26:36)
IA3 92 62.7% (25:67) 38.6% (35:57)
IA4 120 58.8% (35:85) N/A
Final 164 52.3% (53:111)
> 0.986.
CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014763
Page 710
Protocol C4591001

(%) (Total Cases
= 120)
30 0.006 0.315 0.003 0.231 0.002 0.239 0.002
50 0.054 0.078 0.051 0.056 0.063 0.103 0.075
60 0.150 0.021 0.160 0.010 0.175 0.019 0.160
70 0.368 0.003 0.310 <0.001 0.195 0.001 0.085
80 0.722 <0.001 0.238 <0.001 0.037 <0.001 0.003

(Total Cases = 164)

Group ≤53)
30 0.007 0.021
50 0.196 0.439
60 0.220 0.866
70 0.036 >0.999
80 <0.001 >0.999
CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014764
Page 711
Protocol C4591001

Phase 1.
 Safety data through 7 days after Dose 2 and immunogenicity data through 1 month after
Dose 2 from the first 360 participants enrolled (180 to active vaccine and 180 to placebo)
in Phase 2/3.
 Safety and immunogenicity data through 1 month after Dose 2 from the first 6000
participants enrolled (3000 to active vaccine and 3000 to placebo) in Phase 2/3.
all participants in Phase 2/3.


 Select vaccine candidate/dose level(s) to proceed into Phase 2/3. Data supporting the
selection, including results for both binding antibody levels and serum neutralizing
CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014765
Page 712
Protocol C4591001


schedule
as appropriate.
CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014766
Page 713
Protocol C4591001


initiated.
the IRB/EC;
procedures;
of.
CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014767
Page 714
Protocol C4591001

the trial.

or study center.
CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014768
Page 715
Protocol C4591001



EudraCT
CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014769
Page 716
Protocol C4591001
www.pfizer.com
Data Sharing

redacted.

CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014770
Page 717
Protocol C4591001
monitoring plan.
maintained.
CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014771
Page 718
Protocol C4591001


participants.
start date.
to:
CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014772
Page 719
Protocol C4591001


CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014773
Page 720
Protocol C4591001


Platelet count
WBC count
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)


(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
- cells/mm3
cells/mm3
cells/mm3
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014774
Page 721
Protocol C4591001

(Grade 4)
dialysis
phosphate –
increase by factor
– ALT, AST
increase by factor
accompanied
by any increase in
increase by factor
factor
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014775
Page 722
Protocol C4591001

AE Definition






CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014776
Page 723
Protocol C4591001





a. Results in death

considered serious.
CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014777
Page 724
Protocol C4591001



or drug abuse.

CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014778
Page 725
Protocol C4591001

SAE Report Form to
Hours of Awareness
SAE All All



CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014779
Page 726
Protocol C4591001

function.

function.

function.


be ruled out.

CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014780
Page 727
Protocol C4591001

assessment.



CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014781
Page 728
Protocol C4591001


courier service.
CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014782
Page 729
Protocol C4591001

intervention(s):
PLUS either:

OR


OR

pregnancy.
CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014783
Page 730
Protocol C4591001

considered.


CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014784
Page 731
Protocol C4591001


ovulation.

90 days.

 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
 Oral;
 Injectable.

participant.
CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014785
Page 732
Protocol C4591001

CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014786
Page 733
Protocol C4591001

available.
CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014787
Page 734
Protocol C4591001
CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014788
Page 735
Protocol C4591001

Abbreviation Term
AE adverse event
BMI body mass index

DU dosing unit
EC ethics committee
EU European Union
CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014789
Page 736
Protocol C4591001
Abbreviation Term
HR heart rate
IA interim analysis

ID identification
Ig immunoglobulin
IV intravenous(ly)
LL lower limit
LPX lipoplex
CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014790
Page 737
Protocol C4591001
Abbreviation Term
N/A not applicable
NVA nonvaccine antigen
P2 S SARS-CoV-2 full-length, P2 mutant, “heads up,” prefusion spike
glycoprotein
PT prothrombin time
RBC red blood cell

RR respiratory rate
US United States
vax vaccination
CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014791
Page 738
Protocol C4591001
Abbreviation Term
VE vaccine efficacy
CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014792
Page 739
Protocol C4591001

CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014793
Page 740
Protocol C4591001

Rule Value (S)
Group
4 4 N/A
5 5 3.13%
6 6 1.56%
7 7 0.78%
8 7 3.52%
9 8 1.95%
10 9 1.07%
11 9 3.27%
12 10 1.93%
13 10 4.61%
14 11 2.87%
15 12 1.76%
16 12 3.84%
17 13 2.45%
18 13 4.81%
19 14 3.18%
20 15 2.07%
CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014794
Page 741
Protocol C4591001
Value (A)
Vaccine 1:1, 1:1, 2:1, 3:1, 4:1,
2 2 25.00% 25.00% 44.49% 56.25% 64.00%
3 2 37.50% 50.00% 74.12% 84.38% 89.60%
4 3 25.00% 31.25% 59.32% 73.83% 81.92%
5 4 15.63% 18.75% 46.16% 63.28% 73.73%
6 4 23.44% 34.38% 68.10% 83.06% 90.11%
7 5 16.41% 22.66% 57.14% 75.64% 85.20%

8 6 10.94% 14.45% 46.90% 67.85% 79.69%
9 6 16.41% 25.39% 65.11% 83.43% 91.44%
10 7 11.72% 17.19% 56.02% 77.59% 87.91%
11 8 8.06% 11.33% 47.35% 71.33% 83.89%
12 8 12.08% 19.38% 63.25% 84.24% 92.74%
13 9 8.73% 13.34% 55.31% 79.40% 90.09%
14 10 6.11% 8.98% 47.66% 74.15% 87.02%
15 10 9.16% 15.09% 61.94% 85.16% 93.89%
16 11 6.67% 10.51% 54.81% 81.03% 91.83%
17 12 4.72% 7.17% 47.88% 76.53% 89.43%
18 13 3.27% 4.81% 41.34% 71.75% 86.71%
19 13 5.18% 8.35% 54.43% 82.51% 93.24%
20 14 3.70% 5.77% 48.06% 78.58% 91.33%
CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014795
Page 742
Protocol C4591001
11. REFERENCES
1
2
3
4
5

6
7
adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326-34.
8
9
10
1985;4(2):213-26.
CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014796
Page 743
Document Name:
Document Title: !!" # $%&%'()%## * )'*%+,- * %$ ).

)&$#,'* *% &/,'*,'0 (1*2 (% .#1( ( / (2 (
%# )$,#,(2 ,++1'%0 ',,(2 '* //,2 %/ )&%.&
)' .,' '*,*( 0,'( %.,*& ,' #(2
*1#(
#34 4 & & "5 "5" $6 66 # 7
8 8 4 & & "5 5" / 7
FDA-CBER-2021-5683-0014797
Page 744
Protocol C4591001
Protocol Amendment 4, 30 June 2020

CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS

090177e1941f5ede\Approved\Approved On: 01-Jul-2020 13:44 (GMT)

Phase: 1/2/3
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014798
Page 745
Protocol C4591001
Document History

added to Section 3.





template.




monitor for potential enhanced COVID-19 disease.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014799
Page 746
Protocol C4591001

protocol.
BNT162b2.
intervention.






illness e-diary.
In addition:
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014800
Page 747
Protocol C4591001


(BNT162-01):
BNT162c2
Additionally:
after Dose 1 or 2
escalation
antigen to BNT162c2
subunit
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014801
Page 748
Protocol C4591001

will be directed
candidate
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014802
Page 749
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................12
1.1. Synopsis ..................................................................................................................13
1.2. Schema ....................................................................................................................20
1.3.1. Stage 1 Sentinel Cohorts.............................................................................21
1.3.2. Stage 1 Nonsentinel Cohorts and Stage 2 Cohorts .....................................26
1.3.3. Stage 3 Cohort(s) ........................................................................................29
2. INTRODUCTION ...............................................................................................................31
2.1. Study Rationale .......................................................................................................31
2.2. Background .............................................................................................................31

2.3.1. Risk Assessment .........................................................................................33
3.1. For Stages 1 and 2 ...................................................................................................34
3.2. For Stage 3 ..............................................................................................................36
4. STUDY DESIGN.................................................................................................................38
4.1. Overall Design.........................................................................................................38
4.1.1. Stage 1 ........................................................................................................38
4.1.2. Stage 2 ........................................................................................................40
4.1.3. Stage 3 ........................................................................................................40
CONFIDENTIAL
Page 6
FDA-CBER-2021-5683-0014803
Page 750
Protocol C4591001

5.3.1. Contraception..............................................................................................46
5.4. Screen Failures ........................................................................................................46
6.1.1. Administration ............................................................................................50

7.3. Lost to Follow-up ....................................................................................................57
CONFIDENTIAL
Page 7
FDA-CBER-2021-5683-0014804
Page 751
Protocol C4591001
8.2.1. Clinical Safety Laboratory Assessments (Sentinel-Cohort

Participants Only) ............................................................................................61
8.2.2.1. Grading Scales...........................................................................62
8.2.2.2. Local Reactions .........................................................................63
8.2.2.3. Systemic Events ........................................................................63
8.2.2.4. Fever..........................................................................................64
8.2.3. Stopping Rules............................................................................................65
8.2.3.1. Randomization and Vaccination After a Stopping Rule Is
Met.....................................................................................................67
Disease .............................................................................................................67
Exposure ..........................................................................................................70
8.3.8.1. Lack of Efficacy ........................................................................73
CONFIDENTIAL
Page 8
FDA-CBER-2021-5683-0014805
Page 752
Protocol C4591001

8.7. Genetics ...................................................................................................................74
8.8. Biomarkers ..............................................................................................................74
8.11.1. Stage 1 Sentinel Cohorts...........................................................................75
8 Days After Visit 1) .........................................................................79

8 Days After Visit 4) .........................................................................83
16 Days After Visit 4) .......................................................................84
Visit 4) ...............................................................................................85
After Visit 4)......................................................................................86
After Visit 4)......................................................................................86
After Visit 4)......................................................................................87
8.11.2. Stage 1 Nonsentinel Cohorts and Stage 2 Cohorts ...................................87
8.11.2.2. Visit 2 – Vaccination 2: (19 to 23 Days or 56 to 70 Days
After Visit 1)......................................................................................89
8.11.2.3. Visit 3 – 2-Week Follow-up Visit: (12 to 16 Days After
Visit 2) ...............................................................................................91
CONFIDENTIAL
Page 9
FDA-CBER-2021-5683-0014806
Page 753
Protocol C4591001

Visit 2) ...............................................................................................92
After Visit 2)......................................................................................92
After Visit 2)......................................................................................93
After Visit 2)......................................................................................93
8.11.3. Stage 3 Cohort(s) ......................................................................................94
8.11.3.2. Visit 2 – Vaccination 2: (19 to 23 Days or 56 to 70 Days
After Visit 1)......................................................................................96
After Visit 2)......................................................................................99

After Visit 2)......................................................................................99
After Visit 2)....................................................................................100
8.12. Unscheduled Visit for a Grade 3 or Suspected Grade 4 Reaction ......................100
8.13. COVID-19 Disease Surveillance (All Participants)............................................101
9.1.1. Estimands..................................................................................................104
9.3. Analysis Sets .........................................................................................................106
CONFIDENTIAL
Page 10
FDA-CBER-2021-5683-0014807
Page 754
Protocol C4591001

9.4.3. Safety Analyses ........................................................................................114
9.4.4. Other Analyses..........................................................................................115
9.5.1. Analysis Timing........................................................................................118
CONSIDERATIONS ........................................................................................................120
10.1.3. Data Protection .......................................................................................122

10.3.1. Definition of AE .....................................................................................129
CONFIDENTIAL
Page 11
FDA-CBER-2021-5683-0014808
Page 755
Protocol C4591001

11. REFERENCES ................................................................................................................148
LIST OF TABLES
Table 1. Potential Groups in Stage 1 ......................................................................48

Table 10. For 2 to 20 Cases of Severe COVID-19, Probability of Observing
This Number or More of Severe Cases in the Vaccine Group at a
Range of True Adverse Ratios From 1:1 to 4:1......................................146
CONFIDENTIAL
Page 12
FDA-CBER-2021-5683-0014809
Page 756
Protocol C4591001
1. PROTOCOL SUMMARY
1.1. Synopsis
Rationale

There are currently no licensed vaccines to prevent infection with SARS-CoV-2 or antiviral
drugs to treat COVID-19. Given the rapid transmission of COVID-19 and incidence of
disease in the United States and elsewhere, the rapid development of an effective vaccine is
of utmost importance.
the SARS-CoV-2 full-length, P2 mutant, “heads up,” prefusion spike glycoprotein (P2 S)
(version 9), a trimerized SARS-CoV-2 spike glycoprotein receptor-binding domain (RBD)
(version 5), or a membrane-anchored trimerized SARS-CoV-2 RBD. The 3 SARS-CoV-2
vaccine candidates that may be tested in this study are therefore:
BNT162b2 (variant RBP020.2): a modRNA encoding P2 S;
BNT162b3 (variant RBP020.8): a modRNA encoding a membrane-anchored RBD.
CONFIDENTIAL
Page 13
FDA-CBER-2021-5683-0014810
Page 757
Protocol C4591001
It is expected that the various candidate vaccines may not all be available from the start of
the study, in which case they will be rolled into the study in a consecutive fashion as they are
released. A Phase 1/2 study of the same vaccine candidates (BNT162-01), conducted in
Germany by BioNTech in adults 18 to 55 years of age, started in April 2020.
Study C4591001 is designed to complement and expand upon the German study and confirm
the optimal vaccine candidate(s), dose level(s), number of doses, and schedule of
administration.
For Stages 1 and 2

 
Adverse events (AEs) from AEs

dose
In addition, in sentinel cohorts from Hematology and chemistry laboratory
Stage 1, the percentage of participants parameters detailed in Section 10.2
with:
after Dose 2
intervention:
Stage 1 Sentinel Cohorts: 7 and

21 days after Dose 1; 7 and 14 days and
1, 6, 12, and 24 months after Dose 2
Stage 1 Nonsentinel Cohorts and
Stage 2 Cohorts: 21 days after Dose 1;
14 days and 1, 6, 12, and 24 months
after Dose 2
CONFIDENTIAL
Page 14
FDA-CBER-2021-5683-0014811
Page 758
Protocol C4591001

each time point
vaccination
 GMFR from before vaccination to levels
vaccination
geometric mean of SARS-CoV-2  SARS-CoV-2 anti-S1 binding
serum neutralizing titers to the antibody levels
geometric mean of SARS-CoV-2–  SARS-CoV-2 anti-RBD binding
binding antibody levels at each
antibody levels
time point
For Stage 3

Primary Efficacy
To evaluate the efficacies of In participants complying with the COVID-19 incidence per 1000
individual prophylactic BNT162 key protocol criteria (evaluable person-years of follow-up based on
vaccines against confirmed participants) at least 7 days after central laboratory or locally
COVID-19 in participants without receipt of the last dose of study confirmed NAAT in participants with
evidence of infection before intervention: no serological or virological evidence
vaccination 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
COVID-19 in participants with and receipt of the last dose of study confirmed NAAT
without evidence of infection before intervention:
vaccine to placebo]
CONFIDENTIAL
Page 15
FDA-CBER-2021-5683-0014812
Page 759
Protocol C4591001

Primary Safety
To define the safety profiles of In participants receiving at least 1  Local reactions (pain at the
individual prophylactic BNT162 dose of study intervention and having injection site, redness, and
vaccines in the first 360 participants safety data reported after any swelling)
randomized in Stage 3 vaccination, the percentage of  Systemic events (fever, fatigue,
after the last dose
after the last dose
To define the safety profiles of In participants receiving at least  AEs
individual prophylactic BNT162 1 dose of study intervention and  SAEs
vaccines in all participants having safety data reported after any  In a subset of at least 6000
randomized in Stage 3 vaccination, the percentage of participants:

after the last dose
Secondary Efficacy
To evaluate the efficacies of In participants complying with the Confirmed severe COVID-19
individual prophylactic BNT162 key protocol criteria (evaluable incidence per 1000 person-years of
vaccines against confirmed severe participants) at least 7 days after follow-up in participants with no
COVID-19 in participants without receipt of the last dose of study serological or virological evidence of
evidence of infection before intervention: past SARS-CoV-2 infection
vaccine to placebo]
vaccines against confirmed severe participants) at least 7 days after follow-up
COVID-19 in participants with and receipt of the last dose of study
vaccine to placebo]
To describe the efficacies of In participants complying with the COVID-19 incidence per 1000
COVID-19 (according to the receipt of the last dose of study confirmed NAAT in participants with
CDC-defined symptoms) in intervention: no serological or virological evidence
participants without evidence of 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
infection before vaccination vaccine to placebo] dose) of past SARS-CoV-2 infection
COVID-19 (according to the receipt of the last dose of study confirmed NAAT
CDC-defined symptoms) in intervention:
participants with and without 100 × (1 – IRR) [ratio of active
evidence of infection before vaccine to placebo]
vaccination
CONFIDENTIAL
Page 16
FDA-CBER-2021-5683-0014813
Page 760
Protocol C4591001

To evaluate the immune response GMT, GMFR, and percentage of  SARS-CoV-2 anti-S1 binding
over time to BNT162 prophylactic participants with titers greater than antibody levels and/or anti-RBD
vaccines and persistence of immune defined threshold(s), at baseline and binding antibody levels
response in participants with and 1, 6, 12, and 24 months after  SARS-CoV-2 serum neutralizing
without serological or virological completion of vaccination titers
evidence of SARS-CoV-2 infection
before vaccination
Exploratory
study
NAAT
Overall Design
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, and

vaccine candidate–selection study in healthy adults.
The study will evaluate the safety, tolerability, immunogenicity, and efficacy of 3 different
SARS-CoV-2 RNA vaccine candidates against COVID-19:
 As a 2-dose (separated by 21 or 60 days) or single-dose schedule
 At various different dose levels
 In 3 age groups (18 to 55 years of age, 65 to 85 years of age, and 18 to 85 years of age
[stratified as ≤55 or >55 years of age])
may be started at the next highest dose, groups may not be started, groups may be terminated
early, and/or groups may be added with dose levels below the lowest stated dose or
intermediate between the lowest and highest stated doses.
The study consists of 3 stages. Stage 1: to identify preferred vaccine candidate(s), dose
level(s), number of doses, and schedule of administration (with the first 15 participants at
each dose level of each vaccine candidate comprising a sentinel cohort); Stage 2: an
CONFIDENTIAL
Page 17
FDA-CBER-2021-5683-0014814
Page 761
Protocol C4591001
expanded-cohort stage; and Stage 3: an efficacy stage. These stages, and the progression
A vaccine candidate/dose level that, in Stage 1, has an established dose level and
immunization schedule based on induction of an immune response in the sentinel evaluation,
including neutralizing antibodies, and is expected to be associated with protection against
COVID-19, can progress directly into Stage 3.
Vaccine candidate(s) that have preliminary evidence to support a dose and schedule and to
show that the candidate is safe and has evidence of vaccine-elicited antibody, but require
further safety and immunogenicity data to support progression to Stage 3, can progress to
Stage 2.
Each group in Stage 1 will comprise 15 participants (12 receiving active vaccine and
3 receiving placebo). In this stage, assuming 2 dose levels are selected following the initial
dose escalation, up to 42 potential groups are foreseen; if all groups are fully enrolled, this
corresponds to a total of 630 participants.
Each group in Stage 2 will comprise 225 participants (180 receiving active vaccine and
45 receiving placebo). The total number of participants to be enrolled in this stage depends
on the number of groups to be pursued.
Each vaccine candidate/dose level selected for Stage 3 will comprise 14,643 vaccine
recipients. An equal number of participants will receive placebo, ie, randomized in a 1:1
ratio.
The study may evaluate single-dose and 2-dose (separated by 21 or 60 days) schedules of
various different dose levels of 3 investigational RNA vaccine candidates for active
immunization against COVID-19 in 3 age groups (18 to 55 years of age, 65 to 85 years of
age, and 18 to 85 years of age [stratified as ≤55 or >55 years of age]):
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg
 BNT162b3 (BNT162 RNA-LNP vaccine utilizing modRNA and encoding a membrane-

anchored RBD): 10 µg, 20 µg, 30 µg
CONFIDENTIAL
Page 18
FDA-CBER-2021-5683-0014815
Page 762
Protocol C4591001

The duration of study follow-up may be shorter among participants enrolled in Stage 1 and
Stage 2 dosing arms that are not evaluated in Stage 3.
Statistical Methods
The study sample size for the first 2 stages of the study is not based on any statistical
hypothesis testing.
For the third stage, the VE evaluation will be the primary objective. The VE is defined as
placebo group, and 20% of the participants being nonevaluable. If the attack rate is much
higher, case accrual would be expected to be more rapid, enabling the study’s primary
endpoint to be evaluated much sooner. The total number of participants enrolled in Stage 3
may vary depending on the incidence of COVID-19 at the time of the enrollment, the number
of candidate vaccines evaluated, the true underlying VE, and a potential early stop for
efficacy or futility.
parameters (sentinel cohorts only), for each vaccine group. A 3-tier approach will be used to
summarize AEs.
The secondary immunogenicity objectives will be evaluated descriptively by GMT, GMC,

GMFR, percentage of participants with ≥4-fold rise, and GMC ratio, and the associated 95%
confidence intervals (CIs), for SARS-CoV-2 serum neutralizing titers, SARS-CoV-2 anti-S1
binding antibody levels, and anti-RBD binding antibody levels at the various time points.
CONFIDENTIAL
Page 19
FDA-CBER-2021-5683-0014816
Page 763
Protocol C4591001
1.2. Schema
Stage 1 (4:1 randomization active:placebo)
For each vaccine candidate
Age: 18-55 y Age: 65-85 y
Low-dose-level 2-dose group (n=15):
SENTINEL
IRC (safety Low-dose-level 2-dose group (n=15):
IRC (safety)
after Dose 1) SENTINEL
Mid-dose-level 2-dose group (n=15):
SENTINEL
IRC (safety Mid-dose-level 2-dose group (n=15):
IRC (safety)
High-dose-level 2-dose group (n=15):
SENTINEL
IRC (safety High-dose-level 2-dose group (n=15):
IRC choice of group(s) for Stage 2 or 3

(safety & immunogenicity after Dose 1 or 2)
Dose level(s) selected for Stage 2: 2- Direct Dose level(s) selected for Stage 2: 2-
dose (60 days apart) group(s) (n=15) progression to dose (60 days apart) group(s) (n=15)
Stage 3 if Stage 1
& &
data support
Dose level(s) selected for Stage 2: 1- selection of a Dose level(s) selected for Stage 2: 1-
dose group(s) (n=15) single dose group(s) (n=15)
candidate/dose
Stage 2 level (4:1 randomization active:placebo)
Age: 18-85
(Stratified 18-55 or 56-85)
Group for each selected vaccine
candidate/dose level
(n=180 per active group)
IRC choice of group for Stage 3

(safety & immunogenicity after Dose 1 or 2)
Stage 3 (1:1 randomization active:placebo)

Safety and immunogenicity analysis of Age: 18-85
data for first 360 participants by (Stratified 18-55 or 56-85)
unblinded team if candidate
Selected vaccine candidate/dose level
progressed directly from Stage 1 to
(n~14,643 per group)
Stage 3
CONFIDENTIAL
Page 20
FDA-CBER-2021-5683-0014817
Page 764
Protocol C4591001

protocol.
1.3.1. Stage 1 Sentinel Cohorts


(Vax 1)
Illness
Onset
currently taken
CONFIDENTIAL
Page 21
FDA-CBER-2021-5683-0014818
Page 765
Protocol C4591001

(Vax 1)
Illness
Onset
laboratory testsb
COVID-19 infection
(if appropriate)
swab(s)c
information
use
chemistry results
criteria
CONFIDENTIAL
Page 22
FDA-CBER-2021-5683-0014819
Page 766
Protocol C4591001

(Vax 1)
Illness
Onset
(if appropriate)
allocation
~170 mL ~170 mL ~170 mL
device, if required
measuring device
CONFIDENTIAL
Page 23
FDA-CBER-2021-5683-0014820
Page 767
Protocol C4591001

(Vax 1)
Illness
Onset
Review ongoing X X
dates
appropriate
application
CONFIDENTIAL
Page 24
FDA-CBER-2021-5683-0014821
Page 768
Protocol C4591001

(Vax 1)
Illness
Onset
diagnosis)
d. The first 5 participants in in each sentinel group will be observed at the site for at least 4 hours after study intervention administration. Further vaccination
will commence no sooner than 24 hours after the fifth participant received his or her vaccination.
CONFIDENTIAL
Page 25
FDA-CBER-2021-5683-0014822
Page 769
Protocol C4591001
1.3.2. Stage 1 Nonsentinel Cohorts and Stage 2 Cohorts

Visit Number 1 2 3 4 5 6 7 Unplanned Unplanned

Visit Description Vaccination 1 Vaccination 2 2-Week 1-Month 6-Month 12-Month 24-Month Potential Potential
Follow-up Follow-up Follow-up Follow-up Follow-up COVID-19 COVID-19

Visit Visit Visit Visit Visit Illness Visita Convalescent
Visit
Visit Window (Days) Day 1 19 to 23 Days 12 to 16 Days 28 to 35 Days 154 to 168 350 to 378 714 to 742 Optimally 28 to 35 Days
After Visit 1 After Visit 2 After Visit 2 Days After Days After Days After Within 3 After
or Visit 2 Visit 2 Visit 2 Days After Potential
56 to 70 Days Potential COVID-19
After Visit 1b COVID-19 Illness Visit
Illness Onset
Obtain demography and medical X
history data
Perform physical examination X
Measure vital signs X
Perform urine pregnancy test X X
(if appropriate)
Collect nonstudy vaccine information X X X X X
Collect prohibited medication use X X X X X X X X
Confirm use of contraceptives X X X X
(if appropriate)
Obtain randomization number and X
study intervention allocation
CONFIDENTIAL
Page 26
FDA-CBER-2021-5683-0014823
Page 770
Protocol C4591001

Visit

Illness Onset
Collect blood sample for ~25 mL ~25 mL ~25 mL ~25 mL ~25 mL ~25 mL ~25 mL ~50 mL
immunogenicity assessment
Assess acute reactions for at least 30 X X
minutes after study intervention
administration
Explain participant communication X
methods (including for e-diary
completion), assist the participant with
downloading the app, or issue
Provide participant with thermometer X X
and measuring device
Review reactogenicity e-diary data
(daily review is optimal during the
active diary period)
Review ongoing reactogenicity e-diary X X
symptoms and obtain stop dates
Collect AEs and SAEs as appropriate X X X X X X X X X
Collect e-diary or assist the participant X
to delete application
CONFIDENTIAL
Page 27
FDA-CBER-2021-5683-0014824
Page 771
Protocol C4591001

Visit

Illness Onset
Collection of COVID-19–related X X
clinical and laboratory information
b. The window for Visit 2 is dependent on the dosing schedule for the assigned group.
CONFIDENTIAL
Page 28
FDA-CBER-2021-5683-0014825
Page 772
Protocol C4591001
1.3.3. Stage 3 Cohort(s)



Visit
Visit Window (Days) Day 1 19 to 23 Days 28 to 35 Days 154 to 168 350 to 378 714 to 742 Optimally 28 to 35 Days
Illness Onset
Perform clinical assessmentc X
assessment
CONFIDENTIAL
Page 29
FDA-CBER-2021-5683-0014826
Page 773
Protocol C4591001

Visit
Visit Window (Days) Day 1 19 to 23 Days 28 to 35 Days 154 to 168 350 to 378 714 to 742 Optimally 28 to 35 Days

Illness Onset
Provide a thermometer (all participants) and X X
measuring device (reactogenicity subset
participants only)
Collect AEs and SAEs as appropriate X X X X X X X X
application
b. The window for Visit 2 is dependent on the dosing schedule(s) selected for Stage 3.
CONFIDENTIAL
Page 30
FDA-CBER-2021-5683-0014827
Page 774
Protocol C4591001
2. INTRODUCTION
prevention of COVID-19 in healthy adults.

The purpose of the study is to rapidly describe the safety, tolerability, immunogenicity, and
efficacy of 3 BNT162 RNA-based COVID-19 vaccine candidates against COVID-19 in
healthy adults. There are currently no licensed vaccines to prevent infection with
SARS-CoV-2 or antiviral drugs to treat COVID-19. Given the global crisis of COVID-19
and fast expansion of the disease in the United States and elsewhere, the rapid development
of an effective vaccine is of utmost importance.
2.2. Background

CONFIDENTIAL
Page 31
FDA-CBER-2021-5683-0014828
Page 775
Protocol C4591001
Three SARS-CoV-2–RNA lipid nanoparticle (RNA-LNP) vaccines based on a platform of

nucleoside-modified messenger RNA (modRNA, BNT162b) may be evaluated in this study.
“heads up,” prefusion spike glycoprotein (P2 S) (version 9), a trimerized SARS-CoV-2 spike
glycoprotein-receptor binding domain (RBD) (version 5), or a membrane-anchored
trimerized SARS-CoV-2 RBD. The 3 SARS-CoV-2 vaccine candidates that may be tested in
this study are therefore:

the RBD.


above, but encoding a membrane-anchored RBD.

the BNT162-01 study conducted in Germany by BioNTech, at doses between 1 µg and 100
µg. The currently available safety and immunogenicity data are presented in the BNT162 IB.

CONFIDENTIAL
Page 32
FDA-CBER-2021-5683-0014829
Page 776
Protocol C4591001

Significance
Potential for local reactions (injection These are common adverse reactions seen The study design includes the use of sentinel cohorts and dose escalation to
site redness, injection site swelling, with other vaccines, as noted in the FDA closely monitor and limit the rate of enrollment to ensure participant safety.
and injection site pain) and systemic Center for Biologics Evaluation and The study employs the use of a reactogenicity e-diary to monitor local
events (fever, fatigue, headache, Research (CBER) guidelines on toxicity reactions and systemic events in real time. Stopping rules are also in place
chills, vomiting, diarrhea, muscle grading scales for healthy adult volunteers for sentinel cohorts. The first 5 sentinel-cohort participants in each group
pain, and joint pain) following enrolled in preventive vaccine clinical will be observed for 4 hours after vaccination to assess any immediate AEs.
vaccination. trials.8
Unknown AEs and laboratory This study is one of the first 2 parallel- The study design includes the use of sentinel cohorts and dose escalation to
abnormalities with a novel vaccine. running clinical studies with the BNT162 closely monitor and limit the rate of enrollment to ensure participant safety.
vaccine candidates and as such there are no An IRC and DMC will also review safety data throughout the study.
clinical data available for this vaccine. Stopping rules are also in place for sentinel cohorts. The first 5 sentinel-
cohort participants in each group will be observed for 4 hours after
vaccination to assess any immediate AEs.
Potential for COVID-19 disease Disease enhancement has been seen Stages 1 and 2 exclude participants with likely previous or current COVID-
enhancement. following vaccination with respiratory 19. In Stage 3, temporary delay criteria defer vaccination of participants
syncytial virus (RSV), feline coronavirus, with possible current clinical COVID-19. All participants are followed for
and Dengue virus vaccines. SARS-CoV-2 antigen-specific antibody and SARS-CoV-2 serum
neutralizing titers, and COVID-19 illness, including markers of severity.
Study Procedures
healthcare facilities during the global PPE, there is a potential for increased strategy.
SARS-CoV-2 pandemic. exposure to SARS-CoV-2.
venipuncture site.
CONFIDENTIAL
Page 33
FDA-CBER-2021-5683-0014830
Page 777
Protocol C4591001



3.1. For Stages 1 and 2
dose
In addition, in sentinel cohorts from Hematology and chemistry laboratory

Stage 1, the percentage of participants parameters detailed in Section 10.2
with:
after Dose 2
CONFIDENTIAL
Page 34
FDA-CBER-2021-5683-0014831
Page 778
Protocol C4591001

intervention:
Stage 1 Sentinel Cohorts: 7 and

21 days after Dose 1; 7 and 14 days and
1, 6, 12, and 24 months after Dose 2
Stage 1 Nonsentinel Cohorts and
Stage 2 Cohorts: 21 days after Dose 1;
14 days and 1, 6, 12, and 24 months
after Dose 2

each time point
vaccination

 GMFR from prior to first dose of levels

geometric mean of SARS-CoV-2
serum neutralizing titers to the  SARS-CoV-2 anti-S1 binding
geometric mean of SARS-CoV-2 antibody levels
binding antibody levels at each  SARS-CoV-2 anti-RBD binding
time point antibody levels
CONFIDENTIAL
Page 35
FDA-CBER-2021-5683-0014832
Page 779
Protocol C4591001
3.2. For Stage 3

Primary Efficacy
COVID-19 in participants without receipt of the last dose of study confirmed NAAT in participants with
evidence of infection before intervention: no serological or virological evidence
vaccination 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
COVID-19 in participants with and receipt of the last dose of study confirmed NAAT
vaccine to placebo]
Primary Safety
To define the safety profiles of In participants receiving at least 1  Local reactions (pain at the
individual prophylactic BNT162 dose of study intervention and having injection site, redness, and
vaccines in the first 360 participants safety data reported after any swelling)
randomized in Stage 3 vaccination, the percentage of  Systemic events (fever, fatigue,

after the last dose
after the last dose
To define the safety profiles of In participants receiving at least  AEs
individual prophylactic BNT162 1 dose of study intervention and  SAEs
vaccines in all participants having safety data reported after any  In a subset of at least 6000
randomized in Stage 3 vaccination, the percentage of participants:
after the last dose
Secondary Efficacy
vaccines against confirmed severe participants) at least 7 days after follow-up in participants with no
COVID-19 in participants without receipt of the last dose of study serological or virological evidence of
evidence of infection before intervention: past SARS-CoV-2 infection
vaccine to placebo]
CONFIDENTIAL
Page 36
FDA-CBER-2021-5683-0014833
Page 780
Protocol C4591001

vaccines against confirmed severe participants) at least 7 days after follow-up
COVID-19 in participants with and receipt of the last dose of study
vaccine to placebo]
COVID-19 (according to the receipt of the last dose of study confirmed NAAT in participants with
CDC-defined symptoms) in intervention: no serological or virological evidence
participants without evidence of 100 × (1 – IRR) [ratio of active (up to 7 days after receipt of the last
infection before vaccination vaccine to placebo] dose) of past SARS-CoV-2 infection
COVID-19 (according to the receipt of the last dose of study confirmed NAAT
CDC-defined symptoms) in intervention:
participants with and without 100 × (1 – IRR) [ratio of active
evidence of infection before vaccine to placebo]
vaccination
To evaluate the immune response GMT, GMFR, and percentage of  SARS-CoV-2 anti-S1 binding
over time to BNT162 prophylactic participants with titers greater than
antibody levels and/or anti-RBD

vaccines and persistence of immune defined threshold(s), at baseline and binding antibody levels
response in participants with and 1, 6, 12, and 24 months after  SARS-CoV-2 serum neutralizing
without serological or virological completion of vaccination titers
evidence of SARS-CoV-2 infection
before vaccination
Exploratory
study
NAAT
CONFIDENTIAL
Page 37
FDA-CBER-2021-5683-0014834
Page 781
Protocol C4591001
4. STUDY DESIGN
4.1. Overall Design
This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, and
vaccine candidate–selection study in healthy adults.
The study will evaluate the safety, tolerability, immunogenicity, and efficacy of 3 different
SARS-CoV-2 RNA vaccine candidates against COVID-19:
 As a 2-dose (separated by 21 or 60 days) or single-dose schedule
 At various different dose levels
 In 3 age groups (18 to 55 years of age, 65 to 85 years of age, and 18 to 85 years of age
[stratified as ≤55 or >55 years of age])
may be started at the next highest dose, groups may not be started, groups may be terminated
early, and/or groups may be added with dose levels below the lowest stated dose or
intermediate between the lowest and highest stated doses.
The study consists of 3 stages. Stage 1: to identify preferred vaccine candidate(s), dose
level(s), number of doses, and schedule of administration (with the first 15 participants at
each dose level of each vaccine candidate comprising a sentinel cohort); Stage 2: an
expanded-cohort stage; and Stage 3: an efficacy stage. These stages, and the progression
Stages 1 and 2 represent a Phase 1/2a assessment of a number of BNT162 vaccine candidates
and dose levels. Stage 3 is a seamless Phase 2b/3 assessment of one (or possibly more)
selected BNT162 vaccine candidate/dose level, powered to demonstrate efficacy.

unblinded.
allocation for the participants in Stage 1 and Stage 2.
4.1.1. Stage 1
Each group (vaccine candidate/dose level/age group/number of doses) will comprise
15 participants; 12 participants will be randomized to receive active vaccine and 3 to receive
placebo. On Day 22, those in 2-dose groups will receive the same vaccine they received on
Day 1; for those in single-dose groups, all will receive placebo. Full details of all potential
groups in Stage 1 may be found in Table 1.
CONFIDENTIAL
Page 38
FDA-CBER-2021-5683-0014835
Page 782
Protocol C4591001
For each vaccine candidate/dose level/age group, the 15 participants randomized into each
2-dose group will comprise a sentinel cohort, to which the following apply:

55-year age cohort:

Escalation between dose levels will be based on IRC review of at least 7-day
Germany (BNT162-01)
 Note that, since all candidates are based upon the same RNA platform, dose
escalation for the second and subsequent candidate(s) studied may be based upon the
safety profile of the first candidate studied being deemed acceptable at the same, or a
higher, dose level by the IRC
Once the IRC has selected a vaccine candidate/dose level to proceed into a later stage, for
each age cohort, 2 additional groups may be enrolled into Stage 1 for that vaccine
candidate/dose level:
 A 2-dose group, with the 2 doses administered 60 days apart rather than 21
 A 1-dose group
In this stage, assuming 2 dose levels are selected following the initial dose escalation, up to
42 potential groups are foreseen; if all groups are fully enrolled, this corresponds to a total of
630 participants.
CONFIDENTIAL
Page 39
FDA-CBER-2021-5683-0014836
Page 783
Protocol C4591001
A vaccine candidate/dose level that, in Stage 1, has an established dose level and
immunization schedule based on induction of an immune response in the sentinel evaluation,
including neutralizing antibodies, and is expected to be associated with protection against
COVID-19, can progress directly into Stage 3.
Vaccine candidate(s) that have preliminary evidence to support a dose and schedule and to
show that the candidate is safe and has evidence of vaccine-elicited antibody, but require
further safety and immunogenicity data to support progression to Stage 3, can progress to
Stage 2.
Since BNT162b1 and BNT162b3 are so similar, data from BNT162b1 may be used to
support progression of BNT162b3 into either Stage 2 or Stage 3.
4.1.2. Stage 2
and/or the BioNTech study conducted in Germany (BNT162-01), 1 or more groups (vaccine
candidate/dose level) may be selected to proceed into Stage 2. Participants in this stage will
be 18 to 85 years of age, stratified as follows: 18 to 55 or 56 to 85 years. It is targeted to
enroll approximately equal numbers of participants in the 2 age strata. Commencement of
each age stratum will be dependent upon satisfactory safety and immunogenicity data from
the 18- to 55-year and 65- to 85-year groups from Stage 1, respectively. It is therefore
possible that the 2 age strata may not start concurrently.
In each group selected for Stage 2, it is intended that 225 participants will be randomized in a
4:1 ratio to receive active vaccine (180 participants) or placebo (45 participants).
4.1.3. Stage 3
and/or the BioNTech study conducted in Germany (BNT162-01), 1 or more group(s) may be
selected to proceed into Stage 3. Participants in this stage will be 18 to 85 years of age,
stratified as follows: 18 to 55 years or 56 to 85 years. As in Stage 2, it is targeted to enroll
approximately equal numbers of participants in the 2 age strata and it is possible that the 2
age strata may not start concurrently.
Stage 3 is event-driven. Under the assumption of a true VE rate of ≥60%, and using an
efficacy criterion that requires the LL (of the alpha-adjusted CI for VE) to be >30%, a target
of 164 primary-endpoint cases of confirmed COVID-19 due to SARS-CoV-2 occurring at
least 7 days following the last dose of the primary series of the candidate vaccine will be
sufficient to provide 90% power to meet the primary objective. The total number of
participants enrolled in Stage 3 may vary depending on the incidence of COVID-19 at the
time of the enrollment, the number of candidate vaccines evaluated, the true underlying VE,
and a potential early stop for efficacy or futility.
Assuming a COVID-19 attack rate of 1.0% per year in the placebo group, an estimated 20%
nonevaluable rate, and 1:1 randomization, each vaccine candidate/dose level selected for
CONFIDENTIAL
Page 40
FDA-CBER-2021-5683-0014837
Page 784
Protocol C4591001
Stage 3 is expected to comprise approximately 14,643 vaccine recipients per group. This is
the number of participants initially targeted for Stage 3 and may be adjusted based on advice
from DMC analyses of case accumulation and the percentage of participants who are
seropositive at baseline. Dependent upon the evolution of the pandemic, it is possible that the
COVID-19 attack rate may be much higher, in which case accrual would be expected to be
more rapid, enabling the study’s primary endpoint to be evaluated much sooner.
For a vaccine candidate/dose level that progresses directly from Stage 1 to Stage 3, the first
360 participants enrolled (180 to active vaccine and 180 to placebo) will comprise the
“Phase 2” portion. Safety data through 7 days after Dose 2 and immunogenicity data through
21 days after Dose 1 from these 360 participants will be analyzed by the unblinded statistical
team, reviewed by the DMC, and submitted to appropriate regulatory authorities for review.

The duration of study follow-up may be shorter among participants enrolled in Stage 1 and
Stage 2 dosing arms that are not evaluated in Stage 3.


sufficient data are not currently available to experimentally validate the dose selection and
initial starting dose. Therefore, the original planned starting dose of 10 µg (for both
BNT162b1 and BNT162b2) in this study was based on nonclinical experience with the same
RNAs encoding other viral antigens (such as influenza and HIV antigens). The general
safety and effectiveness of uRNA and modRNA platforms have been demonstrated in
oncological clinical trials with different administration routes (NCT02410733,
NCT03871348). Doses of up to 400 µg total uRNA have been administered IV as RNA
lipoplex (RNA-LPX) and doses of up to 1000 µg total naked modRNA have been
administered intratumorally, both without signs of unpredictable overstimulation of the
immune system.
CONFIDENTIAL
Page 41
FDA-CBER-2021-5683-0014838
Page 785
Protocol C4591001
BNT162b2.

the study, including the last visit. Note that participants enrolled in Stages 1 and 2 in groups
that do not proceed to Stage 3 may be followed for fewer than 24 months (but no less than
5. STUDY POPULATION
protocol.

CONFIDENTIAL
Page 42
FDA-CBER-2021-5683-0014839
Page 786
Protocol C4591001

Age and Sex:
1. Male or female participants between the ages of 18 and 55 years, inclusive, 65 and
85 years, inclusive, or 18 and 85 years, inclusive, at randomization (dependent upon
study stage).
3. Healthy participants who are determined by medical history, physical examination, and
clinical judgment of the investigator to be eligible for inclusion in the study.
the 6 weeks before enrollment, can be included.
Informed Consent:

protocol.

Medical Conditions:
study.
2. Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
hepatitis B virus (HBV).
CONFIDENTIAL
Page 43
FDA-CBER-2021-5683-0014840
Page 787
Protocol C4591001
5. Stages 1 and 2 only: Previous clinical or microbiological diagnosis of COVID-19.
6. Sentinel participants in Stage 1 only: Individuals at high risk for severe COVID-19,
including those with any of the following risk factors:
 Hypertension
 Asthma
<60 mL/min/1.73 m2)

 BMI >30 kg/m2
7. Sentinel participants in Stage 1 only: Individuals currently working in occupations with
high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response
personnel).

9. Sentinel participants in Stage 1 only: Individuals with a history of autoimmune disease

or an active autoimmune disease requiring therapeutic intervention, including but not
limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid
arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren’s syndrome, idiopathic
thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell
arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
CONFIDENTIAL
Page 44
FDA-CBER-2021-5683-0014841
Page 788
Protocol C4591001
study intervention administration. Inhaled/nebulized (except for sentinel participants in
Stage 1 – see exclusion criterion 14), intra-articular, intrabursal, or topical (skin or eyes)
14. Sentinel participants in Stage 1 only: Regular receipt of inhaled/nebulized

corticosteroids.

nanoparticles.
18. Sentinel participants in Stage 1 only: Positive serological test for SARS-CoV-2 IgM
and/or IgG antibodies at the screening visit.
19. Sentinel participants in Stage 1 only: Any screening hematology and/or blood
chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.
20. Sentinel participants in Stage 1 only: Positive test for HIV, hepatitis B surface antigen
(HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies
(HCV Abs) at the screening visit.
21. Sentinel participants in Stage 1 only: SARS-CoV-2 NAAT-positive nasal swab within
24 hours before receipt of study intervention.
CONFIDENTIAL
Page 45
FDA-CBER-2021-5683-0014842
Page 789
Protocol C4591001
Other Exclusions:
22. Investigator site staff or Pfizer employees directly involved in the conduct of the study,
site staff otherwise supervised by the investigator, and their respective family members.



Administration
 Chills;
CONFIDENTIAL
Page 46
FDA-CBER-2021-5683-0014843
Page 790
Protocol C4591001
 Sore throat;
 Diarrhea;
 Vomiting.

The study may evaluate 2-dose (separated by 21 or 60 days) and single-dose schedules of
various different dose levels of 3 investigational RNA vaccine candidates for active
immunization against COVID-19 in 3 age groups (18 to 55 years of age, 65 to 85 years of
age, and 18 to 85 years of age [stratified as ≤55 or >55 years of age]).
10 µg, 20 µg, 30 µg, 100 µg
10 µg, 20 µg, 30 µg
 BNT162b3 (BNT162 RNA-LNP vaccine utilizing modRNA and encoding a membrane-

anchored RBD): 10 µg, 20 µg, 30 µg
CONFIDENTIAL
Page 47
FDA-CBER-2021-5683-0014844
Page 791
Protocol C4591001
A list of all potential groups in the Stage 1 are shown in Table 1. Each of these groups may
or may not progress to the later stages of the study.
Table 1. Potential Groups in Stage 1

Groups N Age Dose 1 Dose 2
Group
(Years)
2-Dose Groups (Sentinel Cohorts) Day 1 Day 22
b1-10-2-Y (Sentinel) 15 18 to 55 BNT162b1 10 µg (n=12) BNT162b1 10 µg (n=12)
[modRNA 10 µg (2 doses)] Placebo (n=3) Placebo (n=3)
[modRNA 100 µg Placebo (n=3) Placebo (n=3)
(2 doses)]


b1-10-2-O (Sentinel) 15 65 to 85 BNT162b1 10 µg (n=12) BNT162b1 10 µg (n=12)



CONFIDENTIAL
Page 48
FDA-CBER-2021-5683-0014845
Page 792
Protocol C4591001
Table 1. Potential Groups in Stage 1

Groups N Age Dose 1 Dose 2
Group
(Years)
Single-Dose Groups Day 1 Day 22
b1-x-1-Y 15 18 to 55 BNT162b1 TBD (n=12) Placebo (n=15)
[modRNA dose level(s) Placebo (n=3)
selected for Stage 2
(1 dose)]
(1 dose)]
(1 dose)]
b1-x-1-O 15 65 to 85 BNT162b1 TBD (n=12) Placebo (n=15)

(1 dose)]
(1 dose)]
(1 dose)]
2-Dose Groups (Longer Schedule) Day 1 Day 61

b1-x-2L-Y 15 18 to 55 BNT162b1 TBD (n=12) BNT162b1 TBD (n=12)
[modRNA dose level(s) Placebo (n=3) Placebo (n=3)
(2 doses)]
(2 doses)]
(2 doses)]
b1-x-2L-O 15 65 to 85 BNT162b1 TBD (n=12) BNT162b1 TBD (n=12)

(2 doses)]
(2 doses)]
(2 doses)]
Abbreviations: modRNA = nucleoside-modified messenger ribonucleic acid; TBD = to be determined.
CONFIDENTIAL
Page 49
FDA-CBER-2021-5683-0014846
Page 793
Protocol C4591001

Intervention Name BNT162b1 (BNT162 BNT162b2 (BNT162 BNT162b3 (BNT162 Saline placebo
RNA-LNP vaccine RNA-LNP vaccine RNA-LNP vaccine
utilizing modRNA) utilizing modRNA) utilizing modRNA)
Type Vaccine Vaccine Vaccine Placebo

Dose Formulation modRNA modRNA modRNA Normal saline (0.9%
sodium chloride
solution for injection)
Unit Dose Strength(s) 250 µg/0.5 mL 250 µg/0.5 mL 250 µg/0.5 mL N/A
Dosage Level(s)a 10-, 20-, 30-, 100-µg 10-, 20-, 30-µg 10-, 20-, 30-µg N/A
Route of Intramuscular injection Intramuscular injection Intramuscular injection Intramuscular injection
Administration
Use Experimental Experimental Experimental Placebo
IMP or NIMP IMP IMP IMP IMP
Sourcing Provided centrally by Provided centrally by Provided centrally by Provided centrally by
the sponsor the sponsor the sponsor the sponsor
Packaging and Study intervention will Study intervention will Study intervention will Study intervention will
Labeling be provided in a glass be provided in a glass be provided in a glass be provided in a glass
vial as open-label vial as open-label vial as open-label or plastic vial as open-
supply. Each vial will supply. Each vial will supply. Each vial will label supply. Each
be labeled as required be labeled as required be labeled as required vial will be labeled as
per country per country per country required per country
requirement requirement requirement requirement
(Visits 1 and 4 for Stage 1 sentinel-cohort participants, Visits 1 and 2 for all other
participants) in accordance with the study’s SoA. The volume to be administered may vary
by vaccine candidate and dose level; full details are described in the IP manual.

CONFIDENTIAL
Page 50
FDA-CBER-2021-5683-0014847
Page 794
Protocol C4591001
business.
CONFIDENTIAL
Page 51
FDA-CBER-2021-5683-0014848
Page 795
Protocol C4591001

files.

on its appearance.

CONFIDENTIAL
Page 52
FDA-CBER-2021-5683-0014849
Page 796
Protocol C4591001

intervention allocation for the participants in Stage 1 and in Stage 2. Sponsor staff will be
blinded to study intervention allocation in Stage 3. All laboratory testing personnel
throughout the study.
Those study team members who are involved in ensuring that protocol requirements for
study intervention preparation, handling, allocation, and administration are fulfilled at the site
will be unblinded for the duration of the study (eg, unblinded study manager, unblinded
clinical research associate). Unblinded clinician(s) who are not direct members of the study
team will review unblinded protocol deviations. All statistical analyses conducted on Stage 3
data while the study is ongoing will be performed by an unblinded statistical team.


study intervention.

follow-up visit (Visit 8 for Stage 1 sentinel cohorts, Visit 5 for Stage 1 nonsentinel
cohorts and Stage 2 participants, and Visit 4 for Stage 3 participants).
CONFIDENTIAL
Page 53
FDA-CBER-2021-5683-0014850
Page 797
Protocol C4591001
 In addition, for participants enrolled in the Stage 1 sentinel cohorts, all current
medication at baseline will be recorded, to include start date, name of the medication,
dose, unit, route, and frequency.


prohibited from 28 days prior to enrollment to Visit 7 for Stage 1 sentinel cohorts, Visit 4 for
Stage 1 nonsentinel cohorts and Stage 2 participants, and Visit 3 for Stage 3 participants).

(1-month follow-up visit) for Stage 1 sentinel cohorts.


CONFIDENTIAL
Page 54
FDA-CBER-2021-5683-0014851
Page 798
Protocol C4591001
Inhaled (except in Stage 1 sentinel cohorts – see Section 6.5.1), topical, or localized
injections of corticosteroids (eg, intra-articular or intrabursal administration) are permitted.




meeting 1 or more exclusion criteria).



 Death;
CONFIDENTIAL
Page 55
FDA-CBER-2021-5683-0014852
Page 799
Protocol C4591001

 AEs;

CONFIDENTIAL
Page 56
FDA-CBER-2021-5683-0014853
Page 800
Protocol C4591001

the study;
medical record;


profile by age.
intervention.
CONFIDENTIAL
Page 57
FDA-CBER-2021-5683-0014854
Page 801
Protocol C4591001
The total blood sampling volume for individual participants in this study is approximately
530 mL for participants in the Stage 1 sentinel cohorts; 350 mL for participants in the Stage 1
nonsentinel cohorts and Stage 2 participants; and 125 mL for Stage 3 participants.
Additionally, 50 mL of blood will be taken at an unplanned convalescent visit at any time a
participant develops respiratory symptoms indicating a potential COVID-19 infection. Select
participants in the sentinel cohorts of Stage 1 will also be asked to provide an additional
blood sample of approximately 170 mL at either Visit 5, 6, or 7. These participants would
therefore have a total blood sampling volume of 700 mL during the 24-month study period.
Other additional blood samples may be taken for safety assessments at times specified by
Pfizer, provided the total volume taken during the study does not exceed 550 mL during any
period of 60 consecutive days.

 An assay that is not FDA cleared but was conducted in a laboratory that is currently
CLIA certified; or

CONFIDENTIAL
Page 58
FDA-CBER-2021-5683-0014855
Page 802
Protocol C4591001


SARS-CoV-2 NAAT positive at central laboratory or at a local testing facility (using an
acceptable test):
 Fever;
 Chills;

Sore throat;
 Diarrhea;
 Vomiting.
 Fatigue;
 Headache;
 Nausea.

following:
<300 mm Hg);
CONFIDENTIAL
Page 59
FDA-CBER-2021-5683-0014856
Page 803
Protocol C4591001

 Death.
* If a NAAT-confirmed case in Stage 3 may be considered severe, or not, solely on the basis
of this criterion, the blinded data will be reviewed by 3 medically qualified Pfizer staff
members to assess whether the criterion is met; the majority opinion will prevail.
of COVID-19:

SARS-CoV-2 NVA-binding antibody result in a participant with a prior negative
SARS-CoV-2 NVA-binding antibody result
 SARS-CoV-2 serum neutralization assay
 SARS-CoV-2 anti-S1 IgG direct Luminex immunoassay
 SARS-CoV-2 anti-RBD IgG direct Luminex immunoassay
 Nonvaccine antigen (NVA) Ig direct Luminex immunoassay. The NVA will include a
SARS-CoV-2 target antigen that is not derived from the S glycoprotein, most likely an
antigen derived from the SARS-CoV-2 nucleoprotein.
participants in Stage 1 sentinel cohorts (see Section 8.11.1.1) to determine eligibility.
Serum obtained from the additional ~170-mL blood sample from select participants in the
sentinel cohorts of Stage 1 at either Visit 5, 6, or 7 will be used for exploratory COVID-19
research, intended to establish a surrogate endpoint that is reasonably likely to predict clinical
benefit.
CONFIDENTIAL
Page 60
FDA-CBER-2021-5683-0014857
Page 804
Protocol C4591001



first 5 participants vaccinated in each Stage 1 sentinel group), and within the first 30 minutes
(for the remainder of participants), will be assessed and documented in the AE CRF.
8.2.1. Clinical Safety Laboratory Assessments (Sentinel-Cohort Participants Only)

CONFIDENTIAL
Page 61
FDA-CBER-2021-5683-0014858
Page 805
Protocol C4591001
drug-induced liver injury.

device. All participants in Stages 1 and 2, and a subset of at least 6000 in Stage 3, will be
asked to monitor and record local reactions, systemic events, and antipyretic medication
usage for 7 days following administration of the study intervention. The reactogenicity
e-diary allows recording of these assessments only within a fixed time window, thus
providing the accurate representation of the participant’s experience at that time. Data on
local reactions and systemic events reported in the reactogenicity e-diary will be transferred
electronically to a third-party vendor, where they will be available for review by investigators
and the Pfizer clinicians at all times via an internet-based portal.

CONFIDENTIAL
Page 62
FDA-CBER-2021-5683-0014859
Page 806
Protocol C4591001



(Grade 4)
severe pain
Redness 2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis or
Swelling 2.0 cm to 5.0 cm >5.0 cm to 10.0 cm >10 cm Necrosis


CONFIDENTIAL
Page 63
FDA-CBER-2021-5683-0014860
Page 807
Protocol C4591001


(Grade 4)
hypotensive shock
diarrhea
headache
fatigue
chills
pain
8.2.2.4. Fever

CONFIDENTIAL
Page 64
FDA-CBER-2021-5683-0014861
Page 808
Protocol C4591001


≥38.0-38.4°C (100.4-101.1°F)
>38.4-38.9°C (101.2-102.0°F)
>38.9-40.0°C (102.1-104.0°F)
>40.0°C (>104.0°F)

(Day 1 to Day 7).
8.2.3. Stopping Rules

The following stopping rules are in place for all Stage 1 sentinel-cohort participants, based
on review of AE data and e-diary reactogenicity data. These data will be monitored on an
The sponsor study team will be unblinded during the Stage 1, so will be able to assess
whether or not a stopping rule has been met on the basis of a participant’s individual study
will commence:
CONFIDENTIAL
Page 65
FDA-CBER-2021-5683-0014862
Page 809
Protocol C4591001
should be reviewed to evaluate for enhanced COVID-19 disease.
A separate stopping rule will apply in Stage 3 for enhanced COVID-19 disease. At the time
of each IA, the numbers of severe cases in the vaccine and placebo groups will be assessed.
If there are more severe cases in the vaccine group than in the placebo group, the DMC will
be advised to recommend that enrollment be stopped if the probability of the adverse split
being observed is <1%, assuming that severe cases are truly evenly split. Further details can
be found in Section 10.7. If enrollment is stopped, second doses will still be administered,
and follow-up will continue. If the probability is ≥1% and <11%, the DMC will be advised to
request probability to be recalculated as each additional severe case is accrued.
CONFIDENTIAL
Page 66
FDA-CBER-2021-5683-0014863
Page 810
Protocol C4591001
8.2.3.1. Randomization and Vaccination After a Stopping Rule Is Met

Once the IRC and DMC have reviewed the safety data and provided guidance, a notification
will be sent from the sponsor to the sites with guidance on how to proceed.
8.2.4. Surveillance of Events That Could Represent Enhanced COVID-19 Disease

As this is a sponsor open-label study during Stages 1 and 2, the sponsor will conduct
unblinded reviews of the data during the course of the study, including for the purpose of
safety assessment.
Participants in all stages of the study will be surveilled for potential COVID-19 illness from
Visit 1 onwards (see Section 8.13). All NAAT-confirmed cases in Stages 1 and 2 will be
reviewed contemporaneously by the IRC and the DMC (see Section 9.6).
In Stage 3, the unblinded statistical team, including an unblinded medical monitor, will
review cases of severe COVID-19 as they are received, and will review AEs at least weekly
for additional potential cases of severe COVID-19. At any point the unblinded team may
discuss with the DMC chair whether the DMC should review cases for an adverse imbalance
of cases of COVID-19 and/or severe COVID-19 between the vaccine and placebo groups.
unusual, in particular greater severity, compared to available information at the time of

information at the time of review. Since the DMC is able to review unblinded information, it
will also be able to compare cases in active vaccine and placebo recipients in Stage 3 (when
sponsor staff will be blinded).

CONFIDENTIAL
Page 67
FDA-CBER-2021-5683-0014864
Page 811
Protocol C4591001

Visit 7 for Stage 1 sentinel-cohort participants, Visit 4 for Stage 1 nonsentinel participants
and Stage 2 participants, and Visit 3 for Stage 3 participants. In addition, any AEs occurring
up to 48 hours after each subsequent blood draw must be recorded on the CRF.
approximately 6 months after the last dose of study intervention (Visit 8 for Stage 1
sentinel-cohort participants, Visit 5 for Stage 1 non–sentinel-cohort participants and Stage 2
participants, and Visit 4 for Stage 3 participants).

CONFIDENTIAL
Page 68
FDA-CBER-2021-5683-0014865
Page 812
Protocol C4591001



AE occurrences.

CONFIDENTIAL
Page 69
FDA-CBER-2021-5683-0014866
Page 813
Protocol C4591001


awareness.

An EDP occurs if:

intervention.

CONFIDENTIAL
Page 70
FDA-CBER-2021-5683-0014867
Page 814
Protocol C4591001
reported).
partner.
CONFIDENTIAL
Page 71
FDA-CBER-2021-5683-0014868
Page 815
Protocol C4591001


study intervention.

skin contact.


Not applicable.

or SAEs
Not applicable.
CONFIDENTIAL
Page 72
FDA-CBER-2021-5683-0014869
Page 816
Protocol C4591001

Not applicable.


Not applicable.

medication errors.
of Awareness

CONFIDENTIAL
Page 73
FDA-CBER-2021-5683-0014870
Page 817
Protocol C4591001

CRF.


CRF.

8.7. Genetics
8.8. Biomarkers

CONFIDENTIAL
Page 74
FDA-CBER-2021-5683-0014871
Page 818
Protocol C4591001


8.11.1. Stage 1 Sentinel Cohorts
study.

nodes.
tests.
CONFIDENTIAL
Page 75
FDA-CBER-2021-5683-0014872
Page 819
Protocol C4591001
are met.


vaccination.
CONFIDENTIAL
Page 76
FDA-CBER-2021-5683-0014873
Page 820
Protocol C4591001

are met.
Section 5.5.
 The first 5 participants vaccinated in each Stage 1 sentinel group must be observed by
blinded site staff for any acute reactions for at least 4 hours after vaccination. For
participants enrolled thereafter, blinded site staff must observe the participant for at least
30 minutes after study intervention administration for any acute reactions. Record any
acute reactions (including time of onset) in the participant’s source documents and on the
AE page of the CRF, and on an SAE form as applicable.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 77
FDA-CBER-2021-5683-0014874
Page 821
Protocol C4591001


CONFIDENTIAL
Page 78
FDA-CBER-2021-5683-0014875
Page 822
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).



with Appendix 2.
CONFIDENTIAL
Page 79
FDA-CBER-2021-5683-0014876
Page 823
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).


Ask the participant to contact the site staff or investigator if a medically attended event


vaccination.
CONFIDENTIAL
Page 80
FDA-CBER-2021-5683-0014877
Page 824
Protocol C4591001
with Appendix 2.
(see Section 7.1).
Section 5.5.
CONFIDENTIAL
Page 81
FDA-CBER-2021-5683-0014878
Page 825
Protocol C4591001
 Fever ≥39.0°C (≥102.1°F).



CONFIDENTIAL
Page 82
FDA-CBER-2021-5683-0014879
Page 826
Protocol C4591001
with Appendix 2.
 If the participant (select participants only, details will be provided by the Sponsor)
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 83
FDA-CBER-2021-5683-0014880
Page 827
Protocol C4591001

with Appendix 2.
CONFIDENTIAL
Page 84
FDA-CBER-2021-5683-0014881
Page 828
Protocol C4591001


CONFIDENTIAL
Page 85
FDA-CBER-2021-5683-0014882
Page 829
Protocol C4591001

Section 8.3.
Section 8.3.
CONFIDENTIAL
Page 86
FDA-CBER-2021-5683-0014883
Page 830
Protocol C4591001
Section 8.3.
8.11.2. Stage 1 Nonsentinel Cohorts and Stage 2 Cohorts

study.
It is anticipated that the procedures below will be conducted in a stepwise manner.
nodes.
CONFIDENTIAL
Page 87
FDA-CBER-2021-5683-0014884
Page 831
Protocol C4591001
are met.
Section 5.5.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 88
FDA-CBER-2021-5683-0014885
Page 832
Protocol C4591001


The investigator or appropriately qualified designee reviews the reactogenicity e-diary

8.11.2.2. Visit 2 – Vaccination 2: (19 to 23 Days or 56 to 70 Days After Visit 1)

The window for Visit 2 is dependent on the dosing schedule for the assigned group.
vaccination.
CONFIDENTIAL
Page 89
FDA-CBER-2021-5683-0014886
Page 833
Protocol C4591001
(see Section 7.1).
Section 5.5.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 90
FDA-CBER-2021-5683-0014887
Page 834
Protocol C4591001


8.11.2.3. Visit 3 – 2-Week Follow-up Visit: (12 to 16 Days After Visit 2)

CONFIDENTIAL
Page 91
FDA-CBER-2021-5683-0014888
Page 835
Protocol C4591001

CONFIDENTIAL
Page 92
FDA-CBER-2021-5683-0014889
Page 836
Protocol C4591001
Section 8.3.

Section 8.3.
Section 8.3.
CONFIDENTIAL
Page 93
FDA-CBER-2021-5683-0014890
Page 837
Protocol C4591001
8.11.3. Stage 3 Cohort(s)

study.
It is anticipated that the procedures below will be conducted in a stepwise manner.

Perform a clinical assessment. If the clinical assessment indicates that a physical

are met.
Section 5.5.
CONFIDENTIAL
Page 94
FDA-CBER-2021-5683-0014891
Page 838
Protocol C4591001
(for COVID-19 disease surveillance) and provide instructions on its use.

 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 95
FDA-CBER-2021-5683-0014892
Page 839
Protocol C4591001


8.11.3.2. Visit 2 – Vaccination 2: (19 to 23 Days or 56 to 70 Days After Visit 1)

The window for Visit 2 is dependent on the dosing schedule(s) selected for Stage 3.
vaccination.

CONFIDENTIAL
Page 96
FDA-CBER-2021-5683-0014893
Page 840
Protocol C4591001

(see Section 7.1).
Section 5.5.
 Fever ≥39.0°C (≥102.1°F).

CONFIDENTIAL
Page 97
FDA-CBER-2021-5683-0014894
Page 841
Protocol C4591001


Visit 2)
CONFIDENTIAL
Page 98
FDA-CBER-2021-5683-0014895
Page 842
Protocol C4591001
Section 8.3.
CONFIDENTIAL
Page 99
FDA-CBER-2021-5683-0014896
Page 843
Protocol C4591001
Section 8.3.

following is true:
contact.

CRF.
CONFIDENTIAL
Page 100
FDA-CBER-2021-5683-0014897
Page 844
Protocol C4591001
Section 8.2.2.2.
Section 8.2.2.3.
page of the CRF.
8.13. COVID-19 Disease Surveillance (All Participants)

If a participant experiences any of the following, he or she is instructed to contact the site
immediately and, if confirmed, participate in an in-person or telehealth visit as soon as
possible, optimally within 3 days of symptom onset. During the 7 days following each
vaccination, potential COVID-19 symptoms that overlap with solicited systemic events
(ie, fever, chills, new or increased muscle pain, diarrhea, vomiting) should not trigger a
potential COVID-19 illness visit unless, in the investigator’s opinion, the clinical picture is
more indicative of a possible COVID-19 illness than vaccine reactogenicity. Participants may
utilize a COVID-19 illness e-diary through an application (see Section 8.14) installed on a
provisioned device or on the participant’s own personal device to prompt him/her to report
any symptoms. Note that this does not substitute for a participant’s routine medical care.
Therefore, participants should be encouraged to seek care, if appropriate, from their usual
provider.
 Fever;
 Chills;
CONFIDENTIAL
Page 101
FDA-CBER-2021-5683-0014898
Page 845
Protocol C4591001
 Sore throat;
 Diarrhea;
 Vomiting.
This visit is expected to involve the sharing of healthcare information and services via
telecommunication technologies (eg, audio, video, video-conferencing software) remotely,
thus allowing the participant and investigator to communicate on aspects of clinical care.

 Instruct the participant to self-collect a nasal (midturbinate) swab and ship for assessment
at the central laboratory. The result from this swab will be provided to the site once it is
available, but this will not be in real time, and cannot be relied upon to direct clinical
care. Therefore, the participant should be encouraged to seek care, if appropriate, from
his or her usual provider.


vasopressors)

CONFIDENTIAL
Page 102
FDA-CBER-2021-5683-0014899
Page 846
Protocol C4591001
protein
 Death

The investigator or an authorized designee completes the CRFs.


Section 8.13.1).

CONFIDENTIAL
Page 103
FDA-CBER-2021-5683-0014900
Page 847
Protocol C4591001
see Section 8.2.2.


9.1.1. Estimands
CONFIDENTIAL
Page 104
FDA-CBER-2021-5683-0014901
Page 848
Protocol C4591001
In addition, VE will be analyzed by all-available efficacy population. Missing laboratory

Stage 3 of the study has 2 primary efficacy endpoints evaluating VE, which is defined as
in the vaccine group to the corresponding illness rate in the placebo group. In Stage 3, the
VE1 represents VE for individual prophylactic BNT162 vaccines against confirmed
COVID-19 in participants without evidence of infection before vaccination, and VE2
represents VE for individual prophylactic BNT162 vaccines against confirmed COVID-19 in
all participants after vaccination.
model.

The study sample size for the first 2 stages of the study is not based on any statistical
hypothesis testing. Stage 1 will comprise 15 participants (randomization ratio of 4:1 so that
12 receive active vaccine and 3 receive placebo) per group; up to 28 potential groups are
foreseen; if all groups are fully enrolled, assuming 2 dose levels are selected following the
initial dose escalation, this corresponds to a total of 420 participants. Stage 2 will include 1
or more vaccine groups selected from Stage 1, and 225 participants will be randomized per
selected vaccine candidate in a 4:1 ratio to receive active vaccine (180 participants) or
placebo (45 participants).
For Stage 3, with assumptions of a true VE of 60% after the last dose of investigational
29,286, based on the assumption of a 1.0% illness rate per year in the placebo group, and
20% of the participants being nonevaluable or having serological evidence of prior infection
with SARS-CoV-2, potentially making them immune to further infection. Dependent upon
the evolution of the pandemic, it is possible that the COVID-19 attack rate may be much
higher, in which case accrual would be expected to be more rapid, enabling the study’s
primary endpoint to be evaluated much sooner. The total number of participants enrolled in
CONFIDENTIAL
Page 105
FDA-CBER-2021-5683-0014902
Page 849
Protocol C4591001
Stage 3 may vary depending on the incidence of COVID-19 at the time of the enrollment, the
number of candidate vaccines evaluated, the true underlying VE, and a potential early stop
for efficacy or futility.
1 AE.

Assumed True N=12 N=45 N=180 N=3000 N=6000 N=9000 N=15000
Event Rate of
an AE
0.01% 0.00 0.00 0.02 0.26 0.45 0.59 0.78
0.02% 0.00 0.01 0.04 0.45 0.70 0.83 0.95
0.04% 0.00 0.02 0.07 0.70 0.91 0.97 >0.99
0.06% 0.01 0.03 0.10 0.83 0.97 0.99 >0.99
0.08% 0.01 0.04 0.13 0.91 0.99 0.99 >0.99
0.10% 0.01 0.04 0.16 0.95 0.99 0.99 >0.99
0.15% 0.02 0.07 0.24 0.99 0.99 >0.99 >0.99
0.20% 0.02 0.09 0.30 >0.99 >0.99 >0.99 >0.99

0.25% 0.03 0.11 0.36 >0.99 >0.99 >0.99 >0.99
0.30% 0.04 0.13 0.42 >0.99 >0.99 >0.99 >0.99
0.35% 0.04 0.15 0.47 >0.99 >0.99 >0.99 >0.99
0.50% 0.06 0.20 0.59 >0.99 >0.99 >0.99 >0.99
1.00% 0.11 0.36 0.84 >0.99 >0.99 >0.99 >0.99
2.00% 0.22 0.60 0.97 >0.99 >0.99 >0.99 >0.99
3.00% 0.31 0.75 >0.99 >0.99 >0.99 >0.99 >0.99
5.00% 0.46 0.90 >0.99 >0.99 >0.99 >0.99 >0.99
7.00% 0.58 0.96 >0.99 >0.99 >0.99 >0.99 >0.99
10.00% 0.72 0.99 >0.99 >0.99 >0.99 >0.99 >0.99
9.3. Analysis Sets

the IWR system.
Dose 1 evaluable All eligible randomized participants who receive the vaccine
immunogenicity to which they are randomly assigned at the first dose, have at
least 1 valid and determinate immunogenicity result 21 days
after Dose 1, have blood collection within an appropriate
window after Dose 1, and have no other major protocol
deviations as determined by the clinician.
CONFIDENTIAL
Page 106
FDA-CBER-2021-5683-0014903
Page 850
Protocol C4591001
vaccination(s) as randomized within the predefined window,
have the efficacy measurement after the last dose of study
intervention, and have no other major protocol deviations as
determined by the clinician. A major protocol deviation will
exclude a participant from the evaluable efficacy population
from the date that it occurs through the participant’s remaining
follow-up.
All-available efficacy All eligible randomized participants who receive at least
1 vaccination and have the efficacy measurement at any time
after Dose 1.
study intervention.



CONFIDENTIAL
Page 107
FDA-CBER-2021-5683-0014904
Page 851
Protocol C4591001

immunogenicity SARS-CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1
binding antibody and anti-RBD binding antibody

 Stage 1 sentinel cohorts: 7 and 21 days after Dose 1; 7 and

14 days and 1, 6, 12 and 24 months after Dose 2
 Stage 1 nonsentinel cohorts and Stage 2 cohorts: 21 days after

Dose 1; 14 days and 1, 6, 12, and 24 months after Dose 2
 Stage 3 cohort(s): 1, 6, 12, and 24 months after completion of

vaccination in participants with and without serological or
virological evidence of SARS-CoV-2 infection before
vaccination

GMFRs of SARS-CoV-2 serum neutralizing titers and

antibody


14 days and 1, 6, 12, and 24 months after Dose 2


CONFIDENTIAL
Page 108
FDA-CBER-2021-5683-0014905
Page 852
Protocol C4591001

vaccination

confidence limits.
Percentage of participants with ≥4-fold rise in SARS-CoV-2 serum

neutralizing titers and SARS-CoV-2 anti-S1 binding antibody and
anti-RBD binding antibody

percentages (and 2-sided 95% CIs) of participants with ≥4-fold rise
will be provided for each investigational product within each group at



GMR of SARS-CoV-2 serum neutralizing titer to SARS-CoV-2

anti-S1 binding antibody and SARS-CoV-2 anti-RBD binding
antibody

GMRs and 2-sided 95% CIs will be provided for each investigational


CONFIDENTIAL
Page 109
FDA-CBER-2021-5683-0014906
Page 853
Protocol C4591001

SARS-CoV-2 serum neutralizing titers and SARS-CoV-2 anti-S1
binding antibody/SARS-CoV-2 anti-RBD binding antibody at each
time point. The GMR will be calculated as the mean of the difference
of logarithmically transformed assay results (eg, SARS-CoV-2 serum
neutralizing titers minus SARS-CoV-2 anti-S1 binding antibody for

threshold(s) in participants with and without serological or
virological evidence of SARS-CoV-2 infection before vaccination

percentages (and 2-sided 95% CIs) of participants with antibody levels
≥ predefined thresholds will be provided for each investigational

vaccination
Exploratory For Stage 3 participants with and without confirmed COVID-19,

immunogenicity severe COVID-19, or SARS-CoV-2 infection without confirmed
COVID-19:
GMTs/GMCs of SARS-CoV-2 serum neutralizing titers,

antibody, and SARS-CoV-2 NVA-specific binding antibody
CONFIDENTIAL
Page 110
FDA-CBER-2021-5683-0014907
Page 854
Protocol C4591001

investigational product within each group before vaccination and at 1,
6, 12, and 24 months after completion of vaccination.

GMFRs of SARS-CoV-2 serum neutralizing titers, SARS-CoV-2

anti-S1 binding antibody and anti-RBD binding antibody, and
SARS-CoV-2 NVA-specific binding antibody

product within each group at 1, 6, 12, and 24 months after completion
of vaccination.

confidence limits.

threshold(s) for SARS-CoV-2 serological parameters at baseline
For SARS-CoV-2 serum neutralizing titers, SARS-CoV-2 anti-S1

SARS-CoV-2 NVA-specific binding antibody, and SARS-CoV-2
each investigational product within each group at baseline and 1, 6, 12,
and 24 months after completion of vaccination.
CONFIDENTIAL
Page 111
FDA-CBER-2021-5683-0014908
Page 855
Protocol C4591001

Empirical RCDCs will be provided for SARS-CoV-2 serum

neutralizing titers, SARS-CoV-2 S1-specific binding antibody, and
RBD-specific binding antibody after Dose 1 and after Dose 2.



evaluated as below.

group

CONFIDENTIAL
Page 112
FDA-CBER-2021-5683-0014909
Page 856
Protocol C4591001

values; details will be provided in the SAP.



for the analysis of the secondary efficacy endpoints, with the same
alpha-adjusted CI.

descriptively.



CONFIDENTIAL
Page 113
FDA-CBER-2021-5683-0014910
Page 857
Protocol C4591001


For Stage 1 sentinel cohorts, descriptive statistics will be provided for

abnormal hematology and chemistry laboratory values at 1 and 7 days
after Dose 1 and 7 days after Dose 2, including grading shifts in


used to summarize AEs. Under this approach AEs are classified into 1
of 3 tiers: (1) Tier 1 events are prespecified events of clinical
importance and are identified in a list in the product’s safety review
plan; (2) Tier 2 events are those that are not Tier 1 but are considered
“relatively common”; a MedDRA preferred term is defined as a Tier 2
event if there are at least 1% of participants in at least 1 vaccine group
reporting the event; and (3) Tier 3 events are those that are neither
Tier 1 nor Tier 2 events. For both Tier 1 and Tier 2 events, 2-sided
95% CIs for the difference between the vaccine and placebo groups in
the percentage of participants reporting the events based on the
Miettinen and Nurminen method10 will be provided. In addition, for
Tier 1 events, the asymptotic p-values will also be presented for the
difference between groups in the percentage of participants reporting
the events, based on the same test statistic and under the assumption
that the test statistic is asymptotically normally distributed.
CONFIDENTIAL
Page 114
FDA-CBER-2021-5683-0014911
Page 858
Protocol C4591001

each vaccine group.

vaccine group.

Exploratory N/A

GMFR A is the geometric mean of the ratio of the SARS-CoV-2 serum neutralizing titer at
the postvaccination time point to the corresponding titer at the prevaccination time point,
GFMR B is the geometric mean of the ratio of the SARS-CoV-2 S1-specific binding
antibody level at the postvaccination time point to the corresponding antibody level at the
prevaccination time point, and GMFR C is the geometric mean of the ratio of the
SARS-CoV-2 RBD-specific binding antibody level at the postvaccination time point to the
corresponding antibody level at the prevaccination time point.

As this is a sponsor open-label study during Stages 1 and 2, the sponsor may conduct
unblinded reviews of the data during the course of the study for the purpose of safety
assessment, facilitating dose escalation decisions, and/or supporting clinical development.
During Stage 3, 4 IAs are planned and will be performed by an unblinded statistical team
 VE for both primary objectives will be evaluated sequentially. Overwhelming efficacy

will be declared if the first primary study objective is met. The criteria for success at an
probability is higher than the success threshold. The success threshold for each interim
CONFIDENTIAL
Page 115
FDA-CBER-2021-5683-0014912
Page 859
Protocol C4591001
analysis will be calibrated to protect overall type I error at 2.5%. Additional details about
the success threshold or boundary calculation at each interim analysis will be provided in
the SAP.
calculated using a beta-binomial model. The futility assessment will be done for the first
primary endpoint only and the futility boundary may be subject to change to reflect
Cases
IA1 32 81.5% (5:27) 11.8% (15:17)
IA2 62 70.8% (14:48) 27.8% (26:36)
IA3 92 62.7% (25:67) 35.7% (36:57)
IA4 120 57.1% (36:84) N/A
Final 164 52.3% (53:111)
> 0.986.
CONFIDENTIAL
Page 116
FDA-CBER-2021-5683-0014913
Page 860
Protocol C4591001

(%) (Total Cases
= 120)
30 0.002 0.315 0.002 0.231 0.003 0.217 0.005
50 0.022 0.044 0.034 0.027 0.089 0.033 0.138
60 0.072 0.021 0.132 0.011 0.263 0.010 0.253
70 0.219 0.020 0.335 0.010 0.325 <0.001 0.117
80 0.553 <0.001 0.370 <0.001 0.077 <0.001 <0.001

(Total Cases = 164)

Group ≤53)
30 0.008 0.020
50 0.196 0.479
60 0.204 0.924
70 0.004 >0.999
80 <0.001 >0.999
CONFIDENTIAL
Page 117
FDA-CBER-2021-5683-0014914
Page 861
Protocol C4591001

Stage 1.
Stage 2.
 Safety data through 7 days after Dose 2 and immunogenicity data through 21 days after
Dose 1 from the first 360 participants enrolled (180 to active vaccine and 180 to placebo)
in Stage 3 for a vaccine candidate/dose level that progresses directly to Stage 3.
 Safety and immunogenicity data through 1 month after Dose 2 from the first 6000
participants enrolled (3000 to active vaccine and 3000 to placebo) in Stage 3.
all participants in Stage 3.

All analyses conducted on Stage 3 data while the study is ongoing will be performed by an

The responsibilities of the IRC will include:
 Select vaccine candidate(s)/dose level(s) and schedule(s) to proceed into Stage 2.

Data supporting the selection, including results for both binding antibody levels and
CONFIDENTIAL
Page 118
FDA-CBER-2021-5683-0014915
Page 862
Protocol C4591001
serum neutralizing titers, and the ratio between them, will also be submitted to the
FDA for review
 Select vaccine candidate(s)/dose level(s) and schedule(s) to proceed into Stage 3.

Data supporting the selection, including results for both binding antibody levels and
serum neutralizing titers, and the ratio between them, will also be submitted to the
FDA for review
 Contemporaneous review of all NAAT-confirmed COVID-19 illnesses in Stages 1 and 2



schedule
 Contemporaneous review of all NAAT-confirmed COVID-19 illnesses in Stages 1 and 2
as appropriate.
If a NAAT-confirmed case in Stage 3 may be considered severe, or not, solely on the basis of
“significant acute renal, hepatic, or neurologic dysfunction,” the blinded data will be
reviewed by 3 medically qualified Pfizer staff members to assess whether the criterion is met;
the majority opinion will prevail.
CONFIDENTIAL
Page 119
FDA-CBER-2021-5683-0014916
Page 863
Protocol C4591001


initiated.
the IRB/EC;
procedures;
of.
CONFIDENTIAL
Page 120
FDA-CBER-2021-5683-0014917
Page 864
Protocol C4591001

the trial.

or study center.
CONFIDENTIAL
Page 121
FDA-CBER-2021-5683-0014918
Page 865
Protocol C4591001



EudraCT
CONFIDENTIAL
Page 122
FDA-CBER-2021-5683-0014919
Page 866
Protocol C4591001
www.pfizer.com
Data Sharing

redacted.

CONFIDENTIAL
Page 123
FDA-CBER-2021-5683-0014920
Page 867
Protocol C4591001
monitoring plan.
maintained.
CONFIDENTIAL
Page 124
FDA-CBER-2021-5683-0014921
Page 868
Protocol C4591001


participants.
start date.
to:
CONFIDENTIAL
Page 125
FDA-CBER-2021-5683-0014922
Page 869
Protocol C4591001


CONFIDENTIAL
Page 126
FDA-CBER-2021-5683-0014923
Page 870
Protocol C4591001


Platelet count
WBC count
Eosinophils (Abs)
Monocytes (Abs)
Basophils (Abs)
Lymphocytes (Abs)


(Grade 4)
Hemoglobin 11.0 – 12.0 9.5 – 10.9 8.0 – 9.4 <8.0
(Female) - g/dL
Hemoglobin 12.5 – 13.5 10.5 – 12.4 8.5 – 10.4 <8.5
(Male) - g/dL
WBC increase - 10,800 – 15,000 15,001 – 20,000 20,001 – 25, 000 >25,000
cells/mm3
WBC decrease - 2,500 – 3,500 1,500 – 2,499 1,000 – 1,499 <1,000
cells/mm3
Lymphocytes 750 – 1,000 500 – 749 250 – 499 <250
- cells/mm3
cells/mm3
cells/mm3
CONFIDENTIAL
Page 127
FDA-CBER-2021-5683-0014924
Page 871
Protocol C4591001

(Grade 4)
dialysis
phosphate –
increase by factor
– ALT, AST
increase by factor
accompanied
by any increase in
increase by factor
factor
CONFIDENTIAL
Page 128
FDA-CBER-2021-5683-0014925
Page 872
Protocol C4591001

AE Definition






CONFIDENTIAL
Page 129
FDA-CBER-2021-5683-0014926
Page 873
Protocol C4591001





a. Results in death

considered serious.
CONFIDENTIAL
Page 130
FDA-CBER-2021-5683-0014927
Page 874
Protocol C4591001



or drug abuse.

CONFIDENTIAL
Page 131
FDA-CBER-2021-5683-0014928
Page 875
Protocol C4591001

SAE Report Form to
Hours of Awareness
SAE All All



CONFIDENTIAL
Page 132
FDA-CBER-2021-5683-0014929
Page 876
Protocol C4591001

function.

function.

function.


be ruled out.

CONFIDENTIAL
Page 133
FDA-CBER-2021-5683-0014930
Page 877
Protocol C4591001

assessment.



CONFIDENTIAL
Page 134
FDA-CBER-2021-5683-0014931
Page 878
Protocol C4591001


courier service.
CONFIDENTIAL
Page 135
FDA-CBER-2021-5683-0014932
Page 879
Protocol C4591001

intervention(s):
PLUS either:

OR


OR

pregnancy.
CONFIDENTIAL
Page 136
FDA-CBER-2021-5683-0014933
Page 880
Protocol C4591001

considered.


CONFIDENTIAL
Page 137
FDA-CBER-2021-5683-0014934
Page 881
Protocol C4591001


ovulation.

90 days.

 Oral;
 Intravaginal;
 Transdermal;
 Injectable.
 Oral;
 Injectable.

participant.
CONFIDENTIAL
Page 138
FDA-CBER-2021-5683-0014935
Page 882
Protocol C4591001

CONFIDENTIAL
Page 139
FDA-CBER-2021-5683-0014936
Page 883
Protocol C4591001

available.
CONFIDENTIAL
Page 140
FDA-CBER-2021-5683-0014937
Page 884
Protocol C4591001
CONFIDENTIAL
Page 141
FDA-CBER-2021-5683-0014938
Page 885
Protocol C4591001

Abbreviation Term
AE adverse event
BMI body mass index

DU dosing unit
EC ethics committee
EU European Union
CONFIDENTIAL
Page 142
FDA-CBER-2021-5683-0014939
Page 886
Protocol C4591001
Abbreviation Term
HR heart rate
IA interim analysis

ID identification
Ig immunoglobulin
IV intravenous(ly)
LL lower limit
LPX lipoplex
CONFIDENTIAL
Page 143
FDA-CBER-2021-5683-0014940
Page 887
Protocol C4591001
Abbreviation Term
N/A not applicable
NVA nonvaccine antigen
P2 S SARS-CoV-2 full-length, P2 mutant, “heads up,” prefusion spike
glycoprotein
PT prothrombin time
RBC red blood cell

RR respiratory rate
US United States
vax vaccination
CONFIDENTIAL
Page 144
FDA-CBER-2021-5683-0014941
Page 888
Protocol C4591001
Abbreviation Term
VE vaccine efficacy
CONFIDENTIAL
Page 145
FDA-CBER-2021-5683-0014942
Page 889
Protocol C4591001

At the time of the IAs at 32, 62, 92, and 120 cases, the number of severe COVID-19 cases in
the vaccine and placebo groups will be assessed. If there are more severe cases in the
vaccine group than in the placebo group, the DMC will be advised to recommend that
enrollment be stopped if the probability of the adverse split being observed is <1%, assuming
that severe cases are truly evenly split (stopping rule, see Section 8.2.3). If the probability is
≥1% and <11%, the DMC will be advised to request probability to be recalculated as each
additional severe case is accrued (alert rule). This is illustrated for severe cases, from 2 to
20, in Table 10.
In Stage 3, the unblinded statistical team, including an unblinded medical monitor, will
review cases of severe COVID-19 as they are received, and will review AEs at least weekly
for additional potential cases of severe COVID-19. At any point the unblinded team may
discuss with the DMC chair whether the DMC should review cases for an adverse imbalance
of cases of COVID-19 and/or severe COVID-19 between the vaccine and placebo groups
Table 10. For 2 to 20 Cases of Severe COVID-19, Probability of Observing This

Number or More of Severe Cases in the Vaccine Group at a Range of
True Adverse Ratios From 1:1 to 4:1

Severe Cases Split Probability of Probability of Probability of Observing X or
Observing X Observing X More Severe Cases in Vaccine
Severe Cases or More Group With Different True Split
in Vaccine Severe Cases Ratios
Group if Truly in Vaccine
Evenly Split; Group if Truly
STOPPING Evenly Split;
RULE: <1% ALERT
RULE: <11%
Total Vaccine Placebo True Split Ratio True Split Ratio (Active:Placebo)
severe (X) (Active:Placebo)
cases
True (1:1) (1:1) (2:1) (3:1) (4:1)
ratio
2 2 0
3 3 0
4 4 0 >1% 6.25% 19.79% 31.64% 40.96%
5 5 0 >1% 3.13% 13.20% 23.73% 32.77%
6 5 1 >1% 10.94% 35.18% 53.39% 65.54%
6 6 0 >1% 1.56% 8.81% 17.80% 26.21%
7 6 1 >1% 6.25% 26.40% 44.49% 57.67%
7 7 0 0.78% 0.78% 5.87% 13.35% 20.97%
8 7 1 >1% 3.52% 19.56% 36.71% 50.33%
8 8 0 0.39% 0.39% 3.92% 10.01% 16.78%
9 7 2 >1% 8.98% 37.80% 60.07% 73.82%
9 8 1 >1% 1.95% 14.35% 30.03% 43.62%
9 9 0 0.20% 0.20% 2.61% 7.51% 13.42%
10 8 2 >1% 5.47% 29.99% 52.56% 67.78%
CONFIDENTIAL
Page 146
FDA-CBER-2021-5683-0014943
Page 890
Protocol C4591001
Table 10. For 2 to 20 Cases of Severe COVID-19, Probability of Observing This

Number or More of Severe Cases in the Vaccine Group at a Range of
True Adverse Ratios From 1:1 to 4:1
Severe Cases Split Probability of Probability of Probability of Observing X or
Observing X Observing X More Severe Cases in Vaccine
Severe Cases or More Group With Different True Split
in Vaccine Severe Cases Ratios
Group if Truly in Vaccine
Evenly Split; Group if Truly
STOPPING Evenly Split;
RULE: <1% ALERT
RULE: <11%
Total Vaccine Placebo True Split Ratio True Split Ratio (Active:Placebo)
severe (X) (Active:Placebo)
cases
True (1:1) (1:1) (2:1) (3:1) (4:1)
ratio
10 9 1 0.98% 1.07% 10.44% 24.40% 37.58%
11 9 2 >1% 3.27% 23.48% 45.52% 61.74%
11 10 1 0.54% 0.59% 7.55% 19.71% 32.21%
12 9 3 >1% 7.30% 39.40% 64.88% 79.46%
12 10 2 >1% 1.93% 18.18% 39.07% 55.83%
12 11 1 0.29% 0.32% 5.42% 15.84% 27.49%

13 10 3 >1% 4.61% 32.33% 58.43% 74.73%
13 11 2 0.95% 1.12% 13.93% 33.26% 50.17%
14 10 4 >1% 8.98% 47.66% 74.15% 87.02%
14 11 3 >1% 2.87% 26.21% 52.13% 69.82%
14 12 2 0.56% 0.65% 10.58% 28.11% 44.81%
15 11 4 >1% 5.92% 40.51% 68.65% 83.58%
15 12 3 >1% 1.76% 21.00% 46.13% 64.82%
15 13 2 0.32% 0.37% 7.97% 23.61% 39.80%
16 11 5 >1% 10.51% 54.81% 81.03% 91.83%
16 12 4 >1% 3.84% 34.02% 63.02% 79.82%
16 13 3 0.85% 1.06% 16.66% 40.50% 59.81%
17 12 5 >1% 7.17% 47.88% 76.53% 89.43%
17 13 4 >1% 2.45% 28.24% 57.39% 75.82%
17 14 3 0.52% 0.64% 13.10% 35.30% 54.89%
18 13 5 >1% 4.81% 41.34% 71.75% 86.71%
18 14 4 >1% 1.54% 23.20% 51.87% 71.64%
18 15 3 0.31% 0.38% 10.22% 30.57% 50.10%
19 13 6 >1% 8.35% 54.43% 82.51% 93.24%
19 14 5 >1% 3.18% 35.30% 66.78% 83.69%
19 15 4 0.74% 0.96% 18.88% 46.54% 67.33%
20 14 6 >1% 5.77% 48.06% 78.58% 91.33%
20 15 5 >1% 2.07% 29.83% 61.72% 80.42%
20 16 4 0.46% 0.59% 15.22% 41.48% 62.96%
CONFIDENTIAL
Page 147
FDA-CBER-2021-5683-0014944
Page 891
Protocol C4591001
11. REFERENCES
1
2
3
4
5

6
7
adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326-34.
8
9
10
1985;4(2):213-26.
CONFIDENTIAL
Page 148
FDA-CBER-2021-5683-0014945
Page 892
Document Name:
Document Title: ! "" #!$%&%'()%##!* )'*%+,-!* %$ !).

!)&$#,'* *% !&/,'*,'0 (1*2 (% !.#1(! (! /!(2 (
%#!)$,#,(2 ,++1'%0!',,(2 '* !//,2 %/ ) &%.&
)' .,'! '*,*(! 0,' ( %.,*& ,' !#(2
*1#(
#34 4 & & 565 $7 77 # 8

9 9 4 & & 55 6 / 8
FDA-CBER-2021-5683-0014946
Page 893
Protocol C4591001
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,

DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY,
IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA
VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY ADULTS

090177e193b65c72\Approved\Approved On: 11-Jun-2020 13:54 (GMT)

EudraCT Number: N/A
Phase: 1/2
Short Title: A Phase 1/2 Study to Describe the Safety, Tolerability, Immunogenicity, and
Potential Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults
CONFIDENTIAL
Page 1
FDA-CBER-2021-5683-0014947
Page 894
Protocol C4591001
Document History

protocol.
BNT162b2.
intervention.






illness e-diary.
CONFIDENTIAL
Page 2
FDA-CBER-2021-5683-0014948
Page 895
Protocol C4591001

In addition:


(BNT162-01):
BNT162c2
Additionally:
after Dose 1 or 2
escalation
antigen to BNT162c2
subunit
CONFIDENTIAL
Page 3
FDA-CBER-2021-5683-0014949
Page 896
Protocol C4591001

will be directed

candidate
CONFIDENTIAL
Page 4
FDA-CBER-2021-5683-0014950
Page 897
Protocol C4591001
TABLE OF CONTENTS
LIST OF TABLES...................................................................................................................10
1.1. Synopsis ..................................................................................................................12
1.2. Schema ....................................................................................................................17
1.3.1. Stage 1 Sentinel Cohorts.............................................................................18
1.3.2. Stage 1 Nonsentinel Cohorts and Stage 2 Cohorts .....................................23
1.3.3. Stage 3 Cohort(s) ........................................................................................26
2. INTRODUCTION ...............................................................................................................28
2.1. Study Rationale .......................................................................................................28
2.2. Background .............................................................................................................28

2.3.1. Risk Assessment .........................................................................................30
4. STUDY DESIGN.................................................................................................................33
4.1. Overall Design.........................................................................................................33
4.1.1. Stage 1 ........................................................................................................34
4.1.2. Stage 2 ........................................................................................................35
4.1.3. Stage 3 ........................................................................................................35
CONFIDENTIAL
Page 5
FDA-CBER-2021-5683-0014951
Page 898
Protocol C4591001
5.3.1. Contraception..........................................

S1 M5 5351 C4591001-Fa-Interim-Protocol

Uploaded by

Copyright:

Available Formats

S1 M5 5351 C4591001-Fa-Interim-Protocol

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

S1 M5 5351 C4591001-Fa-Interim-Protocol

Uploaded by

Copyright:

Available Formats

PF-07302048 (BNT162 RNA-Based COVID-19 Vaccines)

A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND,

Study Sponsor: BioNTech

Study Intervention Name: RNA-Based COVID-19 Vaccines

Protocol Amendment Summary of Changes Table

Document Version Date Summary and Rationale for Changes

age enrolled under this amendment in the

Document Version Date Summary and Rationale for Changes

in participants who were affected by a

Document Version Date Summary and Rationale for Changes

Document Version Date Summary and Rationale for Changes

 Clarified the AE reporting requirements for

Document Version Date Summary and Rationale for Changes

Further nonclinical data are available to support the

The 6-month safety follow-up telephone contact has

The COVID-19 illness visit has now added

The COVID-19 illness symptoms have been updated

to align with the FDA-accepted definitions; this

AEs that occur between consent and dosing will now

Changes have been made to the headings to align

Clarified that only an unblinded site staff member

Additional interim analyses have been added to

As a result of regulatory feedback, an appendix has

Document Version Date Summary and Rationale for Changes

Following regulatory feedback, the BNT162b3

Given the rapidly evolving pandemic situation,

In order to increase flexibility enrolling participants,

To increase the number of doses that can be obtained

To facilitate the reporting of COVID-19 illness

Document Version Date Summary and Rationale for Changes

 Following preliminary experience in the

BioNTech study conducted in Germany

Document Version Date Summary and Rationale for Changes

analysis approximately 6 months after Dose 2

2.3.2. Benefit Assessment.....................................................................................39

5.4. Screen Failures ........................................................................................................52

6.4. Study Intervention Compliance...............................................................................58

8.2.2.1. Grading Scales...........................................................................68

8.3.2. Method of Detecting AEs and SAEs ..........................................................75

8.7. Genetics ...................................................................................................................80

8.11.1.7. Visit 6 – 2-Week Follow-up Visit (Vaccination 2): (12 to

8.11.2.6. Visit 6 – 24-Month Follow-up Visit: (714 to 742 Days

9.1.2.1. Statistical Hypothesis Evaluation for Efficacy........................107

10.1.2. Informed Consent Process ......................................................................125

10.4. Appendix 4: Contraceptive Guidance .................................................................140

Table 5. Probability of Observing at Least 1 AE by Assumed True Event

A pneumonia of unknown cause detected in Wuhan, China, was first reported in

There are currently no licensed vaccines to prevent infection with SARS-CoV-2 or

BNT162b1 (variant RBP020.3): a modRNA encoding the RBD;

BNT162b2 (variant RBP020.2): a modRNA encoding P2 S.

Objectives, Estimands, and Endpoints

Objectives Estimands Endpoints

 Grading shifts in hematology and

7 and 21 days after Dose 1; 7 and 14

 Geometric mean titers (GMTs) at SARS-CoV-2 neutralizing titers

Objectives Estimands Endpoints

For Phase 2/3

Objectivesa Estimands Endpoints

Objectivesa Estimands Endpoints